Compositions and methods for car t cell therapy

ABSTRACT

The present disclosure relates to methods of treating a patient with a cancer by administering to the patient a composition comprising CAR T cells and a small molecule linked to a targeting moiety by a linker. The disclosure also relates to compositions for use in such methods.

CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a continuation application of U.S. application Ser.No. 16/489,455, filed 28 Aug. 2019, which is a U.S. national stageapplication under 35 U.S.C. § 371(b) of International Application No.PCT/US2018/020095 filed 28 Feb. 2018, which claims priority under 35U.S.C. § 119(e) to U.S. Provisional Application No. 62/464,792 filed 28Feb. 2017, U.S. Provisional Application No. 62/480,627 filed 3 Apr.2017, U.S. Provisional Application No. 62/554,421 filed 5 Sep. 2017,U.S. Provisional Application No. 62/620,701 filed 23 Jan. 2018, U.S.Provisional Application No. 62/620,384 filed 22 Jan. 2018, U.S.Provisional Application No. 62/620,423 filed 22 Jan. 2018, and U.S.Provisional Application No. 62/634,595 filed 23 Feb. 2018, all of whichare incorporated herein by reference in their entirety.

TECHNICAL FIELD

The present disclosure relates to methods of treating a patient with acancer by administering to the patient a composition comprising CAR Tcells and administering to the patient a small molecule linked to atargeting moiety by a linker. The disclosure also relates tocompositions for use in such methods.

BACKGROUND

Immunotherapy based on adoptive transfer of lymphocytes (e.g., T cells)into a patient is a valuable therapy in the treatment of cancer andother diseases. Important advancements have been made in the developmentof immunotherapies based on adoptive transfer of lymphocytes. Among themany different types of immunotherapeutic agents, one of the mostpromising of the immunotherapeutic agents being developed is T cellsexpressing chimeric antigen receptors (CAR T cells). The chimericantigen receptor (CAR) is a genetically engineered receptor that isdesigned to target a specific antigen, for example, a tumor antigen.This targeting can result in cytotoxicity against the tumor, forexample, such that CAR T cells expressing CARs can target and killtumors via the specific tumor antigens.

First generation CARs are composed of a recognition region, e.g., asingle chain fragment variable (scFv) region derived from an antibodyfor recognition and binding to the antigen expressed by the tumor, andan activation signaling domain, e.g., the CD3ζ chain of T cells canserve as a T cell activation signal in CARs. Although CART cells haveshown positive results in vitro, they have had limited success ineliminating disease (e.g., cancer) in clinical trials. One problem hasbeen the inability to prolong activation and expand the CAR T cellpopulation in vivo.

To address this problem, a co-stimulation domain (e.g., CD137, CD28 orCD134) has been included in second generation CARs to achieve prolongedactivation of T cells in vivo. Addition of a co-stimulation domainenhances the in vivo proliferation and survival of T cells containingCARs, and initial clinical data have shown that such constructs arepromising therapeutic agents in the treatment of diseases, such ascancer.

Although improvements have been made in CAR T cell therapies, severalproblems remain. First, ‘off-target’ toxicity may occur due to normalcells that express the antigen targeted by the CAR T cells (e.g., atumor-associated antigen). Second, unregulated CAR T cell activation maybe found where the rapid and uncontrolled elimination of diseased cells(e.g., cancer cells) by CAR T cells induces a constellation of metabolicdisturbances, called tumor lysis syndrome, or cytokine release syndrome(CRS), which can be fatal to patients. Tumor lysis syndrome and CRS canresult due to administered CAR T cells that cannot be easily regulated,and are activated uncontrollably. Accordingly, although CAR T cells showgreat promise as a tool in the treatment of diseases, such as cancer,additional CAR T cell therapies are needed that provide reducedoff-target toxicity, and more precise control of CAR T cell activation.

SUMMARY OF THE INVENTION

The present inventors have discovered methods of reducing off-targettoxicity, and more precisely controlling CAR T cell activation,providing important advancements in CAR T cell therapy. In the variousembodiments described herein, a small molecule ligand linked to atargeting moiety by a linker is used as a bridge between the cancer andthe CAR T cells directing the CAR T cells to the cancer for ameliorationof the cancer. In one embodiment, the “small molecule ligand” can be,for example, a folate, DUPA, an NK-1R ligand, a CAIX ligand, a ligand ofgamma glutamyl transpeptidase, an NKG2D ligand, or a CCK2R ligand, eachof which is a small molecule ligand that binds specifically to cancercells (i.e., the receptor for these ligands is overexpressed on cancerscompared to normal tissues).

In one embodiment, the “small molecule ligand” is linked to a “targetingmoiety” that binds to the CAR expressed by CAR T cells. In variousembodiments, the “targeting moiety” can be selected, for example, from2,4-dinitrophenol (DNP), 2,4,6-trinitrophenol (TNP), biotin,digoxigenin, fluorescein, fluorescein isothiocyanate (FITC),NHS-fluorescein, pentafluorophenyl ester (PFP), tetrafluorophenyl ester(TFP), a knottin, a centyrin, and a DARPin.

The “targeting moiety” binds to the recognition region of thegenetically engineered CAR expressed by CAR T cells. Accordingly, therecognition region of the CAR (e.g., a single chain fragment variableregion (scFv) of an antibody, an Fab, Fv, Fc, (Fab′)2 fragment, and thelike) is directed to the “targeting moiety.” Thus, the small moleculeligand linked to a targeting moiety by a linker acts as a bridge betweenthe cancer and the CAR T cells, directing the CAR T cells to the cancerfor amelioration of the cancer.

In one embodiment, a method of treatment of a cancer is provided. Themethod comprises i) administering to a patient a compound, or apharmaceutically acceptable salt thereof, wherein the compound comprisesa small molecule ligand linked to a targeting moiety by a linker, ii)administering to the patient a first dose of a CAR T cell compositionwherein the CAR T cell composition comprises CAR T cells and wherein theCAR T cells comprise the CAR directed to the targeting moiety, and iii)administering to the patient a second dose of the CAR T cell compositionwherein the CAR T cell composition comprises CAR T cells and wherein theCAR T cells comprise the CAR directed to the targeting moiety.

In another embodiment, a method of treatment of a cancer is provided.The method comprises i) administering to a patient a compound, or apharmaceutically acceptable salt thereof, wherein the compound comprisesa small molecule ligand linked to a targeting moiety by a linker, andii) administering to the patient a CAR T cell composition comprising CART cells wherein the CAR T cells in the composition comprise the CARdirected to the targeting moiety and wherein the CAR T cell compositioncomprises a mixture of the CAR T cells and non-transformed T cells.

In yet another embodiment, a method of treatment of a cancer isprovided. The method comprises i) administering to a patient a compound,or a pharmaceutically acceptable salt thereof, wherein the compoundcomprises a small molecule ligand linked to a targeting moiety by alinker, ii) administering to the patient a CAR T cell compositionwherein the CAR T cell composition comprises CAR T cells and wherein theCAR T cells comprise the CAR directed to the targeting moiety, and iii)administering to the patient a folate, a conjugate comprising a folatewherein the conjugate comprising a folate does not comprise a targetingmoiety, or an agent that inhibits activation of the CAR T cells.

In another embodiment, a method of treatment of a cancer is provided.The method comprises i) administering to a patient a compound, or apharmaceutically acceptable salt thereof, wherein the compound comprisesa small molecule ligand linked to a targeting moiety by a linker, andwherein the compound, or the pharmaceutically acceptable salt thereof,is at a dose of about 10 nmoles/kg of body weight of the patient toabout 2500 nmoles/kg of body weight of the patient, and ii)administering to the patient a CAR T cell composition comprising CAR Tcells wherein the CAR T cells comprise a CAR directed to the targetingmoiety, and wherein the CAR T cells are at a dose of about 1 million ofthe CAR T cells to about 15 million of the CAR T cells.

In still another embodiment, a method of treatment of a cancer isprovided. The method comprises i) administering continuously to apatient a compound, or a pharmaceutically acceptable salt thereof,wherein the compound comprises a small molecule ligand linked to atargeting moiety by a linker, ii) administering to the patient a CAR Tcell composition comprising CAR T cells wherein the CAR T cells comprisea CAR directed to the targeting moiety, and iii) ending administrationof the compound, or the pharmaceutically acceptable salt thereof, toreduce cytokine release syndrome in the patient.

In another illustrative aspect, a method of treatment of a cancer isprovided. The method comprises i) administering to a patient a compound,or a pharmaceutically acceptable salt thereof, wherein the compoundcomprises a small molecule ligand linked to a targeting moiety by alinker, wherein at least a first dose and a second dose of the compound,or the pharmaceutically acceptable salt thereof, are administered to thepatient, wherein the first dose and the second dose are different,wherein the second dose of the compound, or the pharmaceuticallyacceptable salt thereof, is about 2-fold to about 15000-fold greater inamount than the first dose of the compound, or the pharmaceuticallyacceptable salt thereof, and ii) administering to the patient a CAR Tcell composition comprising CAR T cells wherein the CAR T cells comprisea CAR directed to the targeting moiety.

In another embodiment, a method of treatment of a cancer is provided.The method comprises i) administering to a patient a compound, or apharmaceutically acceptable salt thereof, wherein the compound comprisesa small molecule ligand linked to a targeting moiety by a linker andwherein the compound, or the pharmaceutically acceptable salt thereof,is administered once weekly to the patient, and ii) administering to thepatient a CAR T cell composition comprising CAR T cells wherein the CART cells comprise a CAR directed to the targeting moiety.

In yet another embodiment, a method of treatment of a cancer isprovided. The method comprises i) administering to a patient a firstdose of a compound, or a pharmaceutically acceptable salt thereof,wherein the compound comprises a small molecule ligand linked to atargeting moiety by a linker, ii) administering to the patient at leasta second dose of the compound, or a pharmaceutically acceptable saltthereof, wherein the second dose of the compound, or thepharmaceutically acceptable salt thereof, is at least about 50 percentlower in amount than the first dose of the compound, or thepharmaceutically acceptable salt thereof, and iii) administering to thepatient a dose of a CAR T cell composition comprising CAR T cellswherein the CAR T cells comprise a CAR directed to the targeting moiety.

In still another embodiment, a method of treatment of a cancer isprovided. The method comprises i) administering to a patient a firstdose of a compound, or a pharmaceutically acceptable salt thereof,wherein the compound comprises a small molecule ligand linked to atargeting moiety by a linker and wherein the compound, or thepharmaceutically acceptable salt thereof, is administered to the patientat least about one hour prior to the administration of a CAR T cellcomposition comprising CAR T cells wherein the CAR T cells comprise aCAR directed to the targeting moiety, ii) then administering to thepatient a dose of the CAR T cell composition, and iii) thenadministering to the patient a second dose of the compound, or thepharmaceutically acceptable salt thereof.

In another embodiment, a method of treatment of a cancer is provided.The method comprises i) administering to a patient a compound, or apharmaceutically acceptable salt thereof, wherein the compound comprisesa small molecule ligand linked to a targeting moiety by a linker, andii) administering to the patient a CAR T cell composition wherein theCAR T cell composition comprises CAR T cells and wherein the CAR T cellscomprise a CAR directed to the targeting moiety, and wherein the smallmolecule ligand is a PSMA ligand and the targeting moiety is FITC. Inthis embodiment, the small molecule ligand linked to a targeting moietyby a linker can have the formula

In yet another embodiment, a method of treatment of a cancer isprovided. The method comprises i) administering to a patient a compound,or a pharmaceutically acceptable salt thereof, wherein the compoundcomprises a small molecule ligand linked to a targeting moiety by alinker, and ii) administering to the patient a CAR T cell compositionwherein the CAR T cell composition comprises CAR T cells and wherein theCAR T cells comprise a CAR directed to the targeting moiety, and whereinthe small molecule ligand is a CAIX ligand and the targeting moiety isFITC. In this embodiment, the small molecule ligand linked to atargeting moiety by a linker can have the formula

In still another embodiment, a method of treatment of a cancer isprovided. The method comprises i) administering to a patient a firstcompound, or a pharmaceutically acceptable salt thereof, wherein thefirst compound, or the pharmaceutically acceptable salt thereof,comprises a PSMA ligand linked to FITC by a linker, ii) administering tothe patient a second compound, or a pharmaceutically acceptable saltthereof, wherein the second compound, or the pharmaceutically acceptablesalt thereof, comprises a CAIX ligand linked to FITC by a linker, andiii) administering to the patient a CAR T cell composition wherein theCAR T cell composition comprises CAR T cells and wherein the CAR T cellscomprise a CAR directed to the targeting moiety. In this embodiment, thefirst compound can have the formula

and the second compound can have the formula

Additional embodiments are also described by the following enumeratedclauses. Any of the following embodiments in combination with anyapplicable embodiments described in the Summary section, the DetailedDescription of the Illustrative Embodiments section, the Examplessection, or the claims of this patent application, are alsocontemplated.

1. A method of treatment of a cancer, the method comprising

-   -   i) administering to a patient a compound, or a pharmaceutically        acceptable salt thereof, wherein the compound comprises a small        molecule ligand linked to a targeting moiety by a linker;    -   ii) administering to the patient a first dose of a CAR T cell        composition comprising CAR T cells wherein the CAR T cells        comprise a CAR directed to the targeting moiety; and    -   iii) administering to the patient a second dose of a CAR T cell        composition comprising CAR T cells wherein the CAR T cells        comprise the CAR directed to the targeting moiety.

2. The method of clause 1 wherein the ligand is selected from the groupconsisting of a folate, DUPA, an NK-1R ligand, a CAIX ligand, a ligandof gamma glutamyl transpeptidase, an NKG2D ligand, and a CCK2R ligand.

3. The method of any one of clauses 1 or 2 wherein the ligand is afolate.

4. The method of any one of clauses 1 or 2 wherein the ligand is anNK-1R ligand.

5. The method of any one of clauses 1 or 2 wherein the ligand is DUPA.

6. The method of any one of clauses 1 or 2 wherein the ligand is a CCK2Rligand.

7. The method of any one of clauses 1 or 2 wherein the ligand is aligand of gamma glutamyl transpeptidase.

8. The method of any one of clauses 1 to 7 wherein the targeting moietyis selected from the group consisting of 2,4-dinitrophenol (DNP),2,4,6-trinitrophenol (TNP), biotin, digoxigenin, fluorescein,fluorescein isothiocyanate (FITC), NHS-fluorescein, pentafluorophenylester, tetrafluorophenyl ester, a knottin, a centyrin, and a DARPin.

9. The method of any one of clauses 1 to 8 wherein the targeting moietyis FITC.

10. The method of any one of clauses 1 to 8 wherein the targeting moietyis DNP.

11. The method of any one of clauses 1 to 8 wherein the targeting moietyis TNP.

12. The method of any one of clauses 1 to 11 wherein the linkercomprises polyethylene glycol (PEG), polyproline, a hydrophilic aminoacid, a sugar, an unnatural peptidoglycan, a polyvinylpyrrolidone,pluronic F-127, or a combination thereof.

13. The method of any one of clauses 1 to 12 wherein the linkercomprises PEG.

14. The method of any one of clauses 1 to 13 wherein the compound, orthe pharmaceutically acceptable salt thereof, has the formula

B-L-T,

wherein B represents the small molecule ligand, L represents the linker,and T represents the targeting moiety, and wherein L comprises astructure having the formula

wherein n is an integer from 0 to 200.

15. The method of clause 14 wherein n is an integer from 0 to 150.

16. The method of clause 14 wherein n is an integer from 0 to 110.

17. The method of clause 14 wherein n is an integer from 0 to 20.

18. The method of clause 14 wherein n is an integer from 15 to 20.

19. The method of clause 14 wherein n is an integer from 15 to 110.

20. The method of any one of clauses 1 to 9 or 12 to 19 wherein thelinker comprises PEG and the targeting moiety is FITC, or apharmaceutically acceptable salt thereof.

21. The method of any one of clauses 1 to 20 wherein the compound, orthe pharmaceutically acceptable salt thereof, is administered at a doseof about 10 nmoles/kg to about 10000 nmoles/kg of body weight of thepatient.

22. The method of any one of clauses 1 to 21 wherein the compound, orthe pharmaceutically acceptable salt thereof, is administered at a doseof about 10 nmoles/kg to about 5000 nmoles/kg of body weight of thepatient.

23. The method of any one of clauses 1 to 22 wherein the compound, orthe pharmaceutically acceptable salt thereof, is administered at a doseof about 10 nmoles/kg to about 1000 nmoles/kg of body weight of thepatient.

24. The method of any one of clauses 1 to 23 wherein the compound, orthe pharmaceutically acceptable salt thereof, is administered at a doseof about 10 nmoles/kg to about 600 nmoles/kg of body weight of thepatient.

25. The method of any one of clauses 1 to 24 wherein the compound, orthe pharmaceutically acceptable salt thereof, is administered at a doseof about 200 nmoles/kg to about 600 nmoles/kg of body weight of thepatient.

26. The method of any one of clauses 1 to 25 wherein the compound, orthe pharmaceutically acceptable salt thereof, is administered at a doseof about 250 nmoles/kg to about 600 nmoles/kg of body weight of thepatient.

27. The method of any one of clauses 1 to 26 wherein the cancer isselected from the group consisting of lung cancer, bone cancer,pancreatic cancer, skin cancer, cancer of the head, cancer of the neck,cutaneous melanoma, intraocular melanoma uterine cancer, ovarian cancer,endometrial cancer, rectal cancer, stomach cancer, colon cancer, breastcancer, triple negative breast cancer, carcinoma of the fallopian tubes,carcinoma of the endometrium, carcinoma of the cervix, carcinoma of thevagina, carcinoma of the vulva, Hodgkin's Disease, cancer of theesophagus, cancer of the small intestine, cancer of the endocrinesystem, cancer of the thyroid gland, cancer of the parathyroid gland,non-small cell lung cancer, cancer of the adrenal gland, sarcoma of softtissue, osteosarcoma, cancer of the urethra, prostate cancer, chronicleukemia, acute leukemia, acute myelocytic leukemia, lymphocyticlymphoma, myeloid leukemia, myelomonocytic leukemia, hairy cellleukemia, pleural mesothelioma, cancer of the bladder, Burkitt'slymphoma, cancer of the ureter, cancer of the kidney, renal cellcarcinoma, carcinoma of the renal pelvis, neoplasms of the centralnervous system (CNS), primary CNS lymphoma, spinal axis tumors, brainstem glioma, pituitary adenoma, and adenocarcinoma of thegastroesophageal junction.

1. 28. The method of any one of clauses 1 to 3 or 8 to 27 wherein thecancer is a folate receptor expressing cancer.

2. 29. The method of clause 28 wherein the cancer is an endometrialcancer.

3. 30. The method of clause 28 wherein the cancer is a non-small celllung cancer.

4. 31. The method of clause 28 wherein the cancer is an ovarian cancer.

5. 32. The method of clause 28 wherein the cancer is a triple negativebreast cancer.

33. The method of any one of clauses 1 to 32 wherein the CAR has arecognition region and the recognition region is a single chain fragmentvariable (scFv) region of an antibody.

34. The method of any one of clauses 1 to 9 or 12 to 33 wherein the CARhas a recognition region and the recognition region of the CAR is asingle chain fragment variable (scFv) region of an anti-FITC antibody.35. The method of any one of clauses 1 to 34 wherein the CAR has aco-stimulation domain and the co-stimulation domain is selected from thegroup consisting of CD28, CD137 (4-1BB), CD134 (OX40), and CD278 (ICOS).

36. The method of any one of clauses 1 to 35 wherein the CAR has anactivation signaling domain and the activation signaling domain is a Tcell CD3ζ chain or an Fc receptor γ.

37. The method of any one of clauses 1 to 9 or 12 to 36 wherein the CARhas a recognition region and the recognition region is a single chainfragment variable (scFv) region of an anti-FITC antibody, wherein theCAR has a co-stimulation domain and the co-stimulation domain is CD137(4-1BB), and wherein the CAR has an activation signaling domain and theactivation signaling domain is a T cell CD3ζ chain.

6. 38. The method of any one of clauses 1 to 37 wherein multiple dosesof the compound, or the pharmaceutically acceptable salt thereof, andthe CAR T cell composition are administered.

39. The method of any one of clauses 1 to 38 wherein the patient isimaged prior to administration of the compound, or the pharmaceuticallyacceptable salt thereof, or prior to administration of the CAR T cellcomposition.

7. 40. The method of any one of clauses 1 to 39 wherein the compound, orthe pharmaceutically acceptable salt thereof, is not an antibody, anddoes not comprise a fragment of an antibody.

8. 41. The method of any one of clauses 1 to 40 wherein the targetingmoiety does not comprise a peptide epitope.

42. The method of any one of clauses 1 to 41 wherein cytokine releaseresulting in off-target toxicity in the patient does not occur andwherein CAR T cell toxicity to the cancer occurs.

9. 43. The method of any one of clauses 1 to 41 wherein off-targettissue toxicity does not occur in the patient and wherein CAR T celltoxicity to the cancer occurs.

10. 44. The method of any one of clauses 1 to 41 wherein the cancercomprises a tumor, wherein tumor size is reduced in the patient, andwherein off-target toxicity does not occur.

11. 45. The method of any one of clauses 1 to 44 wherein the CART cellscomprise a nucleic acid comprising SEQ ID NO:1.

12. 46. The method of any one of clauses 1 to 45 wherein the CAR T cellscomprise a polypeptide comprising SEQ ID NO:2.

13. 47. The method of clause 45 wherein the nucleic acid encodes achimeric antigen receptor.

14. 48. The method of any one of clauses 1 to 47 wherein the CARcomprises humanized amino acid sequences.

15. 49. The method of any one of clauses 1 to 47 wherein the CARconsists of humanized amino acid sequences.

16. 50. The method of any one of clauses 1 to 49 wherein the first doseof the CAR T cell composition comprises a mixture of the CAR T cells andnon-transformed T cells in a ratio selected from about 1:5 of the CAR Tcells to the non-transformed T cells, about 1:4 of the CAR T cells tothe non-transformed T cells, about 1:3 of the CART cells to thenon-transformed T cells, about 1:2 of the CAR T cells to thenon-transformed T cells, and about 1:1 of the CAR T cells to thenon-transformed T cells.

17. 51. The method of any one of clauses 1 to 50 wherein the second doseof the CAR T cell composition comprises a mixture of the CAR T cells andnon-transformed T cells in a ratio selected from about 1:5 of the CAR Tcells to the non-transformed T cells, about 1:4 of the CAR T cells tothe non-transformed T cells, about 1:3 of the CART cells to thenon-transformed T cells, about 1:2 of the CAR T cells to thenon-transformed T cells, and about 1:1 of the CAR T cells to thenon-transformed T cells.

18. 52. The method of any one of clauses 1 to 51 wherein the first doseof the CAR T cell composition comprises a mixture of the CAR T cells andnon-transformed T cells in a ratio of from about 1:1 to about 1:5 of theCART cells to the non-transformed T cells.

19. 53. The method of any one of clauses 1 to 52 wherein the second doseof the CAR T cell composition comprises a mixture of the CAR T cells andnon-transformed T cells in a ratio of from about 1:1 to 1:5 of the CARTcells to the non-transformed T cells.

20. 54. The method of any one of clauses 1 to 53 wherein the first doseof the CART cell composition comprises a mixture of about 10 million ofthe CAR T cells and about 40 million non-transformed T cells.

21. 55. The method of any one of clauses 1 to 54 wherein the second doseof the CART cell composition comprises a mixture of about 10 million ofthe CAR T cells and about 40 million non-transformed T cells.

56. A method of treatment of a cancer, the method comprising

-   -   i) administering to a patient a compound, or a pharmaceutically        acceptable salt thereof, wherein the compound comprises a small        molecule ligand linked to a targeting moiety by a linker; and    -   ii) administering to the patient a CAR T cell composition        wherein the CAR T cell composition comprises CAR T cells,        wherein the CAR T cells comprise a CAR directed to the targeting        moiety, and wherein the CAR T cell composition comprises a        mixture of the CAR T cells and non-transformed T cells.

57. The method of clause 56 wherein the ligand is selected from thegroup consisting of a folate, DUPA, an NK-1R ligand, a CAIX ligand, aligand of gamma glutamyl transpeptidase, an NKG2D ligand, and a CCK2Rligand.

58. The method of any one of clauses 56 or 57 wherein the ligand is afolate.

59. The method of any one of clauses 56 or 57 wherein the ligand is anNK-1R ligand.

60. The method of any one of clauses 56 or 57 wherein the ligand isDUPA.

61. The method of any one of clauses 56 or 57 wherein the ligand is aCCK2R ligand.

62. The method of any one of clauses 56 or 57 wherein the ligand is aligand of gamma glutamyl transpeptidase.

63. The method of any one of clauses 56 to 62 wherein the targetingmoiety is selected from the group consisting of 2,4-dinitrophenol (DNP),2,4,6-trinitrophenol (TNP), biotin, digoxigenin, fluorescein,fluorescein isothiocyanate (FITC), NHS-fluorescein, pentafluorophenylester, tetrafluorophenyl ester, a knottin, a centyrin, and a DARPin.

64. The method of any one of clauses 56 to 63 wherein the targetingmoiety is FITC.

65. The method of any one of clauses 56 to 63 wherein the targetingmoiety is DNP.

66. The method of any one of clauses 56 to 63 wherein the targetingmoiety is TNP.

67. The method of any one of clauses 56 to 66 wherein the linkercomprises polyethylene glycol (PEG), polyproline, a hydrophilic aminoacid, a sugar, an unnatural peptidoglycan, a polyvinylpyrrolidone,pluronic F-127, or a combination thereof.

68. The method of any one of clauses 56 to 67 wherein the linkercomprises PEG.

69. The method of any one of clauses 56 to 68 wherein the compound, orthe pharmaceutically acceptable salt thereof, has the formula

B-L-T,

wherein B represents the small molecule ligand, L represents the linker,and T represents the targeting moiety, and wherein L comprises astructure having the formula

wherein n is an integer from 0 to 200.

70. The method of clause 69 wherein n is an integer from 0 to 150.

71. The method of clause 69 wherein n is an integer from 0 to 110.

72. The method of clause 69 wherein n is an integer from 0 to 20.

73. The method of clause 69 wherein n is an integer from 15 to 20.

74. The method of clause 69 wherein n is an integer from 15 to 110.

75. The method of any one of clauses 56 to 64 or 67 to 74 wherein thelinker comprises PEG and the targeting moiety is FITC, or apharmaceutically acceptable salt thereof.

76. The method of any one of clauses 56 to 75 wherein the compound, orthe pharmaceutically acceptable salt thereof, is administered at a doseof about 10 nmoles/kg to about 10000 nmoles/kg of body weight of thepatient.

77. The method of any one of clauses 56 to 76 wherein the compound, orthe pharmaceutically acceptable salt thereof, is administered at a doseof about 10 nmoles/kg to about 5000 nmoles/kg of body weight of thepatient.

78. The method of any one of clauses 56 to 77 wherein the compound, orthe pharmaceutically acceptable salt thereof, is administered at a doseof about 10 nmoles/kg to about 1000 nmoles/kg of body weight of thepatient.

79. The method of any one of clauses 56 to 78 wherein the compound, orthe pharmaceutically acceptable salt thereof, is administered at a doseof about 10 nmoles/kg to about 600 nmoles/kg of body weight of thepatient.

80. The method of any one of clauses 56 to 79 wherein the compound, orthe pharmaceutically acceptable salt thereof, is administered at a doseof about 200 nmoles/kg to about 600 nmoles/kg of body weight of thepatient.

81. The method of any one of clauses 56 to 80 wherein the compound, orthe pharmaceutically acceptable salt thereof, is administered at a doseof about 250 nmoles/kg to about 600 nmoles/kg of body weight of thepatient.

82. The method of any one of clauses 56 to 81 wherein the cancer isselected from the group consisting of lung cancer, bone cancer,pancreatic cancer, skin cancer, cancer of the head, cancer of the neck,cutaneous melanoma, intraocular melanoma uterine cancer, ovarian cancer,endometrial cancer, rectal cancer, stomach cancer, colon cancer, breastcancer, triple negative breast cancer, carcinoma of the fallopian tubes,carcinoma of the endometrium, carcinoma of the cervix, carcinoma of thevagina, carcinoma of the vulva, Hodgkin's Disease, cancer of theesophagus, cancer of the small intestine, cancer of the endocrinesystem, cancer of the thyroid gland, cancer of the parathyroid gland,non-small cell lung cancer, cancer of the adrenal gland, sarcoma of softtissue, osteosarcoma, cancer of the urethra, prostate cancer, chronicleukemia, acute leukemia, acute myelocytic leukemia, lymphocyticlymphoma, myeloid leukemia, myelomonocytic leukemia, hairy cellleukemia, pleural mesothelioma, cancer of the bladder, Burkitt'slymphoma, cancer of the ureter, cancer of the kidney, renal cellcarcinoma, carcinoma of the renal pelvis, neoplasms of the centralnervous system (CNS), primary CNS lymphoma, spinal axis tumors, brainstem glioma, pituitary adenoma, and adenocarcinoma of thegastroesophageal junction.

22. 83. The method of any one of clauses 56 to 58 or 63 to 82 whereinthe cancer is a folate receptor expressing cancer.

23. 84. The method of clause 83 wherein the cancer is an endometrialcancer.

24. 85. The method of clause 83 wherein the cancer is a non-small celllung cancer.

25. 86. The method of clause 83 wherein the cancer is an ovarian cancer.

26. 87. The method of clause 83 wherein the cancer is a triple negativebreast cancer.

88. The method of any one of clauses 56 to 87 wherein the CAR has arecognition region and the recognition region is a single chain fragmentvariable (scFv) region of an antibody.

89. The method of any one of clauses 56 to 64 or 67 to 88 wherein theCAR has a recognition region and the recognition region of the CAR is asingle chain fragment variable (scFv) region of an anti-FITC antibody.

90. The method of any one of clauses 56 to 89 wherein the CAR has aco-stimulation domain and the co-stimulation domain is selected from thegroup consisting of CD28, CD137 (4-1BB), CD134 (OX40), and CD278 (ICOS).

91. The method of any one of clauses 56 to 90 wherein the CAR has anactivation signaling domain and the activation signaling domain is a Tcell CD3ζ chain or an Fc receptor γ.

92. The method of any one of clauses 56 to 64 or 67 to 91 wherein theCAR has a recognition region and the recognition region is a singlechain fragment variable (scFv) region of an anti-FITC antibody, whereinthe CAR has a co-stimulation domain and the co-stimulation domain isCD137 (4-1BB), and wherein the CAR has an activation signaling domainand the activation signaling domain is a T cell CD3ζ chain.

27. 93. The method of any one of clauses 56 to 92 wherein multiple dosesof the compound, or the pharmaceutically acceptable salt thereof, areadministered.

94. The method of any one of clauses 56 to 93 wherein the patient isimaged prior to administration of the compound, or the pharmaceuticallyacceptable salt thereof, or prior to administration of the CAR T cellcomposition.

28. 95. The method of any one of clauses 56 to 94 wherein the compound,or the pharmaceutically acceptable salt thereof, is not an antibody, anddoes not comprise a fragment of an antibody.

29. 96. The method of any one of clauses 56 to 95 wherein the targetingmoiety does not comprise a peptide epitope.

30. 97. The method of any one of clauses 56 to 96 wherein cytokinerelease resulting in off-target toxicity in the patient does not occurand wherein CAR T cell toxicity to the cancer occurs.

31. 98. The method of any one of clauses 56 to 96 wherein off-targettissue toxicity does not occur in the patient and wherein CAR T celltoxicity to the cancer occurs.

32. 99. The method of any one of clauses 56 to 96 wherein the cancercomprises a tumor, wherein tumor size is reduced in the patient, andwherein off-target toxicity does not occur.

33. 100. The method of any one of clauses 56 to 99 wherein the CARTcells comprise a nucleic acid comprising SEQ ID NO:1.

34. 101. The method of any one of clauses 56 to 100 wherein the CAR Tcells comprise a polypeptide comprising SEQ ID NO:2.

35. 102. The method of clause 100 wherein the nucleic acid encodes achimeric antigen receptor.

36. 103. The method of any one of clauses 56 to 102 wherein the CARcomprises humanized amino acid sequences.

37. 104. The method of any one of clauses 56 to 102 wherein the CARconsists of humanized amino acid sequences.

38. 105. The method of any one of clauses 56 to 104 wherein the mixtureof the CAR T cells and the non-transformed T cells is in a ratioselected from about 1:5 of the CART cells to the non-transformed Tcells, about 1:4 of the CAR T cells to the non-transformed T cells,about 1:3 of the CART cells to the non-transformed T cells, about 1:2 ofthe CAR T cells to the non-transformed T cells, and about 1:1 of theCART cells to the non-transformed T cells.

39. 106. The method of any one of clauses 56 to 105 wherein the mixtureof the CAR T cells and the non-transformed T cells is in a ratio of fromabout 1:1 to about 1:5 of the CAR T cells to the non-transformed Tcells.

40. 107. The method of any one of clauses 56 to 106 wherein the mixtureof the CAR T cells and the non-transformed T cells comprises about 10million of the CAR T cells and about 40 million of the non-transformed Tcells.

108. A method of treatment of a cancer, the method comprising

-   -   i) administering to a patient a compound, or a pharmaceutically        acceptable salt thereof, wherein the compound comprises a small        molecule ligand linked to a targeting moiety by a linker;    -   ii) administering to the patient a CAR T cell composition        wherein the CAR T cell composition comprises CAR T cells and        wherein the CAR T cells comprise a CAR directed to the targeting        moiety; and    -   iii) administering to the patient a folate, a conjugate        comprising a folate wherein the conjugate comprising a folate        does not comprise a targeting moiety, or an agent that inhibits        activation of the CAR T cells.

109. The method of clause 108 wherein step iii comprises administering afolate.

110. The method of any one of clauses 108 or 109 wherein step iiicomprises administering folic acid or leucovorin.

111. The method of clause 108 wherein step iii comprises administeringthe conjugate comprising a folate.

112. The method of clause 111 wherein the conjugate comprising a folatecomprises a folate linked to one or more amino acids.

113. The method of clause 111 wherein the conjugate comprising a folatehas the formula

114. The method of any one of clauses 109 to 112 wherein the folate hasthe formula

wherein X¹ and Y¹ are each-independently selected from the groupconsisting of halo, R², OR², SR³, and NR⁴R⁵;

U, V, and W represent divalent moieties each independently selected fromthe group consisting of —(R^(6a))C═, —N═, —(R^(6a))C(R^(7a))—, and—N(R^(4a))—; Q is selected from the group consisting of C and CH; T isselected from the group consisting of S, O, N, and —C═C—;

X² and X³ are each independently selected from the group consisting ofoxygen, sulfur, —C(Z)—, —C(Z)O—, —OC(Z)—, —N(R^(4b))—, —C(Z)N(R^(4b))—,—N(R^(4b))C(Z)—, —OC(Z)N(R^(4b))—, —N(R^(4b))C(Z)O—,—N(R^(4b))C(Z)N(R^(5b))—, —S(O)—, —S(O)₂—, —N(R^(4a))S(O)₂—, —C(R^(6b))(R^(7b))—, —N(C≡CH)—, —N(CH₂C≡CH)—, C₁-C₁₂ alkylene, and C₁-C₁₂alkyeneoxy, where Z is oxygen or sulfur;

R¹ is selected-from the group consisting of hydrogen, halo, C₁-C₁₂alkyl, and C₁-C₁₂ alkoxy;

R², R³, R⁴, R^(4a), R^(4b), R⁵, R^(5b), R^(6b), and R^(7b) are eachindependently selected from the group consisting of hydrogen, halo,C₁-C₁₂ alkyl, C₁-C₁₂ alkoxy, C₁-C₁₂ alkanoyl, C₁-C₁₂ alkenyl, C₁-C₁₂alkynyl, (C₁-C₁₂ alkoxy)carbonyl, and (C₁-C₁₂ alkylamino)carbonyl;

R⁶ and R⁷ are each independently selected from the group consisting ofhydrogen, halo, C₁-C₁₂ alkyl, and C₁-C₁₂ alkoxy; or, R⁶ and R⁷ are takentogether to form a carbonyl group;

R^(6a) and R^(7a) are each independently selected from the groupconsisting of hydrogen, halo, C₁-C₁₂ alkyl, and C₁-C₁₂ alkoxy; or R^(6a)and R^(7a) are taken together to form a carbonyl group;

p, r, s, and t are each independently either 0 or 1; and

* represents an optional covalent bond to the rest of the conjugate, ifany additional chemical moieties are part of the folate.

115. The method of any one of clauses 108 to 114 wherein the targetingmoiety is selected from the group consisting of 2,4-dinitrophenol (DNP),2,4,6-trinitrophenol (TNP), biotin, digoxigenin, fluorescein,fluorescein isothiocyanate (FITC), NHS-fluorescein, pentafluorophenylester, tetrafluorophenyl ester, a knottin, a centyrin, and a DARPin.

116. The method of any one of clauses 108 to 115 wherein the targetingmoiety is FITC.

117. The method of any one of clauses 108 to 115 wherein the targetingmoiety is DNP.

118. The method of any one of clauses 108 to 115 wherein the targetingmoiety is TNP.

119. The method of any one of clauses 108 to 118 wherein the linkercomprises polyethylene glycol (PEG), polyproline, a hydrophilic aminoacid, a sugar, an unnatural peptidoglycan, a polyvinylpyrrolidone,pluronic F-127, or a combination thereof.

120. The method of any one of clauses 108 to 119 wherein the linkercomprises PEG.

121. The method of any one of clauses 108 to 120 wherein the compound,or the pharmaceutically acceptable salt thereof, has the formula

B-L-T,

wherein B represents the small molecule ligand, L represents the linker,and T represents the targeting moiety, and wherein L comprises astructure having the formula

wherein n is an integer from 0 to 200.

122. The method of clause 121 wherein n is an integer from 0 to 12.

123. The method of clause 121 wherein n is an integer from 0 to 150.

124. The method of clause 121 wherein n is an integer from 0 to 110.

125. The method of clause 121 wherein n is an integer from 0 to 20.

126. The method of clause 121 wherein n is an integer from 15 to 20.

127. The method of clause 121 wherein n is an integer from 15 to 110.

128. The method of any one of clauses 108 to 116 or 119 to 127 whereinthe linker comprises PEG and the targeting moiety is FITC, or apharmaceutically acceptable salt thereof.

129. The method of any one of clauses 108 to 128 wherein the compound,or the pharmaceutically acceptable salt thereof, is administered at adose of about 10 nmoles/kg to about 10000 nmoles/kg of body weight ofthe patient.

130. The method of any one of clauses 108 to 129 wherein the compound,or the pharmaceutically acceptable salt thereof, is administered at adose of about 10 nmoles/kg to about 5000 nmoles/kg of body weight of thepatient.

131. The method of any one of clauses 108 to 130 wherein the compound,or the pharmaceutically acceptable salt thereof, is administered at adose of about 10 nmoles/kg to about 1000 nmoles/kg of body weight of thepatient.

132. The method of any one of clauses 108 to 131 wherein the compound,or the pharmaceutically acceptable salt thereof, is administered at adose of about 10 nmoles/kg to about 600 nmoles/kg of body weight of thepatient.

133. The method of any one of clauses 108 to 132 wherein the compound,or the pharmaceutically acceptable salt thereof, is administered at adose of about 200 nmoles/kg to about 600 nmoles/kg of body weight of thepatient.

134. The method of any one of clauses 108 to 133 wherein the compound,or the pharmaceutically acceptable salt thereof, is administered at adose of about 250 nmoles/kg to about 600 nmoles/kg of body weight of thepatient.

135. The method of any one of clauses 108 to 134 wherein the cancer isselected from the group consisting of lung cancer, bone cancer,pancreatic cancer, skin cancer, cancer of the head, cancer of the neck,cutaneous melanoma, intraocular melanoma uterine cancer, ovarian cancer,endometrial cancer, rectal cancer, stomach cancer, colon cancer, breastcancer, triple negative breast cancer, carcinoma of the fallopian tubes,carcinoma of the endometrium, carcinoma of the cervix, carcinoma of thevagina, carcinoma of the vulva, Hodgkin's Disease, cancer of theesophagus, cancer of the small intestine, cancer of the endocrinesystem, cancer of the thyroid gland, cancer of the parathyroid gland,non-small cell lung cancer, cancer of the adrenal gland, sarcoma of softtissue, osteosarcoma, cancer of the urethra, prostate cancer, chronicleukemia, acute leukemia, acute myelocytic leukemia, lymphocyticlymphoma, myeloid leukemia, myelomonocytic leukemia, hairy cellleukemia, pleural mesothelioma, cancer of the bladder, Burkitt'slymphoma, cancer of the ureter, cancer of the kidney, renal cellcarcinoma, carcinoma of the renal pelvis, neoplasms of the centralnervous system (CNS), primary CNS lymphoma, spinal axis tumors, brainstem glioma, pituitary adenoma, and adenocarcinoma of thegastroesophageal junction.

41. 136. The method of any one of clauses 108 to 135 wherein the ligandportion of the small molecule ligand linked to a targeting moiety by alinker is a folate and the cancer is a folate receptor expressingcancer.

42. 137. The method of clause 136 wherein the cancer is an endometrialcancer.

43. 138. The method of clause 136 wherein the cancer is a non-small celllung cancer.

44. 139. The method of clause 136 wherein the cancer is an ovariancancer.

45. 140. The method of clause 136 wherein the cancer is a triplenegative breast cancer.

141. The method of any one of clauses 108 to 140 wherein the CAR has arecognition region and the recognition region is a single chain fragmentvariable (scFv) region of an antibody.

142. The method of any one of clauses 108 to 116 or 119 to 141 whereinthe CAR has a recognition region and the recognition region of the CARis a single chain fragment variable (scFv) region of an anti-FITCantibody.

143. The method of any one of clauses 108 to 142 wherein the CAR has aco-stimulation domain and the co-stimulation domain is selected from thegroup consisting of CD28, CD137 (4-1BB), CD134 (OX40), and CD278 (ICOS).

144. The method of any one of clauses 108 to 143 wherein the CAR has anactivation signaling domain and the activation signaling domain is a Tcell CD3ζ chain or an Fc receptor γ.

145. The method of any one of clauses 108 to 116 or 119 to 144 whereinthe CAR has a recognition region and the recognition region is a singlechain fragment variable (scFv) region of an anti-FITC antibody, whereinthe CAR has a co-stimulation domain and the co-stimulation domain isCD137 (4-1BB), and wherein the CAR has an activation signaling domainand the activation signaling domain is a T cell CD3ζ chain.

46. 146. The method of any one of clauses 108 to 145 wherein multipledoses of the compound, or the pharmaceutically acceptable salt thereof,and/or the CAR T cell composition are administered.

147. The method of any one of clauses 108 to 146 wherein the patient isimaged prior to administration of the compound, or the pharmaceuticallyacceptable salt thereof, or prior to administration of the CAR T cellcomposition.

47. 148. The method of any one of clauses 108 to 147 wherein thecompound, or the pharmaceutically acceptable salt thereof, is not anantibody, and does not comprise a fragment of an antibody.

48. 149. The method of any one of clauses 108 to 148 wherein thetargeting moiety does not comprise a peptide epitope.

49. 150. The method of any one of clauses 108 to 149 wherein cytokinerelease resulting in off-target toxicity in the patient does not occurand wherein CAR T cell toxicity to the cancer occurs.

50. 151. The method of any one of clauses 108 to 149 wherein off-targettissue toxicity does not occur in the patient and wherein CAR T celltoxicity to the cancer occurs.

51. 152. The method of any one of clauses 108 to 149 wherein the cancercomprises a tumor, wherein tumor size is reduced in the patient, andwherein off-target toxicity does not occur.

52. 153. The method of any one of clauses 108 to 152 wherein the CARTcells comprise a nucleic acid comprising SEQ ID NO:1.

53. 154. The method of any one of clauses 108 to 153 wherein the CAR Tcells comprise a polypeptide comprising SEQ ID NO:2.

54. 155. The method of clause 153 wherein the nucleic acid encodes achimeric antigen receptor.

55. 156. The method of any one of clauses 108 to 155 wherein the CARcomprises humanized amino acid sequences.

56. 157. The method of any one of clauses 108 to 155 wherein the CARconsists of humanized amino acid sequences.

57. 158. The method of any one of clauses 108 to 157 wherein the CAR Tcell composition comprises a mixture of the CAR T cells andnon-transformed T cells in a ratio selected from about 1:5 of the CAR Tcells to the non-transformed T cells, about 1:4 of the CAR T cells tothe non-transformed T cells, about 1:3 of the CART cells to thenon-transformed T cells, about 1:2 of the CAR T cells to thenon-transformed T cells, and about 1:1 of the CAR T cells to thenon-transformed T cells.

58. 159. The method of any one of clauses 108 to 158 wherein the CAR Tcell composition comprises a mixture of the CAR T cells andnon-transformed T cells in a ratio of from about 1:1 to about 1:5 of theCART cells to the non-transformed T cells.

59. 160. The method of any one of clauses 108 to 159 wherein the CAR Tcell composition comprises a mixture comprising about 10 million of theCAR T cells and about 40 million of the non-transformed T cells.

60. 161. The method of any one of clauses 108 to 160 wherein the agentthat inhibits activation of the CAR T cells is selected from the groupconsisting of a lymphocyte-specific protein tyrosine kinase inhibitor, aPI3 kinase inhibitor, an inhibitor of an IL-2 inducible T cell kinase, aJAK inhibitor, a BTK inhibitor, EC2319, and an agent that blocks CAR Tcell binding to the compound, or the pharmaceutically acceptable saltthereof, but does not bind to the cancer.

61. 162. The method of clause 161 wherein the agent that inhibitsactivation of the CAR T cells is administered and the agent is alymphocyte-specific protein tyrosine kinase inhibitor.

62. 163. The method of clause 162 wherein the lymphocyte-specificprotein tyrosine kinase inhibitor is Dasatinib.

63. 164. The method of clause 161 wherein the agent that inhibitsactivation of the CAR T cells is administered and the agent is a PI3kinase inhibitor.

64. 165. The method of clause 164 wherein the PI3 kinase inhibitor isGDC0980.

65. 166. The method of clause 161 wherein the agent that inhibitsactivation of the CAR T cells is administered and the agent is an IL-2inducible T cell kinase inhibitor.

66. 167. The method of clause 166 wherein the IL-2 inducible T cellkinase inhibitor is BMS-509744.

67. 168. The method of any one of clauses 1 to 160 wherein the CAR Tcell composition is administered by injection into the patient'sbloodstream, and wherein the CAR T cells in the patient's bloodstreamare at least 10 percent of the patient's total T cells in the patient'sbloodstream by about four weeks after injection of the CAR T cellcomposition.

68. 169. The method of any one of clauses 1 to 160 wherein the CAR Tcell composition is administered by injection into the patient'sbloodstream, and wherein the CAR T cells in the patient's bloodstreamare at least 12 percent of the patient's total T cells in the patient'sbloodstream by about four weeks after injection of the CAR T cellcomposition.

69. 170. The method of any one of clauses 1 to 160 wherein the CAR Tcell composition is administered by injection into the patient'sbloodstream, and wherein the CAR T cells in the patient's bloodstreamare at least 15 percent of the patient's total T cells in the patient'sbloodstream by about four weeks after injection of the CAR T cellcomposition.

70. 171. The method of any one of clauses 1 to 160 or 168 to 170 whereinthe CAR T cells administered to the patient in the CAR T cellcomposition comprise from about 1 million to about 15 million of the CART cells.

71. 172. The method of any one of clauses 1 to 160 or 168 to 171 whereinthe dose of the CAR T cells administered to the patient in the CAR Tcell composition is selected from the group consisting of about 1million, about 2 million, about 3 million, about 4 million, about 5million, about 6 million, about 7 million, about 8 million, about 9million, about 10 million, about 11 million, about 12 million, about12.5 million, about 13 million, about 14 million, and about 15 millionof the CART cells.

72. 173. The method of any one of clauses 1 to 160 or 168 to 170 whereinthe CAR T cells administered to the patient in the CAR T cellcomposition comprise at least about 2 million of the CAR T cells.

73. 174. The method of any one of clauses 1 to 160 or 168 to 170 whereinthe CAR T cells administered to the patient in the CAR T cellcomposition comprise at least about 5 million of the CAR T cells.

74. 175. The method of any one of clauses 1 to 160 or 168 to 170 whereinthe CAR T cells administered to the patient in the CAR T cellcomposition comprise at least about 10 million of the CAR T cells.

75. 176. The method of any one of clauses 1 to 175 wherein the CAR Tcells comprise a nucleic acid comprising SEQ ID NO:3.

76. 177. The method of any one of clauses 1 to 176 wherein the CAR Tcells comprise a vector comprising SEQ ID NO:1.

77. 178. The method of any one of clauses 1 to 177 wherein the CAR Tcells comprise a vector comprising SEQ ID NO:3.

78. 179. The method of clause 176 wherein the nucleic acid encodes achimeric antigen receptor.

79. 180. The method of any one of clauses 108 to 160 wherein the agentthat inhibits activation of the CAR T cells is administered and is anagent that blocks CAR T cell binding to the compound, or thepharmaceutically acceptable salt thereof, but does not bind to thecancer.

80. 181. The method of clause 180 wherein the agent is fluoresceinamine,FITC, or sodium fluorescein.

81. 182. The method of clause 180 wherein the agent is FITC.

183. A method of treatment of a cancer, the method comprising

-   -   i) administering to a patient a compound, or a pharmaceutically        acceptable salt thereof, wherein the compound comprises a small        molecule ligand linked to a targeting moiety by a linker, and        wherein the compound, or the pharmaceutically acceptable salt        thereof, is at a dose of about 10 nmoles/kg of body weight of        the patient to about 2500 nmoles/kg of body weight of the        patient; and    -   ii) administering to the patient a CAR T cell composition        comprising CAR T cells wherein the CAR T cells comprise a CAR        directed to the targeting moiety, and wherein the CART cells are        at a dose of about 1 million of the CART cells to about 15        million of the CAR T cells.

184. The method of clause 183 wherein the ligand is selected from thegroup consisting of a folate, DUPA, an NK-1R ligand, a CAIX ligand, aligand of gamma glutamyl transpeptidase, an NKG2D ligand, and a CCK2Rligand.

185. The method of any one of clauses 183 or 184 wherein the ligand is afolate.

186. The method of any one of clauses 183 to 185 wherein the targetingmoiety is selected from the group consisting of 2,4-dinitrophenol (DNP),2,4,6-trinitrophenol (TNP), biotin, digoxigenin, fluorescein,fluorescein isothiocyanate (FITC), NHS-fluorescein, pentafluorophenylester, tetrafluorophenyl ester, a knottin, a centyrin, and a DARPin.

187. The method of any one of clauses 183 to 186 wherein the targetingmoiety is FITC.

188. The method of any one of clauses 183 to 187 wherein the linkercomprises polyethylene glycol (PEG), polyproline, a hydrophilic aminoacid, a sugar, an unnatural peptidoglycan, a polyvinylpyrrolidone,pluronic F-127, or a combination thereof.

189. The method of any one of clauses 183 to 188 wherein the linkercomprises PEG.

190. The method of any one of clauses 183 to 189 wherein the compound,or the pharmaceutically acceptable salt thereof, has the formula

B-L-T,

wherein B represents the small molecule ligand, L represents the linker,and T represents the targeting moiety, and wherein L comprises astructure having the formula

wherein n is an integer from 0 to 200.

191. The method of any one of clauses 183 to 190 wherein the linkercomprises PEG and the targeting moiety is FITC, or a pharmaceuticallyacceptable salt thereof.

192. The method of any one of clauses 183 to 191 wherein the compound,or the pharmaceutically acceptable salt thereof, is administered at adose of about 10 nmoles/kg to about 100 nmoles/kg of body weight of thepatient.

193. The method of any one of clauses 183 to 191 wherein the compound,or the pharmaceutically acceptable salt thereof, is administered at adose of about 10 nmoles/kg to about 50 nmoles/kg of body weight of thepatient.

194. The method of any one of clauses 183 to 191 wherein the compound,or the pharmaceutically acceptable salt thereof, is administered at adose of about 10 nmoles/kg to about 20 nmoles/kg of body weight of thepatient.

195. The method of any one of clauses 183 to 191 wherein the compound,or the pharmaceutically acceptable salt thereof, is administered at adose of about 10 nmoles/kg to about 600 nmoles/kg of body weight of thepatient.

196. The method of any one of clauses 183 to 191 wherein the compound,or the pharmaceutically acceptable salt thereof, is administered at adose of about 200 nmoles/kg to about 600 nmoles/kg of body weight of thepatient.

197. The method of any one of clauses 183 to 191 wherein the compound,or the pharmaceutically acceptable salt thereof, is administered at adose of about 400 nmoles/kg to about 600 nmoles/kg of body weight of thepatient.

198. The method of any one of clauses 183 to 197 wherein the CART cellsare at a dose of about 1 million of the CART cells to about 12.5 millionof the CART cells.

199. The method of any one of clauses 183 to 197 wherein the CART cellsare at a dose of about 1 million of the CART cells to about 7 million ofthe CART cells.

200. The method of any one of clauses 183 to 197 wherein the CART cellsare at a dose of about 1 million of the CART cells to about 5 million ofthe CART cells.

201. The method of any one of clauses 183 to 197 wherein the CART cellsare at a dose of about 2 million of the CAR T cells to about 5 millionof the CAR T cells.

202. The method of any one of clauses 183 to 201 wherein the cancer isselected from the group consisting of lung cancer, bone cancer,pancreatic cancer, skin cancer, cancer of the head, cancer of the neck,cutaneous melanoma, intraocular melanoma uterine cancer, ovarian cancer,endometrial cancer, rectal cancer, stomach cancer, colon cancer, breastcancer, triple negative breast cancer, carcinoma of the fallopian tubes,carcinoma of the endometrium, carcinoma of the cervix, carcinoma of thevagina, carcinoma of the vulva, Hodgkin's Disease, cancer of theesophagus, cancer of the small intestine, cancer of the endocrinesystem, cancer of the thyroid gland, cancer of the parathyroid gland,non-small cell lung cancer, cancer of the adrenal gland, sarcoma of softtissue, osteosarcoma, cancer of the urethra, prostate cancer, chronicleukemia, acute leukemia, acute myelocytic leukemia, lymphocyticlymphoma, myeloid leukemia, myelomonocytic leukemia, hairy cellleukemia, pleural mesothelioma, cancer of the bladder, Burkitt'slymphoma, cancer of the ureter, cancer of the kidney, renal cellcarcinoma, carcinoma of the renal pelvis, neoplasms of the centralnervous system (CNS), primary CNS lymphoma, spinal axis tumors, brainstem glioma, pituitary adenoma, and adenocarcinoma of thegastroesophageal junction.

82. 203. The method of any one of clauses 183 to 202 wherein the canceris a folate receptor expressing cancer.

204. The method of any one of clauses 183 to 203 wherein the CAR has arecognition region and the recognition region is a single chain fragmentvariable (scFv) region of an anti-FITC antibody, wherein the CAR has aco-stimulation domain and the co-stimulation domain is CD137 (4-1BB),and wherein the CAR has an activation signaling domain and theactivation signaling domain is a T cell CD3ζ chain.

83. 205. The method of any one of clauses 183 to 204 wherein thecompound, or the pharmaceutically acceptable salt thereof, is not anantibody, and does not comprise a fragment of an antibody.

84. 206. The method of any one of clauses 183 to 205 wherein thetargeting moiety does not comprise a peptide epitope.

207. The method of any one of clauses 183 to 206 wherein cytokinerelease resulting in off-target toxicity in the patient does not occurand wherein CAR T cell toxicity to the cancer occurs.

85. 208. The method of any one of clauses 183 to 206 wherein off-targettissue toxicity does not occur in the patient and wherein CAR T celltoxicity to the cancer occurs.

86. 209. The method of any one of clauses 183 to 206 wherein the cancercomprises a tumor, wherein tumor size is reduced in the patient, andwherein off-target toxicity does not occur.

87. 210. The method of any one of clauses 183 to 209 wherein the CARTcells comprise a nucleic acid comprising SEQ ID NO:1.

88. 211. The method of any one of clauses 183 to 209 wherein the CAR Tcells comprise a polypeptide comprising SEQ ID NO:2.

89. 212. The method of any one of clauses 183 to 211 wherein the CARcomprises humanized amino acid sequences.

90. 213. The method of any one of clauses 183 to 212 wherein the CARconsists of humanized amino acid sequences.

91. 214. The method of any one of clauses 183 to 213 wherein the CAR Tcell composition further comprises non-transformed T cells.

215. A method of treatment of a cancer, the method comprising

-   -   i) administering continuously to a patient a compound, or a        pharmaceutically acceptable salt thereof, wherein the compound        comprises a small molecule ligand linked to a targeting moiety        by a linker;    -   ii) administering to the patient a CAR T cell composition        comprising CAR T cells wherein the CAR T cells comprise a CAR        directed to the targeting moiety; and    -   iii) ending the continuous administration of the compound, or        the pharmaceutically acceptable salt thereof, to inhibit or        prevent cytokine release syndrome in the patient.

216. The method of clause 215 wherein the ligand is selected from thegroup consisting of a folate, DUPA, an NK-1R ligand, a CAIX ligand, aligand of gamma glutamyl transpeptidase, an NKG2D ligand, and a CCK2Rligand.

217. The method of any one of clauses 215 or 216 wherein the ligand is afolate.

218. The method of any one of clauses 215 to 217 wherein the targetingmoiety is selected from the group consisting of 2,4-dinitrophenol (DNP),2,4,6-trinitrophenol (TNP), biotin, digoxigenin, fluorescein,fluorescein isothiocyanate (FITC), NHS-fluorescein, pentafluorophenylester, tetrafluorophenyl ester, a knottin, a centyrin, and a DARPin.

219. The method of any one of clauses 215 to 218 wherein the targetingmoiety is FITC.

220. The method of any one of clauses 215 to 219 wherein the linkercomprises polyethylene glycol (PEG), polyproline, a hydrophilic aminoacid, a sugar, an unnatural peptidoglycan, a polyvinylpyrrolidone,pluronic F-127, or a combination thereof.

221. The method of any one of clauses 215 to 220 wherein the linkercomprises PEG.

222. The method of any one of clauses 215 to 221 wherein the compound,or the pharmaceutically acceptable salt thereof, has the formula

B-L-T,

wherein B represents the small molecule ligand, L represents the linker,and T represents the targeting moiety, and wherein L comprises astructure having the formula

wherein n is an integer from 0 to 200.

223. The method of any one of clauses 215 to 222 wherein the linkercomprises PEG and the targeting moiety is FITC, or a pharmaceuticallyacceptable salt thereof.

224. The method of any one of clauses 215 to 223 wherein the compound,or the pharmaceutically acceptable salt thereof, is administeredcontinuously for at least one hour to the patient.

225. The method of any one of clauses 215 to 223 wherein the compound,or the pharmaceutically acceptable salt thereof, is administeredcontinuously for at least four hours to the patient.

226. The method of any one of clauses 215 to 223 wherein the compound,or the pharmaceutically acceptable salt thereof, is administeredcontinuously for at least six hours to the patient.

227. The method of any one of clauses 215 to 223 wherein the continuousadministration of the compound, or the pharmaceutically acceptable saltthereof, is a regimen of administration every other day.

228. The method of any one of clauses 215 to 223 wherein the continuousadministration of the compound, or the pharmaceutically acceptable saltthereof, is a regimen of administration three times weekly.

229. The method of any one of clauses 215 to 223 wherein the continuousadministration of the compound, or the pharmaceutically acceptable saltthereof, is administration until an unacceptable loss of body weight ofthe patient, a fever, a drop in blood pressure, or pulmonary edemaoccurs.

230. The method of any one of clauses 215 to 229 wherein the compound,or the pharmaceutically acceptable salt thereof, is administered at adose of about 200 nmoles/kg to about 600 nmoles/kg of body weight of thepatient.

231. The method of any one of clauses 215 to 229 wherein the compound,or the pharmaceutically acceptable salt thereof, is administered at adose of about 400 nmoles/kg to about 600 nmoles/kg of body weight of thepatient.

232. The method of any one of clauses 215 to 231 wherein about 2 millionto about 5 million of the CAR T cells are administered.

233. The method of any one of clauses 215 to 232 wherein theadministration is by intravenous administration.

234. The method of any one of clauses 215 to 233 wherein the cancer isselected from the group consisting of lung cancer, bone cancer,pancreatic cancer, skin cancer, cancer of the head, cancer of the neck,cutaneous melanoma, intraocular melanoma uterine cancer, ovarian cancer,endometrial cancer, rectal cancer, stomach cancer, colon cancer, breastcancer, triple negative breast cancer, carcinoma of the fallopian tubes,carcinoma of the endometrium, carcinoma of the cervix, carcinoma of thevagina, carcinoma of the vulva, Hodgkin's Disease, cancer of theesophagus, cancer of the small intestine, cancer of the endocrinesystem, cancer of the thyroid gland, cancer of the parathyroid gland,non-small cell lung cancer, cancer of the adrenal gland, sarcoma of softtissue, osteosarcoma, cancer of the urethra, prostate cancer, chronicleukemia, acute leukemia, acute myelocytic leukemia, lymphocyticlymphoma, myeloid leukemia, myelomonocytic leukemia, hairy cellleukemia, pleural mesothelioma, cancer of the bladder, Burkitt'slymphoma, cancer of the ureter, cancer of the kidney, renal cellcarcinoma, carcinoma of the renal pelvis, neoplasms of the centralnervous system (CNS), primary CNS lymphoma, spinal axis tumors, brainstem glioma, pituitary adenoma, and adenocarcinoma of thegastroesophageal junction.

92. 235. The method of any one of clauses 215 to 234 wherein the canceris a folate receptor expressing cancer.

236. The method of any one of clauses 215 to 235 wherein the CAR has arecognition region and the recognition region is a single chain fragmentvariable (scFv) region of an anti-FITC antibody, wherein the CAR has aco-stimulation domain and the co-stimulation domain is CD137 (4-1BB),and wherein the CAR has an activation signaling domain and theactivation signaling domain is a T cell CD3ζ chain.

93. 237. The method of any one of clauses 215 to 236 wherein thecompound, or the pharmaceutically acceptable salt thereof, is not anantibody, and does not comprise a fragment of an antibody.

94. 238. The method of any one of clauses 215 to 237 wherein thetargeting moiety does not comprise a peptide epitope.

239. The method of any one of clauses 215 to 238 wherein cytokinerelease resulting in off-target toxicity in the patient does not occurand wherein CAR T cell toxicity to the cancer occurs.

95. 240. The method of any one of clauses 215 to 238 wherein off-targettissue toxicity does not occur in the patient and wherein CAR T celltoxicity to the cancer occurs.

96. 241. The method of any one of clauses 215 to 238 wherein the cancercomprises a tumor, wherein tumor size is reduced in the patient, andwherein off-target toxicity does not occur.

97. 242. The method of any one of clauses 215 to 241 wherein the CARTcells comprise a nucleic acid comprising SEQ ID NO:1.

98. 243. The method of any one of clauses 215 to 242 wherein the CAR Tcells comprise a polypeptide comprising SEQ ID NO:2.

99. 244. The method of any one of clauses 215 to 243 wherein the CARcomprises humanized amino acid sequences.

100. 245. The method of any one of clauses 215 to 243 wherein the CARconsists of humanized amino acid sequences.

101. 246. The method of any one of clauses 215 to 245 wherein the CAR Tcell composition further comprises non-transformed T cells.

102. 247. The method of any one of clauses 215 to 246 wherein the CAR Tcell composition further comprises non-transformed T cells in a ratioselected from about 1:5 of the CAR T cells to the non-transformed Tcells, about 1:4 of the CAR T cells to the non-transformed T cells,about 1:3 of the CAR T cells to the non-transformed T cells, about 1:2of the CAR T cells to the non-transformed T cells, and about 1:1 of theCAR T cells to the non-transformed T cells.

103. 248. The method of any one of clauses 215 to 247 wherein the CAR Tcell composition further comprises non-transformed T cells in a ratio offrom about 1:1 to about 1:5 of the CAR T cells to the non-transformed Tcells.

104. 249. The method of any one of clauses 215 to 248 wherein the CAR Tcell composition further comprises non-transformed T cells in a mixtureof about 10 million of the CAR T cells and about 40 millionnon-transformed T cells.

105. 250. The method of any one of clauses 215 to 249 wherein the canceris a non-small cell lung cancer.

106. 251. The method of any one of clauses 215 to 249 wherein the canceris an ovarian cancer.

252. A method of treatment of a cancer, the method comprising

-   -   i) administering to a patient a compound, or a pharmaceutically        acceptable salt thereof, wherein the compound comprises a small        molecule ligand linked to a targeting moiety by a linker and        wherein the compound, or the pharmaceutically acceptable salt        thereof, is administered once weekly to the patient; and    -   ii) administering to the patient a CAR T cell composition        comprising CAR T cells wherein the CAR T cells comprise a CAR        directed to the targeting moiety.

253. The method of clause 252 wherein the ligand is selected from thegroup consisting of a folate, DUPA, an NK-1R ligand, a CAIX ligand, aligand of gamma glutamyl transpeptidase, an NKG2D ligand, and a CCK2Rligand.

254. The method of any one of clauses 252 or 253 wherein the ligand is afolate.

255. The method of any one of clauses 252 to 254 wherein the targetingmoiety is selected from the group consisting of 2,4-dinitrophenol (DNP),2,4,6-trinitrophenol (TNP), biotin, digoxigenin, fluorescein,fluorescein isothiocyanate (FITC), NHS-fluorescein, pentafluorophenylester, tetrafluorophenyl ester, a knottin, a centyrin, and a DARPin.

256. The method of any one of clauses 252 to 255 wherein the targetingmoiety is FITC.

257. The method of any one of clauses 252 to 256 wherein the linkercomprises polyethylene glycol (PEG), polyproline, a hydrophilic aminoacid, a sugar, an unnatural peptidoglycan, a polyvinylpyrrolidone,pluronic F-127, or a combination thereof.

258. The method of any one of clauses 252 to 257 wherein the linkercomprises PEG.

259. The method of any one of clauses 252 to 258 wherein the compound,or the pharmaceutically acceptable salt thereof, has the formula

B-L-T,

wherein B represents the small molecule ligand, L represents the linker,and T represents the targeting moiety, and wherein L comprises astructure having the formula

wherein n is an integer from 0 to 200.

260. The method of any one of clauses 252 to 259 wherein the linkercomprises PEG and the targeting moiety is FITC, or a pharmaceuticallyacceptable salt thereof.

261. The method of any one of clauses 252 to 260 wherein the compound,or the pharmaceutically acceptable salt thereof, is administered at adose of about 10 nmoles/kg to about 100 nmoles/kg of body weight of thepatient.

262. The method of any one of clauses 252 to 261 wherein the compound,or the pharmaceutically acceptable salt thereof, is administered at adose of about 10 nmoles/kg to about 50 nmoles/kg of body weight of thepatient.

263. The method of any one of clauses 252 to 262 wherein the compound,or the pharmaceutically acceptable salt thereof, is administered at adose of about 10 nmoles/kg to about 20 nmoles/kg of body weight of thepatient.

264. The method of any one of clauses 252 to 263 wherein the compound,or the pharmaceutically acceptable salt thereof, is administered at adose of about 10 nmoles/kg to about 600 nmoles/kg of body weight of thepatient.

265. The method of any one of clauses 252 to 264 wherein the compound,or the pharmaceutically acceptable salt thereof, is administered at adose of about 200 nmoles/kg to about 600 nmoles/kg of body weight of thepatient.

266. The method of any one of clauses 252 to 265 wherein the compound,or the pharmaceutically acceptable salt thereof, is administered at adose of about 400 nmoles/kg to about 600 nmoles/kg of body weight of thepatient.

267. The method of any one of clauses 252 to 266 wherein the CAR T cellsare at a dose of about 1 million of the CART cells to about 15 millionof the CART cells.

268. The method of any one of clauses 252 to 267 wherein the CART cellsare at a dose of about 1 million of the CART cells to about 7 million ofthe CART cells.

269. The method of any one of clauses 252 to 268 wherein the CAR T cellsare at a dose of about 1 million of the CART cells to about 5 million ofthe CART cells.

270. The method of any one of clauses 252 to 269 wherein the CAR T cellsare at a dose of about 2 million of the CAR T cells to about 5 millionof the CAR T cells.

271. The method of any one of clauses 252 to 270 wherein the cancer isselected from the group consisting of lung cancer, bone cancer,pancreatic cancer, skin cancer, cancer of the head, cancer of the neck,cutaneous melanoma, intraocular melanoma uterine cancer, ovarian cancer,endometrial cancer, rectal cancer, stomach cancer, colon cancer, breastcancer, triple negative breast cancer, carcinoma of the fallopian tubes,carcinoma of the endometrium, carcinoma of the cervix, carcinoma of thevagina, carcinoma of the vulva, Hodgkin's Disease, cancer of theesophagus, cancer of the small intestine, cancer of the endocrinesystem, cancer of the thyroid gland, cancer of the parathyroid gland,non-small cell lung cancer, cancer of the adrenal gland, sarcoma of softtissue, osteosarcoma, cancer of the urethra, prostate cancer, chronicleukemia, acute leukemia, acute myelocytic leukemia, lymphocyticlymphoma, myeloid leukemia, myelomonocytic leukemia, hairy cellleukemia, pleural mesothelioma, cancer of the bladder, Burkitt'slymphoma, cancer of the ureter, cancer of the kidney, renal cellcarcinoma, carcinoma of the renal pelvis, neoplasms of the centralnervous system (CNS), primary CNS lymphoma, spinal axis tumors, brainstem glioma, pituitary adenoma, and adenocarcinoma of thegastroesophageal junction.

107. 272. The method of any one of clauses 252 to 271 wherein the canceris a folate receptor expressing cancer.

273. The method of any one of clauses 252 to 272 wherein the CAR has arecognition region and the recognition region is a single chain fragmentvariable (scFv) region of an anti-FITC antibody, wherein the CAR has aco-stimulation domain and the co-stimulation domain is CD137 (4-1BB),and wherein the CAR has an activation signaling domain and theactivation signaling domain is a T cell CD3ζ chain.

108. 274. The method of any one of clauses 252 to 273 wherein thecompound, or the pharmaceutically acceptable salt thereof, is not anantibody, and does not comprise a fragment of an antibody.

109. 275. The method of any one of clauses 252 to 274 wherein thetargeting moiety does not comprise a peptide epitope.

276. The method of any one of clauses 252 to 275 wherein cytokinerelease resulting in off-target toxicity in the patient does not occurand wherein CAR T cell toxicity to the cancer occurs.

110. 277. The method of any one of clauses 252 to 275 wherein off-targettissue toxicity does not occur in the patient and wherein CAR T celltoxicity to the cancer occurs.

111. 278. The method of any one of clauses 252 to 275 wherein the cancercomprises a tumor, wherein tumor size is reduced in the patient, andwherein off-target toxicity does not occur.

112. 279. The method of any one of clauses 252 to 278 wherein the CARTcells comprise a nucleic acid comprising SEQ ID NO:1.

113. 280. The method of any one of clauses 252 to 278 wherein the CAR Tcells comprise a polypeptide comprising SEQ ID NO:2.

114. 281. The method of any one of clauses 252 to 280 wherein the CARcomprises humanized amino acid sequences.

115. 282. The method of any one of clauses 252 to 280 wherein the CARconsists of humanized amino acid sequences.

116. 283. The method of any one of clauses 252 to 282 wherein the CAR Tcell composition further comprises non-transformed T cells.

284. A method of treatment of a cancer, the method comprising

-   -   i) administering to a patient a compound, or a pharmaceutically        acceptable salt thereof, wherein the compound comprises a small        molecule ligand linked to a targeting moiety by a linker,        wherein at least a first dose and a second dose of the compound,        or the pharmaceutically acceptable salt thereof, are        administered to the patient, wherein the first dose and the        second dose are different, wherein the second dose of the        compound, or the pharmaceutically acceptable salt thereof, is        about 2-fold to about 15000-fold greater in amount than the        first dose of the compound, or the pharmaceutically acceptable        salt thereof; and    -   ii) administering to the patient a CAR T cell composition        comprising CAR T cells wherein the CAR T cells comprise a CAR        directed to the targeting moiety.

285. The method of clause 284 wherein at least a first dose, a seconddose, and a third dose of the compound, or the pharmaceuticallyacceptable salt thereof, are administered to the patient, wherein thefirst dose, the second dose, and the third dose are different, whereinthe second dose of the compound, or the pharmaceutically acceptable saltthereof, is about 2-fold to about 750-fold greater in amount than thefirst dose of the compound, or the pharmaceutically acceptable saltthereof, and wherein the third dose of the compound, or thepharmaceutically acceptable salt thereof, is about 800-fold to about10000-fold greater in amount than the first dose of the compound, or thepharmaceutically acceptable salt thereof.

286. The method of clause 285 wherein at least a first dose, a seconddose, a third dose, and a fourth dose of the compound, or thepharmaceutically acceptable salt thereof, are administered to thepatient, wherein the first dose, the second dose, the third dose, andthe fourth dose are different, wherein the second dose of the compound,or the pharmaceutically acceptable salt thereof, is about 2-fold toabout 750-fold greater in amount than the first dose of the compound, orthe pharmaceutically acceptable salt thereof, wherein the third dose ofthe compound, or the pharmaceutically acceptable salt thereof, is about800-fold to about 7500-fold greater in amount than the first dose of thecompound, or the pharmaceutically acceptable salt thereof, and whereinthe fourth dose of the compound, or the pharmaceutically acceptable saltthereof, is about 8000 to about 15000-fold greater in amount than thefirst dose of the compound, or the pharmaceutically acceptable saltthereof.

287. The method of clause 286 wherein the second dose of the compound,or the pharmaceutically acceptable salt thereof, is about 100-foldgreater in amount than the first dose of the compound, or thepharmaceutically acceptable salt thereof, wherein the third dose of thecompound, or the pharmaceutically acceptable salt thereof, is about1000-fold greater in amount than the first dose of the compound, or thepharmaceutically acceptable salt thereof, and wherein the fourth dose ofthe compound, or the pharmaceutically acceptable salt thereof, is about10000-fold greater in amount than the first dose of the compound, or thepharmaceutically acceptable salt thereof.

288. The method of any one of clauses 284 to 287 wherein the ligand isselected from the group consisting of a folate, DUPA, an NK-1R ligand, aCAIX ligand, a ligand of gamma glutamyl transpeptidase, an NKG2D ligand,and a CCK2R ligand.

289. The method of any one of clauses 284 to 288 wherein the ligand is afolate.

290. The method of any one of clauses 284 to 289 wherein the targetingmoiety is selected from the group consisting of 2,4-dinitrophenol (DNP),2,4,6-trinitrophenol (TNP), biotin, digoxigenin, fluorescein,fluorescein isothiocyanate (FITC), NHS-fluorescein, pentafluorophenylester, tetrafluorophenyl ester, a knottin, a centyrin, and a DARPin.

291. The method of any one of clauses 284 to 290 wherein the targetingmoiety is FITC.

292. The method of any one of clauses 284 to 291 wherein the linkercomprises polyethylene glycol (PEG), polyproline, a hydrophilic aminoacid, a sugar, an unnatural peptidoglycan, a polyvinylpyrrolidone,pluronic F-127, or a combination thereof.

293. The method of any one of clauses 284 to 292 wherein the linkercomprises PEG.

294. The method of any one of clauses 284 to 293 wherein the compound,or the pharmaceutically acceptable salt thereof, has the formula

B-L-T,

wherein B represents the small molecule ligand, L represents the linker,and T represents the targeting moiety, and wherein L comprises astructure having the formula

wherein n is an integer from 0 to 200.

295. The method of any one of clauses 284 to 294 wherein the linkercomprises PEG and the targeting moiety is FITC, or a pharmaceuticallyacceptable salt thereof.

296. The method of any one of clauses 284 to 295 wherein the compound,or the pharmaceutically acceptable salt thereof, is administered at adose of about 10 nmoles/kg to about 100 nmoles/kg of body weight of thepatient.

297. The method of any one of clauses 284 to 296 wherein the compound,or the pharmaceutically acceptable salt thereof, is administered at adose of about 10 nmoles/kg to about 50 nmoles/kg of body weight of thepatient.

298. The method of any one of clauses 284 to 297 wherein the compound,or the pharmaceutically acceptable salt thereof, is administered at adose of about 10 nmoles/kg to about 20 nmoles/kg of body weight of thepatient.

299. The method of any one of clauses 284 to 298 wherein the compound,or the pharmaceutically acceptable salt thereof, is administered at adose of about 10 nmoles/kg to about 600 nmoles/kg of body weight of thepatient.

300. The method of any one of clauses 284 to 299 wherein the compound,or the pharmaceutically acceptable salt thereof, is administered at adose of about 200 nmoles/kg to about 600 nmoles/kg of body weight of thepatient.

301. The method of any one of clauses 284 to 300 wherein the compound,or the pharmaceutically acceptable salt thereof, is administered at adose of about 400 nmoles/kg to about 600 nmoles/kg of body weight of thepatient.

302. The method of any one of clauses 284 to 301 wherein the CART cellsare at a dose of about 1 million of the CART cells to about 15 millionof the CART cells.

303. The method of any one of clauses 284 to 302 wherein the CART cellsare at a dose of about 1 million of the CART cells to about 7 million ofthe CART cells.

304. The method of any one of clauses 284 to 303 wherein the CART cellsare at a dose of about 1 million of the CART cells to about 5 million ofthe CART cells.

305. The method of any one of clauses 284 to 304 wherein the CART cellsare at a dose of about 2 million of the CAR T cells to about 5 millionof the CAR T cells.

306. The method of any one of clauses 284 to 305 wherein the cancer isselected from the group consisting of lung cancer, bone cancer,pancreatic cancer, skin cancer, cancer of the head, cancer of the neck,cutaneous melanoma, intraocular melanoma uterine cancer, ovarian cancer,endometrial cancer, rectal cancer, stomach cancer, colon cancer, breastcancer, triple negative breast cancer, carcinoma of the fallopian tubes,carcinoma of the endometrium, carcinoma of the cervix, carcinoma of thevagina, carcinoma of the vulva, Hodgkin's Disease, cancer of theesophagus, cancer of the small intestine, cancer of the endocrinesystem, cancer of the thyroid gland, cancer of the parathyroid gland,non-small cell lung cancer, cancer of the adrenal gland, sarcoma of softtissue, osteosarcoma, cancer of the urethra, prostate cancer, chronicleukemia, acute leukemia, acute myelocytic leukemia, lymphocyticlymphoma, myeloid leukemia, myelomonocytic leukemia, hairy cellleukemia, pleural mesothelioma, cancer of the bladder, Burkitt'slymphoma, cancer of the ureter, cancer of the kidney, renal cellcarcinoma, carcinoma of the renal pelvis, neoplasms of the centralnervous system (CNS), primary CNS lymphoma, spinal axis tumors, brainstem glioma, pituitary adenoma, and adenocarcinoma of thegastroesophageal junction.

117. 307. The method of any one of clauses 284 to 306 wherein the canceris a folate receptor expressing cancer.

308. The method of any one of clauses 284 to 307 wherein the CAR has arecognition region and the recognition region is a single chain fragmentvariable (scFv) region of an anti-FITC antibody, wherein the CAR has aco-stimulation domain and the co-stimulation domain is CD137 (4-1BB),and wherein the CAR has an activation signaling domain and theactivation signaling domain is a T cell CD3ζ chain.

118. 309. The method of any one of clauses 284 to 308 wherein thecompound, or the pharmaceutically acceptable salt thereof, is not anantibody, and does not comprise a fragment of an antibody.

119. 310. The method of any one of clauses 284 to 309 wherein thetargeting moiety does not comprise a peptide epitope.

311. The method of any one of clauses 284 to 310 wherein cytokinerelease resulting in off-target toxicity in the patient does not occurand wherein CAR T cell toxicity to the cancer occurs.

120. 312. The method of any one of clauses 284 to 310 wherein off-targettissue toxicity does not occur in the patient and wherein CAR T celltoxicity to the cancer occurs.

121. 313. The method of any one of clauses 284 to 310 wherein the cancercomprises a tumor, wherein tumor size is reduced in the patient, andwherein off-target toxicity does not occur.

122. 314. The method of any one of clauses 284 to 313 wherein the CARTcells comprise a nucleic acid comprising SEQ ID NO:1.

123. 315. The method of any one of clauses 284 to 313 wherein the CAR Tcells comprise a polypeptide comprising SEQ ID NO:2.

124. 316. The method of any one of clauses 284 to 315 wherein the CARcomprises humanized amino acid sequences.

125. 317. The method of any one of clauses 284 to 315 wherein the CARconsists of humanized amino acid sequences.

126. 318. The method of any one of clauses 284 to 317 wherein the CAR Tcell composition further comprises non-transformed T cells.

319. The method of any one of clauses 1 to 214 or 252 to 318 wherein thecompound, or the pharmaceutically acceptable salt thereof, isadministered continuously to the patient and the method furthercomprises ending the continuous administration of the compound, or thepharmaceutically acceptable salt thereof, to inhibit or prevent cytokinerelease syndrome in the patient.

320. The method of any one of clauses 1 to 107 or 183 to 318 furthercomprising administering to the patient a folate, a conjugate comprisinga folate wherein the conjugate comprising a folate does not comprise atargeting moiety, or an agent that inhibits activation of the CAR Tcells.

321. The method of any one of clauses 1 to 182 or 215 to 318 wherein thecompound, or the pharmaceutically acceptable salt thereof, is at a doseof about 10 nmoles/kg of body weight of the patient to about 2500nmoles/kg of body weight of the patient and the CART cells are at a doseof about 1 million of the CART cells to about 15 million of the CARTcells.

322. The method of any one of clauses 1 to 251 or 284 to 318 wherein thecompound, or the pharmaceutically acceptable salt thereof, isadministered once weekly to the patient.

323. The method of any one of clauses 1 to 283 wherein at least a firstdose and a second dose of the compound, or the pharmaceuticallyacceptable salt thereof, are administered to the patient, wherein thefirst dose and the second dose are different, wherein the second dose ofthe compound, or the pharmaceutically acceptable salt thereof, is about2-fold to about 15000-fold greater in amount than the first dose of thecompound, or the pharmaceutically acceptable salt thereof.

324. The method of any one of clauses 56 to 318 wherein the CAR T cellcomposition is administered in at least two doses.

325. A method of treatment of a cancer, the method comprising

-   -   i) administering to a patient a first dose of a compound, or a        pharmaceutically acceptable salt thereof, wherein the compound        comprises a small molecule ligand linked to a targeting moiety        by a linker;    -   ii) administering to the patient at least a second dose of the        compound, or a pharmaceutically acceptable salt thereof, wherein        the second dose of the compound, or the pharmaceutically        acceptable salt thereof, is at least about 50 percent lower in        amount than the first dose of the compound, or the        pharmaceutically acceptable salt thereof; and    -   iii) administering to the patient a dose of a CAR T cell        composition comprising CAR T cells wherein the CAR T cells        comprise a CAR directed to the targeting moiety.

326. The method of clause 325 wherein the second dose of the compound,or the pharmaceutically acceptable salt thereof, is at least about 60percent lower in amount than the first dose of the compound, or thepharmaceutically acceptable salt thereof.

327. The method of clause 325 wherein the second dose of the compound,or the pharmaceutically acceptable salt thereof, is at least about 70percent lower in amount than the first dose of the compound, or thepharmaceutically acceptable salt thereof.

328. The method of clause 325 wherein the second dose of the compound,or the pharmaceutically acceptable salt thereof, is at least about 80percent lower in amount than the first dose of the compound, or thepharmaceutically acceptable salt thereof.

329. The method of clause 325 wherein the second dose of the compound,or the pharmaceutically acceptable salt thereof, is at least about 90percent lower in amount than the first dose of the compound, or thepharmaceutically acceptable salt thereof.

330. The method of clause 325 wherein the second dose of the compound,or the pharmaceutically acceptable salt thereof, is at least about 95percent lower in amount than the first dose of the compound, or thepharmaceutically acceptable salt thereof.

331. The method of clause 325 wherein the second dose of the compound,or the pharmaceutically acceptable salt thereof, is at least about 96percent lower in amount than the first dose of the compound, or thepharmaceutically acceptable salt thereof.

332. The method of clause 325 wherein the second dose of the compound,or the pharmaceutically acceptable salt thereof, is at least about 97percent lower in amount than the first dose of the compound, or thepharmaceutically acceptable salt thereof.

333. The method of clause 325 wherein the second dose of the compound,or the pharmaceutically acceptable salt thereof, is at least about 98percent lower in amount than the first dose of the compound, or thepharmaceutically acceptable salt thereof.

334. The method of clause 325 wherein the second dose of the compound,or the pharmaceutically acceptable salt thereof, is at least about 99percent lower in amount than the first dose of the compound, or thepharmaceutically acceptable salt thereof.

335. The method of clause 325 wherein the second dose of the compound,or the pharmaceutically acceptable salt thereof, is at least about 99.5percent lower in amount than the first dose of the compound, or thepharmaceutically acceptable salt thereof.

336. The method of any one of clauses 325 to 335 wherein the first doseof the compound, or the pharmaceutically acceptable salt thereof, isabout 100 nmoles/kg to about 1000 nmoles/kg of body weight of thepatient.

337. The method of any one of clauses 325 to 335 wherein the first doseof the compound, or the pharmaceutically acceptable salt thereof, isabout 100 nmoles/kg to about 900 nmoles/kg of body weight of thepatient.

338. The method of any one of clauses 325 to 335 wherein the first doseof the compound, or the pharmaceutically acceptable salt thereof, isabout 100 nmoles/kg to about 800 nmoles/kg of body weight of thepatient.

339. The method of any one of clauses 325 to 335 wherein the first doseof the compound, or the pharmaceutically acceptable salt thereof, isabout 100 nmoles/kg to about 700 nmoles/kg of body weight of thepatient.

340. The method of any one of clauses 325 to 335 wherein the first doseof the compound, or the pharmaceutically acceptable salt thereof, isabout 100 nmoles/kg to about 600 nmoles/kg of body weight of thepatient.

341. The method of any one of clauses 325 to 335 wherein the first doseof the compound, or the pharmaceutically acceptable salt thereof, isabout 200 nmoles/kg to about 600 nmoles/kg of body weight of thepatient.

342. The method of any one of clauses 325 to 335 wherein the first doseof the compound, or the pharmaceutically acceptable salt thereof, isabout 400 nmoles/kg to about 600 nmoles/kg of body weight of thepatient.

343. The method of any one of clauses 325 to 335 wherein the first doseof the compound, or the pharmaceutically acceptable salt thereof, isabout 500 nmoles/kg of body weight of the patient.

344. The method of clause 336 wherein the second dose of the compound,or the pharmaceutically acceptable salt thereof, is about 0.5 nmoles/kgto about 500 nmoles/kg of body weight of the patient.

345. The method of clause 337 wherein the second dose of the compound,or the pharmaceutically acceptable salt thereof, is about 0.5 nmoles/kgto about 450 nmoles/kg of body weight of the patient.

346. The method of clause 338 wherein the second dose of the compound,or the pharmaceutically acceptable salt thereof, is about 0.5 nmoles/kgto about 400 nmoles/kg of body weight of the patient.

347. The method of clause 339 wherein the second dose of the compound,or the pharmaceutically acceptable salt thereof, is about 0.5 nmoles/kgto about 350 nmoles/kg of body weight of the patient.

348. The method of clause 340 wherein the second dose of the compound,or the pharmaceutically acceptable salt thereof, is about 0.5 nmoles/kgto about 300 nmoles/kg of body weight of the patient.

349. The method of clause 341 wherein the second dose of the compound,or the pharmaceutically acceptable salt thereof, is about 1 nmole/kg toabout 300 nmoles/kg of body weight of the patient.

350. The method of clause 342 wherein the second dose of the compound,or the pharmaceutically acceptable salt thereof, is about 2 nmoles/kg toabout 300 nmoles/kg of body weight of the patient.

351. The method of clause 343 wherein the second dose of the compound,or the pharmaceutically acceptable salt thereof, is about 2 nmoles/kg toabout 250 nmoles/kg of body weight of the patient.

352. The method of any one of clauses 336 to 343 wherein the second doseof the compound, or the pharmaceutically acceptable salt thereof, isabout 5 nmoles/kg to about 40 nmoles/kg of body weight of the patient.

353. The method of any one of clauses 336 to 343 wherein the second doseof the compound, or the pharmaceutically acceptable salt thereof, isabout 40 nmoles/kg to about 150 nmoles/kg of body weight of the patient.

354. The method of any one of clauses 325 to 353 further comprisingadministering a third dose of the compound, or the pharmaceuticallyacceptable salt thereof, wherein the third dose of the compound, or thepharmaceutically acceptable salt thereof, is the same as the second doseof the compound, or the pharmaceutically acceptable salt thereof.

355. The method of clause 354 further comprising administering a fourthdose of the compound, or the pharmaceutically acceptable salt thereof,wherein the fourth dose of the compound, or the pharmaceuticallyacceptable salt thereof, is the same as the second dose, or thepharmaceutically acceptable salt thereof, and the third dose of thecompound, or the pharmaceutically acceptable salt thereof.

356. The method of any one of clauses 325 to 355 wherein the dose(s) ofthe compound, or the pharmaceutically acceptable salt thereof,administered after the first dose of the compound, or thepharmaceutically acceptable salt thereof, maintain inhibition of growthof the cancer relative to the first dose of the compound, or thepharmaceutically acceptable salt thereof.

357. The method of any one of clauses 325 to 356 wherein the CART cellsare administered at a dose of about 1 million of the CART cells to about40 million of the CART cells.

358. The method of any one of clauses 325 to 357 wherein the dose(s) ofthe compound, or the pharmaceutically acceptable salt thereof,administered after the first dose of the compound, or thepharmaceutically acceptable salt thereof, are administered once weekly.

359. The method of any one of clauses 325 to 357 wherein the dose(s) ofthe compound, or the pharmaceutically acceptable salt thereof, areadministered twice weekly.

360. The method of any one of clauses 325 to 359 wherein the ligand isselected from the group consisting of a folate, DUPA, an NK-1R ligand, aCAIX ligand, a ligand of gamma glutamyl transpeptidase, an NKG2D ligand,and a CCK2R ligand.

361. The method of any one of clauses 325 to 360 wherein the ligand is afolate.

362. The method of any one of clauses 325 to 360 wherein the ligand isan NK-1R ligand.

363. The method of any one of clauses 325 to 360 wherein the ligand isDUPA.

364. The method of any one of clauses 325 to 360 wherein the ligand is aCCK2R ligand.

365. The method of any one of clauses 325 to 360 wherein the ligand is aligand of gamma glutamyl transpeptidase.

366. The method of any one of clauses 325 to 365 wherein the targetingmoiety is selected from the group consisting of 2,4-dinitrophenol (DNP),2,4,6-trinitrophenol (TNP), biotin, digoxigenin, fluorescein,fluorescein isothiocyanate (FITC), NHS-fluorescein, pentafluorophenylester, tetrafluorophenyl ester, a knottin, a centyrin, and a DARPin.

367. The method of any one of clauses 325 to 366 wherein the targetingmoiety is FITC.

368. The method of any one of clauses 325 to 366 wherein the targetingmoiety is DNP.

369. The method of any one of clauses 325 to 366 wherein the targetingmoiety is TNP.

370. The method of any one of clauses 325 to 369 wherein the linkercomprises polyethylene glycol (PEG), polyproline, a hydrophilic aminoacid, a sugar, an unnatural peptidoglycan, a polyvinylpyrrolidone,pluronic F-127, or a combination thereof.

371. The method of any one of clauses 325 to 370 wherein the linkercomprises PEG.

372. The method of any one of clauses 325 to 371 wherein the compound,or the pharmaceutically acceptable salt thereof, has the formula

B-L-T,

wherein B represents the small molecule ligand, L represents the linker,and T represents the targeting moiety, and wherein L comprises astructure having the formula

wherein n is an integer from 0 to 200.

373. The method of clause 372 wherein n is an integer from 0 to 150.

374. The method of clause 372 wherein n is an integer from 0 to 110.

375. The method of clause 372 wherein n is an integer from 0 to 20.

376. The method of clause 372 wherein n is an integer from 15 to 20.

377. The method of clause 372 wherein n is an integer from 15 to 110.

378. The method of any one of clauses 325 to 367 or 370 to 377 whereinthe linker comprises PEG and the targeting moiety is FITC, or apharmaceutically acceptable salt thereof.

379. The method of any one of clauses 325 to 378 wherein the cancer isselected from the group consisting of lung cancer, bone cancer,pancreatic cancer, skin cancer, cancer of the head, cancer of the neck,cutaneous melanoma, intraocular melanoma uterine cancer, ovarian cancer,endometrial cancer, rectal cancer, stomach cancer, colon cancer, breastcancer, triple negative breast cancer, carcinoma of the fallopian tubes,carcinoma of the endometrium, carcinoma of the cervix, carcinoma of thevagina, carcinoma of the vulva, Hodgkin's Disease, cancer of theesophagus, cancer of the small intestine, cancer of the endocrinesystem, cancer of the thyroid gland, cancer of the parathyroid gland,non-small cell lung cancer, cancer of the adrenal gland, sarcoma of softtissue, osteosarcoma, cancer of the urethra, prostate cancer, chronicleukemia, acute leukemia, acute myelocytic leukemia, lymphocyticlymphoma, myeloid leukemia, myelomonocytic leukemia, hairy cellleukemia, pleural mesothelioma, cancer of the bladder, Burkitt'slymphoma, cancer of the ureter, cancer of the kidney, renal cellcarcinoma, carcinoma of the renal pelvis, neoplasms of the centralnervous system (CNS), primary CNS lymphoma, spinal axis tumors, brainstem glioma, pituitary adenoma, and adenocarcinoma of thegastroesophageal junction.

127. 380. The method of any one of clauses 325 to 361 or 366 to 379wherein the cancer is a folate receptor expressing cancer.

128. 381. The method of clause 380 wherein the cancer is an endometrialcancer.

129. 382. The method of clause 380 wherein the cancer is a non-smallcell lung cancer.

130. 383. The method of clause 380 wherein the cancer is an ovariancancer.

131. 384. The method of clause 380 wherein the cancer is a triplenegative breast cancer.

385. The method of any one of clauses 325 to 384 wherein the CAR has arecognition region and the recognition region is a single chain fragmentvariable (scFv) region of an antibody.

386. The method of any one of clauses 325 to 367 or 370 to 385 whereinthe CAR has a recognition region and the recognition region of the CARis a single chain fragment variable (scFv) region of an anti-FITCantibody.

387. The method of any one of clauses 325 to 386 wherein the CAR has aco-stimulation domain and the co-stimulation domain is selected from thegroup consisting of CD28, CD137 (4-1BB), CD134 (OX40), and CD278 (ICOS).

388. The method of any one of clauses 325 to 387 wherein the CAR has anactivation signaling domain and the activation signaling domain is a Tcell CD3ζ chain or an Fc receptor γ.

389. The method of any one of clauses 325 to 367 or 370 to 388 whereinthe CAR has a recognition region and the recognition region is a singlechain fragment variable (scFv) region of an anti-FITC antibody, whereinthe CAR has a co-stimulation domain and the co-stimulation domain isCD137 (4-1BB), and wherein the CAR has an activation signaling domainand the activation signaling domain is a T cell CD3ζ chain.

132. 390. The method of any one of clauses 325 to 389 wherein multipledoses of the CAR T cell composition are administered.

391. The method of any one of clauses 325 to 390 wherein the patient isimaged prior to administration of the compound, or the pharmaceuticallyacceptable salt thereof, or prior to administration of the CAR T cellcomposition.

133. 392. The method of any one of clauses 325 to 391 wherein thecompound, or the pharmaceutically acceptable salt thereof, is not anantibody, and does not comprise a fragment of an antibody.

134. 393. The method of any one of clauses 325 to 392 wherein thetargeting moiety does not comprise a peptide epitope.

394. The method of any one of clauses 325 to 393 wherein cytokinerelease resulting in off-target toxicity in the patient does not occurand wherein CAR T cell toxicity to the cancer occurs.

135. 395. The method of any one of clauses 325 to 393 wherein off-targettissue toxicity does not occur in the patient and wherein CAR T celltoxicity to the cancer occurs.

136. 396. The method of any one of clauses 325 to 393 wherein the cancercomprises a tumor, wherein tumor size is reduced in the patient, andwherein off-target toxicity does not occur.

137. 397. The method of any one of clauses 325 to 398 wherein the CARTcells comprise a nucleic acid comprising SEQ ID NO:1.

138. 398. The method of any one of clauses 325 to 397 wherein the CAR Tcells comprise a polypeptide comprising SEQ ID NO:2.

139. 399. The method of clause 397 wherein the nucleic acid encodes achimeric antigen receptor.

140. 400. The method of any one of clauses 325 to 399 wherein the CARcomprises humanized amino acid sequences.

141. 401. The method of any one of clauses 325 to 399 wherein the CARconsists of humanized amino acid sequences.

402. The method of any one of clauses 325 to 401 further comprising thestep of administering to the patient a folate, a conjugate comprising afolate wherein the conjugate comprising a folate does not comprise atargeting moiety, or an agent that inhibits activation of the CAR Tcells.

142. 403. The method of clause 402 wherein the agent that inhibitsactivation of the CAR T cells is administered to the patient and theagent is an agent that blocks CAR T cell binding to the compound, or thepharmaceutically acceptable salt thereof, but does not bind to thecancer.

143. 404 The method of clause 403 wherein the agent is fluoresceinamine,sodium fluorescein, or fluorescein.

144. 405. The method of clause 404 wherein the agent is sodiumfluorescein.

406. A method of treatment of a cancer, the method comprising

-   -   i) administering to a patient a first dose of a compound, or a        pharmaceutically acceptable salt thereof, wherein the compound        comprises a small molecule ligand linked to a targeting moiety        by a linker and wherein the compound, or the pharmaceutically        acceptable salt thereof, is administered to the patient at least        about one hour prior to the administration of a CAR T cell        composition comprising CAR T cells wherein the CAR T cells        comprise a CAR directed to the targeting moiety;    -   ii) then administering to the patient a dose of the CAR T cell        composition; and    -   iii) then administering to the patient a second dose of the        compound, or the pharmaceutically acceptable salt thereof.

407. The method of clause 406 wherein the first dose of the compound, orthe pharmaceutically acceptable salt thereof, is administered to thepatient at least about two hours prior to the administration of the CART cell composition.

408. The method of clause 406 wherein the first dose of the compound, orthe pharmaceutically acceptable salt thereof, is administered to thepatient at least about four hours prior to the administration of the CART cell composition.

409. The method of clause 406 wherein the first dose of the compound, orthe pharmaceutically acceptable salt thereof, is administered to thepatient at least about eight hours prior to the administration of theCAR T cell composition.

410. The method of clause 406 wherein the first dose of the compound, orthe pharmaceutically acceptable salt thereof, is administered to thepatient at least about twelve hours prior to the administration of theCAR T cell composition.

411. The method of clause 406 wherein the first dose of the compound, orthe pharmaceutically acceptable salt thereof, is administered to thepatient at least about sixteen hours prior to the administration of theCAR T cell composition.

412. The method of clause 406 wherein the first dose of the compound, orthe pharmaceutically acceptable salt thereof, is administered to thepatient at least about twenty hours prior to the administration of theCAR T cell composition.

413. The method of clause 406 wherein the first dose of the compound, orthe pharmaceutically acceptable salt thereof, is administered to thepatient at least about twenty-four hours prior to the administration ofthe CAR T cell composition.

414. The method of any one of clauses 406 to 413 wherein the second doseof the compound, or the pharmaceutically acceptable salt thereof, isadministered to the patient by at least about twenty-four hours afterthe administration of the CAR T cell composition.

415. The method of any one of clauses 406 to 413 wherein the second doseof the compound, or the pharmaceutically acceptable salt thereof, isadministered to the patient by at least about sixteen hours after theadministration of the CAR T cell composition.

416. The method of any one of clauses 406 to 413 wherein the second doseof the compound, or the pharmaceutically acceptable salt thereof, isadministered to the patient by at least about twelve hours after theadministration of the CAR T cell composition.

417. The method of any one of clauses 406 to 413 wherein the second doseof the compound, or the pharmaceutically acceptable salt thereof, isadministered to the patient by at least about eight hours after theadministration of the CAR T cell composition.

418. The method of any one of clauses 406 to 413 wherein the second doseof the compound, or the pharmaceutically acceptable salt thereof, isadministered to the patient by at least about four hours after theadministration of the CAR T cell composition.

145. 419. The method of any one of clauses 406 to 418 wherein cytokinerelease resulting in off-target toxicity in the patient does not occurand wherein CAR T cell toxicity to the cancer occurs.

146. 420. The method of any one of clauses 406 to 418 wherein off-targettissue toxicity does not occur in the patient and wherein CAR T celltoxicity to the cancer occurs.

147. 421. The method of any one of clauses 406 to 418 wherein the cancercomprises a tumor, wherein tumor size is reduced in the patient, andwherein off-target toxicity does not occur.

148. 422. The method of any one of clauses 406 to 418 wherein the cancercomprises a tumor, and wherein reduction in tumor size in the patient isgreater than in a patient not pre-treated with the compound, or thepharmaceutically acceptable salt thereof, prior to administration of theCAR T cell composition.

423. The method of any one of clauses 406 to 422 wherein the ligand isselected from the group consisting of a folate, DUPA, an NK-1R ligand, aCAIX ligand, a ligand of gamma glutamyl transpeptidase, an NKG2D ligand,and a CCK2R ligand.

424. The method of any one of clauses 406 to 423 wherein the ligand is afolate.

425. The method of any one of clauses 406 to 423 wherein the ligand isan NK-1R ligand.

426. The method of any one of clauses 406 to 423 wherein the ligand isDUPA.

427. The method of any one of clauses 406 to 423 wherein the ligand is aCCK2R ligand.

428. The method of any one of clauses 406 to 423 wherein the ligand is aligand of gamma glutamyl transpeptidase.

429. The method of any one of clauses 406 to 428 wherein the targetingmoiety is selected from the group consisting of 2,4-dinitrophenol (DNP),2,4,6-trinitrophenol (TNP), biotin, digoxigenin, fluorescein,fluorescein isothiocyanate (FITC), NHS-fluorescein, pentafluorophenylester, tetrafluorophenyl ester, a knottin, a centyrin, and a DARPin.

430. The method of any one of clauses 406 to 429 wherein the targetingmoiety is FITC.

431. The method of any one of clauses 406 to 429 wherein the targetingmoiety is DNP.

432. The method of any one of clauses 406 to 429 wherein the targetingmoiety is TNP.

433. The method of any one of clauses 406 to 432 wherein the linkercomprises polyethylene glycol (PEG), polyproline, a hydrophilic aminoacid, a sugar, an unnatural peptidoglycan, a polyvinylpyrrolidone,pluronic F-127, or a combination thereof.

434. The method of any one of clauses 406 to 433 wherein the linkercomprises PEG.

435. The method of any one of clauses 406 to 434 wherein the compound,or the pharmaceutically acceptable salt thereof, has the formula

B-L-T,

wherein B represents the small molecule ligand, L represents the linker,and T represents the targeting moiety, and wherein L comprises astructure having the formula

wherein n is an integer from 0 to 200.

436. The method of clause 435 wherein n is an integer from 0 to 150.

437. The method of clause 435 wherein n is an integer from 0 to 110.

438. The method of clause 435 wherein n is an integer from 0 to 20.

439. The method of clause 435 wherein n is an integer from 15 to 20.

440. The method of clause 435 wherein n is an integer from 15 to 110.

441. The method of any one of clauses 406 to 430 or 433 to 440 whereinthe linker comprises PEG and the targeting moiety is FITC, or apharmaceutically acceptable salt thereof.

442. The method of any one of clauses 406 to 441 wherein the compound,or the pharmaceutically acceptable salt thereof, is administered at adose of about 10 nmoles/kg to about 10000 nmoles/kg of body weight ofthe patient.

443. The method of any one of clauses 406 to 441 wherein the compound,or the pharmaceutically acceptable salt thereof, is administered at adose of about 10 nmoles/kg to about 5000 nmoles/kg of body weight of thepatient.

444. The method of any one of clauses 406 to 441 wherein the compound,or the pharmaceutically acceptable salt thereof, is administered at adose of about 10 nmoles/kg to about 1000 nmoles/kg of body weight of thepatient.

445. The method of any one of clauses 406 to 441 wherein the compound,or the pharmaceutically acceptable salt thereof, is administered at adose of about 10 nmoles/kg to about 600 nmoles/kg of body weight of thepatient.

446. The method of any one of clauses 406 to 441 wherein the compound,or the pharmaceutically acceptable salt thereof, is administered at adose of about 200 nmoles/kg to about 600 nmoles/kg of body weight of thepatient.

447. The method of any one of clauses 406 to 441 wherein the compound,or the pharmaceutically acceptable salt thereof, is administered at adose of about 250 nmoles/kg to about 600 nmoles/kg of body weight of thepatient.

448. The method of any one of clauses 406 to 447 wherein the cancer isselected from the group consisting of lung cancer, bone cancer,pancreatic cancer, skin cancer, cancer of the head, cancer of the neck,cutaneous melanoma, intraocular melanoma uterine cancer, ovarian cancer,endometrial cancer, rectal cancer, stomach cancer, colon cancer, breastcancer, triple negative breast cancer, carcinoma of the fallopian tubes,carcinoma of the endometrium, carcinoma of the cervix, carcinoma of thevagina, carcinoma of the vulva, Hodgkin's Disease, cancer of theesophagus, cancer of the small intestine, cancer of the endocrinesystem, cancer of the thyroid gland, cancer of the parathyroid gland,non-small cell lung cancer, cancer of the adrenal gland, sarcoma of softtissue, osteosarcoma, cancer of the urethra, prostate cancer, chronicleukemia, acute leukemia, acute myelocytic leukemia, lymphocyticlymphoma, myeloid leukemia, myelomonocytic leukemia, hairy cellleukemia, pleural mesothelioma, cancer of the bladder, Burkitt'slymphoma, cancer of the ureter, cancer of the kidney, renal cellcarcinoma, carcinoma of the renal pelvis, neoplasms of the centralnervous system (CNS), primary CNS lymphoma, spinal axis tumors, brainstem glioma, pituitary adenoma, and adenocarcinoma of thegastroesophageal junction.

149. 449. The method of any one of clauses 406 to 424 or 429 to 448wherein the cancer is a βexpressing cancer.

150. 450. The method of clause 448 wherein the cancer is an endometrialcancer.

151. 451. The method of clause 448 wherein the cancer is a non-smallcell lung cancer.

152. 452. The method of clause 448 wherein the cancer is an ovariancancer.

153. 453. The method of clause 448 wherein the cancer is a triplenegative breast cancer.

454. The method of any one of clauses 406 to 453 wherein the CAR has arecognition region and the recognition region is a single chain fragmentvariable (scFv) region of an antibody.

455. The method of any one of clauses 406 to 430 or 433 to 454 whereinthe CAR has a recognition region and the recognition region of the CARis a single chain fragment variable (scFv) region of an anti-FITCantibody.

456. The method of any one of clauses 406 to 455 wherein the CAR has aco-stimulation domain and the co-stimulation domain is selected from thegroup consisting of CD28, CD137 (4-1BB), CD134 (OX40), and CD278 (ICOS).

457. The method of any one of clauses 406 to 456 wherein the CAR has anactivation signaling domain and the activation signaling domain is a Tcell CD3ζ chain or an Fc receptor γ.

458. The method of any one of clauses 406 to 430 or 433 to 457 whereinthe CAR has a recognition region and the recognition region is a singlechain fragment variable (scFv) region of an anti-FITC antibody, whereinthe CAR has a co-stimulation domain and the co-stimulation domain isCD137 (4-1BB), and wherein the CAR has an activation signaling domainand the activation signaling domain is a T cell CD3ζ chain.

154. 459. The method of any one of clauses 406 to 458 wherein multipledoses of the CAR T cell composition are administered.

460. The method of any one of clauses 406 to 459 wherein the patient isimaged prior to administration of the compound, or the pharmaceuticallyacceptable salt thereof.

155. 461. The method of any one of clauses 406 to 460 wherein thecompound, or the pharmaceutically acceptable salt thereof, is not anantibody, and does not comprise a fragment of an antibody.

156. 462. The method of any one of clauses 406 to 461 wherein thetargeting moiety does not comprise a peptide epitope.

463. The method of any one of clauses 406 to 462 wherein the CART cellscomprise a nucleic acid comprising SEQ ID NO:1.

157. 464. The method of any one of clauses 406 to 463 wherein the CAR Tcells comprise a polypeptide comprising SEQ ID NO:2.

158. 465. The method of clause 463 wherein the nucleic acid encodes achimeric antigen receptor.

159. 466. The method of any one of clauses 406 to 465 wherein the CARcomprises humanized amino acid sequences.

160. 467. The method of any one of clauses 406 to 465 wherein the CARconsists of humanized amino acid sequences.

468. The method of any one of clauses 108 to 182 wherein more than onedose is administered to the patient of the folate, the conjugatecomprising a folate wherein the conjugate comprising a folate does notcomprise a targeting moiety, or the agent that inhibits activation ofthe CAR T cells.

469. The method of any one of clauses 108 to 182 wherein the folate, theconjugate comprising a folate wherein the conjugate comprising a folatedoes not comprise a targeting moiety, or the agent that inhibitsactivation of the CAR T cells is administered to the patient beforeand/or after the compound, or the pharmaceutically acceptable saltthereof.

470. The method of any one of clauses 108 to 182 wherein administrationof the folate, the conjugate comprising a folate wherein the conjugatecomprising a folate does not comprise a targeting moiety, or the agentthat inhibits activation of the CAR T cells causes reduction in cytokinelevels in the patient.

471. The method of clause 470 wherein the reduction in cytokine levelsoccurs by about 3 hours after administration to the patient of thefolate, the conjugate comprising a folate wherein the conjugatecomprising a folate does not comprise a targeting moiety, or the agentthat inhibits activation of the CAR T cells.

472. The method of clause 470 wherein the reduction in cytokine levelsoccurs by about 6 hours after administration to the patient of thefolate, the conjugate comprising a folate wherein the conjugatecomprising a folate does not comprise a targeting moiety, or the agentthat inhibits activation of the CAR T cells.

473. The method of clause 470 wherein the reduction in cytokine levelsis a reduction to about the cytokine levels in an untreated patient.

474. The method of any one of clauses 108 to 182 wherein the compound,or the pharmaceutically acceptable salt thereof, is administered beforeand subsequent to administration of the folate, the conjugate comprisinga folate wherein the conjugate comprising a folate does not comprise atargeting moiety, or the agent that inhibits activation of the CAR Tcells.

475. The method of any one of clauses 108 to 182 wherein CART cellnumber increases in the blood of the patient after administration of thefolate, the conjugate comprising a folate wherein the conjugatecomprising a folate does not comprise a targeting moiety, or the agentthat inhibits activation of the CAR T cells, even though cytokine levelsin the patient are reduced.

476. The method of any one of clauses 108 to 182 wherein CART cellactivation is enhanced or maintained, relative to a patient not treatedwith a rescue agent, after administration of the folate, the conjugatecomprising a folate wherein the conjugate comprising a folate does notcomprise a targeting moiety, or the agent that inhibits activation ofthe CAR T cells, even though cytokine levels in the treated patient arereduced.

477. The method of any one of clauses 108 to 182 wherein the cancercomprises a tumor and tumor size in the patient is not increased whenthe folate, the conjugate comprising a folate wherein the conjugatecomprising a folate does not comprise a targeting moiety, or the agentthat inhibits activation of the CAR T cells is administered to thepatient.

478. The method of clause 477 wherein a complete response for the tumoris obtained.

479. The method of any one of clauses 108, 115-160, 168-182, and 468-478wherein the agent that inhibits activation of the CAR T cells isadministered to the patient when the CRS grade reaches 1, 2, 3, or 4.

480. The method of any one of clauses 108, 115-160, 168-182, and 468-478wherein the agent that inhibits activation of the CAR T cells isadministered to the patient when the CRS grade reaches 3 or 4.

481. The method of any one of clauses 108 to 182 and 468 to 480 whereinlung edema is reduced.

482. The method of any one of clauses 108, 115-160, 168-182, and 468-481wherein the agent that inhibits activation of the CAR T cells isadministered at a dose of about 0.01 to about 300 umoles/kg of bodyweight of the patient.

483. The method of any one of clauses 108, 115-160, 168-182, and 468-481wherein the agent that inhibits activation of the CAR T cells isadministered at a dose of about 0.06 to about 100 umoles/kg of bodyweight of the patient.

484. The method of any one of clauses 108, 115-160, 168-182, and 468-481wherein the agent that inhibits activation of the CAR T cells isadministered at a dose of about 0.06 to about 90 umoles/kg of bodyweight of the patient.

485. The method of any one of clauses 108, 115-160, 168-182, and 468-481wherein the agent that inhibits activation of the CAR T cells isadministered at a dose of about 0.06 to about 80 umoles/kg of bodyweight of the patient.

486. The method of any one of clauses 108, 115-160, 168-182, and 468-481wherein the agent that inhibits activation of the CAR T cells isadministered at a dose of about 0.06 to about 70 umoles/kg of bodyweight of the patient.

487. The method of any one of clauses 108, 115-160, 168-182, and 468-481wherein the agent that inhibits activation of the CAR T cells isadministered at a dose of about 0.06 to about 60 umoles/kg of bodyweight of the patient.

488. The method of any one of clauses 108, 115-160, 168-182, and 468-481wherein the agent that inhibits activation of the CAR T cells isadministered at a dose of about 0.06 to about 50 umoles/kg of bodyweight of the patient.

489. The method of any one of clauses 108, 115-160, 168-182, and 468-481wherein the agent that inhibits activation of the CAR T cells isadministered at a dose of about 0.06 to about 40 umoles/kg of bodyweight of the patient.

490. The method of any one of clauses 108, 115-160, 168-182, and 468-481wherein the agent that inhibits activation of the CAR T cells isadministered at a dose of about 0.06 to about 30 umoles/kg of bodyweight of the patient.

491. The method of any one of clauses 108, 115-160, 168-182, and 468-481wherein the agent that inhibits activation of the CAR T cells isadministered at a dose of about 0.06 to about 20 umoles/kg of bodyweight of the patient.

492. The method of any one of clauses 108, 115-160, 168-182, and 468-481wherein the agent that inhibits activation of the CAR T cells isadministered at a dose of about 0.06 to about 10 umoles/kg of bodyweight of the patient.

493. The method of any one of clauses 108, 115-160, 168-182, and 468-481wherein the agent that inhibits activation of the CAR T cells isadministered at a dose of about 0.06 to about 8 umoles/kg of body weightof the patient.

494. The method of any one of clauses 108, 115-160, 168-182, and 468-481wherein the agent that inhibits activation of the CAR T cells isadministered at a dose of about 0.06 to about 6 umoles/kg of body weightof the patient.

495. The method of any one of clauses 108, 115-160, 168-181, and 468-494wherein the agent that inhibits activation of the CAR T cells isadministered to the patient and the agent is sodium fluorescein.

496. The method of any one of clauses 1 to 495 wherein CRS is reduced orprevented and the method results in a decrease in tumor volume in thepatient.

497. The method of any one of clauses 1 to 496 wherein body weight lossdue to CRS is reduced or prevented.

498. The method of any one of clauses 1-3, 8-28, 33-58, 63-83, 88-136,141-249, 252-361, 366-380, 385-424, 429-449, and 454 to 497 wherein thecancer is acute myelocytic leukemia.

499. The method of clause 498 wherein the cancer expresses the folatereceptor-β.

500. The method of clause 498 or 499 wherein the CAR-T cells have acentral memory/effector memory phenotype.

501. The method of any one of clauses 1 to 500 wherein the CD8:CD4 ratioof the CART cells is about 1:1.

502. The method of any one of clauses 215 to 251 further comprising stepiv) of re-administering the compound, or the pharmaceutically acceptablesalt thereof, to the patient.

503. The method of clause 474 wherein the subsequent administration ofthe compound, or the pharmaceutically acceptable salt thereof, causesCAR T cell activation and an increase in cytokine levels in the patient.

504. The method of any one of clauses 1 to 107, 183 to 476, or 479 to503 wherein the cancer comprises a tumor and wherein a complete responsefor the tumor is obtained.

505. A method of treatment of a cancer, the method comprising

-   -   i) administering to a patient a compound, or a pharmaceutically        acceptable salt thereof, wherein the compound comprises a small        molecule ligand linked to a targeting moiety by a linker; and    -   ii) administering to the patient a CAR T cell composition        wherein the CAR T cell composition comprises CAR T cells and        wherein the CAR T cells comprise a CAR directed to the targeting        moiety; and wherein the small molecule ligand is a PSMA ligand        and the targeting moiety is FITC.

506. The method of clause 505 wherein the small molecule ligand linkedto a targeting moiety by a linker has the formula

507. A method of treatment of a cancer, the method comprising

-   -   i) administering to a patient a compound, or a pharmaceutically        acceptable salt thereof, wherein the compound comprises a small        molecule ligand linked to a targeting moiety by a linker; and    -   ii) administering to the patient a CAR T cell composition        wherein the CAR T cell composition comprises CAR T cells and        wherein the CAR T cells comprise a CAR directed to the targeting        moiety; and wherein the small molecule ligand is a CAIX ligand        and the targeting moiety is FITC.

508. The method of clause 507 wherein the small molecule ligand linkedto a targeting moiety by a linker has the formula

509. A method of treatment of a cancer, the method comprising

-   -   i) administering to a patient a first compound, or a        pharmaceutically acceptable salt thereof, wherein the first        compound, or the pharmaceutically acceptable salt thereof,        comprises a PSMA ligand linked to FITC by a linker;    -   ii) administering to the patient a second compound, or a        pharmaceutically acceptable salt thereof, wherein the second        compound, or the pharmaceutically acceptable salt thereof,        comprises a CAIX ligand linked to FITC by a linker; and    -   iii) administering to the patient a CAR T cell composition        wherein the CAR T cell composition comprises CAR T cells and        wherein the CAR T cells comprise a CAR directed to the targeting        moiety.

510. The method of clause 509 wherein the first compound has the formula

and the second compound has the formula

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1A and FIG. 1B show anti-FITC CAR T cell mediated toxicity. FIG. 1Ashows the changes in bodyweight for the mice of different treatmentgroups. FIG. 1B shows the detected concentration of IFN-gamma for thedifferent treatment groups. FIG. 1C shows the first-week survival (%) ofthe mice in the different treatment groups.

FIG. 2A and FIG. 2B show the effect of anti-FITC CAR T cell regulationon the tumor response. FIG. 2A shows tumor growth for mice that aretreated with either CAR T cells and PBS or CAR T cells and FITC-Folate.FIG. 2B shows a summary of the tumor response results for mice used inthe study.

FIG. 3A-FIG. 3D show the effect of FITC-Folate concentration on thetumor response. FIG. 3A shows the detected concentration of IFN-gamma atthe different FITC-folate concentrations. FIG. 3B shows post CAR T cellinjection tumor growth in the presence of different FITC-folateconcentrations. FIG. 3C shows the first-week survival (%) of the mice.FIG. 3D shows a summary of the tumor response results for the mice usedin the study.

FIG. 4A and FIG. 4B show suppressing FITC CAR T cell activation withagents that inhibit a mediator of T cell activation signal. FIG. 4Ashows the changes in IFN-gamma concentration as a function of agentconcentration. FIG. 4B shows the changes in CD69 expression as afunction of agent concentration.

FIG. 5 shows a general diagram of the constructs used for CAR Ttransduction.

FIG. 6A-FIG. 6D show anti-tumor efficacy and toxicity at different EC17doses and numbers of CART cells. FIG. 6A shows tumor volume over time.FIG. 6B shows body weight changes over time. FIG. 6C shows the maximalpercentage body weight loss for each EC17 dose. FIG. 6D shows thepercentage of mice showing sCRS (cytokine release syndrome) for eachEC17 dose. (1) no CAR-T+EC17 500 nmoles/kg; (2) 12.5 million CAR-T+EC1710000 nmoles/kg; (3) 12.5 million CAR-T+EC17 1500 nmoles/kg; (4) 12.5million CAR-T+EC17 500 nmoles/kg; (5) 10 million CAR-T+EC17 100nmoles/kg; (6) 10 million CAR-T+EC17 20 nmoles/kg.

FIG. 7 shows the rescue with EC0923 of mice having sCRS and observedresponses of mice treated with or without EC0923, and harvested organsfrom mice treated with or without EC0923.

FIG. 8A-FIG. 8D show anti-tumor efficacy and toxicity of different CAR Tdoses. FIG. 8A shows tumor volume over time. FIG. 8B shows body weightchanges over time. FIG. 8C shows the maximal percentage of body weightloss for each CAR T dose. FIG. 8D shows the percentage of mice showingsCRS for each CAR T dose.

FIG. 9A and FIG. 9B show anti-tumor efficacy and body weight change fordifferent EC 17 doses. FIG. 9A shows tumor volume over time. FIG. 9Bshows body weight change over time.

FIG. 10A-FIG. 10C show anti-tumor efficacy of different CART cell andnon-transformed T cell mixtures. FIG. 10A shows tumor volume over time;(●) no CAR-T, (∘) CAR-T on Day 0, (▪) CAR-T on Day 0, unmodified T onDay 52, (▾) CAR-T on Day 0, Day 46 and Day 52. FIG. 10B shows bodyweight change over time; (●) no CAR-T, (∘) CAR-T on Day 0, (▪) CAR-T onDay 0, unmodified T on Day 52, (▾) CAR-T on Day 0, Day 46 and Day 52.FIG. 10C shows the amount of CART cells in blood and tumor volume fordifferent CAR T cell and non-transformed T cell mixtures.

FIG. 11A and FIG. 11B show anti-tumor efficacy and toxicity of 5 millionCAR T cells and different EC17 dosing schedules. FIG. 11A shows tumorvolume over time. FIG. 11B shows body weight change over time.

FIG. 12 shows control of CAR T cell mediated toxicity via regulation ofCAR T cell activation by the use of competitors to inhibit CAR T cellactivation and by ending administration of the bridge.

FIG. 13A-FIG. 13C show the results of a FITC-Folate dose escalationstudy. FIG. 13A shows the percent body weight change over time afteradministration of the bridge and the CAR T cells. FIG. 13B shows thechange in tumor volume over time after injection of CAR T cells and thebridge. FIG. 13C shows the percent of survival after the first week oftreatment with the bridge and the CAR T cells.

FIG. 14A and FIG. 14B show the effect of the FITC-ligand bridge moleculeon CAR T cell proliferation and cytokine production. FIG. 14A shows thenumber of CAR T cells 6 days after the introduction of the CAR T cellsinto mice. FIG. 14B shows the concentration of the serum cytokines IL-2,IFN-γ, and TNF-α 6 days after the introduction of CAR T cells into mice.

FIG. 15 shows the concentration of IFN-γ as a function of theconcentration of FITC-folate in an in vitro assay.

FIG. 16 shows the rescue (based on a measurement of cytokine production)with EC0923 or fluorescein or mice having cytokine release syndrome.

FIG. 17 shows that CAR-T cell activity (based on a measurement ofcytokine production) is dependent on the presence of the tumor and onEC17 dose level.

FIG. 18A-FIG. 18C show that CAR-T cells do not proliferate in naïve micewith no tumors. FIG. 18A shows body weight change in mice (with notumors) injected with CAR-T cells, but no EC17 or with 500 nmoles/kg ofEC17 three times weekly. FIG. 18B and FIG. 18C show CAR-T cell numberand spleen size in these mice versus mice with HEK (folate-receptorpositive) tumors. For FIG. 18B and FIG. 18C, the left-hand bar in eachgroup of three bars is mice without tumors injected with no EC17 butwith CAR-T cells, the middle bar is mice without tumors injected withCAR-T cells and EC17, and the right-hand bar is mice with tumorsinjected with CAR-T cells and EC17. In FIG. 18B, N.D. is not determinedand the y-axis is logarithmic for FIG. 18.

FIG. 19A and FIG. 19B show effects on tumor size of CAR-T cells and EC17injected into mice using an MDA-MB-231 model (high folate receptorexpression levels—FIG. 19A) or an OV90 tumor model (low folate receptorexpression levels—FIG. 19B).

FIGS. 20A and 20B show effects on tumor size (FIG. 20A) and body weightloss (FIG. 20B) of CAR-T cells and various doses of EC17 injected intomice using an MDA-MB-231 model.

FIG. 21A and FIG. 21B show FITC-CAR-T anti-tumor activity in aMDA-MB-231 model.

FIG. 22A and FIG. 22B show FITC-CAR-T anti-tumor activity in an OV-90model.

FIG. 23A and FIG. 23B show FITC-CAR-T anti-tumor activity in a KB model.For the EC17 group, ⅔ had sCRS on day 23 and ⅓ had sCRS on day 37.

FIG. 24A and FIG. 24B show FITC-CAR-T anti-tumor activity in a HEK-FRamodel.

FIG. 25A and FIG. 25B show FITC-CAR-T anti-tumor activity in a SKOV-3model.

FIG. 26A-FIG. 26E, FIG. 26C and FIG. 26E, show toxicity studies in micewith EC17 prep-painting. FIG. 26A and FIG. 26B show the protocol fortreatment. FIG. 26D shows the effect of EC17 pre-painting on tumor size.

FIG. 27A-FIG. 27C, FIG. 27A shows the protocols for treatment. FIG. 27Bshows toxicity studies. FIG. 27C shows the effect of EC17 pre-paintingon tumor toxicity. Line 1: no EC17. Line 2: EC17 4 h pre-done. Line 3:EC17 4 h pre-dose then 24 h post-CARTs. Line 4: EC17 48 h post CAR-Ts.

FIG. 28A, FIG. 28B, FIG. 28C, and FIG. 28D, show CAR-T cell number inblood. CAR-T number in mice without rescue was considered as 1.

FIG. 29A, FIG. 29B, FIG. 29C, FIG. 29D, and FIG. 29E, show comparisonstudies of three rescue agents (folic acid, sodium fluorescein (NAFL),and leucovorin).

FIG. 30A and FIG. 30B show rescue assays. Mice with fluorescein rescuehad the least body weight loss. All mice with rescue reached completeresponse, except 2/9 in the fluorescein rescue group. Line 1 no EC17.Line 2: no EC17 but Fluorescein. Line 3: Fluorescein rescue. Line 4:Leucovorin rescue. Line 5: Folic acid rescue. Line 6: no rescue.

FIG. 31 shows a sodium fluorescein (60 umol/kg) rescue study schema.

FIG. 32A and FIG. 32B show NaFL rescue related organ weight changes. (1)CAR-T; (2) CAR-T+EC17; (3) CAR-T+EC17+NaFL rescue.

FIG. 33A, FIG. 33B, FIG. 33C, FIG. 33D, FIG. 33E, FIG. 33F, and FIG.33G, show cytokine production in mouse blood 7 hours after NaFL rescue.

FIG. 34A, FIG. 34B, FIG. 34C, FIG. 34D, FIG. 34E, FIG. 34F, and FIG.34G, show cytokine production in mice (27 hours after NaFL rescue).

FIG. 35A, FIG. 35B, FIG. 35C, FIG. 35D, and FIG. 35E, show cytokineproduction reduced in mouse blood (<7 hours after NaFL rescue).

FIG. 36A and FIG. 36B show NaFL rescue effect on FITC CAR-T anti-tumoractivity and body weight change. (1) CAR-T only; (2) CAR-T+EC17; (3)CAR-T+EC17+NaFL.

FIG. 37A and FIG. 37B show the effect of rescue on cytokine levels.

FIG. 38A shows a CAR-T administration schedule. FIG. 38B shows bodyweight changes.

FIG. 39A, FIG. 39B, FIG. 39C, and FIG. 39D, show that cytokineproduction in blood is CAR-T dose dependent.

FIG. 40A shows the dosing schedule and FIG. 40B shows that CAR-T numberin blood is EC17 dose dependent (day 3 in vivo).

FIG. 41A shows the dosing schedule and FIG. 41B shows that CAR-T countin blood is EC17 dose dependent although the difference is smaller (day6 in vivo).

FIG. 42 shows mouse body weight changes following CAR-T and EC17injection.

FIG. 43A and FIG. 43B show CAR-T cell count and spleen size in mice postCAR-T cell and EC17 injection. (1) Mice with tumor: CAR-T 5 million+EC17SIW; (2) naïve mice: CAR-T 8 million no EC17; (3) naïve mice: CAR-T 8million+EC17 TIW; (4) naïve mice: CAR-T 5 million no EC17; (5) naïvemice: CAR-T 5 million+EC17 TIW.

FIG. 44 shows cytokine production following EC17 and CAR-T cellinjection in the presence and absence of a tumor.

FIG. 45 shows the universality of anti-FITC CAR T cell therapy: bindingof various adaptors to CAR T cells. (1) CART cell without staining; (2)CAR T cell labeled with FITC-Alexa 647+FITC-folate (Competition); (3)CAR T cell labeled with FITC-Alexa 647; (4) CAR T cell labeled withFITC-Alexa 647+FITC-DUPA (Competition); (5) CAR T cell labeled withFITX-Alexa 647+FITC-CA9 (Competition).

FIG. 46A and FIG. 46B show that the universal Car T cell can eliminatevarious cancer cells expressing orthogonal antigens upon addition ofantigen matched bridges in vitro.

FIG. 47 shows the relationship between concentration of bridges and theuniversal CAR T cell's anti-tumor activity in vitro.

FIG. 48 shows that the universal CAR T cell can eliminate various cancercells expressing orthogonal antigens upon addition of antigen matchedbridges in vivo.

FIG. 49A and FIG. 49B show that the universal CAR T cell can eliminatetwo tumors via cocktail of bridges in vivo.

FIG. 50 shows a sodium fluorescein (0.06, 0.6, 6 umol/kg) rescue studyschema.

FIG. 51A shows anti-tumor activity (6 umol/kg NaFL rescue). FIG. 51Bshows the corresponding body weight changes.

FIG. 52A, FIG. 52B, FIG. 52C, FIG. 52D, and FIG. 52E, show cytokinelevels in mouse blood following sodium fluorescein rescue.

FIG. 53A-FIG. 53C, FIG. 53A shows a rescue schema. FIG. 53B and FIG. 53Cshow enumeration of FITC CAR T cells in the blood after rescue.

FIG. 54 shows the characterization of circulating CAR T cells in mouseblood after rescue.

FIG. 55A-FIG. 55C, FIG. 55A shows a rescue schema. FIG. 55B and FIG. 55Cshow enumeration of CAR T cells in the blood after rescue. (1) Control[No NaFL]; (2) 0.06 umol/kg NaFL; (3) 0.6 umol/kg NAFL; (4) 6 umol·kgNaFL.

FIG. 56 shows tumor burden in EC17 treated and non-treated animals.

FIG. 57A and FIG. 57B summarize the estimated numbers of tumor massesand total tumor weights in all groups examined.

FIG. 58A and FIG. 58B show the characterization of circulating tumorcells.

FIG. 59A and FIG. 59B show the characterization of circulating tumorcells.

FIG. 60A and FIG. 60B show the percent of whole blood that is CAR Tcells upon EC17 injection.

FIG. 61A and FIG. 61B show the persistence of blood-borne CAR T cellspost infusion of EC17 with and without rescue and the phenotype postinfusion of EC17.

FIG. 62A and FIG. 62B show that CAR T cells localized in metastatictumor lesions, not adjacent healthy tissues, when EC17 is injected.

FIG. 63A-FIG. 63D show the design and characterization of ananti-fluorescein CAR T cell and fluorescein-folate bridge. FIG. 63Ashows the structure of fluorescein-folate (FITC-folate). FIG. 63B showsa diagram showing construction of anti-fluorescein CAR, where SP=signalpeptide, scFv=single chain variable fragment that recognizes fluoresceinwith a KD=270 fM, TM=transmembrane domain, 4-1BB=cytoplasmic activationdomain from CD137, and CD3=the cytoplasmic activation domain of CD3zeta. FIG. 63C shows transduction efficiency of CART cells evaluated byflow cytometry. Open histogram: Non-transduced T cells; filledhistogram: T cells transduced with lentivirus expressing GFP and the CARconstruct shown in (FIG. 63B). FIG. 63D demonstrates that FITC-folatebinds to anti-fluorescein CAR T cell. Filled histogram (grey):anti-fluorescein CAR T cell without staining; open histogram:anti-fluorescein CAR T cell labeled with FITC-Alexa647 (10 nM); filledhistogram (black): anti-fluorescein CAR T cell labeled withFITC-Alexa647 (10 nM) in the presence of competing 100-fold excessFITC-folate (1 μM)).

FIG. 64A-FIG. 64F show that FITC-folate bridge mediates anti-fluoresceinCAR T cell engagement with folate receptor-expressing cancer cells (KBcells). FIG. 64A demonstrates that FR is expressed on KB cells. Greyhistogram: KB cells without staining; Black histogram: KB cells labeledwith 100 nM FITC-folate in the presence of excess (10 μM) free folate ascompetitor; Open histogram: KB cells labeled with 100 nM FITC-folate.FIG. 64B shows cytotoxicity of CAR T cells towards KB cells uponaddition of correct FITC-folate (100 nM) but not mismatched FITC-DUPA(100 nM) or no (PBS) bridge. FIG. 64C shows an impact of effector:targetcell ratio on CART cell lysis of KB cells in presence of FITC-folate,FITC-DUPA, or no bridge. FIG. 64D shows IFNγ production is induced byaddition of FITC-folate (100 nM) but not FITC-DUPA (100 nM). FIG. 64Eshows proliferation of anti-fluorescein CAR T cells is induced byFITC-folate but not FITC-DUPA.

FIG. 64F shows expression of activation marker (CD69) onanti-fluorescein CAR T cells occurs only upon addition of correctbridge. For FIG. 64B, FIG. 64D, FIG. 64E and FIG. 64F, the ratio ofanti-fluorescein CAR T cells to KB cells was 10 to 1. Bar graphsrepresent mean±s.d. n=3. One-way ANOVA performed for all comparisons(****P<0.0001, **P<0.005, *P<0.01, ns (not significant)).

FIG. 65A-FIG. 65C show the dependence of CRS on presence ofanti-fluorescein CAR T cells, folate receptor positive cancer cells(MDA-MB-231 cells) and FITC-folate in vivo. FIG. 65A shows bodyweightchange (%) determined 4 days after anti-fluorescein CAR T cell (5×106)infusion into either tumor-free or tumor-bearing mice in the presence orabsence of FITC-folate (500 nmole/kg administered on days 1 and 2).**P<0.01 by one-way ANOVA test. FIG. 65B shows an effect of CAR T cellnumber on bodyweight change (%) on day 4 in tumor-bearing mice afteradministration of either PBS or 500 nmole/kg FITC-folate on days 1 and2. **P<0.05, ****P<0.0001 by one-way ANOVA test. FIG. 65C shows aneffect of CAR T cell number in tumor-bearing mice on plasma IFNγconcentration on day 4. ***P<0.001, ****P<0.0001, ns (not significant)by one-way ANOVA test. n=5 mice per group. Bar graphs representmean±s.e.m.

FIG. 66A-FIG. 66C show the control of CRS intensity by interruption ofbridge administration. FIG. 66A shows an analysis of body weight change(%) as a measure of CRS intensity after administration of a high dose ofanti-fluorescein CART cells (15×106) in the either absence (PBS) orpresence of FITC-folate (500 nmole/kg administered on days 1, and 2, andalternate days thereafter). In the interrupted dosing regimen, thecontinuous dosing schedule was followed except FITC-folate injectionswere omitted on days 4 and 6. FIG. 66B shows an analysis of IFNγ levelsin mouse plasma on day 6 using the dosing regimens described in part A.FIG. 66C shows a measurement of tumor volumes in mice treated asdescribed in part A. n=5 mice per group. Data represent mean±s.e.m.****P<0.0001 by one-way ANOVA test.

FIG. 67A-FIG. 67D show the effect of blockade of bridge via competitionwith free folate or free fluorescein on CAR T cell-mediatedcytotoxicity. FIG. 67A shows a measurement of body weight change (%)after administration of anti-fluorescein CAR T cells (15×106) in theabsence (PBS) or presence of FITC-folate (500 nmole/kg administered ondays 1, and 2, and alternate days thereafter). For competition studies,100-fold excess folate was co-injected on days 4 and 6. ****P<0.0001.FIG. 67B shows an analysis on day 6 of IFNγ levels in plasma of abovetreatment groups. **P<0.005. FIG. 67C shows measurements of tumor volumein same treatment groups. n=5 mice per group. Error bars representmean±s.e.m. FIG. 67D shows an analysis of time dependence of cytokinelevels in plasma of CAR T cell after administration of 12-fold excessfree fluorescein to suppress CRS. CRS was induced in all mice byinjection of 10×106 anti-fluorescein CART cells plus FITC-folate (500nmole/kg on day 3). On day 4, to suppress a potent CRS, 6 μmole/kg freefluorescein was injected, and the indicated cytokines were measured inplasma at 3 and 6 hours after administration of fluorescein. n=3mice/group. Data represent mean±s.e.m. **P<0.01, ***P<0.001,****P<0.0001 by two-way ANOVA test.

FIG. 68A-FIG. 68D show the effect of bridge concentration on theregulation of anti-fluorescein CAR T cell cytokine release andanti-tumor activity in vitro and in vivo. FIG. 68A shows lysis ofMDA-MB-231 cells in culture by anti-fluorescein CART cells(5:1=Effector:Tumor cell ratio) in the presence of variousconcentrations of FITC-folate (0.001 nM to 100000 nM). FIG. 68B showsIFNγ release from cells described in FIG. 68A. FIG. 68C shows the levelof IFNγ in the plasma of MDA-MB-231 tumor bearing mice 6 days afterinitiation of therapy by injection of 15×106 CAR T cells. Mice weretreated with 5, 50, 500, or 2500 nmole/kg FITC-folate on days 1, 2, 8,10 and alternate days thereafter (treatments on days 4 and 6 wereomitted to avoid a CRS). FIG. 68D shows an analysis of tumor growth intreatment groups of FIG. 68C. n=5 mice per group. Bar graphs representmean±s.e.m. ****P<0.0001 by one-way ANOVA test.

FIG. 69A-FIG. 69D show the prevention of CRS by gradual escalation ofbridge dose or decrease in bridge dosing frequency. Measurement of bodyweight change (FIG. 69A) and tumor volume (FIG. 69B) in MDA-MB-231tumor-bearing mice treated with 15×106 CAR T cells plus either PBS, or agradual escalation of FITC-folate dose (0.5 nmole/kg on days 1 and 2, 5nmole/kg on days 4 and 6, 50 nmole/kg on days 8 and 10, and 500 nmole/kgfrom day 12 onward), or a constant dose of 500 nmole/kg on alternatedays. ****P<0.0001 by two-way ANOVA test. Measurement of body weightchange (FIG. 69C) and tumor volume (FIG. 69D) in MDA-MB-231tumor-bearing mice treated with 5×106 CAR T cells plus either PBS orFITC-folate (500 nmole/kg) at different dosing frequencies of 1) onedose/week (on days 1, 8, 15 & etc.), 2), two doses/week (days 1, 4, 8,11, 15 & etc.), or three doses/week (days 1, 3, 5, 8, 10, 12, 15 &etc.). n=5 mice per group. All data represent mean±s.e.m.

FIG. 70A-FIG. 70C, FIG. 70A shows a dose escalation schema. FIG. 70B andFIG. 70C show the effect of EC17 dose escalation on the anti-tumoractivity and the toxicity (body weight changes) of CAR-T therapy.

FIG. 71A-FIG. 71C, FIG. 71A shows a scheme for testing whether tumorsize correlates with body weight changes and IL-6 release duringCAR-T/EC17 therapy. FIG. 71B and FIG. 71C show the results for bodyweight change and IL-6 levels, respectively.

FIG. 72A and FIG. 72B, FIG. 72A shows a scheme for testing whetherCAR-T/EC17 therapy is effective in an osteosarcoma model. FIG. 72B showsthe tumor size results.

FIG. 73 shows body weight changes for the tests described for FIG. 72Aand FIG. 72B.

FIG. 74A, FIG. 74B, FIG. 74C, FIG. 74D, FIG. 74E, and FIG. 74F show thatHOS cancer cells express the FR-α.

FIG. 75 shows a scheme for testing whether cytokines are produced inresponse to CAR-T/EC17 therapy and whether NaFL rescues the mice fromCRS.

FIG. 76A, FIG. 76B, FIG. 76C, FIG. 76D, and FIG. 76E show reduction ofmouse cytokine production by 60 umol/kg NaFL 7 hours post NaFL rescue.

FIG. 77A, FIG. 77B, and FIG. 77C show reduction of mouse cytokineproduction by 60 umol/kg NaFL 27 hours post NaFL rescue.

FIG. 78 shows a scheme for testing reduction of mouse cytokineproduction in response to CAR-T/EC17 therapy by various concentrationsof NaFL.

FIG. 79 shows reduction of MCP-1 in response to CAR-T/EC17 therapy byNaFL rescue.

FIG. 80 shows reduction of IL-6 in response to CAR-T/EC17 therapy byNaFL rescue.

FIG. 81 shows reduction of IL-10 in response to CAR-T/EC17 therapy byNaFL rescue.

FIG. 82A and FIG. 82B, FIG. 82A shows a scheme for testing whether MCP-1production in response to CAR-T/EC17 therapy correlates with CAR-T cellnumber. FIG. 82B shows that MCP-1 production in response to CAR-T/EC17therapy correlates with CAR-T cell number.

DEFINITIONS

As used herein, “a” or “an” may mean one or more. As used herein,“about” in reference to a numeric value, including, for example, wholenumbers, fractions, and percentages, generally refers to a range ofnumerical values (e.g., +/−5% to 10% of the recited value) that one ofordinary skill in the art would consider equivalent to the recited value(e.g., having the same function or result).

As used herein, the terms “treat,” “treating,” “treated,” or “treatment”refer to both therapeutic treatment and prophylactic or preventativetreatment.

As used herein, the terms “ameliorate,” “ameliorating,” “amelioration,”or “ameliorated” in reference to cancer can mean reducing the symptomsof the cancer, reducing the size of a tumor, completely or partiallyremoving the tumor (e.g., a complete or partial response), causingstable disease, preventing progression of the cancer (e.g., progressionfree survival), or any other effect on the cancer that would beconsidered by a physician to be a therapeutic, prophylactic, orpreventative treatment of the cancer.

As used herein, the terms “administer,” administering,” or“administered” mean all means of introducing the compound, orpharmaceutically acceptable salt thereof, or CAR T cell compositiondescribed herein to the patient, including, but not limited to, oral,intravenous, intramuscular, subcutaneous, and transdermal.

As used herein, the term “off-target toxicity” means organ damage or areduction in the patient's weight that is unacceptable to the physiciantreating the patient, or any other effect on the patient that isunacceptable to the physician treating the patient, for example, B cellaplasia, a fever, a drop in blood pressure, or pulmonary edema.

As used herein, the terms “transduction” and “transfection” are usedequivalently and the terms mean introducing a nucleic acid into a cellby any artificial method, including viral and non-viral methods.

DETAILED DESCRIPTION OF THE ILLUSTRATIVE EMBODIMENTS

In the various embodiments described herein, a small molecule ligandlinked to a targeting moiety by a linker is used as a bridge between acancer and CAR T cells (i.e, T cells expressing a chimeric antigenreceptor). The bridge directs the CAR T cells to the cancer foramelioration of the cancer. In one embodiment, the “small moleculeligand” can be a folate, a CAIX ligand, DUPA, an NK-1R ligand, a ligandof gamma glutamyl transpeptidase, an NKG2D ligand, or a CCK2R ligand,each of which is a small molecule ligand that binds specifically to acancer cell type (i.e., the receptor for each of these ligands isoverexpressed on cancers compared to normal tissues).

The “targeting moiety” linked to the small molecule ligand binds to therecognition region of the genetically engineered CAR expressed by CAR Tcells.

Accordingly, the recognition region of the CAR (e.g., a single chainfragment variable region (scFv) of an antibody, an Fab, Fv, Fc, or(Fab′)2 fragment, and the like) is directed to the “targeting moiety.”Thus, the small molecule ligand linked to a targeting moiety by a linkeracts as a bridge between the cancer and the CAR T cells directing theCAR T cells to the cancer for amelioration of the cancer. In variousembodiments, the bridge between the cancer and the CAR T cells can beany of the conjugates shown in the Examples.

The bridge is a small organic molecule so clearance from the bloodstreamcan be rapidly achieved (e.g., about 20 minutes or less). In one aspect,the CAR T cell response can be targeted to only those cancer cellsexpressing a receptor for the small molecule ligand portion of the‘bridge,’ thereby reducing off-target toxicity to normal tissues.Additionally, this system can be ‘universal’ because one type of CAR Tcell construct can be used to target a wide variety of cancers usingdifferent ‘bridges’. Illustratively, the targeting moiety recognized bythe CAR T cell may remain constant so that one type of CAR T cellconstruct can be used, while the small molecule ligand that binds to thecancer can be altered to allow targeting of a wide variety of cancers.

In various embodiments described in the clause list below and in theclaims and throughout the application, the small molecule ligand linkedto a targeting moiety by a linker is referred to as a “compound.”

Several embodiments are described by the following enumerated clauses.Any of the following embodiments in combination with any applicableembodiments described in the Summary section of this patent application,in the Detailed Description of the Illustrative Embodiments section, theExamples section, or the claims of this patent application, are alsocontemplated.

1. A method of treatment of a cancer, the method comprising

-   -   i) administering to a patient a compound, or a pharmaceutically        acceptable salt thereof, wherein the compound comprises a small        molecule ligand linked to a targeting moiety by a linker;    -   ii) administering to the patient a first dose of a CAR T cell        composition comprising CAR T cells wherein the CAR T cells        comprise a CAR directed to the targeting moiety; and    -   iii) administering to the patient a second dose of a CAR T cell        composition comprising CAR T cells wherein the CAR T cells        comprise the CAR directed to the targeting moiety.

2. The method of clause 1 wherein the ligand is selected from the groupconsisting of a folate, DUPA, an NK-1R ligand, a CAIX ligand, a ligandof gamma glutamyl transpeptidase, an NKG2D ligand, and a CCK2R ligand.

3. The method of any one of clauses 1 or 2 wherein the ligand is afolate.

4. The method of any one of clauses 1 or 2 wherein the ligand is anNK-1R ligand.

5. The method of any one of clauses 1 or 2 wherein the ligand is DUPA.

6. The method of any one of clauses 1 or 2 wherein the ligand is a CCK2Rligand.

7. The method of any one of clauses 1 or 2 wherein the ligand is aligand of gamma glutamyl transpeptidase.

8. The method of any one of clauses 1 to 7 wherein the targeting moietyis selected from the group consisting of 2,4-dinitrophenol (DNP),2,4,6-trinitrophenol (TNP), biotin, digoxigenin, fluorescein,fluorescein isothiocyanate (FITC), NHS-fluorescein, pentafluorophenylester, tetrafluorophenyl ester, a knottin, a centyrin, and a DARPin.

9. The method of any one of clauses 1 to 8 wherein the targeting moietyis FITC.

10. The method of any one of clauses 1 to 8 wherein the targeting moietyis DNP.

11. The method of any one of clauses 1 to 8 wherein the targeting moietyis TNP.

12. The method of any one of clauses 1 to 11 wherein the linkercomprises polyethylene glycol (PEG), polyproline, a hydrophilic aminoacid, a sugar, an unnatural peptidoglycan, a polyvinylpyrrolidone,pluronic F-127, or a combination thereof.

13. The method of any one of clauses 1 to 12 wherein the linkercomprises PEG.

14. The method of any one of clauses 1 to 13 wherein the compound, orthe pharmaceutically acceptable salt thereof, has the formula

B-L-T,

wherein B represents the small molecule ligand, L represents the linker,and T represents the targeting moiety, and wherein L comprises astructure having the formula

wherein n is an integer from 0 to 200.

15. The method of clause 14 wherein n is an integer from 0 to 150.

16. The method of clause 14 wherein n is an integer from 0 to 110.

17. The method of clause 14 wherein n is an integer from 0 to 20.

18. The method of clause 14 wherein n is an integer from 15 to 20.

19. The method of clause 14 wherein n is an integer from 15 to 110.

20. The method of any one of clauses 1 to 9 or 12 to 19 wherein thelinker comprises PEG and the targeting moiety is FITC, or apharmaceutically acceptable salt thereof.

21. The method of any one of clauses 1 to 20 wherein the compound, orthe pharmaceutically acceptable salt thereof, is administered at a doseof about 10 nmoles/kg to about 10000 nmoles/kg of body weight of thepatient.

22. The method of any one of clauses 1 to 21 wherein the compound, orthe pharmaceutically acceptable salt thereof, is administered at a doseof about 10 nmoles/kg to about 5000 nmoles/kg of body weight of thepatient.

23. The method of any one of clauses 1 to 22 wherein the compound, orthe pharmaceutically acceptable salt thereof, is administered at a doseof about 10 nmoles/kg to about 1000 nmoles/kg of body weight of thepatient.

24. The method of any one of clauses 1 to 23 wherein the compound, orthe pharmaceutically acceptable salt thereof, is administered at a doseof about 10 nmoles/kg to about 600 nmoles/kg of body weight of thepatient.

25. The method of any one of clauses 1 to 24 wherein the compound, orthe pharmaceutically acceptable salt thereof, is administered at a doseof about 200 nmoles/kg to about 600 nmoles/kg of body weight of thepatient.

26. The method of any one of clauses 1 to 25 wherein the compound, orthe pharmaceutically acceptable salt thereof, is administered at a doseof about 250 nmoles/kg to about 600 nmoles/kg of body weight of thepatient.

27. The method of any one of clauses 1 to 26 wherein the cancer isselected from the group consisting of lung cancer, bone cancer,pancreatic cancer, skin cancer, cancer of the head, cancer of the neck,cutaneous melanoma, intraocular melanoma uterine cancer, ovarian cancer,endometrial cancer, rectal cancer, stomach cancer, colon cancer, breastcancer, triple negative breast cancer, carcinoma of the fallopian tubes,carcinoma of the endometrium, carcinoma of the cervix, carcinoma of thevagina, carcinoma of the vulva, Hodgkin's Disease, cancer of theesophagus, cancer of the small intestine, cancer of the endocrinesystem, cancer of the thyroid gland, cancer of the parathyroid gland,non-small cell lung cancer, cancer of the adrenal gland, sarcoma of softtissue, osteosarcoma, cancer of the urethra, prostate cancer, chronicleukemia, acute leukemia, acute myelocytic leukemia, lymphocyticlymphoma, myeloid leukemia, myelomonocytic leukemia, hairy cellleukemia, pleural mesothelioma, cancer of the bladder, Burkitt'slymphoma, cancer of the ureter, cancer of the kidney, renal cellcarcinoma, carcinoma of the renal pelvis, neoplasms of the centralnervous system (CNS), primary CNS lymphoma, spinal axis tumors, brainstem glioma, pituitary adenoma, and adenocarcinoma of thegastroesophageal junction.

161. 28. The method of any one of clauses 1 to 3 or 8 to 27 wherein thecancer is a folate receptor expressing cancer.

162. 29. The method of clause 28 wherein the cancer is an endometrialcancer.

163. 30. The method of clause 28 wherein the cancer is a non-small celllung cancer.

164. 31. The method of clause 28 wherein the cancer is an ovariancancer.

165. 32. The method of clause 28 wherein the cancer is a triple negativebreast cancer.

33. The method of any one of clauses 1 to 32 wherein the CAR has arecognition region and the recognition region is a single chain fragmentvariable (scFv) region of an antibody.

34. The method of any one of clauses 1 to 9 or 12 to 33 wherein the CARhas a recognition region and the recognition region of the CAR is asingle chain fragment variable (scFv) region of an anti-FITC antibody.

35. The method of any one of clauses 1 to 34 wherein the CAR has aco-stimulation domain and the co-stimulation domain is selected from thegroup consisting of CD28, CD137 (4-1BB), CD134 (OX40), and CD278 (ICOS).

36. The method of any one of clauses 1 to 35 wherein the CAR has anactivation signaling domain and the activation signaling domain is a Tcell CD3ζ chain or an Fc receptor γ.

37. The method of any one of clauses 1 to 9 or 12 to 36 wherein the CARhas a recognition region and the recognition region is a single chainfragment variable (scFv) region of an anti-FITC antibody, wherein theCAR has a co-stimulation domain and the co-stimulation domain is CD137(4-1BB), and wherein the CAR has an activation signaling domain and theactivation signaling domain is a T cell CD3ζ chain.

166. 38. The method of any one of clauses 1 to 37 wherein multiple dosesof the compound, or the pharmaceutically acceptable salt thereof, andthe CAR T cell composition are administered.

39. The method of any one of clauses 1 to 38 wherein the patient isimaged prior to administration of the compound, or the pharmaceuticallyacceptable salt thereof, or prior to administration of the CAR T cellcomposition.

167. 40. The method of any one of clauses 1 to 39 wherein the compound,or the pharmaceutically acceptable salt thereof, is not an antibody, anddoes not comprise a fragment of an antibody.

168. 41. The method of any one of clauses 1 to 40 wherein the targetingmoiety does not comprise a peptide epitope.

42. The method of any one of clauses 1 to 41 wherein cytokine releaseresulting in off-target toxicity in the patient does not occur andwherein CAR T cell toxicity to the cancer occurs.

169. 43. The method of any one of clauses 1 to 41 wherein off-targettissue toxicity does not occur in the patient and wherein CAR T celltoxicity to the cancer occurs.

170. 44. The method of any one of clauses 1 to 41 wherein the cancercomprises a tumor, wherein tumor size is reduced in the patient, andwherein off-target toxicity does not occur.

171. 45. The method of any one of clauses 1 to 44 wherein the CART cellscomprise a nucleic acid comprising SEQ ID NO:1.

172. 46. The method of any one of clauses 1 to 45 wherein the CAR Tcells comprise a polypeptide comprising SEQ ID NO:2.

173. 47. The method of clause 45 wherein the nucleic acid encodes achimeric antigen receptor.

174. 48. The method of any one of clauses 1 to 47 wherein the CARcomprises humanized amino acid sequences.

175. 49. The method of any one of clauses 1 to 47 wherein the CARconsists of humanized amino acid sequences.

176. 50. The method of any one of clauses 1 to 49 wherein the first doseof the CAR T cell composition comprises a mixture of the CAR T cells andnon-transformed T cells in a ratio selected from about 1:5 of the CAR Tcells to the non-transformed T cells, about 1:4 of the CAR T cells tothe non-transformed T cells, about 1:3 of the CART cells to thenon-transformed T cells, about 1:2 of the CAR T cells to thenon-transformed T cells, and about 1:1 of the CAR T cells to thenon-transformed T cells.

177. 51. The method of any one of clauses 1 to 50 wherein the seconddose of the CAR T cell composition comprises a mixture of the CAR Tcells and non-transformed T cells in a ratio selected from about 1:5 ofthe CAR T cells to the non-transformed T cells, about 1:4 of the CAR Tcells to the non-transformed T cells, about 1:3 of the CART cells to thenon-transformed T cells, about 1:2 of the CAR T cells to thenon-transformed T cells, and about 1:1 of the CAR T cells to thenon-transformed T cells.

178. 52. The method of any one of clauses 1 to 51 wherein the first doseof the CAR T cell composition comprises a mixture of the CAR T cells andnon-transformed T cells in a ratio of from about 1:1 to about 1:5 of theCART cells to the non-transformed T cells.

179. 53. The method of any one of clauses 1 to 52 wherein the seconddose of the CAR T cell composition comprises a mixture of the CAR Tcells and non-transformed T cells in a ratio of from about 1:1 to 1:5 ofthe CART cells to the non-transformed T cells.

180. 54. The method of any one of clauses 1 to 53 wherein the first doseof the CART cell composition comprises a mixture of about 10 million ofthe CAR T cells and about 40 million non-transformed T cells.

181. 55. The method of any one of clauses 1 to 54 wherein the seconddose of the CART cell composition comprises a mixture of about 10million of the CAR T cells and about 40 million non-transformed T cells.

56. A method of treatment of a cancer, the method comprising

-   -   i) administering to a patient a compound, or a pharmaceutically        acceptable salt thereof, wherein the compound comprises a small        molecule ligand linked to a targeting moiety by a linker; and    -   ii) administering to the patient a CAR T cell composition        wherein the CAR T cell composition comprises CAR T cells,        wherein the CAR T cells comprise a CAR directed to the targeting        moiety, and wherein the CAR T cell composition comprises a        mixture of the CAR T cells and non-transformed T cells.

57. The method of clause 56 wherein the ligand is selected from thegroup consisting of a folate, DUPA, an NK-1R ligand, a CAIX ligand, aligand of gamma glutamyl transpeptidase, an NKG2D ligand, and a CCK2Rligand.

58. The method of any one of clauses 56 or 57 wherein the ligand is afolate.

59. The method of any one of clauses 56 or 57 wherein the ligand is anNK-1R ligand.

60. The method of any one of clauses 56 or 57 wherein the ligand isDUPA.

61. The method of any one of clauses 56 or 57 wherein the ligand is aCCK2R ligand.

62. The method of any one of clauses 56 or 57 wherein the ligand is aligand of gamma glutamyl transpeptidase.

63. The method of any one of clauses 56 to 62 wherein the targetingmoiety is selected from the group consisting of 2,4-dinitrophenol (DNP),2,4,6-trinitrophenol (TNP), biotin, digoxigenin, fluorescein,fluorescein isothiocyanate (FITC), NHS-fluorescein, pentafluorophenylester, tetrafluorophenyl ester, a knottin, a centyrin, and a DARPin.

64. The method of any one of clauses 56 to 63 wherein the targetingmoiety is FITC.

65. The method of any one of clauses 56 to 63 wherein the targetingmoiety is DNP.

66. The method of any one of clauses 56 to 63 wherein the targetingmoiety is TNP.

67. The method of any one of clauses 56 to 66 wherein the linkercomprises polyethylene glycol (PEG), polyproline, a hydrophilic aminoacid, a sugar, an unnatural peptidoglycan, a polyvinylpyrrolidone,pluronic F-127, or a combination thereof.

68. The method of any one of clauses 56 to 67 wherein the linkercomprises PEG.

69. The method of any one of clauses 56 to 68 wherein the compound, orthe pharmaceutically acceptable salt thereof, has the formula

B-L-T,

wherein B represents the small molecule ligand, L represents the linker,and T represents the targeting moiety, and wherein L comprises astructure having the formula

wherein n is an integer from 0 to 200.

70. The method of clause 69 wherein n is an integer from 0 to 150.

71. The method of clause 69 wherein n is an integer from 0 to 110.

72. The method of clause 69 wherein n is an integer from 0 to 20.

73. The method of clause 69 wherein n is an integer from 15 to 20.

74. The method of clause 69 wherein n is an integer from 15 to 110.

75. The method of any one of clauses 56 to 64 or 67 to 74 wherein thelinker comprises PEG and the targeting moiety is FITC, or apharmaceutically acceptable salt thereof.

76. The method of any one of clauses 56 to 75 wherein the compound, orthe pharmaceutically acceptable salt thereof, is administered at a doseof about 10 nmoles/kg to about 10000 nmoles/kg of body weight of thepatient.

77. The method of any one of clauses 56 to 76 wherein the compound, orthe pharmaceutically acceptable salt thereof, is administered at a doseof about 10 nmoles/kg to about 5000 nmoles/kg of body weight of thepatient.

78. The method of any one of clauses 56 to 77 wherein the compound, orthe pharmaceutically acceptable salt thereof, is administered at a doseof about 10 nmoles/kg to about 1000 nmoles/kg of body weight of thepatient.

79. The method of any one of clauses 56 to 78 wherein the compound, orthe pharmaceutically acceptable salt thereof, is administered at a doseof about 10 nmoles/kg to about 600 nmoles/kg of body weight of thepatient.

80. The method of any one of clauses 56 to 79 wherein the compound, orthe pharmaceutically acceptable salt thereof, is administered at a doseof about 200 nmoles/kg to about 600 nmoles/kg of body weight of thepatient.

81. The method of any one of clauses 56 to 80 wherein the compound, orthe pharmaceutically acceptable salt thereof, is administered at a doseof about 250 nmoles/kg to about 600 nmoles/kg of body weight of thepatient.

82. The method of any one of clauses 56 to 81 wherein the cancer isselected from the group consisting of lung cancer, bone cancer,pancreatic cancer, skin cancer, cancer of the head, cancer of the neck,cutaneous melanoma, intraocular melanoma uterine cancer, ovarian cancer,endometrial cancer, rectal cancer, stomach cancer, colon cancer, breastcancer, triple negative breast cancer, carcinoma of the fallopian tubes,carcinoma of the endometrium, carcinoma of the cervix, carcinoma of thevagina, carcinoma of the vulva, Hodgkin's Disease, cancer of theesophagus, cancer of the small intestine, cancer of the endocrinesystem, cancer of the thyroid gland, cancer of the parathyroid gland,non-small cell lung cancer, cancer of the adrenal gland, sarcoma of softtissue, osteosarcoma, cancer of the urethra, prostate cancer, chronicleukemia, acute leukemia, acute myelocytic leukemia, lymphocyticlymphoma, myeloid leukemia, myelomonocytic leukemia, hairy cellleukemia, pleural mesothelioma, cancer of the bladder, Burkitt'slymphoma, cancer of the ureter, cancer of the kidney, renal cellcarcinoma, carcinoma of the renal pelvis, neoplasms of the centralnervous system (CNS), primary CNS lymphoma, spinal axis tumors, brainstem glioma, pituitary adenoma, and adenocarcinoma of thegastroesophageal junction.

182. 83. The method of any one of clauses 56 to 58 or 63 to 82 whereinthe cancer is a folate receptor expressing cancer.

183. 84. The method of clause 83 wherein the cancer is an endometrialcancer.

184. 85. The method of clause 83 wherein the cancer is a non-small celllung cancer.

185. 86. The method of clause 83 wherein the cancer is an ovariancancer.

186. 87. The method of clause 83 wherein the cancer is a triple negativebreast cancer.

88. The method of any one of clauses 56 to 87 wherein the CAR has arecognition region and the recognition region is a single chain fragmentvariable (scFv) region of an antibody.

89. The method of any one of clauses 56 to 64 or 67 to 88 wherein theCAR has a recognition region and the recognition region of the CAR is asingle chain fragment variable (scFv) region of an anti-FITC antibody.

90. The method of any one of clauses 56 to 89 wherein the CAR has aco-stimulation domain and the co-stimulation domain is selected from thegroup consisting of CD28, CD137 (4-1BB), CD134 (OX40), and CD278 (ICOS).

91. The method of any one of clauses 56 to 90 wherein the CAR has anactivation signaling domain and the activation signaling domain is a Tcell CD3ζ chain or an Fc receptor γ.

92. The method of any one of clauses 56 to 64 or 67 to 91 wherein theCAR has a recognition region and the recognition region is a singlechain fragment variable (scFv) region of an anti-FITC antibody, whereinthe CAR has a co-stimulation domain and the co-stimulation domain isCD137 (4-1BB), and wherein the CAR has an activation signaling domainand the activation signaling domain is a T cell CD3ζ chain.

187. 93. The method of any one of clauses 56 to 92 wherein multipledoses of the compound, or the pharmaceutically acceptable salt thereof,are administered.

94. The method of any one of clauses 56 to 93 wherein the patient isimaged prior to administration of the compound, or the pharmaceuticallyacceptable salt thereof, or prior to administration of the CAR T cellcomposition.

188. 95. The method of any one of clauses 56 to 94 wherein the compound,or the pharmaceutically acceptable salt thereof, is not an antibody, anddoes not comprise a fragment of an antibody.

189. 96. The method of any one of clauses 56 to 95 wherein the targetingmoiety does not comprise a peptide epitope.

190. 97. The method of any one of clauses 56 to 96 wherein cytokinerelease resulting in off-target toxicity in the patient does not occurand wherein CAR T cell toxicity to the cancer occurs.

191. 98. The method of any one of clauses 56 to 96 wherein off-targettissue toxicity does not occur in the patient and wherein CAR T celltoxicity to the cancer occurs.

192. 99. The method of any one of clauses 56 to 96 wherein the cancercomprises a tumor, wherein tumor size is reduced in the patient, andwherein off-target toxicity does not occur.

193. 100. The method of any one of clauses 56 to 99 wherein the CARTcells comprise a nucleic acid comprising SEQ ID NO:1.

194. 101. The method of any one of clauses 56 to 100 wherein the CAR Tcells comprise a polypeptide comprising SEQ ID NO:2.

195. 102. The method of clause 100 wherein the nucleic acid encodes achimeric antigen receptor.

196. 103. The method of any one of clauses 56 to 102 wherein the CARcomprises humanized amino acid sequences.

197. 104. The method of any one of clauses 56 to 102 wherein the CARconsists of humanized amino acid sequences.

198. 105. The method of any one of clauses 56 to 104 wherein the mixtureof the CAR T cells and the non-transformed T cells is in a ratioselected from about 1:5 of the CART cells to the non-transformed Tcells, about 1:4 of the CAR T cells to the non-transformed T cells,about 1:3 of the CART cells to the non-transformed T cells, about 1:2 ofthe CAR T cells to the non-transformed T cells, and about 1:1 of theCART cells to the non-transformed T cells.

199. 106. The method of any one of clauses 56 to 105 wherein the mixtureof the CAR T cells and the non-transformed T cells is in a ratio of fromabout 1:1 to about 1:5 of the CAR T cells to the non-transformed Tcells.

200. 107. The method of any one of clauses 56 to 106 wherein the mixtureof the CAR T cells and the non-transformed T cells comprises about 10million of the CAR T cells and about 40 million of the non-transformed Tcells.

108. A method of treatment of a cancer, the method comprising

-   -   i) administering to a patient a compound, or a pharmaceutically        acceptable salt thereof, wherein the compound comprises a small        molecule ligand linked to a targeting moiety by a linker;    -   ii) administering to the patient a CAR T cell composition        wherein the CAR T cell composition comprises CAR T cells and        wherein the CAR T cells comprise a CAR directed to the targeting        moiety; and    -   iii) administering to the patient a folate, a conjugate        comprising a folate wherein the conjugate comprising a folate        does not comprise a targeting moiety, or an agent that inhibits        activation of the CAR T cells.

109. The method of clause 108 wherein step iii comprises administering afolate.

110. The method of any one of clauses 108 or 109 wherein step iiicomprises administering folic acid or leucovorin.

111. The method of clause 108 wherein step iii comprises administeringthe conjugate comprising a folate.

112. The method of clause 111 wherein the conjugate comprising a folatecomprises a folate linked to one or more amino acids.

113. The method of clause 111 wherein the conjugate comprising a folatehas the formula

114. The method of any one of clauses 109 to 112 wherein the folate hasthe formula

wherein X¹ and Y¹ are each-independently selected from the groupconsisting of halo, R², OR², SR³, and NR⁴R⁵;

U, V, and W represent divalent moieties each independently selected fromthe group consisting of —(R^(6a))C═, —N═, —(R^(6a))C(R^(7a))—, and—N(R^(4a))—; Q is selected from the group consisting of C and CH; T isselected from the group consisting of S, O, N, and —C═C—;

X² and X³ are each independently selected from the group consisting ofoxygen, sulfur, —C(Z)—, —C(Z)O—, —OC(Z)—, —N(R^(4b))—, —C(Z)N(R^(4b))—,—N(R^(4b))C(Z)—, —OC(Z)N(R^(4b))—, —N(R^(4b))C(Z)O—,—N(R^(4b))C(Z)N(R^(5b))—, —S(O)—, —S(O)₂—, —N(R^(4a))S(O)₂—, —C(R^(6b))(R^(7b))—, —N(C≡CH)—, —N(CH₂C≡CH)—, C₁-C₁₂ alkylene, and C₁-C₁₂alkyeneoxy, where Z is oxygen or sulfur;

R¹ is selected-from the group consisting of hydrogen, halo, C₁-C₁₂alkyl, and

C₁-C₁₂ alkoxy;

R², R³, R⁴, R^(4a), R^(4b), R⁵, R^(5b), R^(6b), and R^(7b) are eachindependently selected from the group consisting of hydrogen, halo,C₁-C₁₂ alkyl, C₁-C₁₂ alkoxy, C₁-C₁₂ alkanoyl, C₁-C₁₂ alkenyl, C₁-C₁₂alkynyl, (C₁-C₁₂ alkoxy)carbonyl, and (C₁-C₁₂ alkylamino)carbonyl;

R⁶ and R⁷ are each independently selected from the group consisting ofhydrogen, halo, C₁-C₁₂ alkyl, and C₁-C₁₂ alkoxy; or, R⁶ and R⁷ are takentogether to form a carbonyl group;

R^(6a) and R^(7a) are each independently selected from the groupconsisting of hydrogen, halo, C₁-C₁₂ alkyl, and C₁-C₁₂ alkoxy; or R^(6a)and R^(7a) are taken together to form a carbonyl group;

p, r, s, and t are each independently either 0 or 1; and

* represents an optional covalent bond to the rest of the conjugate, ifany additional chemical moieties are part of the folate.

115. The method of any one of clauses 108 to 114 wherein the targetingmoiety is selected from the group consisting of 2,4-dinitrophenol (DNP),2,4,6-trinitrophenol (TNP), biotin, digoxigenin, fluorescein,fluorescein isothiocyanate (FITC), NHS-fluorescein, pentafluorophenylester, tetrafluorophenyl ester, a knottin, a centyrin, and a DARPin.

116. The method of any one of clauses 108 to 115 wherein the targetingmoiety is FITC.

117. The method of any one of clauses 108 to 115 wherein the targetingmoiety is DNP.

118. The method of any one of clauses 108 to 115 wherein the targetingmoiety is TNP.

119. The method of any one of clauses 108 to 118 wherein the linkercomprises polyethylene glycol (PEG), polyproline, a hydrophilic aminoacid, a sugar, an unnatural peptidoglycan, a polyvinylpyrrolidone,pluronic F-127, or a combination thereof.

120. The method of any one of clauses 108 to 119 wherein the linkercomprises PEG.

121. The method of any one of clauses 108 to 120 wherein the compound,or the pharmaceutically acceptable salt thereof, has the formula

B-L-T,

wherein B represents the small molecule ligand, L represents the linker,and T represents the targeting moiety, and wherein L comprises astructure having the formula

wherein n is an integer from 0 to 200.

122. The method of clause 121 wherein n is an integer from 0 to 12.

123. The method of clause 121 wherein n is an integer from 0 to 150.

124. The method of clause 121 wherein n is an integer from 0 to 110.

125. The method of clause 121 wherein n is an integer from 0 to 20.

126. The method of clause 121 wherein n is an integer from 15 to 20.

127. The method of clause 121 wherein n is an integer from 15 to 110.

128. The method of any one of clauses 108 to 116 or 119 to 127 whereinthe linker comprises PEG and the targeting moiety is FITC, or apharmaceutically acceptable salt thereof.

129. The method of any one of clauses 108 to 128 wherein the compound,or the pharmaceutically acceptable salt thereof, is administered at adose of about 10 nmoles/kg to about 10000 nmoles/kg of body weight ofthe patient.

130. The method of any one of clauses 108 to 129 wherein the compound,or the pharmaceutically acceptable salt thereof, is administered at adose of about 10 nmoles/kg to about 5000 nmoles/kg of body weight of thepatient.

131. The method of any one of clauses 108 to 130 wherein the compound,or the pharmaceutically acceptable salt thereof, is administered at adose of about 10 nmoles/kg to about 1000 nmoles/kg of body weight of thepatient.

132. The method of any one of clauses 108 to 131 wherein the compound,or the pharmaceutically acceptable salt thereof, is administered at adose of about 10 nmoles/kg to about 600 nmoles/kg of body weight of thepatient.

133. The method of any one of clauses 108 to 132 wherein the compound,or the pharmaceutically acceptable salt thereof, is administered at adose of about 200 nmoles/kg to about 600 nmoles/kg of body weight of thepatient.

134. The method of any one of clauses 108 to 133 wherein the compound,or the pharmaceutically acceptable salt thereof, is administered at adose of about 250 nmoles/kg to about 600 nmoles/kg of body weight of thepatient.

135. The method of any one of clauses 108 to 134 wherein the cancer isselected from the group consisting of lung cancer, bone cancer,pancreatic cancer, skin cancer, cancer of the head, cancer of the neck,cutaneous melanoma, intraocular melanoma uterine cancer, ovarian cancer,endometrial cancer, rectal cancer, stomach cancer, colon cancer, breastcancer, triple negative breast cancer, carcinoma of the fallopian tubes,carcinoma of the endometrium, carcinoma of the cervix, carcinoma of thevagina, carcinoma of the vulva, Hodgkin's Disease, cancer of theesophagus, cancer of the small intestine, cancer of the endocrinesystem, cancer of the thyroid gland, cancer of the parathyroid gland,non-small cell lung cancer, cancer of the adrenal gland, sarcoma of softtissue, osteosarcoma, cancer of the urethra, prostate cancer, chronicleukemia, acute leukemia, acute myelocytic leukemia, lymphocyticlymphoma, myeloid leukemia, myelomonocytic leukemia, hairy cellleukemia, pleural mesothelioma, cancer of the bladder, Burkitt'slymphoma, cancer of the ureter, cancer of the kidney, renal cellcarcinoma, carcinoma of the renal pelvis, neoplasms of the centralnervous system (CNS), primary CNS lymphoma, spinal axis tumors, brainstem glioma, pituitary adenoma, and adenocarcinoma of thegastroesophageal junction.

201. 136. The method of any one of clauses 108 to 135 wherein the ligandportion of the small molecule ligand linked to a targeting moiety by alinker is a folate and the cancer is a folate receptor expressingcancer.

202. 137. The method of clause 136 wherein the cancer is an endometrialcancer.

203. 138. The method of clause 136 wherein the cancer is a non-smallcell lung cancer.

204. 139. The method of clause 136 wherein the cancer is an ovariancancer.

205. 140. The method of clause 136 wherein the cancer is a triplenegative breast cancer.

141. The method of any one of clauses 108 to 140 wherein the CAR has arecognition region and the recognition region is a single chain fragmentvariable (scFv) region of an antibody.

142. The method of any one of clauses 108 to 116 or 119 to 141 whereinthe CAR has a recognition region and the recognition region of the CARis a single chain fragment variable (scFv) region of an anti-FITCantibody.

143. The method of any one of clauses 108 to 142 wherein the CAR has aco-stimulation domain and the co-stimulation domain is selected from thegroup consisting of CD28, CD137 (4-1BB), CD134 (OX40), and CD278 (ICOS).

144. The method of any one of clauses 108 to 143 wherein the CAR has anactivation signaling domain and the activation signaling domain is a Tcell CD3ζ chain or an Fc receptor γ.

145. The method of any one of clauses 108 to 116 or 119 to 144 whereinthe CAR has a recognition region and the recognition region is a singlechain fragment variable (scFv) region of an anti-FITC antibody, whereinthe CAR has a co-stimulation domain and the co-stimulation domain isCD137 (4-1BB), and wherein the CAR has an activation signaling domainand the activation signaling domain is a T cell CD3ζ chain.

206. 146. The method of any one of clauses 108 to 145 wherein multipledoses of the compound, or the pharmaceutically acceptable salt thereof,and/or the CAR T cell composition are administered.

147. The method of any one of clauses 108 to 146 wherein the patient isimaged prior to administration of the compound, or the pharmaceuticallyacceptable salt thereof, or prior to administration of the CAR T cellcomposition.

207. 148. The method of any one of clauses 108 to 147 wherein thecompound, or the pharmaceutically acceptable salt thereof, is not anantibody, and does not comprise a fragment of an antibody.

208. 149. The method of any one of clauses 108 to 148 wherein thetargeting moiety does not comprise a peptide epitope.

209. 150. The method of any one of clauses 108 to 149 wherein cytokinerelease resulting in off-target toxicity in the patient does not occurand wherein CAR T cell toxicity to the cancer occurs.

210. 151. The method of any one of clauses 108 to 149 wherein off-targettissue toxicity does not occur in the patient and wherein CAR T celltoxicity to the cancer occurs.

211. 152. The method of any one of clauses 108 to 149 wherein the cancercomprises a tumor, wherein tumor size is reduced in the patient, andwherein off-target toxicity does not occur.

212. 153. The method of any one of clauses 108 to 152 wherein the CARTcells comprise a nucleic acid comprising SEQ ID NO:1.

213. 154. The method of any one of clauses 108 to 153 wherein the CAR Tcells comprise a polypeptide comprising SEQ ID NO:2.

214. 155. The method of clause 153 wherein the nucleic acid encodes achimeric antigen receptor.

215. 156. The method of any one of clauses 108 to 155 wherein the CARcomprises humanized amino acid sequences.

216. 157. The method of any one of clauses 108 to 155 wherein the CARconsists of humanized amino acid sequences.

217. 158. The method of any one of clauses 108 to 157 wherein the CAR Tcell composition comprises a mixture of the CAR T cells andnon-transformed T cells in a ratio selected from about 1:5 of the CAR Tcells to the non-transformed T cells, about 1:4 of the CAR T cells tothe non-transformed T cells, about 1:3 of the CART cells to thenon-transformed T cells, about 1:2 of the CAR T cells to thenon-transformed T cells, and about 1:1 of the CAR T cells to thenon-transformed T cells.

218. 159. The method of any one of clauses 108 to 158 wherein the CAR Tcell composition comprises a mixture of the CAR T cells andnon-transformed T cells in a ratio of from about 1:1 to about 1:5 of theCART cells to the non-transformed T cells.

219. 160. The method of any one of clauses 108 to 159 wherein the CAR Tcell composition comprises a mixture comprising about 10 million of theCAR T cells and about 40 million of the non-transformed T cells.

220. 161. The method of any one of clauses 108 to 160 wherein the agentthat inhibits activation of the CAR T cells is selected from the groupconsisting of a lymphocyte-specific protein tyrosine kinase inhibitor, aPI3 kinase inhibitor, an inhibitor of an IL-2 inducible T cell kinase, aJAK inhibitor, a BTK inhibitor, EC2319, and an agent that blocks CAR Tcell binding to the compound, or the pharmaceutically acceptable saltthereof, but does not bind to the cancer.

221. 162. The method of clause 161 wherein the agent that inhibitsactivation of the CAR T cells is administered and the agent is alymphocyte-specific protein tyrosine kinase inhibitor.

222. 163. The method of clause 162 wherein the lymphocyte-specificprotein tyrosine kinase inhibitor is Dasatinib.

223. 164. The method of clause 161 wherein the agent that inhibitsactivation of the CAR T cells is administered and the agent is a PI3kinase inhibitor.

224. 165. The method of clause 164 wherein the PI3 kinase inhibitor isGDC0980.

225. 166. The method of clause 161 wherein the agent that inhibitsactivation of the CAR T cells is administered and the agent is an IL-2inducible T cell kinase inhibitor.

226. 167. The method of clause 166 wherein the IL-2 inducible T cellkinase inhibitor is BMS-509744.

227. 168. The method of any one of clauses 1 to 160 wherein the CAR Tcell composition is administered by injection into the patient'sbloodstream, and wherein the CAR T cells in the patient's bloodstreamare at least 10 percent of the patient's total T cells in the patient'sbloodstream by about four weeks after injection of the CAR T cellcomposition.

228. 169. The method of any one of clauses 1 to 160 wherein the CAR Tcell composition is administered by injection into the patient'sbloodstream, and wherein the CAR T cells in the patient's bloodstreamare at least 12 percent of the patient's total T cells in the patient'sbloodstream by about four weeks after injection of the CAR T cellcomposition.

229. 170. The method of any one of clauses 1 to 160 wherein the CAR Tcell composition is administered by injection into the patient'sbloodstream, and wherein the CAR T cells in the patient's bloodstreamare at least 15 percent of the patient's total T cells in the patient'sbloodstream by about four weeks after injection of the CAR T cellcomposition.

230. 171. The method of any one of clauses 1 to 160 or 168 to 170wherein the CAR T cells administered to the patient in the CAR T cellcomposition comprise from about 1 million to about 15 million of the CART cells.

231. 172. The method of any one of clauses 1 to 160 or 168 to 171wherein the dose of the CAR T cells administered to the patient in theCAR T cell composition is selected from the group consisting of about 1million, about 2 million, about 3 million, about 4 million, about 5million, about 6 million, about 7 million, about 8 million, about 9million, about 10 million, about 11 million, about 12 million, about12.5 million, about 13 million, about 14 million, and about 15 millionof the CART cells.

232. 173. The method of any one of clauses 1 to 160 or 168 to 170wherein the CAR T cells administered to the patient in the CAR T cellcomposition comprise at least about 2 million of the CAR T cells.

233. 174. The method of any one of clauses 1 to 160 or 168 to 170wherein the CAR T cells administered to the patient in the CAR T cellcomposition comprise at least about 5 million of the CAR T cells.

234. 175. The method of any one of clauses 1 to 160 or 168 to 170wherein the CAR T cells administered to the patient in the CAR T cellcomposition comprise at least about 10 million of the CAR T cells.

235. 176. The method of any one of clauses 1 to 175 wherein the CAR Tcells comprise a nucleic acid comprising SEQ ID NO:3.

236. 177. The method of any one of clauses 1 to 176 wherein the CARTcells comprise a vector comprising SEQ ID NO:1.

237. 178. The method of any one of clauses 1 to 177 wherein the CAR Tcells comprise a vector comprising SEQ ID NO:3.

238. 179. The method of clause 176 wherein the nucleic acid encodes achimeric antigen receptor.

239. 180. The method of any one of clauses 108 to 160 wherein the agentthat inhibits activation of the CAR T cells is administered and is anagent that blocks CAR T cell binding to the compound, or thepharmaceutically acceptable salt thereof, but does not bind to thecancer.

240. 181. The method of clause 180 wherein the agent isfluoresceinamine, FITC, or sodium fluorescein.

241. 182. The method of clause 180 wherein the agent is FITC.

183. A method of treatment of a cancer, the method comprising

-   -   i) administering to a patient a compound, or a pharmaceutically        acceptable salt thereof, wherein the compound comprises a small        molecule ligand linked to a targeting moiety by a linker, and        wherein the compound, or the pharmaceutically acceptable salt        thereof, is at a dose of about 10 nmoles/kg of body weight of        the patient to about 2500 nmoles/kg of body weight of the        patient; and    -   ii) administering to the patient a CAR T cell composition        comprising CAR T cells wherein the CAR T cells comprise a CAR        directed to the targeting moiety, and wherein the CART cells are        at a dose of about 1 million of the CART cells to about 15        million of the CAR T cells.

184. The method of clause 183 wherein the ligand is selected from thegroup consisting of a folate, DUPA, an NK-1R ligand, a CAIX ligand, aligand of gamma glutamyl transpeptidase, an NKG2D ligand, and a CCK2Rligand.

185. The method of any one of clauses 183 or 184 wherein the ligand is afolate.

186. The method of any one of clauses 183 to 185 wherein the targetingmoiety is selected from the group consisting of 2,4-dinitrophenol (DNP),2,4,6-trinitrophenol (TNP), biotin, digoxigenin, fluorescein,fluorescein isothiocyanate (FITC), NHS-fluorescein, pentafluorophenylester, tetrafluorophenyl ester, a knottin, a centyrin, and a DARPin.

187. The method of any one of clauses 183 to 186 wherein the targetingmoiety is FITC.

188. The method of any one of clauses 183 to 187 wherein the linkercomprises polyethylene glycol (PEG), polyproline, a hydrophilic aminoacid, a sugar, an unnatural peptidoglycan, a polyvinylpyrrolidone,pluronic F-127, or a combination thereof.

189. The method of any one of clauses 183 to 188 wherein the linkercomprises PEG.

190. The method of any one of clauses 183 to 189 wherein the compound,or the pharmaceutically acceptable salt thereof, has the formula

B-L-T,

wherein B represents the small molecule ligand, L represents the linker,and T represents the targeting moiety, and wherein L comprises astructure having the formula

wherein n is an integer from 0 to 200.

191. The method of any one of clauses 183 to 190 wherein the linkercomprises PEG and the targeting moiety is FITC, or a pharmaceuticallyacceptable salt thereof.

192. The method of any one of clauses 183 to 191 wherein the compound,or the pharmaceutically acceptable salt thereof, is administered at adose of about 10 nmoles/kg to about 100 nmoles/kg of body weight of thepatient.

193. The method of any one of clauses 183 to 191 wherein the compound,or the pharmaceutically acceptable salt thereof, is administered at adose of about 10 nmoles/kg to about 50 nmoles/kg of body weight of thepatient.

194. The method of any one of clauses 183 to 191 wherein the compound,or the pharmaceutically acceptable salt thereof, is administered at adose of about 10 nmoles/kg to about 20 nmoles/kg of body weight of thepatient.

195. The method of any one of clauses 183 to 191 wherein the compound,or the pharmaceutically acceptable salt thereof, is administered at adose of about 10 nmoles/kg to about 600 nmoles/kg of body weight of thepatient.

196. The method of any one of clauses 183 to 191 wherein the compound,or the pharmaceutically acceptable salt thereof, is administered at adose of about 200 nmoles/kg to about 600 nmoles/kg of body weight of thepatient.

197. The method of any one of clauses 183 to 191 wherein the compound,or the pharmaceutically acceptable salt thereof, is administered at adose of about 400 nmoles/kg to about 600 nmoles/kg of body weight of thepatient.

198. The method of any one of clauses 183 to 197 wherein the CART cellsare at a dose of about 1 million of the CART cells to about 12.5 millionof the CART cells.

199. The method of any one of clauses 183 to 197 wherein the CART cellsare at a dose of about 1 million of the CART cells to about 7 million ofthe CART cells.

200. The method of any one of clauses 183 to 197 wherein the CART cellsare at a dose of about 1 million of the CART cells to about 5 million ofthe CART cells.

201. The method of any one of clauses 183 to 197 wherein the CART cellsare at a dose of about 2 million of the CAR T cells to about 5 millionof the CAR T cells.

202. The method of any one of clauses 183 to 201 wherein the cancer isselected from the group consisting of lung cancer, bone cancer,pancreatic cancer, skin cancer, cancer of the head, cancer of the neck,cutaneous melanoma, intraocular melanoma uterine cancer, ovarian cancer,endometrial cancer, rectal cancer, stomach cancer, colon cancer, breastcancer, triple negative breast cancer, carcinoma of the fallopian tubes,carcinoma of the endometrium, carcinoma of the cervix, carcinoma of thevagina, carcinoma of the vulva, Hodgkin's Disease, cancer of theesophagus, cancer of the small intestine, cancer of the endocrinesystem, cancer of the thyroid gland, cancer of the parathyroid gland,non-small cell lung cancer, cancer of the adrenal gland, sarcoma of softtissue, osteosarcoma, cancer of the urethra, prostate cancer, chronicleukemia, acute leukemia, acute myelocytic leukemia, lymphocyticlymphoma, myeloid leukemia, myelomonocytic leukemia, hairy cellleukemia, pleural mesothelioma, cancer of the bladder, Burkitt'slymphoma, cancer of the ureter, cancer of the kidney, renal cellcarcinoma, carcinoma of the renal pelvis, neoplasms of the centralnervous system (CNS), primary CNS lymphoma, spinal axis tumors, brainstem glioma, pituitary adenoma, and adenocarcinoma of thegastroesophageal junction.

242. 203. The method of any one of clauses 183 to 202 wherein the canceris a folate receptor expressing cancer.

204. The method of any one of clauses 183 to 203 wherein the CAR has arecognition region and the recognition region is a single chain fragmentvariable (scFv) region of an anti-FITC antibody, wherein the CAR has aco-stimulation domain and the co-stimulation domain is CD137 (4-1BB),and wherein the CAR has an activation signaling domain and theactivation signaling domain is a T cell CD3ζ chain.

243. 205. The method of any one of clauses 183 to 204 wherein thecompound, or the pharmaceutically acceptable salt thereof, is not anantibody, and does not comprise a fragment of an antibody.

244. 206. The method of any one of clauses 183 to 205 wherein thetargeting moiety does not comprise a peptide epitope.

207. The method of any one of clauses 183 to 206 wherein cytokinerelease resulting in off-target toxicity in the patient does not occurand wherein CAR T cell toxicity to the cancer occurs.

245. 208. The method of any one of clauses 183 to 206 wherein off-targettissue toxicity does not occur in the patient and wherein CAR T celltoxicity to the cancer occurs.

246. 209. The method of any one of clauses 183 to 206 wherein the cancercomprises a tumor, wherein tumor size is reduced in the patient, andwherein off-target toxicity does not occur.

247. 210. The method of any one of clauses 183 to 209 wherein the CARTcells comprise a nucleic acid comprising SEQ ID NO:1.

248. 211. The method of any one of clauses 183 to 209 wherein the CAR Tcells comprise a polypeptide comprising SEQ ID NO:2.

249. 212. The method of any one of clauses 183 to 211 wherein the CARcomprises humanized amino acid sequences.

250. 213. The method of any one of clauses 183 to 212 wherein the CARconsists of humanized amino acid sequences.

251. 214. The method of any one of clauses 183 to 213 wherein the CAR Tcell composition further comprises non-transformed T cells.

215. A method of treatment of a cancer, the method comprising

-   -   i) administering continuously to a patient a compound, or a        pharmaceutically acceptable salt thereof, wherein the compound        comprises a small molecule ligand linked to a targeting moiety        by a linker;    -   ii) administering to the patient a CAR T cell composition        comprising CAR T cells wherein the CAR T cells comprise a CAR        directed to the targeting moiety; and    -   iii) ending the continuous administration of the compound, or        the pharmaceutically acceptable salt thereof, to inhibit or        prevent cytokine release syndrome in the patient.

216. The method of clause 215 wherein the ligand is selected from thegroup consisting of a folate, DUPA, an NK-1R ligand, a CAIX ligand, aligand of gamma glutamyl transpeptidase, an NKG2D ligand, and a CCK2Rligand.

217. The method of any one of clauses 215 or 216 wherein the ligand is afolate.

218. The method of any one of clauses 215 to 217 wherein the targetingmoiety is selected from the group consisting of 2,4-dinitrophenol (DNP),2,4,6-trinitrophenol (TNP), biotin, digoxigenin, fluorescein,fluorescein isothiocyanate (FITC), NHS-fluorescein, pentafluorophenylester, tetrafluorophenyl ester, a knottin, a centyrin, and a DARPin.

219. The method of any one of clauses 215 to 218 wherein the targetingmoiety is FITC.

220. The method of any one of clauses 215 to 219 wherein the linkercomprises polyethylene glycol (PEG), polyproline, a hydrophilic aminoacid, a sugar, an unnatural peptidoglycan, a polyvinylpyrrolidone,pluronic F-127, or a combination thereof.

221. The method of any one of clauses 215 to 220 wherein the linkercomprises PEG.

222. The method of any one of clauses 215 to 221 wherein the compound,or the pharmaceutically acceptable salt thereof, has the formula

B-L-T,

wherein B represents the small molecule ligand, L represents the linker,and T represents the targeting moiety, and wherein L comprises astructure having the formula

wherein n is an integer from 0 to 200.

223. The method of any one of clauses 215 to 222 wherein the linkercomprises PEG and the targeting moiety is FITC, or a pharmaceuticallyacceptable salt thereof.

224. The method of any one of clauses 215 to 223 wherein the compound,or the pharmaceutically acceptable salt thereof, is administeredcontinuously for at least one hour to the patient.

225. The method of any one of clauses 215 to 223 wherein the compound,or the pharmaceutically acceptable salt thereof, is administeredcontinuously for at least four hours to the patient.

226. The method of any one of clauses 215 to 223 wherein the compound,or the pharmaceutically acceptable salt thereof, is administeredcontinuously for at least six hours to the patient.

227. The method of any one of clauses 215 to 223 wherein the continuousadministration of the compound, or the pharmaceutically acceptable saltthereof, is a regimen of administration every other day.

228. The method of any one of clauses 215 to 223 wherein the continuousadministration of the compound, or the pharmaceutically acceptable saltthereof, is a regimen of administration three times weekly.

229. The method of any one of clauses 215 to 223 wherein the continuousadministration of the compound, or the pharmaceutically acceptable saltthereof, is administration until an unacceptable loss of body weight ofthe patient, a fever, a drop in blood pressure, or pulmonary edemaoccurs.

230. The method of any one of clauses 215 to 229 wherein the compound,or the pharmaceutically acceptable salt thereof, is administered at adose of about 200 nmoles/kg to about 600 nmoles/kg of body weight of thepatient.

231. The method of any one of clauses 215 to 229 wherein the compound,or the pharmaceutically acceptable salt thereof, is administered at adose of about 400 nmoles/kg to about 600 nmoles/kg of body weight of thepatient.

232. The method of any one of clauses 215 to 231 wherein about 2 millionto about 5 million of the CAR T cells are administered.

233. The method of any one of clauses 215 to 232 wherein theadministration is by intravenous administration.

234. The method of any one of clauses 215 to 233 wherein the cancer isselected from the group consisting of lung cancer, bone cancer,pancreatic cancer, skin cancer, cancer of the head, cancer of the neck,cutaneous melanoma, intraocular melanoma uterine cancer, ovarian cancer,endometrial cancer, rectal cancer, stomach cancer, colon cancer, breastcancer, triple negative breast cancer, carcinoma of the fallopian tubes,carcinoma of the endometrium, carcinoma of the cervix, carcinoma of thevagina, carcinoma of the vulva, Hodgkin's Disease, cancer of theesophagus, cancer of the small intestine, cancer of the endocrinesystem, cancer of the thyroid gland, cancer of the parathyroid gland,non-small cell lung cancer, cancer of the adrenal gland, sarcoma of softtissue, osteosarcoma, cancer of the urethra, prostate cancer, chronicleukemia, acute leukemia, acute myelocytic leukemia, lymphocyticlymphoma, myeloid leukemia, myelomonocytic leukemia, hairy cellleukemia, pleural mesothelioma, cancer of the bladder, Burkitt'slymphoma, cancer of the ureter, cancer of the kidney, renal cellcarcinoma, carcinoma of the renal pelvis, neoplasms of the centralnervous system (CNS), primary CNS lymphoma, spinal axis tumors, brainstem glioma, pituitary adenoma, and adenocarcinoma of thegastroesophageal junction.

252. 235. The method of any one of clauses 215 to 234 wherein the canceris a folate receptor expressing cancer.

236. The method of any one of clauses 215 to 235 wherein the CAR has arecognition region and the recognition region is a single chain fragmentvariable (scFv) region of an anti-FITC antibody, wherein the CAR has aco-stimulation domain and the co-stimulation domain is CD137 (4-1BB),and wherein the CAR has an activation signaling domain and theactivation signaling domain is a T cell CD3ζ chain.

253. 237. The method of any one of clauses 215 to 236 wherein thecompound, or the pharmaceutically acceptable salt thereof, is not anantibody, and does not comprise a fragment of an antibody.

254. 238. The method of any one of clauses 215 to 237 wherein thetargeting moiety does not comprise a peptide epitope.

239. The method of any one of clauses 215 to 238 wherein cytokinerelease resulting in off-target toxicity in the patient does not occurand wherein CAR T cell toxicity to the cancer occurs.

255. 240. The method of any one of clauses 215 to 238 wherein off-targettissue toxicity does not occur in the patient and wherein CAR T celltoxicity to the cancer occurs.

256. 241. The method of any one of clauses 215 to 238 wherein the cancercomprises a tumor, wherein tumor size is reduced in the patient, andwherein off-target toxicity does not occur.

257. 242. The method of any one of clauses 215 to 241 wherein the CAR Tcells comprise a nucleic acid comprising SEQ ID NO:1.

258. 243. The method of any one of clauses 215 to 242 wherein the CAR Tcells comprise a polypeptide comprising SEQ ID NO:2.

259. 244. The method of any one of clauses 215 to 243 wherein the CARcomprises humanized amino acid sequences.

260. 245. The method of any one of clauses 215 to 243 wherein the CARconsists of humanized amino acid sequences.

261. 246. The method of any one of clauses 215 to 245 wherein the CAR Tcell composition further comprises non-transformed T cells.

262. 247. The method of any one of clauses 215 to 246 wherein the CAR Tcell composition further comprises non-transformed T cells in a ratioselected from about 1:5 of the CAR T cells to the non-transformed Tcells, about 1:4 of the CAR T cells to the non-transformed T cells,about 1:3 of the CAR T cells to the non-transformed T cells, about 1:2of the CAR T cells to the non-transformed T cells, and about 1:1 of theCAR T cells to the non-transformed T cells.

263. 248. The method of any one of clauses 215 to 247 wherein the CAR Tcell composition further comprises non-transformed T cells in a ratio offrom about 1:1 to about 1:5 of the CAR T cells to the non-transformed Tcells.

264. 249. The method of any one of clauses 215 to 248 wherein the CAR Tcell composition further comprises non-transformed T cells in a mixtureof about 10 million of the CAR T cells and about 40 millionnon-transformed T cells.

265. 250. The method of any one of clauses 215 to 249 wherein the canceris a non-small cell lung cancer.

266. 251. The method of any one of clauses 215 to 249 wherein the canceris an ovarian cancer.

252. A method of treatment of a cancer, the method comprising

-   -   i) administering to a patient a compound, or a pharmaceutically        acceptable salt thereof, wherein the compound comprises a small        molecule ligand linked to a targeting moiety by a linker and        wherein the compound, or the pharmaceutically acceptable salt        thereof, is administered once weekly to the patient; and    -   ii) administering to the patient a CAR T cell composition        comprising CAR T cells wherein the CAR T cells comprise a CAR        directed to the targeting moiety.

253. The method of clause 252 wherein the ligand is selected from thegroup consisting of a folate, DUPA, an NK-1R ligand, a CAIX ligand, aligand of gamma glutamyl transpeptidase, an NKG2D ligand, and a CCK2Rligand.

254. The method of any one of clauses 252 or 253 wherein the ligand is afolate.

255. The method of any one of clauses 252 to 254 wherein the targetingmoiety is selected from the group consisting of 2,4-dinitrophenol (DNP),2,4,6-trinitrophenol (TNP), biotin, digoxigenin, fluorescein,fluorescein isothiocyanate (FITC), NHS-fluorescein, pentafluorophenylester, tetrafluorophenyl ester, a knottin, a centyrin, and a DARPin.

256. The method of any one of clauses 252 to 255 wherein the targetingmoiety is FITC.

257. The method of any one of clauses 252 to 256 wherein the linkercomprises polyethylene glycol (PEG), polyproline, a hydrophilic aminoacid, a sugar, an unnatural peptidoglycan, a polyvinylpyrrolidone,pluronic F-127, or a combination thereof.

258. The method of any one of clauses 252 to 257 wherein the linkercomprises PEG.

259. The method of any one of clauses 252 to 258 wherein the compound,or the pharmaceutically acceptable salt thereof, has the formula

B-L-T,

wherein B represents the small molecule ligand, L represents the linker,and T represents the targeting moiety, and wherein L comprises astructure having the formula

wherein n is an integer from 0 to 200.

260. The method of any one of clauses 252 to 259 wherein the linkercomprises PEG and the targeting moiety is FITC, or a pharmaceuticallyacceptable salt thereof.

261. The method of any one of clauses 252 to 260 wherein the compound,or the pharmaceutically acceptable salt thereof, is administered at adose of about 10 nmoles/kg to about 100 nmoles/kg of body weight of thepatient.

262. The method of any one of clauses 252 to 261 wherein the compound,or the pharmaceutically acceptable salt thereof, is administered at adose of about 10 nmoles/kg to about 50 nmoles/kg of body weight of thepatient.

263. The method of any one of clauses 252 to 262 wherein the compound,or the pharmaceutically acceptable salt thereof, is administered at adose of about 10 nmoles/kg to about 20 nmoles/kg of body weight of thepatient.

264. The method of any one of clauses 252 to 263 wherein the compound,or the pharmaceutically acceptable salt thereof, is administered at adose of about 10 nmoles/kg to about 600 nmoles/kg of body weight of thepatient.

265. The method of any one of clauses 252 to 264 wherein the compound,or the pharmaceutically acceptable salt thereof, is administered at adose of about 200 nmoles/kg to about 600 nmoles/kg of body weight of thepatient.

266. The method of any one of clauses 252 to 265 wherein the compound,or the pharmaceutically acceptable salt thereof, is administered at adose of about 400 nmoles/kg to about 600 nmoles/kg of body weight of thepatient.

267. The method of any one of clauses 252 to 266 wherein the CAR T cellsare at a dose of about 1 million of the CART cells to about 15 millionof the CART cells.

268. The method of any one of clauses 252 to 267 wherein the CART cellsare at a dose of about 1 million of the CART cells to about 7 million ofthe CART cells.

269. The method of any one of clauses 252 to 268 wherein the CAR T cellsare at a dose of about 1 million of the CART cells to about 5 million ofthe CART cells.

270. The method of any one of clauses 252 to 269 wherein the CAR T cellsare at a dose of about 2 million of the CAR T cells to about 5 millionof the CAR T cells.

271. The method of any one of clauses 252 to 270 wherein the cancer isselected from the group consisting of lung cancer, bone cancer,pancreatic cancer, skin cancer, cancer of the head, cancer of the neck,cutaneous melanoma, intraocular melanoma uterine cancer, ovarian cancer,endometrial cancer, rectal cancer, stomach cancer, colon cancer, breastcancer, triple negative breast cancer, carcinoma of the fallopian tubes,carcinoma of the endometrium, carcinoma of the cervix, carcinoma of thevagina, carcinoma of the vulva, Hodgkin's Disease, cancer of theesophagus, cancer of the small intestine, cancer of the endocrinesystem, cancer of the thyroid gland, cancer of the parathyroid gland,non-small cell lung cancer, cancer of the adrenal gland, sarcoma of softtissue, osteosarcoma, cancer of the urethra, prostate cancer, chronicleukemia, acute leukemia, acute myelocytic leukemia, lymphocyticlymphoma, myeloid leukemia, myelomonocytic leukemia, hairy cellleukemia, pleural mesothelioma, cancer of the bladder, Burkitt'slymphoma, cancer of the ureter, cancer of the kidney, renal cellcarcinoma, carcinoma of the renal pelvis, neoplasms of the centralnervous system (CNS), primary CNS lymphoma, spinal axis tumors, brainstem glioma, pituitary adenoma, and adenocarcinoma of thegastroesophageal junction.

267. 272. The method of any one of clauses 252 to 271 wherein the canceris a folate receptor expressing cancer.

273. The method of any one of clauses 252 to 272 wherein the CAR has arecognition region and the recognition region is a single chain fragmentvariable (scFv) region of an anti-FITC antibody, wherein the CAR has aco-stimulation domain and the co-stimulation domain is CD137 (4-1BB),and wherein the CAR has an activation signaling domain and theactivation signaling domain is a T cell CD3ζ chain.

268. 274. The method of any one of clauses 252 to 273 wherein thecompound, or the pharmaceutically acceptable salt thereof, is not anantibody, and does not comprise a fragment of an antibody.

269. 275. The method of any one of clauses 252 to 274 wherein thetargeting moiety does not comprise a peptide epitope.

276. The method of any one of clauses 252 to 275 wherein cytokinerelease resulting in off-target toxicity in the patient does not occurand wherein CAR T cell toxicity to the cancer occurs.

270. 277. The method of any one of clauses 252 to 275 wherein off-targettissue toxicity does not occur in the patient and wherein CAR T celltoxicity to the cancer occurs.

271. 278. The method of any one of clauses 252 to 275 wherein the cancercomprises a tumor, wherein tumor size is reduced in the patient, andwherein off-target toxicity does not occur.

272. 279. The method of any one of clauses 252 to 278 wherein the CARTcells comprise a nucleic acid comprising SEQ ID NO:1.

273. 280. The method of any one of clauses 252 to 278 wherein the CAR Tcells comprise a polypeptide comprising SEQ ID NO:2.

274. 281. The method of any one of clauses 252 to 280 wherein the CARcomprises humanized amino acid sequences.

275. 282. The method of any one of clauses 252 to 280 wherein the CARconsists of humanized amino acid sequences.

276. 283. The method of any one of clauses 252 to 282 wherein the CAR Tcell composition further comprises non-transformed T cells.

284. A method of treatment of a cancer, the method comprising

-   -   i) administering to a patient a compound, or a pharmaceutically        acceptable salt thereof, wherein the compound comprises a small        molecule ligand linked to a targeting moiety by a linker,        wherein at least a first dose and a second dose of the compound,        or the pharmaceutically acceptable salt thereof, are        administered to the patient, wherein the first dose and the        second dose are different, wherein the second dose of the        compound, or the pharmaceutically acceptable salt thereof, is        about 2-fold to about 15000-fold greater in amount than the        first dose of the compound, or the pharmaceutically acceptable        salt thereof; and    -   ii) administering to the patient a CAR T cell composition        comprising CAR T cells wherein the CAR T cells comprise a CAR        directed to the targeting moiety.

285. The method of clause 284 wherein at least a first dose, a seconddose, and a third dose of the compound, or the pharmaceuticallyacceptable salt thereof, are administered to the patient, wherein thefirst dose, the second dose, and the third dose are different, whereinthe second dose of the compound, or the pharmaceutically acceptable saltthereof, is about 2-fold to about 750-fold greater in amount than thefirst dose of the compound, or the pharmaceutically acceptable saltthereof, and wherein the third dose of the compound, or thepharmaceutically acceptable salt thereof, is about 800-fold to about10000-fold greater in amount than the first dose of the compound, or thepharmaceutically acceptable salt thereof.

286. The method of clause 285 wherein at least a first dose, a seconddose, a third dose, and a fourth dose of the compound, or thepharmaceutically acceptable salt thereof, are administered to thepatient, wherein the first dose, the second dose, the third dose, andthe fourth dose are different, wherein the second dose of the compound,or the pharmaceutically acceptable salt thereof, is about 2-fold toabout 750-fold greater in amount than the first dose of the compound, orthe pharmaceutically acceptable salt thereof, wherein the third dose ofthe compound, or the pharmaceutically acceptable salt thereof, is about800-fold to about 7500-fold greater in amount than the first dose of thecompound, or the pharmaceutically acceptable salt thereof, and whereinthe fourth dose of the compound, or the pharmaceutically acceptable saltthereof, is about 8000 to about 15000-fold greater in amount than thefirst dose of the compound, or the pharmaceutically acceptable saltthereof.

287. The method of clause 286 wherein the second dose of the compound,or the pharmaceutically acceptable salt thereof, is about 100-foldgreater in amount than the first dose of the compound, or thepharmaceutically acceptable salt thereof, wherein the third dose of thecompound, or the pharmaceutically acceptable salt thereof, is about1000-fold greater in amount than the first dose of the compound, or thepharmaceutically acceptable salt thereof, and wherein the fourth dose ofthe compound, or the pharmaceutically acceptable salt thereof, is about10000-fold greater in amount than the first dose of the compound, or thepharmaceutically acceptable salt thereof.

288. The method of any one of clauses 284 to 287 wherein the ligand isselected from the group consisting of a folate, DUPA, an NK-1R ligand, aCAIX ligand, a ligand of gamma glutamyl transpeptidase, an NKG2D ligand,and a CCK2R ligand.

289. The method of any one of clauses 284 to 288 wherein the ligand is afolate.

290. The method of any one of clauses 284 to 289 wherein the targetingmoiety is selected from the group consisting of 2,4-dinitrophenol (DNP),2,4,6-trinitrophenol (TNP), biotin, digoxigenin, fluorescein,fluorescein isothiocyanate (FITC), NHS-fluorescein, pentafluorophenylester, tetrafluorophenyl ester, a knottin, a centyrin, and a DARPin.

291. The method of any one of clauses 284 to 290 wherein the targetingmoiety is FITC.

292. The method of any one of clauses 284 to 291 wherein the linkercomprises polyethylene glycol (PEG), polyproline, a hydrophilic aminoacid, a sugar, an unnatural peptidoglycan, a polyvinylpyrrolidone,pluronic F-127, or a combination thereof.

293. The method of any one of clauses 284 to 292 wherein the linkercomprises PEG.

294. The method of any one of clauses 284 to 293 wherein the compound,or the pharmaceutically acceptable salt thereof, has the formula

B-L-T,

wherein B represents the small molecule ligand, L represents the linker,and T represents the targeting moiety, and wherein L comprises astructure having the formula

wherein n is an integer from 0 to 200.

295. The method of any one of clauses 284 to 294 wherein the linkercomprises PEG and the targeting moiety is FITC, or a pharmaceuticallyacceptable salt thereof.

296. The method of any one of clauses 284 to 295 wherein the compound,or the pharmaceutically acceptable salt thereof, is administered at adose of about 10 nmoles/kg to about 100 nmoles/kg of body weight of thepatient.

297. The method of any one of clauses 284 to 296 wherein the compound,or the pharmaceutically acceptable salt thereof, is administered at adose of about 10 nmoles/kg to about 50 nmoles/kg of body weight of thepatient.

298. The method of any one of clauses 284 to 297 wherein the compound,or the pharmaceutically acceptable salt thereof, is administered at adose of about 10 nmoles/kg to about 20 nmoles/kg of body weight of thepatient.

299. The method of any one of clauses 284 to 298 wherein the compound,or the pharmaceutically acceptable salt thereof, is administered at adose of about 10 nmoles/kg to about 600 nmoles/kg of body weight of thepatient.

300. The method of any one of clauses 284 to 299 wherein the compound,or the pharmaceutically acceptable salt thereof, is administered at adose of about 200 nmoles/kg to about 600 nmoles/kg of body weight of thepatient.

301. The method of any one of clauses 284 to 300 wherein the compound,or the pharmaceutically acceptable salt thereof, is administered at adose of about 400 nmoles/kg to about 600 nmoles/kg of body weight of thepatient.

302. The method of any one of clauses 284 to 301 wherein the CART cellsare at a dose of about 1 million of the CART cells to about 15 millionof the CART cells.

303. The method of any one of clauses 284 to 302 wherein the CART cellsare at a dose of about 1 million of the CART cells to about 7 million ofthe CART cells.

304. The method of any one of clauses 284 to 303 wherein the CART cellsare at a dose of about 1 million of the CART cells to about 5 million ofthe CART cells.

305. The method of any one of clauses 284 to 304 wherein the CART cellsare at a dose of about 2 million of the CAR T cells to about 5 millionof the CAR T cells.

306. The method of any one of clauses 284 to 305 wherein the cancer isselected from the group consisting of lung cancer, bone cancer,pancreatic cancer, skin cancer, cancer of the head, cancer of the neck,cutaneous melanoma, intraocular melanoma uterine cancer, ovarian cancer,endometrial cancer, rectal cancer, stomach cancer, colon cancer, breastcancer, triple negative breast cancer, carcinoma of the fallopian tubes,carcinoma of the endometrium, carcinoma of the cervix, carcinoma of thevagina, carcinoma of the vulva, Hodgkin's Disease, cancer of theesophagus, cancer of the small intestine, cancer of the endocrinesystem, cancer of the thyroid gland, cancer of the parathyroid gland,non-small cell lung cancer, cancer of the adrenal gland, sarcoma of softtissue, osteosarcoma, cancer of the urethra, prostate cancer, chronicleukemia, acute leukemia, acute myelocytic leukemia, lymphocyticlymphoma, myeloid leukemia, myelomonocytic leukemia, hairy cellleukemia, pleural mesothelioma, cancer of the bladder, Burkitt'slymphoma, cancer of the ureter, cancer of the kidney, renal cellcarcinoma, carcinoma of the renal pelvis, neoplasms of the centralnervous system (CNS), primary CNS lymphoma, spinal axis tumors, brainstem glioma, pituitary adenoma, and adenocarcinoma of thegastroesophageal junction.

277. 307. The method of any one of clauses 284 to 306 wherein the canceris a folate receptor expressing cancer.

308. The method of any one of clauses 284 to 307 wherein the CAR has arecognition region and the recognition region is a single chain fragmentvariable (scFv) region of an anti-FITC antibody, wherein the CAR has aco-stimulation domain and the co-stimulation domain is CD137 (4-1BB),and wherein the CAR has an activation signaling domain and theactivation signaling domain is a T cell CD3ζ chain.

278. 309. The method of any one of clauses 284 to 308 wherein thecompound, or the pharmaceutically acceptable salt thereof, is not anantibody, and does not comprise a fragment of an antibody.

279. 310. The method of any one of clauses 284 to 309 wherein thetargeting moiety does not comprise a peptide epitope.

311. The method of any one of clauses 284 to 310 wherein cytokinerelease resulting in off-target toxicity in the patient does not occurand wherein CAR T cell toxicity to the cancer occurs.

280. 312. The method of any one of clauses 284 to 310 wherein off-targettissue toxicity does not occur in the patient and wherein CAR T celltoxicity to the cancer occurs.

281. 313. The method of any one of clauses 284 to 310 wherein the cancercomprises a tumor, wherein tumor size is reduced in the patient, andwherein off-target toxicity does not occur.

282. 314. The method of any one of clauses 284 to 313 wherein the CARTcells comprise a nucleic acid comprising SEQ ID NO:1.

283. 315. The method of any one of clauses 284 to 313 wherein the CAR Tcells comprise a polypeptide comprising SEQ ID NO:2.

284. 316. The method of any one of clauses 284 to 315 wherein the CARcomprises humanized amino acid sequences.

285. 317. The method of any one of clauses 284 to 315 wherein the CARconsists of humanized amino acid sequences.

286. 318. The method of any one of clauses 284 to 317 wherein the CAR Tcell composition further comprises non-transformed T cells.

319. The method of any one of clauses 1 to 214 or 252 to 318 wherein thecompound, or the pharmaceutically acceptable salt thereof, isadministered continuously to the patient and the method furthercomprises ending the continuous administration of the compound, or thepharmaceutically acceptable salt thereof, to inhibit or prevent cytokinerelease syndrome in the patient.

320. The method of any one of clauses 1 to 107 or 183 to 318 furthercomprising administering to the patient a folate, a conjugate comprisinga folate wherein the conjugate comprising a folate does not comprise atargeting moiety, or an agent that inhibits activation of the CAR Tcells.

321. The method of any one of clauses 1 to 182 or 215 to 318 wherein thecompound, or the pharmaceutically acceptable salt thereof, is at a doseof about 10 nmoles/kg of body weight of the patient to about 2500nmoles/kg of body weight of the patient and the CART cells are at a doseof about 1 million of the CART cells to about 15 million of the CARTcells.

322. The method of any one of clauses 1 to 251 or 284 to 318 wherein thecompound, or the pharmaceutically acceptable salt thereof, isadministered once weekly to the patient.

323. The method of any one of clauses 1 to 283 wherein at least a firstdose and a second dose of the compound, or the pharmaceuticallyacceptable salt thereof, are administered to the patient, wherein thefirst dose and the second dose are different, wherein the second dose ofthe compound, or the pharmaceutically acceptable salt thereof, is about2-fold to about 15000-fold greater in amount than the first dose of thecompound, or the pharmaceutically acceptable salt thereof.

324. The method of any one of clauses 56 to 318 wherein the CAR T cellcomposition is administered in at least two doses.

325. A method of treatment of a cancer, the method comprising

-   -   i) administering to a patient a first dose of a compound, or a        pharmaceutically acceptable salt thereof, wherein the compound        comprises a small molecule ligand linked to a targeting moiety        by a linker;    -   ii) administering to the patient at least a second dose of the        compound, or a pharmaceutically acceptable salt thereof, wherein        the second dose of the compound, or the pharmaceutically        acceptable salt thereof, is at least about 50 percent lower in        amount than the first dose of the compound, or the        pharmaceutically acceptable salt thereof; and    -   iii) administering to the patient a dose of a CAR T cell        composition comprising CAR T cells wherein the CAR T cells        comprise a CAR directed to the targeting moiety.

326. The method of clause 325 wherein the second dose of the compound,or the pharmaceutically acceptable salt thereof, is at least about 60percent lower in amount than the first dose of the compound, or thepharmaceutically acceptable salt thereof.

327. The method of clause 325 wherein the second dose of the compound,or the pharmaceutically acceptable salt thereof, is at least about 70percent lower in amount than the first dose of the compound, or thepharmaceutically acceptable salt thereof.

328. The method of clause 325 wherein the second dose of the compound,or the pharmaceutically acceptable salt thereof, is at least about 80percent lower in amount than the first dose of the compound, or thepharmaceutically acceptable salt thereof.

329. The method of clause 325 wherein the second dose of the compound,or the pharmaceutically acceptable salt thereof, is at least about 90percent lower in amount than the first dose of the compound, or thepharmaceutically acceptable salt thereof.

330. The method of clause 325 wherein the second dose of the compound,or the pharmaceutically acceptable salt thereof, is at least about 95percent lower in amount than the first dose of the compound, or thepharmaceutically acceptable salt thereof.

331. The method of clause 325 wherein the second dose of the compound,or the pharmaceutically acceptable salt thereof, is at least about 96percent lower in amount than the first dose of the compound, or thepharmaceutically acceptable salt thereof.

332. The method of clause 325 wherein the second dose of the compound,or the pharmaceutically acceptable salt thereof, is at least about 97percent lower in amount than the first dose of the compound, or thepharmaceutically acceptable salt thereof.

333. The method of clause 325 wherein the second dose of the compound,or the pharmaceutically acceptable salt thereof, is at least about 98percent lower in amount than the first dose of the compound, or thepharmaceutically acceptable salt thereof.

334. The method of clause 325 wherein the second dose of the compound,or the pharmaceutically acceptable salt thereof, is at least about 99percent lower in amount than the first dose of the compound, or thepharmaceutically acceptable salt thereof.

335. The method of clause 325 wherein the second dose of the compound,or the pharmaceutically acceptable salt thereof, is at least about 99.5percent lower in amount than the first dose of the compound, or thepharmaceutically acceptable salt thereof.

336. The method of any one of clauses 325 to 335 wherein the first doseof the compound, or the pharmaceutically acceptable salt thereof, isabout 100 nmoles/kg to about 1000 nmoles/kg of body weight of thepatient.

337. The method of any one of clauses 325 to 335 wherein the first doseof the compound, or the pharmaceutically acceptable salt thereof, isabout 100 nmoles/kg to about 900 nmoles/kg of body weight of thepatient.

338. The method of any one of clauses 325 to 335 wherein the first doseof the compound, or the pharmaceutically acceptable salt thereof, isabout 100 nmoles/kg to about 800 nmoles/kg of body weight of thepatient.

339. The method of any one of clauses 325 to 335 wherein the first doseof the compound, or the pharmaceutically acceptable salt thereof, isabout 100 nmoles/kg to about 700 nmoles/kg of body weight of thepatient.

340. The method of any one of clauses 325 to 335 wherein the first doseof the compound, or the pharmaceutically acceptable salt thereof, isabout 100 nmoles/kg to about 600 nmoles/kg of body weight of thepatient.

341. The method of any one of clauses 325 to 335 wherein the first doseof the compound, or the pharmaceutically acceptable salt thereof, isabout 200 nmoles/kg to about 600 nmoles/kg of body weight of thepatient.

342. The method of any one of clauses 325 to 335 wherein the first doseof the compound, or the pharmaceutically acceptable salt thereof, isabout 400 nmoles/kg to about 600 nmoles/kg of body weight of thepatient.

343. The method of any one of clauses 325 to 335 wherein the first doseof the compound, or the pharmaceutically acceptable salt thereof, isabout 500 nmoles/kg of body weight of the patient.

344. The method of clause 336 wherein the second dose of the compound,or the pharmaceutically acceptable salt thereof, is about 0.5 nmoles/kgto about 500 nmoles/kg of body weight of the patient.

345. The method of clause 337 wherein the second dose of the compound,or the pharmaceutically acceptable salt thereof, is about 0.5 nmoles/kgto about 450 nmoles/kg of body weight of the patient.

346. The method of clause 338 wherein the second dose of the compound,or the pharmaceutically acceptable salt thereof, is about 0.5 nmoles/kgto about 400 nmoles/kg of body weight of the patient.

347. The method of clause 339 wherein the second dose of the compound,or the pharmaceutically acceptable salt thereof, is about 0.5 nmoles/kgto about 350 nmoles/kg of body weight of the patient.

348. The method of clause 340 wherein the second dose of the compound,or the pharmaceutically acceptable salt thereof, is about 0.5 nmoles/kgto about 300 nmoles/kg of body weight of the patient.

349. The method of clause 341 wherein the second dose of the compound,or the pharmaceutically acceptable salt thereof, is about 1 nmole/kg toabout 300 nmoles/kg of body weight of the patient.

350. The method of clause 342 wherein the second dose of the compound,or the pharmaceutically acceptable salt thereof, is about 2 nmoles/kg toabout 300 nmoles/kg of body weight of the patient.

351. The method of clause 343 wherein the second dose of the compound,or the pharmaceutically acceptable salt thereof, is about 2 nmoles/kg toabout 250 nmoles/kg of body weight of the patient.

352. The method of any one of clauses 336 to 343 wherein the second doseof the compound, or the pharmaceutically acceptable salt thereof, isabout 5 nmoles/kg to about 40 nmoles/kg of body weight of the patient.

353. The method of any one of clauses 336 to 343 wherein the second doseof the compound, or the pharmaceutically acceptable salt thereof, isabout 40 nmoles/kg to about 150 nmoles/kg of body weight of the patient.

354. The method of any one of clauses 325 to 353 further comprisingadministering a third dose of the compound, or the pharmaceuticallyacceptable salt thereof, wherein the third dose of the compound, or thepharmaceutically acceptable salt thereof, is the same as the second doseof the compound, or the pharmaceutically acceptable salt thereof.

355. The method of clause 354 further comprising administering a fourthdose of the compound, or the pharmaceutically acceptable salt thereof,wherein the fourth dose of the compound, or the pharmaceuticallyacceptable salt thereof, is the same as the second dose, or thepharmaceutically acceptable salt thereof, and the third dose of thecompound, or the pharmaceutically acceptable salt thereof.

356. The method of any one of clauses 325 to 355 wherein the dose(s) ofthe compound, or the pharmaceutically acceptable salt thereof,administered after the first dose of the compound, or thepharmaceutically acceptable salt thereof, maintain inhibition of growthof the cancer relative to the first dose of the compound, or thepharmaceutically acceptable salt thereof.

357. The method of any one of clauses 325 to 356 wherein the CART cellsare administered at a dose of about 1 million of the CART cells to about40 million of the CART cells.

358. The method of any one of clauses 325 to 357 wherein the dose(s) ofthe compound, or the pharmaceutically acceptable salt thereof,administered after the first dose of the compound, or thepharmaceutically acceptable salt thereof, are administered once weekly.

359. The method of any one of clauses 325 to 357 wherein the dose(s) ofthe compound, or the pharmaceutically acceptable salt thereof, areadministered twice weekly.

360. The method of any one of clauses 325 to 359 wherein the ligand isselected from the group consisting of a folate, DUPA, an NK-1R ligand, aCAIX ligand, a ligand of gamma glutamyl transpeptidase, an NKG2D ligand,and a CCK2R ligand.

361. The method of any one of clauses 325 to 360 wherein the ligand is afolate.

362. The method of any one of clauses 325 to 360 wherein the ligand isan NK-1R ligand.

363. The method of any one of clauses 325 to 360 wherein the ligand isDUPA.

364. The method of any one of clauses 325 to 360 wherein the ligand is aCCK2R ligand.

365. The method of any one of clauses 325 to 360 wherein the ligand is aligand of gamma glutamyl transpeptidase.

366. The method of any one of clauses 325 to 365 wherein the targetingmoiety is selected from the group consisting of 2,4-dinitrophenol (DNP),2,4,6-trinitrophenol (TNP), biotin, digoxigenin, fluorescein,fluorescein isothiocyanate (FITC), NHS-fluorescein, pentafluorophenylester, tetrafluorophenyl ester, a knottin, a centyrin, and a DARPin.

367. The method of any one of clauses 325 to 366 wherein the targetingmoiety is FITC.

368. The method of any one of clauses 325 to 366 wherein the targetingmoiety is DNP.

369. The method of any one of clauses 325 to 366 wherein the targetingmoiety is TNP.

370. The method of any one of clauses 325 to 369 wherein the linkercomprises polyethylene glycol (PEG), polyproline, a hydrophilic aminoacid, a sugar, an unnatural peptidoglycan, a polyvinylpyrrolidone,pluronic F-127, or a combination thereof.

371. The method of any one of clauses 325 to 370 wherein the linkercomprises PEG.

372. The method of any one of clauses 325 to 371 wherein the compound,or the pharmaceutically acceptable salt thereof, has the formula

B-L-T,

wherein B represents the small molecule ligand, L represents the linker,and T represents the targeting moiety, and wherein L comprises astructure having the formula

wherein n is an integer from 0 to 200.

373. The method of clause 372 wherein n is an integer from 0 to 150.

374. The method of clause 372 wherein n is an integer from 0 to 110.

375. The method of clause 372 wherein n is an integer from 0 to 20.

376. The method of clause 372 wherein n is an integer from 15 to 20.

377. The method of clause 372 wherein n is an integer from 15 to 110.

378. The method of any one of clauses 325 to 367 or 370 to 377 whereinthe linker comprises PEG and the targeting moiety is FITC, or apharmaceutically acceptable salt thereof.

379. The method of any one of clauses 325 to 378 wherein the cancer isselected from the group consisting of lung cancer, bone cancer,pancreatic cancer, skin cancer, cancer of the head, cancer of the neck,cutaneous melanoma, intraocular melanoma uterine cancer, ovarian cancer,endometrial cancer, rectal cancer, stomach cancer, colon cancer, breastcancer, triple negative breast cancer, carcinoma of the fallopian tubes,carcinoma of the endometrium, carcinoma of the cervix, carcinoma of thevagina, carcinoma of the vulva, Hodgkin's Disease, cancer of theesophagus, cancer of the small intestine, cancer of the endocrinesystem, cancer of the thyroid gland, cancer of the parathyroid gland,non-small cell lung cancer, cancer of the adrenal gland, sarcoma of softtissue, osteosarcoma, cancer of the urethra, prostate cancer, chronicleukemia, acute leukemia, acute myelocytic leukemia, lymphocyticlymphoma, myeloid leukemia, myelomonocytic leukemia, hairy cellleukemia, pleural mesothelioma, cancer of the bladder, Burkitt'slymphoma, cancer of the ureter, cancer of the kidney, renal cellcarcinoma, carcinoma of the renal pelvis, neoplasms of the centralnervous system (CNS), primary CNS lymphoma, spinal axis tumors, brainstem glioma, pituitary adenoma, and adenocarcinoma of thegastroesophageal junction.

287. 380. The method of any one of clauses 325 to 361 or 366 to 379wherein the cancer is a folate receptor expressing cancer.

288. 381. The method of clause 380 wherein the cancer is an endometrialcancer.

289. 382. The method of clause 380 wherein the cancer is a non-smallcell lung cancer.

290. 383. The method of clause 380 wherein the cancer is an ovariancancer.

291. 384. The method of clause 380 wherein the cancer is a triplenegative breast cancer.

385. The method of any one of clauses 325 to 384 wherein the CAR has arecognition region and the recognition region is a single chain fragmentvariable (scFv) region of an antibody.

386. The method of any one of clauses 325 to 367 or 370 to 385 whereinthe CAR has a recognition region and the recognition region of the CARis a single chain fragment variable (scFv) region of an anti-FITCantibody.

387. The method of any one of clauses 325 to 386 wherein the CAR has aco-stimulation domain and the co-stimulation domain is selected from thegroup consisting of CD28, CD137 (4-1BB), CD134 (OX40), and CD278 (ICOS).

388. The method of any one of clauses 325 to 387 wherein the CAR has anactivation signaling domain and the activation signaling domain is a Tcell CD3ζ chain or an Fc receptor γ.

389. The method of any one of clauses 325 to 367 or 370 to 388 whereinthe CAR has a recognition region and the recognition region is a singlechain fragment variable (scFv) region of an anti-FITC antibody, whereinthe CAR has a co-stimulation domain and the co-stimulation domain isCD137 (4-1BB), and wherein the CAR has an activation signaling domainand the activation signaling domain is a T cell CD3ζ chain.

292. 390. The method of any one of clauses 325 to 389 wherein multipledoses of the CAR T cell composition are administered.

391. The method of any one of clauses 325 to 390 wherein the patient isimaged prior to administration of the compound, or the pharmaceuticallyacceptable salt thereof, or prior to administration of the CAR T cellcomposition.

293. 392. The method of any one of clauses 325 to 391 wherein thecompound, or the pharmaceutically acceptable salt thereof, is not anantibody, and does not comprise a fragment of an antibody.

294. 393. The method of any one of clauses 325 to 392 wherein thetargeting moiety does not comprise a peptide epitope.

394. The method of any one of clauses 325 to 393 wherein cytokinerelease resulting in off-target toxicity in the patient does not occurand wherein CAR T cell toxicity to the cancer occurs.

295. 395. The method of any one of clauses 325 to 393 wherein off-targettissue toxicity does not occur in the patient and wherein CAR T celltoxicity to the cancer occurs.

296. 396. The method of any one of clauses 325 to 393 wherein the cancercomprises a tumor, wherein tumor size is reduced in the patient, andwherein off-target toxicity does not occur.

297. 397. The method of any one of clauses 325 to 398 wherein the CARTcells comprise a nucleic acid comprising SEQ ID NO:1.

298. 398. The method of any one of clauses 325 to 397 wherein the CAR Tcells comprise a polypeptide comprising SEQ ID NO:2.

299. 399. The method of clause 397 wherein the nucleic acid encodes achimeric antigen receptor.

300. 400. The method of any one of clauses 325 to 399 wherein the CARcomprises humanized amino acid sequences.

301. 401. The method of any one of clauses 325 to 399 wherein the CARconsists of humanized amino acid sequences.

402. The method of any one of clauses 325 to 401 further comprising thestep of administering to the patient a folate, a conjugate comprising afolate wherein the conjugate comprising a folate does not comprise atargeting moiety, or an agent that inhibits activation of the CAR Tcells.

302. 403. The method of clause 402 wherein the agent that inhibitsactivation of the CAR T cells is administered to the patient and theagent is an agent that blocks CAR T cell binding to the compound, or thepharmaceutically acceptable salt thereof, but does not bind to thecancer.

303. 404 The method of clause 403 wherein the agent is fluoresceinamine,sodium fluorescein, or fluorescein.

304. 405. The method of clause 404 wherein the agent is sodiumfluorescein.

406. A method of treatment of a cancer, the method comprising

-   -   i) administering to a patient a first dose of a compound, or a        pharmaceutically acceptable salt thereof, wherein the compound        comprises a small molecule ligand linked to a targeting moiety        by a linker and wherein the compound, or the pharmaceutically        acceptable salt thereof, is administered to the patient at least        about one hour prior to the administration of a CAR T cell        composition comprising CAR T cells wherein the CAR T cells        comprise a CAR directed to the targeting moiety;    -   ii) then administering to the patient a dose of the CAR T cell        composition; and    -   iii) then administering to the patient a second dose of the        compound, or the pharmaceutically acceptable salt thereof.

407. The method of clause 406 wherein the first dose of the compound, orthe pharmaceutically acceptable salt thereof, is administered to thepatient at least about two hours prior to the administration of the CART cell composition.

408. The method of clause 406 wherein the first dose of the compound, orthe pharmaceutically acceptable salt thereof, is administered to thepatient at least about four hours prior to the administration of the CART cell composition.

409. The method of clause 406 wherein the first dose of the compound, orthe pharmaceutically acceptable salt thereof, is administered to thepatient at least about eight hours prior to the administration of theCAR T cell composition.

410. The method of clause 406 wherein the first dose of the compound, orthe pharmaceutically acceptable salt thereof, is administered to thepatient at least about twelve hours prior to the administration of theCAR T cell composition.

411. The method of clause 406 wherein the first dose of the compound, orthe pharmaceutically acceptable salt thereof, is administered to thepatient at least about sixteen hours prior to the administration of theCAR T cell composition.

412. The method of clause 406 wherein the first dose of the compound, orthe pharmaceutically acceptable salt thereof, is administered to thepatient at least about twenty hours prior to the administration of theCAR T cell composition.

413. The method of clause 406 wherein the first dose of the compound, orthe pharmaceutically acceptable salt thereof, is administered to thepatient at least about twenty-four hours prior to the administration ofthe CAR T cell composition.

414. The method of any one of clauses 406 to 413 wherein the second doseof the compound, or the pharmaceutically acceptable salt thereof, isadministered to the patient by at least about twenty-four hours afterthe administration of the CAR T cell composition.

415. The method of any one of clauses 406 to 413 wherein the second doseof the compound, or the pharmaceutically acceptable salt thereof, isadministered to the patient by at least about sixteen hours after theadministration of the CAR T cell composition.

416. The method of any one of clauses 406 to 413 wherein the second doseof the compound, or the pharmaceutically acceptable salt thereof, isadministered to the patient by at least about twelve hours after theadministration of the CAR T cell composition.

417. The method of any one of clauses 406 to 413 wherein the second doseof the compound, or the pharmaceutically acceptable salt thereof, isadministered to the patient by at least about eight hours after theadministration of the CAR T cell composition.

418. The method of any one of clauses 406 to 413 wherein the second doseof the compound, or the pharmaceutically acceptable salt thereof, isadministered to the patient by at least about four hours after theadministration of the CAR T cell composition.

305. 419. The method of any one of clauses 406 to 418 wherein cytokinerelease resulting in off-target toxicity in the patient does not occurand wherein CAR T cell toxicity to the cancer occurs.

306. 420. The method of any one of clauses 406 to 418 wherein off-targettissue toxicity does not occur in the patient and wherein CAR T celltoxicity to the cancer occurs.

307. 421. The method of any one of clauses 406 to 418 wherein the cancercomprises a tumor, wherein tumor size is reduced in the patient, andwherein off-target toxicity does not occur.

308. 422. The method of any one of clauses 406 to 418 wherein the cancercomprises a tumor, and wherein reduction in tumor size in the patient isgreater than in a patient not pre-treated with the compound, or thepharmaceutically acceptable salt thereof, prior to administration of theCAR T cell composition.

423. The method of any one of clauses 406 to 422 wherein the ligand isselected from the group consisting of a folate, DUPA, an NK-1R ligand, aCAIX ligand, a ligand of gamma glutamyl transpeptidase, an NKG2D ligand,and a CCK2R ligand.

424. The method of any one of clauses 406 to 423 wherein the ligand is afolate.

425. The method of any one of clauses 406 to 423 wherein the ligand isan NK-1R ligand.

426. The method of any one of clauses 406 to 423 wherein the ligand isDUPA.

427. The method of any one of clauses 406 to 423 wherein the ligand is aCCK2R ligand.

428. The method of any one of clauses 406 to 423 wherein the ligand is aligand of gamma glutamyl transpeptidase.

429. The method of any one of clauses 406 to 428 wherein the targetingmoiety is selected from the group consisting of 2,4-dinitrophenol (DNP),2,4,6-trinitrophenol (TNP), biotin, digoxigenin, fluorescein,fluorescein isothiocyanate (FITC), NHS-fluorescein, pentafluorophenylester, tetrafluorophenyl ester, a knottin, a centyrin, and a DARPin.

430. The method of any one of clauses 406 to 429 wherein the targetingmoiety is FITC.

431. The method of any one of clauses 406 to 429 wherein the targetingmoiety is DNP.

432. The method of any one of clauses 406 to 429 wherein the targetingmoiety is TNP.

433. The method of any one of clauses 406 to 432 wherein the linkercomprises polyethylene glycol (PEG), polyproline, a hydrophilic aminoacid, a sugar, an unnatural peptidoglycan, a polyvinylpyrrolidone,pluronic F-127, or a combination thereof.

434. The method of any one of clauses 406 to 433 wherein the linkercomprises PEG.

435. The method of any one of clauses 406 to 434 wherein the compound,or the pharmaceutically acceptable salt thereof, has the formula

B-L-T,

wherein B represents the small molecule ligand, L represents the linker,and T represents the targeting moiety, and wherein L comprises astructure having the formula

wherein n is an integer from 0 to 200.

436. The method of clause 435 wherein n is an integer from 0 to 150.

437. The method of clause 435 wherein n is an integer from 0 to 110.

438. The method of clause 435 wherein n is an integer from 0 to 20.

439. The method of clause 435 wherein n is an integer from 15 to 20.

440. The method of clause 435 wherein n is an integer from 15 to 110.

441. The method of any one of clauses 406 to 430 or 433 to 440 whereinthe linker comprises PEG and the targeting moiety is FITC, or apharmaceutically acceptable salt thereof.

442. The method of any one of clauses 406 to 441 wherein the compound,or the pharmaceutically acceptable salt thereof, is administered at adose of about 10 nmoles/kg to about 10000 nmoles/kg of body weight ofthe patient.

443. The method of any one of clauses 406 to 441 wherein the compound,or the pharmaceutically acceptable salt thereof, is administered at adose of about 10 nmoles/kg to about 5000 nmoles/kg of body weight of thepatient.

444. The method of any one of clauses 406 to 441 wherein the compound,or the pharmaceutically acceptable salt thereof, is administered at adose of about 10 nmoles/kg to about 1000 nmoles/kg of body weight of thepatient.

445. The method of any one of clauses 406 to 441 wherein the compound,or the pharmaceutically acceptable salt thereof, is administered at adose of about 10 nmoles/kg to about 600 nmoles/kg of body weight of thepatient.

446. The method of any one of clauses 406 to 441 wherein the compound,or the pharmaceutically acceptable salt thereof, is administered at adose of about 200 nmoles/kg to about 600 nmoles/kg of body weight of thepatient.

447. The method of any one of clauses 406 to 441 wherein the compound,or the pharmaceutically acceptable salt thereof, is administered at adose of about 250 nmoles/kg to about 600 nmoles/kg of body weight of thepatient.

448. The method of any one of clauses 406 to 447 wherein the cancer isselected from the group consisting of lung cancer, bone cancer,pancreatic cancer, skin cancer, cancer of the head, cancer of the neck,cutaneous melanoma, intraocular melanoma uterine cancer, ovarian cancer,endometrial cancer, rectal cancer, stomach cancer, colon cancer, breastcancer, triple negative breast cancer, carcinoma of the fallopian tubes,carcinoma of the endometrium, carcinoma of the cervix, carcinoma of thevagina, carcinoma of the vulva, Hodgkin's Disease, cancer of theesophagus, cancer of the small intestine, cancer of the endocrinesystem, cancer of the thyroid gland, cancer of the parathyroid gland,non-small cell lung cancer, cancer of the adrenal gland, sarcoma of softtissue, osteosarcoma, cancer of the urethra, prostate cancer, chronicleukemia, acute leukemia, acute myelocytic leukemia, lymphocyticlymphoma, myeloid leukemia, myelomonocytic leukemia, hairy cellleukemia, pleural mesothelioma, cancer of the bladder, Burkitt'slymphoma, cancer of the ureter, cancer of the kidney, renal cellcarcinoma, carcinoma of the renal pelvis, neoplasms of the centralnervous system (CNS), primary CNS lymphoma, spinal axis tumors, brainstem glioma, pituitary adenoma, and adenocarcinoma of thegastroesophageal junction.

309. 449. The method of any one of clauses 406 to 424 or 429 to 448wherein the cancer is a folate receptor expressing cancer.

310. 450. The method of clause 448 wherein the cancer is an endometrialcancer.

311. 451. The method of clause 448 wherein the cancer is a non-smallcell lung cancer.

312. 452. The method of clause 448 wherein the cancer is an ovariancancer.

313. 453. The method of clause 448 wherein the cancer is a triplenegative breast cancer.

454. The method of any one of clauses 406 to 453 wherein the CAR has arecognition region and the recognition region is a single chain fragmentvariable (scFv) region of an antibody.

455. The method of any one of clauses 406 to 430 or 433 to 454 whereinthe CAR has a recognition region and the recognition region of the CARis a single chain fragment variable (scFv) region of an anti-FITCantibody.

456. The method of any one of clauses 406 to 455 wherein the CAR has aco-stimulation domain and the co-stimulation domain is selected from thegroup consisting of CD28, CD137 (4-1BB), CD134 (OX40), and CD278 (ICOS).

457. The method of any one of clauses 406 to 456 wherein the CAR has anactivation signaling domain and the activation signaling domain is a Tcell CD3ζ chain or an Fc receptor γ.

458. The method of any one of clauses 406 to 430 or 433 to 457 whereinthe CAR has a recognition region and the recognition region is a singlechain fragment variable (scFv) region of an anti-FITC antibody, whereinthe CAR has a co-stimulation domain and the co-stimulation domain isCD137 (4-1BB), and wherein the CAR has an activation signaling domainand the activation signaling domain is a T cell CD3ζ chain.

314. 459. The method of any one of clauses 406 to 458 wherein multipledoses of the CAR T cell composition are administered.

460. The method of any one of clauses 406 to 459 wherein the patient isimaged prior to administration of the compound, or the pharmaceuticallyacceptable salt thereof.

315. 461. The method of any one of clauses 406 to 460 wherein thecompound, or the pharmaceutically acceptable salt thereof, is not anantibody, and does not comprise a fragment of an antibody.

316. 462. The method of any one of clauses 406 to 461 wherein thetargeting moiety does not comprise a peptide epitope.

463. The method of any one of clauses 406 to 462 wherein the CART cellscomprise a nucleic acid comprising SEQ ID NO:1.

317. 464. The method of any one of clauses 406 to 463 wherein the CAR Tcells comprise a polypeptide comprising SEQ ID NO:2.

318. 465. The method of clause 463 wherein the nucleic acid encodes achimeric antigen receptor.

319. 466. The method of any one of clauses 406 to 465 wherein the CARcomprises humanized amino acid sequences.

320. 467. The method of any one of clauses 406 to 465 wherein the CARconsists of humanized amino acid sequences.

468. The method of any one of clauses 108 to 182 wherein more than onedose is administered to the patient of the folate, the conjugatecomprising a folate wherein the conjugate comprising a folate does notcomprise a targeting moiety, or the agent that inhibits activation ofthe CAR T cells.

469. The method of any one of clauses 108 to 182 wherein the folate, theconjugate comprising a folate wherein the conjugate comprising a folatedoes not comprise a targeting moiety, or the agent that inhibitsactivation of the CAR T cells is administered to the patient beforeand/or after the compound, or the pharmaceutically acceptable saltthereof.

470. The method of any one of clauses 108 to 182 wherein administrationof the folate, the conjugate comprising a folate wherein the conjugatecomprising a folate does not comprise a targeting moiety, or the agentthat inhibits activation of the CAR T cells causes reduction in cytokinelevels in the patient.

471. The method of clause 470 wherein the reduction in cytokine levelsoccurs by about 3 hours after administration to the patient of thefolate, the conjugate comprising a folate wherein the conjugatecomprising a folate does not comprise a targeting moiety, or the agentthat inhibits activation of the CAR T cells.

472. The method of clause 470 wherein the reduction in cytokine levelsoccurs by about 6 hours after administration to the patient of thefolate, the conjugate comprising a folate wherein the conjugatecomprising a folate does not comprise a targeting moiety, or the agentthat inhibits activation of the CAR T cells.

473. The method of clause 470 wherein the reduction in cytokine levelsis a reduction to about the cytokine levels in an untreated patient.

474. The method of any one of clauses 108 to 182 wherein the compound,or the pharmaceutically acceptable salt thereof, is administered beforeand subsequent to administration of the folate, the conjugate comprisinga folate wherein the conjugate comprising a folate does not comprise atargeting moiety, or the agent that inhibits activation of the CAR Tcells.

475. The method of any one of clauses 108 to 182 wherein CART cellnumber increases in the blood of the patient after administration of thefolate, the conjugate comprising a folate wherein the conjugatecomprising a folate does not comprise a targeting moiety, or the agentthat inhibits activation of the CAR T cells, even though cytokine levelsin the patient are reduced.

476. The method of any one of clauses 108 to 182 wherein CART cellactivation is enhanced or maintained, relative to a patient not treatedwith a rescue agent, after administration of the folate, the conjugatecomprising a folate wherein the conjugate comprising a folate does notcomprise a targeting moiety, or the agent that inhibits activation ofthe CAR T cells, even though cytokine levels in the treated patient arereduced.

477. The method of any one of clauses 108 to 182 wherein the cancercomprises a tumor and tumor size in the patient is not increased whenthe folate, the conjugate comprising a folate wherein the conjugatecomprising a folate does not comprise a targeting moiety, or the agentthat inhibits activation of the CAR T cells is administered to thepatient.

478. The method of clause 477 wherein a complete response for the tumoris obtained.

479. The method of any one of clauses 108, 115-160, 168-182, and 468-478wherein the agent that inhibits activation of the CAR T cells isadministered to the patient when the CRS grade reaches 1, 2, 3, or 4.

480. The method of any one of clauses 108, 115-160, 168-182, and 468-478wherein the agent that inhibits activation of the CAR T cells isadministered to the patient when the CRS grade reaches 3 or 4.

481. The method of any one of clauses 108 to 182 and 468 to 480 whereinlung edema is reduced.

482. The method of any one of clauses 108, 115-160, 168-182, and 468-481wherein the agent that inhibits activation of the CAR T cells isadministered at a dose of about 0.01 to about 300 umoles/kg of bodyweight of the patient.

483. The method of any one of clauses 108, 115-160, 168-182, and 468-481wherein the agent that inhibits activation of the CAR T cells isadministered at a dose of about 0.06 to about 100 umoles/kg of bodyweight of the patient.

484. The method of any one of clauses 108, 115-160, 168-182, and 468-481wherein the agent that inhibits activation of the CAR T cells isadministered at a dose of about 0.06 to about 90 umoles/kg of bodyweight of the patient.

485. The method of any one of clauses 108, 115-160, 168-182, and 468-481wherein the agent that inhibits activation of the CAR T cells isadministered at a dose of about 0.06 to about 80 umoles/kg of bodyweight of the patient.

486. The method of any one of clauses 108, 115-160, 168-182, and 468-481wherein the agent that inhibits activation of the CAR T cells isadministered at a dose of about 0.06 to about 70 umoles/kg of bodyweight of the patient.

487. The method of any one of clauses 108, 115-160, 168-182, and 468-481wherein the agent that inhibits activation of the CAR T cells isadministered at a dose of about 0.06 to about 60 umoles/kg of bodyweight of the patient.

488. The method of any one of clauses 108, 115-160, 168-182, and 468-481wherein the agent that inhibits activation of the CAR T cells isadministered at a dose of about 0.06 to about 50 umoles/kg of bodyweight of the patient.

489. The method of any one of clauses 108, 115-160, 168-182, and 468-481wherein the agent that inhibits activation of the CAR T cells isadministered at a dose of about 0.06 to about 40 umoles/kg of bodyweight of the patient.

490. The method of any one of clauses 108, 115-160, 168-182, and 468-481wherein the agent that inhibits activation of the CAR T cells isadministered at a dose of about 0.06 to about 30 umoles/kg of bodyweight of the patient.

491. The method of any one of clauses 108, 115-160, 168-182, and 468-481wherein the agent that inhibits activation of the CAR T cells isadministered at a dose of about 0.06 to about 20 umoles/kg of bodyweight of the patient.

492. The method of any one of clauses 108, 115-160, 168-182, and 468-481wherein the agent that inhibits activation of the CAR T cells isadministered at a dose of about 0.06 to about 10 umoles/kg of bodyweight of the patient.

493. The method of any one of clauses 108, 115-160, 168-182, and 468-481wherein the agent that inhibits activation of the CAR T cells isadministered at a dose of about 0.06 to about 8 umoles/kg of body weightof the patient.

494. The method of any one of clauses 108, 115-160, 168-182, and 468-481wherein the agent that inhibits activation of the CAR T cells isadministered at a dose of about 0.06 to about 6 umoles/kg of body weightof the patient.

495. The method of any one of clauses 108, 115-160, 168-181, and 468-494wherein the agent that inhibits activation of the CAR T cells isadministered to the patient and the agent is sodium fluorescein.

496. The method of any one of clauses 1 to 495 wherein CRS is reduced orprevented and the method results in a decrease in tumor volume in thepatient.

497. The method of any one of clauses 1 to 496 wherein body weight lossdue to CRS is reduced or prevented.

498. The method of any one of clauses 1-3, 8-28, 33-58, 63-83, 88-136,141-249, 252-361, 366-380, 385-424, 429-449, and 454 to 497 wherein thecancer is acute myelocytic leukemia.

499. The method of clause 498 wherein the cancer expresses the folatereceptor-β.

500. The method of clause 498 or 499 wherein the CAR-T cells have acentral memory/effector memory phenotype.

501. The method of any one of clauses 1 to 500 wherein the CD8:CD4 ratioof the CART cells is about 1:1.

502. The method of any one of clauses 215 to 251 further comprising stepiv) of re-administering the compound, or the pharmaceutically acceptablesalt thereof, to the patient.

503. The method of clause 474 wherein the subsequent administration ofthe compound, or the pharmaceutically acceptable salt thereof, causesCAR T cell activation and an increase in cytokine levels in the patient.

504. The method of any one of clauses 1 to 107, 183 to 476, or 479 to503 wherein the cancer comprises a tumor and wherein a complete responsefor the tumor is obtained.

505. A method of treatment of a cancer, the method comprising

-   -   i) administering to a patient a compound, or a pharmaceutically        acceptable salt thereof, wherein the compound comprises a small        molecule ligand linked to a targeting moiety by a linker; and    -   ii) administering to the patient a CAR T cell composition        wherein the CAR T cell composition comprises CAR T cells and        wherein the CAR T cells comprise a CAR directed to the targeting        moiety; and wherein the small molecule ligand is a PSMA ligand        and the targeting moiety is FITC.

506. The method of clause 505 wherein the small molecule ligand linkedto a targeting moiety by a linker has the formula

507. A method of treatment of a cancer, the method comprising

-   -   i) administering to a patient a compound, or a pharmaceutically        acceptable salt thereof, wherein the compound comprises a small        molecule ligand linked to a targeting moiety by a linker; and    -   ii) administering to the patient a CAR T cell composition        wherein the CAR T cell composition comprises CAR T cells and        wherein the CAR T cells comprise a CAR directed to the targeting        moiety; and wherein the small molecule ligand is a CAIX ligand        and the targeting moiety is FITC.

508. The method of clause 507 wherein the small molecule ligand linkedto a targeting moiety by a linker has the formula

509. A method of treatment of a cancer, the method comprising

-   -   i) administering to a patient a first compound, or a        pharmaceutically acceptable salt thereof, wherein the first        compound, or the pharmaceutically acceptable salt thereof,        comprises a PSMA ligand linked to FITC by a linker;    -   ii) administering to the patient a second compound, or a        pharmaceutically acceptable salt thereof, wherein the second        compound, or the pharmaceutically acceptable salt thereof,        comprises a CAIX ligand linked to FITC by a linker; and    -   iii) administering to the patient a CAR T cell composition        wherein the CAR T cell composition comprises CAR T cells and        wherein the CAR T cells comprise a CAR directed to the targeting        moiety.

510. The method of clause 509 wherein the first compound has the formula

and the second compound has the formula

Thus, in one embodiment, a method of treatment of a cancer is provided.The method comprises i) administering to a patient a compound, or apharmaceutically acceptable salt thereof, wherein the compound comprisesa small molecule ligand linked to a targeting moiety by a linker, ii)administering to the patient a first dose of a CAR T cell compositionwherein the CAR T cell composition comprises CAR T cells and wherein theCAR T cells comprise the CAR directed to the targeting moiety, and iii)administering to the patient a second dose of the CAR T cell compositionwherein the CAR T cell composition comprises CAR T cells and wherein theCAR T cells comprise the CAR directed to the targeting moiety.

In another embodiment, a method of treatment of a cancer is provided.The method comprises i) administering to a patient a compound, or apharmaceutically acceptable salt thereof, wherein the compound comprisesa small molecule ligand linked to a targeting moiety by a linker, andii) administering to the patient a CAR T cell composition comprising CART cells wherein the CAR T cells in the composition comprise the CARdirected to the targeting moiety and wherein the CAR T cell compositioncomprises a mixture of the CAR T cells and non-transformed T cells.

In yet another embodiment, a method of treatment of a cancer isprovided. The method comprises i) administering to a patient a compound,or a pharmaceutically acceptable salt thereof, wherein the compoundcomprises a small molecule ligand linked to a targeting moiety by alinker, ii) administering to the patient a CAR T cell compositionwherein the CAR T cell composition comprises CAR T cells and wherein theCAR T cells comprise the CAR directed to the targeting moiety, and iii)administering to the patient a folate, a conjugate comprising a folatewherein the conjugate comprising a folate does not comprise a targetingmoiety, or a drug that inhibits activation of the CAR T cells.

In another embodiment, a method of treatment of a cancer is provided.The method comprises i) administering to a patient a compound, or apharmaceutically acceptable salt thereof, wherein the compound comprisesa small molecule ligand linked to a targeting moiety by a linker, andwherein the compound, or the pharmaceutically acceptable salt thereof,is at a dose of about 10 nmoles/kg of body weight of the patient toabout 2500 nmoles/kg of body weight of the patient, and ii)administering to the patient a CAR T cell composition comprising CAR Tcells wherein the CAR T cells comprise a CAR directed to the targetingmoiety, and wherein the CAR T cells are at a dose of about 1 million ofthe CAR T cells to about 15 million of the CAR T cells.

In still another embodiment, a method of treatment of a cancer isprovided. The method comprises i) administering continuously to apatient a compound, or a pharmaceutically acceptable salt thereof,wherein the compound comprises a small molecule ligand linked to atargeting moiety by a linker, ii) administering to the patient a CAR Tcell composition comprising CAR T cells wherein the CAR T cells comprisea CAR directed to the targeting moiety, and iii) ending the continuousadministration of the compound, or the pharmaceutically acceptable saltthereof, to inhibit or prevent cytokine release syndrome in the patient.

In another illustrative aspect, a method of treatment of a cancer isprovided. The method comprises i) administering to a patient a compound,or a pharmaceutically acceptable salt thereof, wherein the compoundcomprises a small molecule ligand linked to a targeting moiety by alinker, wherein at least a first dose and a second dose of the compound,or the pharmaceutically acceptable salt thereof, are administered to thepatient, wherein the first dose and the second dose are different,wherein the second dose of the compound, or the pharmaceuticallyacceptable salt thereof, is about 2-fold to about 15000-fold greater inamount than the first dose of the compound, or the pharmaceuticallyacceptable salt thereof, and ii) administering to the patient a CAR Tcell composition comprising CAR T cells wherein the CAR T cells comprisea CAR directed to the targeting moiety.

In another embodiment, a method of treatment of a cancer is provided.The method comprises i) administering to a patient a compound, or apharmaceutically acceptable salt thereof, wherein the compound comprisesa small molecule ligand linked to a targeting moiety by a linker andwherein the compound, or the pharmaceutically acceptable salt thereof,is administered once weekly to the patient, and ii) administering to thepatient a CAR T cell composition comprising CAR T cells wherein the CART cells comprise a CAR directed to the targeting moiety.

In yet another embodiment, a method of treatment of a cancer isprovided. The method comprises i) administering to a patient a firstdose of a compound, or a pharmaceutically acceptable salt thereof,wherein the compound comprises a small molecule ligand linked to atargeting moiety by a linker, ii) administering to the patient at leasta second dose of the compound, or a pharmaceutically acceptable saltthereof, wherein the second dose of the compound, or thepharmaceutically acceptable salt thereof, is at least about 50 percentlower in amount than the first dose of the compound, or thepharmaceutically acceptable salt thereof, and iii) administering to thepatient a dose of a CAR T cell composition comprising CAR T cellswherein the CAR T cells comprise a CAR directed to the targeting moiety.

In still another embodiment, a method of treatment of a cancer isprovided. The method comprises i) administering to a patient a firstdose of a compound, or a pharmaceutically acceptable salt thereof,wherein the compound comprises a small molecule ligand linked to atargeting moiety by a linker and wherein the compound, or thepharmaceutically acceptable salt thereof, is administered to the patientat least about one hour prior to the administration of a CAR T cellcomposition comprising CAR T cells wherein the CAR T cells comprise aCAR directed to the targeting moiety, ii) then administering to thepatient a dose of the CAR T cell composition, and iii) thenadministering to the patient a second dose of the compound, or thepharmaceutically acceptable salt thereof.

In another embodiment, a method of treatment of a cancer is provided.The method comprises i) administering to a patient a compound, or apharmaceutically acceptable salt thereof, wherein the compound comprisesa small molecule ligand linked to a targeting moiety by a linker, andii) administering to the patient a CAR T cell composition wherein theCAR T cell composition comprises CAR T cells and wherein the CAR T cellscomprise a CAR directed to the targeting moiety, and wherein the smallmolecule ligand is a PSMA ligand and the targeting moiety is FITC. Inthis embodiment, the small molecule ligand linked to a targeting moietyby a linker can have the formula

In yet another embodiment, a method of treatment of a cancer isprovided. The method comprises i) administering to a patient a compound,or a pharmaceutically acceptable salt thereof, wherein the compoundcomprises a small molecule ligand linked to a targeting moiety by alinker, and ii) administering to the patient a CAR T cell compositionwherein the CAR T cell composition comprises CAR T cells and wherein theCAR T cells comprise a CAR directed to the targeting moiety, and whereinthe small molecule ligand is a CAIX ligand and the targeting moiety isFITC. In this embodiment, the small molecule ligand linked to atargeting moiety by a linker can have the formula

In still another embodiment, a method of treatment of a cancer isprovided. The method comprises i) administering to a patient a firstcompound, or a pharmaceutically acceptable salt thereof, wherein thefirst compound, or the pharmaceutically acceptable salt thereof,comprises a PSMA ligand linked to FITC by a linker, ii) administering tothe patient a second compound, or a pharmaceutically acceptable saltthereof, wherein the second compound, or the pharmaceutically acceptablesalt thereof, comprises a CAIX ligand linked to FITC by a linker, andiii) administering to the patient a CAR T cell composition wherein theCAR T cell composition comprises CAR T cells and wherein the CAR T cellscomprise a CAR directed to the targeting moiety. In this embodiment, thefirst compound can have the formula

and the second compound can have the formula

321. Accordingly, various embodiments are provided in the twelvepreceding paragraphs and in the clause list above, and all applicableembodiments described in this “Detailed Description of IllustrativeEmbodiments,” the Summary section, the Examples, and the claims apply tothe these embodiments.

As described herein, a “patient” can be a human or, in the case ofveterinary applications, the patient can be a laboratory, anagricultural, a domestic, or a wild animal. In various aspects, thepatient can be a laboratory animal such as a rodent (e.g., mouse, rat,hamster, etc.), a rabbit, a monkey, a chimpanzee, a domestic animal suchas a dog, a cat, or a rabbit, an agricultural animal such as a cow, ahorse, a pig, a sheep, a goat, or a wild animal in captivity such as abear, a panda, a lion, a tiger, a leopard, an elephant, a zebra, agiraffe, a gorilla, a dolphin, or a whale.

In various embodiments, the cancer to be treated can be selected from acarcinoma, a sarcoma, an osteosarcoma, a lymphoma, a melanoma, amesothelioma, a nasopharyngeal carcinoma, a leukemia, an adenocarcinoma,or a myeloma. In other embodiments, the cancer may be lung cancer, bonecancer, pancreatic cancer, skin cancer, cancer of the head, cancer ofthe neck, cutaneous melanoma, intraocular melanoma uterine cancer,ovarian cancer, endometrial cancer, rectal cancer, stomach cancer, coloncancer, breast cancer, triple negative breast cancer, carcinoma of thefallopian tubes, carcinoma of the endometrium, carcinoma of the cervix,carcinoma of the vagina, carcinoma of the vulva, Hodgkin's Disease,cancer of the esophagus, cancer of the small intestine, cancer of theendocrine system, cancer of the thyroid gland, cancer of the parathyroidgland, non-small cell lung cancer, cancer of the adrenal gland, sarcomaof soft tissue, osteosarcoma, cancer of the urethra, prostate cancer,chronic leukemia, acute leukemia, including acute myelocytic leukemia, alymphocytic lymphoma, myeloid leukemia, myelomonocytic leukemia, hairycell leukemia, pleural mesothelioma, cancer of the bladder, Burkitt'slymphoma, cancer of the ureter, cancer of the kidney, renal cellcarcinoma, carcinoma of the renal pelvis, a neoplasm of the centralnervous system (CNS), primary CNS lymphoma, a spinal axis tumor, a brainstem glioma, a pituitary adenoma, and an adenocarcinoma of thegastroesophageal junction.

In some aspects of these embodiments, the cancer is a folate receptorexpressing cancer. In another embodiment, the cancer is a folatereceptor α-expressing cancer. In yet another embodiment, the cancer is afolate receptor β-expressing cancer. In some aspects of theseembodiments, the cancer is an endometrial cancer, a non-small cell lungcancer, an ovarian cancer, or a triple-negative breast cancer. Inanother embodiment, the cancer being treated is a tumor. In anotherembodiment, the cancer is malignant. In another embodiment, the canceris acute myelocytic leukemia. In yet another embodiment, the cancer isacute myelocytic leukemia and the cancer expresses the folatereceptor-β. In still another embodiment, the cancer is acute myelocyticleukemia and the CAR-T cells have a central memory/effector memoryphenotype. In yet another embodiment, the CD8:CD4 ratio of the CARTcells is about a 1:1 ratio. In another embodiment, the CD8:CD4 ratio isabout a 1.2 to 1 ratio, about a 1 to 1.2 ratio, about a 1.3 to 1 ratio,about a 1 to 1.3 ratio, about a 1.4 to 1 ratio, about a 1 to 1.4 ratio,about a 1.5 to 1 ratio, or about a 1 to 1.5 ratio. In still otherembodiments where the cancer is acute myelocytic leukemia and a rescueagent is used, the CAR T cells can remain present in the patient for atleast about 40 days, at least about 45 days, at least about 50 days, atleast about 55 days, at least about 60 days, at least about 70 days, atleast about 80 days, at least about 90 days, or at least about 100 daysafter administration of the CAR T cells, even after a rescue agent isused to inhibit or prevent CRS. In another embodiment where the canceris acute myelocytic leukemia or another cancer, the CAR T cellsassociated with the tumor can have increased CD25 expression relative tothe CAR T cells not associated with the tumor.

In one embodiment, the “small molecule ligand” can be a folate, DUPA (aligand bound by PSMA-positive human prostate cancer cells and othercancer cell types), an NK-1R ligand (receptors for the NK-1R ligand arefound, for example, on cancers of the colon and pancreas), a CAIX ligand(receptors for the CAIX ligand are found, for example, on renal,ovarian, vulvar, and breast cancers), a ligand of gamma glutamyltranspeptidase (the transpeptidase is overexpressed, for example, inovarian cancer, colon cancer, liver cancer, astrocytic gliomas,melanomas, and leukemias), an NKG2D ligand (receptors for the NKG2Dligand are found, for example, on cancers of the lung, colon, kidney,prostate, and on T and B cell lymphomas), or a CCK2R ligand (receptorsfor the CCK2R ligand are found on cancers of the thyroid, lung,pancreas, ovary, brain, stomach, gastrointestinal stroma, and colon,among others), each of which is a small molecule ligand that bindsspecifically to a cancer cell type (i.e., the receptor for each of theseligands can be overexpressed on cancers compared to normal tissues).

In one embodiment, the small molecule ligand may have a mass of lessthan about 10,000 Daltons, less than about 9000 Daltons, less than about8,000 Daltons, less than about 7000 Daltons, less than about 6000Daltons, less than about 5000 Daltons, less than about 4500 Daltons,less than about 4000 Daltons, less than about 3500 Daltons, less thanabout 3000 Daltons, less than about 2500 Daltons, less than about 2000Daltons, less than about 1500 Daltons, less than about 1000 Daltons, orless than about 500 Daltons. In another embodiment, the small moleculeligand may have a mass of about 1 to about 10,000 Daltons, about 1 toabout 9000 Daltons, about 1 to about 8,000 Daltons, about 1 to about7000 Daltons, about 1 to about 6000 Daltons, about 1 to about 5000Daltons, about 1 to about 4500 Daltons, about 1 to about 4000 Daltons,about 1 to about 3500 Daltons, about 1 to about 3000 Daltons, about 1 toabout 2500 Daltons, about 1 to about 2000 Daltons, about 1 to about 1500Daltons, about 1 to about 1000 Daltons, or about 1 to about 500 Daltons.

In one embodiment, a DUPA derivative can be the ligand of the smallmolecule ligand linked to a targeting moiety, and DUPA derivatives aredescribed in WO 2015/057852, incorporated herein by reference.

In one embodiment, the small molecule ligand in the context of the“small molecule ligand linked to a linker” is a folate. In variousembodiments, the folate can be folic acid, a folic acid analog, oranother folate receptor-binding molecule. In various embodiments,analogs of folate that can be used include folinic acid (e.g.,leucovorin), pteropolyglutamic acid, and folate receptor-bindingpteridines such as tetrahydropterins, dihydrofolates, tetrahydrofolates,and their deaza and dideaza analogs. The terms “deaza” and “dideaza”analogs refers to the art recognized analogs having a carbon atomsubstituted for one or two nitrogen atoms in the naturally occurringfolic acid structure. For example, the deaza analogs include the1-deaza, 3-deaza, 5-deaza, 8-deaza, and 10-deaza analogs. The dideazaanalogs include, for example, 1,5 dideaza, 5,10-dideaza, 8,10-dideaza,and 5,8-dideaza analogs. The foregoing folic acid analogs areconventionally termed “folates,” reflecting their capacity to bind tofolate receptors. Other folate receptor-binding analogs includeaminopterin, amethopterin (methotrexate), N10-methylfolate,2-deamino-hydroxyfolate, deaza analogs such as 1-deazamethopterin or3-deazamethopterin, and 3′,5′-dichloro-4-amino-4-deoxy-N10-methylpteroylglutamic acid(dichloromethotrexate).

In another embodiment, the small molecule ligand in the context of the“small molecule ligand linked to a linker” can have the formula

wherein X¹ and Y¹ are each-independently selected from the groupconsisting of halo, R², OR², SR³, and NR⁴R⁵;

U, V, and W represent divalent moieties each independently selected fromthe group consisting of —(R^(6a))C═, —N═, —(R^(6a))C(R^(7a))—, and—N(R^(4a))—; Q is selected from the group consisting of C and CH; T isselected from the group consisting of S, O, N, and —C═C—;

X² and X³ are each independently selected from the group consisting ofoxygen, sulfur, —C(Z)—, —C(Z)O—, —OC(Z)—, —N(R^(4b))—, —C(Z)N(R^(4b))—,—N(R^(4b))C(Z)—, —OC(Z)N(R^(4b))—, —N(R^(4b))C(Z)O—,—N(R^(4b))C(Z)N(R^(5b))—, —S(O)—, —S(O)₂—, —N(R^(4a))S(O)₂—, —C(R^(6b))(R^(7b))—, —N(C≡CH)—, —N(CH₂C≡CH)—, C₁-C₁₂ alkylene, and C₁-C₁₂alkyeneoxy, where Z is oxygen or sulfur;

R¹ is selected-from the group consisting of hydrogen, halo, C₁-C₁₂alkyl, and

C₁-C₁₂ alkoxy;

R², R³, R⁴, R^(4a), R^(4b), R⁵, R^(5b), R^(6b), and R^(7b) are eachindependently selected from the group consisting of hydrogen, halo,C₁-C₁₂ alkyl, C₁-C₁₂ alkoxy, C₁-C₁₂ alkanoyl, C₁-C₁₂ alkenyl, C₁-C₁₂alkynyl, (C₁-C₁₂ alkoxy)carbonyl, and (C₁-C₁₂ alkylamino)carbonyl;

R⁶ and R⁷ are each independently selected from the group consisting ofhydrogen, halo, C₁-C₁₂ alkyl, and C₁-C₁₂ alkoxy; or, R⁶ and R⁷ are takentogether to form a carbonyl group;

R^(6a) and R^(7a) are each independently selected from the groupconsisting of hydrogen, halo, C₁-C₁₂ alkyl, and C₁-C₁₂ alkoxy; or R^(6a)and R^(7a) are taken together to form a carbonyl group;

p, r, s, and t are each independently either 0 or 1; and

* represents an optional covalent bond to the rest of the conjugate, ifany additional chemical moieties are part of the folate.

In one aspect, the “targeting moiety” that binds to the CAR expressed byCAR T cells can be selected, for example, from 2,4-dinitrophenol (DNP),2,4,6-trinitrophenol (TNP), biotin, digoxigenin, fluorescein,fluorescein isothiocyanate (FITC), NHS-fluorescein, pentafluorophenylester, tetrafluorophenyl ester, a knottin, a centyrin, a DARPin, anaffibody, an affilin, an anticalin, an atrimer, an avimer, a bicicyclicpeptide, an FN3 scaffold, a cys-knot, a fynomer, a Kunitz domain, or anObody. The identity of the targeting moiety is limited only in that itshould be recognized and bound by the CAR, preferably with specificity,and that it have a relatively low molecular weight. In various aspects,exemplary targeting moieties are haptens, including small molecularweight organic molecules.

In one illustrative embodiment, the targeting moiety can have thefollowing illustrative structure:

where X is oxygen, nitrogen, or sulfur, and where X is attached tolinker L; Y is OR^(a), NR^(a) ₂, or NR^(a) ₃ ⁺; and Y′ is O, NR^(a), orNR^(a) ₂ ⁺; where each R is independently selected in each instance fromH, fluoro, sulfonic acid, sulfonate, and salts thereof, and the like;and R^(a) is hydrogen or alkyl.

In one illustrative aspect, the linker can comprise polyethylene glycol(PEG), polyproline, a hydrophilic amino acid, a sugar, an unnaturalpeptidoglycan, a polyvinylpyrrolidone, pluronic F-127, or a combinationthereof.

In another illustrative aspect, the linker in the compound, orpharmaceutically acceptable salt thereof, described herein can comprisea direct linkage (e.g., a reaction between the isothiocyanate group ofFITC and a free amine group of a small molecule ligand) or the linkagecan be through an intermediary linker. In one embodiment, if present, anintermediary linker can be any biocompatible linker known in the art,such as a divalent linker. In one illustrative embodiment, the divalentlinker can comprise about 1 to about 30 carbon atoms. In anotherillustrative embodiment, the divalent linker can comprise about 2 toabout 20 carbon atoms. In other embodiments, lower molecular weightdivalent linkers (i.e., those having an approximate molecular weight ofabout 30 to about 300 Daltons) are employed. In another embodiment,linker lengths that are suitable include, but are not limited to,linkers having 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17,18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35,36, 37, 38, 39 or 40, or more atoms.

In various embodiments, the small molecule ligand linked to a targetingmoiety can be of the formula

B-L-T,

wherein B represents the small molecule ligand, L represents the linker,and T represents the targeting moiety, and wherein L comprises astructure having the formula

wherein n is an integer from 0 to 200. In another embodiment, n can bean integer from 0 to 150, 0 to 110, 0 to 100, 0 to 90, 0 to 80, 0 to 70,0 to 60, 0 to 50, 0 to 40, 0 to 30, 0 to 20, 0 to 15, 0 to 14, 0 to 13,0 to 12, 0 to 11, 0 to 10, 0 to 9, 0 to 8, 0 to 7, 0 to 6, 0 to 5, 0 to4, 0 to 3, 0 to 2, 0 to 1, 15 to 16, 15 to 17, 15 to 18, 15 to 19, 15 to20, 15 to 21, 15 to 22, 15 to 23, 15 to 24, 15 to 25, 15 to 26, 15 to27, 15 to 28, 15 to 29, 15 to 30, 15 to 31, 15 to 32, 15 to 33, 15 to34, 15 to 35, 15 to 36, 15 to 37, 15 to 38, 15 to 39, 15 to 40, 15 to50, 15 to 60, 15 to 70, 15 to 80, 15 to 90, 15 to 100, 15 to 110, 15 to120, 15 to 130, 15 to 140, 15 to 150, or n can be 1, 2, 3, 4, 5, 6, 7,8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25,26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 50, 60, 70,80, 90, 100, 108, 110, 120, 130, 140, or 150.

In another embodiment, the linker may be a divalent linker that mayinclude one or more spacers. Illustrative spacers are shown in thefollowing table. The following non-limiting, illustrative spacers aredescribed where * indicates the point of attachment to the smallmolecule ligand or to the targeting moiety, or to other divalent linkerportions.

In other embodiments, the small molecule ligand linked to a targetingmoiety (bridge) can have any of the following structures.

326. In other embodiments, the compound, or the pharmaceuticallyacceptable salt thereof, is not an antibody, and does not comprise afragment of an antibody. In yet another embodiment, the targeting moietydoes not comprise a peptide epitope.

327. In one illustrative embodiment, the small molecule ligand linked toa targeting moiety by a linker (the bridge) comprises fluoresceinisothiocyanate (FITC) linked to the small molecule ligand. In oneaspect, the cancer may overexpress a receptor for the small moleculeligand. In another aspect, for example, cytotoxic T cells, or anothertype of T cell, can be transformed to express a CAR that comprisesanti-FITC scFv. In this aspect, the CAR may target FITC decorating thecancer with FITC molecules as a result of binding of the small moleculeligand to the cancer. Thus, toxicity to normal, non-target cells can beavoided. In this embodiment, when the anti-FITC CAR-expressing T cellsbind FITC, the CAR T cells are activated and the cancer is ameliorated.

328. A “pharmaceutically acceptable salt” of a small molecule ligandlinked to a targeting moiety by a linker is contemplated. As usedherein, the term “pharmaceutically acceptable salt” refers to thosesalts whose counter ions may be used in pharmaceuticals. In variousembodiments, such salts include, but are not limited to 1) acid additionsalts, which can be obtained by reaction of the free base of the parentcompound with inorganic acids such as hydrochloric acid, hydrobromicacid, nitric acid, phosphoric acid, sulfuric acid, and perchloric acidand the like, or with organic acids such as acetic acid, oxalic acid,(D) or (L) malic acid, maleic acid, methane sulfonic acid,ethanesulfonic acid, p-toluenesulfonic acid, salicylic acid, tartaricacid, citric acid, succinic acid or malonic acid and the like; or 2)salts formed when an acidic proton present in the parent compound eitheris replaced by a metal ion, e.g., an alkali metal ion, an alkaline earthion, or an aluminum ion; or coordinates with an organic base such asethanolamine, diethanolamine, triethanolamine, trimethamine,N-methylglucamine, and the like. Pharmaceutically acceptable salts arewell-known to those skilled in the art, and any such pharmaceuticallyacceptable salt is contemplated in connection with the embodimentsdescribed herein.

In various embodiments, suitable acid addition salts are formed fromacids which form non-toxic salts. Illustrative examples include theacetate, aspartate, benzoate, besylate, bicarbonate/carbonate,bisulphate/sulphate, borate, camsylate, citrate, edisylate, esylate,formate, fumarate, gluceptate, gluconate, glucuronate,hexafluorophosphate, hibenzate, hydrochloride/chloride,hydrobromide/bromide, hydroiodide/iodide, isethionate, lactate, malate,maleate, malonate, mesylate, methylsulphate, naphthylate, 2-napsylate,nicotinate, nitrate, orotate, oxalate, palmitate, pamoate,phosphate/hydrogen phosphate/dihydrogen phosphate, saccharate, stearate,succinate, tartrate, tosylate and trifluoroacetate salts.

In various embodiments, suitable base salts are formed from bases whichform non-toxic salts. Illustrative examples include the arginine,benzathine, calcium, choline, diethylamine, diolamine, glycine, lysine,magnesium, meglumine, olamine, potassium, sodium, tromethamine and zincsalts. Hemisalts of acids and bases may also be formed, for example,hemisulphate and hemicalcium salts.

In one illustrative aspect, the compound, or a pharmaceutically saltthereof, described herein may contain one or more chiral centers, or mayotherwise be capable of existing as multiple stereoisomers. Accordingly,various embodiments may include pure stereoisomers as well as mixturesof stereoisomers, such as enantiomers, diastereomers, andenantiomerically or diastereomerically enriched mixtures. In one aspect,the compound, or pharmaceutically acceptable salt thereof, describedherein may be capable of existing as geometric isomers. Accordingly,various embodiments may include pure geometric isomers or mixtures ofgeometric isomers.

In some aspects, the compound, or pharmaceutically acceptable saltthereof, described herein may exist in unsolvated forms as well assolvated forms, including hydrated forms. In general, the solvated formsare equivalent to unsolvated forms and are encompassed within the scopeof the present invention.

The methods described herein also utilize T lymphocytes (e.g., cytotoxicT lymphocytes) engineered to express a chimeric antigen receptor (CAR)that recognizes and binds to the targeting moiety (e.g., FITC, DNP, orTNP) of the bridge. In one embodiment, the CARs described hereincomprise three domains including 1) a recognition region (e.g., a singlechain fragment variable (scFv) region of an antibody, a Fab fragment,and the like) which recognizes and binds to the targeting moiety withspecificity, 2) a co-stimulation domain which enhances the proliferationand survival of the T lymphocytes, and 3) an activation signaling domainwhich generates a T lymphocyte activation signal.

In various aspects, as non-limiting examples, scFv regions of antibodiesthat bind a folate, DUPA, a CAIX ligand, an NK-1R ligand, a ligand ofgamma glutamyl transpeptidase, an NKG2D ligand, or a CCK2R ligand can beused. In illustrative non-limiting embodiments, the scFv regions can beprepared from (i) an antibody known in the art that binds a targetingmoiety, (ii) an antibody newly prepared using a selected targetingmoiety, such as a hapten, and (iii) sequence variants derived from thescFv regions of such antibodies, e.g., scFv regions having at leastabout 80%, at least about 90%, at least about 91%, at least about 92%,at least about 93%, at least about 94%, at least about 95%, at leastabout 96%, at least about 97%, at least about 98%, at least about 99%,or at least about 99.5% sequence identity with the amino acid sequenceof the scFv region from which they are derived.

In one aspect, the co-stimulation domain serves to enhance theproliferation and survival of the cytotoxic T lymphocytes upon bindingof the CAR to a targeting moiety. Suitable co-stimulation domainsinclude, but are not limited to, CD28, CD137 (4-1BB), a member of thetumor necrosis factor (TNF) receptor family, CD134 (OX40), a member ofthe TNFR-superfamily of receptors, CD27, CD30, CD150, DAP10, NKG2D, andCD278 (ICOS), a CD28-superfamily co-stimulatory molecule expressed onactivated T cells, or combinations thereof. A skilled artisan willunderstand that sequence variants of these co-stimulation domains can beused without adversely impacting the invention, where the variants havethe same or similar activity as the domain upon which they are modeled.In various embodiments, such variants can have at least about 80%, atleast about 90%, at least about 91%, at least about 92%, at least about93%, at least about 94%, at least about 95%, at least about 96%, atleast about 97%, at least about 98%, at least about 99%, or at leastabout 99.5% sequence identity to the amino acid sequence of the domainfrom which they are derived.

In an illustrative embodiment, the activation signaling domain serves toactivate T lymphocytes (e.g., cytotoxic T lymphocytes) upon binding ofthe CAR to a targeting moiety. In various embodiments, suitableactivation signaling domains include the T cell CD3ζ chain, CD3 deltareceptor protein, mbl receptor protein, B29 receptor protein, and Fcreceptor γ. The skilled artisan will understand that sequence variantsof these activation signaling domains can be used where the variantshave the same or similar activity as the domain upon which they aremodeled. In various embodiments, the variants have at least about 80%,at least about 90%, at least about 91%, at least about 92%, at leastabout 93%, at least about 94%, at least about 95%, at least about 96%,at least about 97%, at least about 98%, at least about 99%, or at leastabout 99.5% sequence identity with the amino acid sequence of the domainfrom which they are derived.

In one aspect, constructs encoding the CARs are prepared using geneticengineering techniques. Such techniques are described in detail inSambrook et al., “Molecular Cloning: A Laboratory Manual”, 3rd Edition,Cold Spring Harbor Laboratory Press, (2001), incorporated herein byreference, and Green and Sambrook, “Molecular Cloning: A LaboratoryManual”, 4th Edition, Cold Spring Harbor Laboratory Press, (2012),incorporated herein by reference.

As examples, a plasmid or viral expression vector (e.g., a lentiviralvector, a retrovirus vector, sleeping beauty, and piggyback(transposon/transposase systems that include a non-viral mediated CARgene delivery system)) can be prepared that encodes a fusion proteincomprising a recognition region, one or more co-stimulation domains, andan activation signaling domain, in frame and linked in a 5′ to 3′direction. In other embodiments, other arrangements are acceptable andinclude a recognition region, an activation signaling domain, and one ormore co-stimulation domains. In one embodiment, the placement of therecognition region in the fusion protein will generally be such thatdisplay of the region on the exterior of the cell is achieved. In oneembodiment, the CARs may include additional elements, such as a signalpeptide (e.g., CD8α signal peptide) to ensure proper export of thefusion protein to the cell surface, a transmembrane domain to ensure thefusion protein is maintained as an integral membrane protein (e.g., CD8αtransmembrane domain, CD28 transmembrane domain, or CD3ζ transmembranedomain), and a hinge domain (e.g., CD8α hinge) that imparts flexibilityto the recognition region and allows strong binding to the targetingmoiety.

A diagram of an exemplary CAR is shown in FIG. 5 where the fusionprotein sequence is incorporated into a lentivirus expression vector andwhere “SP” is a signal peptide, the CAR is an anti-FITC CAR, a CD8αhinge and a CD8α transmembrane domain are present, the co-stimulationdomain is 4-1BB, and the activation signaling domain is CD3ζ. Exemplarynucleic acid sequences of a CAR insert are provided as SEQ ID NOS:1 and3 and the encoded amino acid sequence is provided as SEQ ID NO:2. In yetanother embodiment, SEQ ID NO:2 can comprise or consist of humanized, orhuman amino acid sequences.

In one embodiment, the CAR has a recognition region and the recognitionregion is a single chain fragment variable (scFv) region of an anti-FITCantibody, a co-stimulation domain and the co-stimulation domain is CD137(4-1BB), and an activation signaling domain and the activation signalingdomain is a T cell CD3ζ chain. It is well-known to the skilled artisanthat an anti-FITC scFv and an anti-fluorescein scFv are equivalentterms.

In one embodiment, T lymphocytes (e.g., cytotoxic T lymphocytes) can begenetically engineered to express CAR constructs by transfecting apopulation of the T lymphocytes with an expression vector encoding theCAR construct. Suitable methods for preparing a transduced population ofT lymphocytes expressing a selected CAR construct are well-known to theskilled artisan, and are described in Sambrook et al., “MolecularCloning: A Laboratory Manual”, 3rd Edition, Cold Spring HarborLaboratory Press, (2001), incorporated herein by reference, and Greenand Sambrook, “Molecular Cloning: A Laboratory Manual”, 4th Edition,Cold Spring Harbor Laboratory Press, (2012), incorporated herein byreference.

In one embodiment, CAR T cells comprising a nucleic acid of SEQ ID NO:1or 3 are provided. In another embodiment, CAR T cells comprising apolypeptide of SEQ ID NO:2 is provided. In another illustrative aspect,a nucleic acid (e.g., an isolated nucleic acid) comprising SEQ ID NO:1or 3 and encoding a chimeric antigen receptor is provided. In yetanother embodiment, a chimeric antigen receptor polypeptide comprisingSEQ ID NO:2 is provided. In another embodiment, a vector is providedcomprising SEQ ID NO:1 or 3. In another aspect, a lentiviral vector isprovided comprising SEQ ID NO:1 or 3. In yet another embodiment, SEQ IDNO:2 can comprise or consist of humanized, or human amino acidsequences.

In each of these embodiments, variant nucleic acid sequences or aminoacid sequences having at least about 80%, at least about 90%, at leastabout 95%, at least about 97%, at least about 98%, at least about 99%,or at least about 99.5% sequence identity to SEQ ID NOS:1 to 3 arecontemplated. In another embodiment, the nucleic acid sequence can be avariant nucleic acid sequence having at least about 80%, at least about90%, at least about 95%, at least about 97%, at least about 98%, atleast about 99%, or at least about 99.5% sequence identity to SEQ IDNO:1 or 2 as long as the variant sequence encodes a polypeptide of SEQID NO:2. In another embodiment, the nucleic acid sequence or the aminoacid sequence can be a variant nucleic acid or amino acid sequencehaving at least about 80%, at least about 90%, at least about 95%, atleast about 97%, at least about 98%, at least about 99%, or at leastabout 99.5% sequence identity to SEQ ID NO:1 or 3 along a stretch of 200nucleic acids or, for SEQ ID NO:2, along a stretch of 200 amino acids.In one embodiment, determination of percent identity or similaritybetween sequences can be done, for example, by using the GAP program(Genetics Computer Group, software; now available via Accelrys onhttp://www.accelrys.com), and alignments can be done using, for example,the ClustalW algorithm (VNTI software, InforMax Inc.). A sequencedatabase can be searched using the nucleic acid or amino acid sequenceof interest. Algorithms for database searching are typically based onthe BLAST software (Altschul et al., 1990). In some embodiments, thepercent identity can be determined along the full-length of the nucleicacid or amino acid sequence.

Also within the scope of the invention are nucleic acids complementaryto the nucleic acids represented by SEQ ID NO:1 and 3, and those thathybridize to the nucleic acids represented by SEQ ID NO:1 and 3, orthose that hybridize to their complements under highly stringentconditions. In accordance with the invention “highly stringentconditions” means hybridization at 65° C. in 5×SSPE and 50% formamide,and washing at 65° C. in 0.5×SSPE. Conditions for high stringency, lowstringency and moderately stringent hybridization are described inSambrook et al., “Molecular Cloning: A Laboratory Manual”, 3rd Edition,Cold Spring Harbor Laboratory Press, (2001), incorporated herein byreference, and Green and Sambrook, “Molecular Cloning: A LaboratoryManual”, 4th Edition, Cold Spring Harbor Laboratory Press, (2012),incorporated herein by reference. In some illustrative aspects,hybridization occurs along the full-length of the nucleic acid.

In one embodiment, the T lymphocytes (e.g., cytotoxic T lymphocytes usedto prepare CAR T cells or non-transformed T cells), used in the methodsdescribed herein, can be autologous cells, although heterologous cellscan also be used, such as when the patient being treated has receivedhigh-dose chemotherapy or radiation treatment to destroy the patient'simmune system. In one embodiment, allogenic cells can be used.

In one aspect, the T lymphocytes can be obtained from a patient by meanswell-known in the art. For example, T cells (e.g., cytotoxic T cells ornon-transformed T cells) can be obtained by collecting peripheral bloodfrom the patient, subjecting the blood to Ficoll density gradientcentrifugation, and then using a negative T cell isolation kit (such asEasySep™ T Cell Isolation Kit) to isolate a population of T cells fromthe peripheral blood. In one illustrative embodiment, the population ofT lymphocytes (e.g., cytotoxic T cells or non-transformed T cells) neednot be pure and may contain other cells such as other types of T cells(in the case of cytotoxic T cells, for example), monocytes, macrophages,natural killer cells, and B cells. In one aspect, the population beingcollected can comprise at least about 90% of the selected cell type, atleast about 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% of theselected cell type.

In one embodiment, after the T lymphocytes (e.g., cytotoxic T cells usedto prepare CAR T cells) are obtained, the cells are cultured underconditions that promote the activation of the cells. In this embodiment,the culture conditions may be such that the cells can be administered toa patient without concern for reactivity against components of theculture medium. For example, the culture conditions may not includebovine serum products, such as bovine serum albumin. In one illustrativeaspect, the activation can be achieved by introducing known activatorsinto the culture medium, such as anti-CD3 antibodies in the case ofcytotoxic T cells. Other suitable activators include anti-CD28antibodies. In one aspect, the population of lymphocytes can be culturedunder conditions promoting activation for about 1 to about 4 days. Inone embodiment, the appropriate level of activation can be determined bycell size, proliferation rate, or activation markers determined by flowcytometry.

In one illustrative embodiment, after the population of T lymphocytes(e.g., cytotoxic T lymphocytes used to prepare CAR T cells) has beencultured under conditions promoting activation, the cells can betransfected with an expression vector encoding a CAR. Suitable vectorsand transfection methods for use in various embodiments are describedabove. In one aspect, after transfection, the cells can be immediatelyadministered to the patient or the cells can be cultured for at leastabout 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18 ormore days, or between about 5 and about 12 days, between about 6 andabout 13 days, between about 7 and about 14 days, or between about 8 andabout 15 days, for example, to allow time for the cells to recover fromthe transfection. In one aspect, suitable culture conditions can besimilar to the conditions under which the cells were cultured foractivation either with or without the agent that was used to promoteactivation.

Thus, as described above, in one illustrative aspect, the methods oftreatment described herein can further comprise 1) obtaining apopulation of autologous or heterologous T lymphocytes (e.g., cytotoxicT lymphocytes used to prepare CAR T cells), 2) culturing the Tlymphocytes under conditions that promote the activation of the cells,and 3) transfecting the lymphocytes with an expression vector encoding aCAR to form CAR T cells.

In one illustrative embodiment, when the cells have been transfected andactivated, a composition comprising the CAR T cells can be prepared andadministered to the patient, with or without non-transformed T cells. Inone embodiment, culture media that lacks any animal products, such asbovine serum, can be used to culture the CAR T cells and/or thenon-transformed T cells. In another embodiment, tissue cultureconditions typically used by the skilled artisan to avoid contaminationwith bacteria, fungi and mycoplasma can be used. In an exemplaryembodiment, prior to being administered to a patient, the cells (e.g.,CAR T cells and/or non-transformed T cells are pelleted, washed, and areresuspended in a pharmaceutically acceptable carrier or diluent.Exemplary compositions comprising CAR-expressing T lymphocytes (e.g.,cytotoxic T lymphocytes) or non-transformed T cells include compositionscomprising the cells in sterile 290 mOsm saline, in infusible cryomedia(containing Plasma-Lyte A, dextrose, sodium chloride injection, humanserum albumin and DMSO), in 0.9% NaCl with 2% human serum albumin, or inany other sterile 290 mOsm infusible materials. Alternatively, inanother embodiment, depending on the identity of the culture medium, theCAR T cells or non-transformed T cells can be administered in theculture media as the composition, or concentrated and resuspended in theculture medium before administration. In various embodiments, the CAR Tcell composition, with or without non-transformed T cells, can beadministered to the patient via any suitable means, such as parenteraladministration, e.g., intradermally, subcutaneously, intramuscularly,intraperitoneally, intravenously, or intrathecally.

In one aspect, the total number of CAR T cells and the concentration ofthe cells in the composition administered to the patient will varydepending on a number of factors including the type of T lymphocytes(e.g., cytotoxic T lymphocytes) being used, the binding specificity ofthe CAR, the identity of the targeting moiety and the small moleculeligand, the identity of the cancer, the location of the cancer in thepatient, the means used to administer the compositions to the patient,and the health, age and weight of the patient being treated. In variousembodiments, suitable compositions comprising transduced CAR T cellsinclude those having a volume of about 0.1 ml to about 200 ml and about0.1 ml to about 125 ml.

In various embodiments, the transduced CAR T cells administered to thepatient can comprise from about 1×10⁵ to about 1×10¹⁵ or 1×10⁶ to about1×10¹⁵ transduced CAR T cells. In various embodiments about 1×10⁵ toabout 1×10¹⁰, about 1×10⁶ to about 1×10¹⁰, about 1×10⁶ to about 1×10⁹,about 1×10⁶ to about 1×10⁸, about 1×10⁶ to about 2×10⁷, about 1×10⁶ toabout 3×10⁷, about 1×10⁶ to about 1.5×10⁷, about 1×10⁶ to about 1×10⁷,about 1×10⁶ to about 9×10⁶, about 1×10⁶ to about 8×10⁶, about 1×10⁶ toabout 7×10⁶, about 1×10⁶ to about 6×10⁶, about 1×10⁶ to about 5×10⁶,about 1×10⁶ to about 4×10⁶, about 1×10⁶ to about 3×10⁶, about 1×10⁶ toabout 2×10⁶, about 2×10⁶ to about 6×10⁶, about 2×10⁶ to about 5×10⁶,about 3×10⁶ to about 6×10⁶, about 4×10⁶ to about 6×10⁶, about 4×10⁶ toabout 1×10⁷, about 1×10⁶ to about 1×10⁷, about 1×10⁶ to about 1.5×10⁷,about 1×10⁶ to about 2×10⁷, about 0.2×10⁶ to about 1×10⁷, about 0.2×10⁶to about 1.5×10⁷, about 0.2×10⁶ to about 2×10⁷, or about 5×10⁶ CAR Tcells can be administered to the patient. In one aspect, in anyembodiment described herein, a single dose or multiple doses of the CART cells can be administered to the patient. In any of the embodimentsdescribed in this paragraph, the CAR T cell dose can be in numbers ofCAR T cells per kg of patient body weight. In any embodiment describedherein, the CAR T cells can be administered before the compound, or thepharmaceutically acceptable salt thereof. As would be understood, thedesignations i), ii), and iii), etc. for steps of any method describedherein do not indicate an order unless otherwise stated.

In the various embodiments described herein, non-transformed T cells canalso be administered with the CAR T cells and can be administered inamounts described herein for the CAR T cells and the non-transformed Tcells. In one aspect, a mixture of CAR T cells and non-transformed Tcells can be administered a single time or multiple times, orcombinations of doses of pure CART cells and mixtures of CART cells andnon-transformed T cells can be administered (e.g., a dose of CART cellsfollowed by one or more doses of a mixture of CAR T cells andnon-transformed T cells). As is clear to the skilled artisan from thedisclosure herein, a mixture of CAR T cells and non-transformed T cellsas described herein, means that CAR T cells are mixed withnon-transformed T cells that have not been exposed to a construct usedfor expression of a chimeric antigen receptor.

329. In other embodiments, the dose of the CAR T cells administered tothe patient in the CAR T cell composition is selected from the groupconsisting of about 1 million, about 2 million, about 3 million, about 4million, about 5 million, about 6 million, about 7 million, about 8million, about 9 million, about 10 million, about 11 million, about 12million, about 12.5 million, about 13 million, about 14 million, andabout 15 million of the CAR T cells. In these embodiments, the CAR Tcell dose can be in numbers of CAR T cells per kg of patient bodyweight.

330. In still other illustrative embodiments, the CAR T cell compositionis administered by injection into the patient's bloodstream, and the CART cells in the patient's bloodstream are at least 5 percent, at least 7percent, at least 10 percent, at least 11 percent, at least 12 percent,at least 13 percent, at least 14 percent, or at least 15 percent of thepatient's total T cells in the patient's bloodstream by about four weeksafter injection of the CAR T cell composition, at least 20 percent, 25percent, 30 percent, 35 percent, 40 percent, or 50 percent by about 3weeks after injection of the CAR T cell composition, at least 60percent, 65 percent, 70 percent, 75 percent, or 80 percent by about 2weeks after injection of the CAR T cell composition, or at least 85percent, 90 percent, or 95 by about 1 week after injection of the CAR Tcell composition.

331. In embodiments described herein, the CART cell composition cancomprise CAR T cells without any other cell type, or non-transformed Tcells can be administered to the patient in combination with CAR Tcells. For embodiments where multiple doses of the CAR T cellcomposition are administered, any dose can comprise CAR T cells or amixture of CAR T cells and non-transformed T cells. In variousembodiments, the non-transformed T cells can be administered in amountsdescribed herein for the CAR T cells.

332. In another embodiment, any dose of the CAR T cell composition cancomprise a mixture of the CAR T cells and non-transformed T cells in aratio selected from about 1:5 of the CAR T cells to the non-transformedT cells, about 1:4 of the CART cells to the non-transformed T cells,about 1:3 of the CAR T cells to the non-transformed T cells, about 1:2of the CAR T cells to the non-transformed T cells, and about 1:1 of theCAR T cells to the non-transformed T cells.

333. In still other embodiments, any dose of the CAR T cell compositioncan comprise a mixture of the CAR T cells and non-transformed T cells ina ratio of from about 1:1 to about 1:5 of the CART cells to thenon-transformed T cells, or the CART cell composition can comprise amixture of about 10 million of the CAR T cells and about 40 millionnon-transformed T cells, about 15 million of the CAR T cells and about35 million of the non-transformed T cells, about 20 million of the CAR Tcells and about 30 million of the non-transformed T cells, or about 25million of the CAR T cells and about 25 million of the non-transformed Tcells.

The compound, or pharmaceutically acceptable salt thereof, or CAR T cellcomposition described herein can be administered to the patient usingany suitable method known in the art. As described herein, the term“administering” or “administered” includes all means of introducing thecompound, or pharmaceutically acceptable salt thereof, or CAR T cellcomposition to the patient, including, but not limited to, oral,intravenous, intramuscular, subcutaneous, transdermal, and the like. Inone aspect, the compound, or pharmaceutically acceptable salt thereof,described herein may be administered in unit dosage forms and/orformulations containing conventional nontoxicpharmaceutically-acceptable carriers, adjuvants, and vehicles.

In one aspect, the compound, or pharmaceutically acceptable saltthereof, or CAR T cell composition as described herein may beadministered directly into the blood stream, into muscle, or into aninternal organ. In various embodiments, suitable routes for suchparenteral administration include intravenous, intraarterial,intraperitoneal, intrathecal, epidural, intracerebroventricular,intraurethral, intrasternal, intracranial, intratumoral, intramuscularand subcutaneous delivery. In one embodiment, means for parenteraladministration include needle (including microneedle) injectors,needle-free injectors and infusion techniques.

In one illustrative aspect, parenteral formulations are typicallyaqueous solutions which may contain carriers or excipients such assalts, carbohydrates and buffering agents (preferably at a pH of from 3to 9), but they may be more suitably formulated as a sterile non-aqueoussolution or as a dried form to be used in conjunction with a suitablevehicle such as sterile, pyrogen-free water or sterile saline. In otherembodiments, any of the liquid formulations described herein may beadapted for parenteral administration as described herein. Thepreparation under sterile conditions, by lyophilization to produce asterile lyophilized powder for a parenteral formulation, may readily beaccomplished using standard pharmaceutical techniques well-known tothose skilled in the art. In one embodiment, the solubility of thecompound, or pharmaceutically acceptable salt thereof, used in thepreparation of a parenteral formulation may be increased by the use ofappropriate formulation techniques, such as the incorporation ofsolubility-enhancing agents.

The amount of the compound, or pharmaceutically acceptable salt thereof,to be administered to the patient can vary significantly depending onthe cancer being treated, the route of administration of the compound,or pharmaceutically acceptable salt thereof, and the tissuedistribution. The amount to be administered to a patient can be based onbody surface area, mass, and physician assessment. In variousembodiments, amounts to be administered can range, for example, fromabout 0.05 mg to about 30 mg, 0.05 mg to about 25.0 mg, about 0.05 mg toabout 20.0 mg, about 0.05 mg to about 15.0 mg, about 0.05 mg to about10.0 mg, about 0.05 mg to about 9.0 mg, about 0.05 mg to about 8.0 mg,about 0.05 mg to about 7.0 mg, about 0.05 mg to about 6.0 mg, about 0.05mg to about 5.0 mg, about 0.05 mg to about 4.0 mg, about 0.05 mg toabout 3.0 mg, about 0.05 mg to about 2.0 mg, about 0.05 mg to about 1.0mg, about 0.05 mg to about 0.5 mg, about 0.05 mg to about 0.4 mg, about0.05 mg to about 0.3 mg, about 0.05 mg to about 0.2 mg, about 0.05 mg toabout 0.1 mg, about 0.01 mg to about 2 mg, about 0.3 mg to about 10 mg,about 0.1 mg to about 20 mg, or about 0.8 to about 3 mg. One of skill inthe art will readily appreciate that the dose may vary within thevarious ranges provided above based on the factors noted above, and maybe at the physician's discretion.

In other embodiments, the dose of the compound, or pharmaceuticallyacceptable salt thereof, can range, for example, from about 50 nmoles/kgto about 3000 nmoles/kg of patient body weight, about 50 nmoles/kg toabout 2000 nmoles/kg, about 50 nmoles/kg to about 1000 nmoles/kg, about50 nmoles/kg to about 900 nmoles/kg, about 50 nmoles/kg to about 800nmoles/kg, about 50 nmoles/kg to about 700 nmoles/kg, about 50 nmoles/kgto about 600 nmoles/kg, about 50 nmoles/kg to about 500 nmoles/kg, about50 nmoles/kg to about 400 nmoles/kg, about 50 nmoles/kg to about 300nmoles/kg, about 50 nmoles/kg to about 200 nmoles/kg, about 50 nmoles/kgto about 100 nmoles/kg, about 100 nmoles/kg to about 300 nmoles/kg,about 100 nmoles/kg to about 500 nmoles/kg, about 100 nmoles/kg to about1000 nmoles/kg, about 100 nmoles/kg to about 2000 nmoles/kg of patientbody weight. In other embodiments, the dose may be about 1 nmoles/kg,about 5 nmoles/kg, about 10 nmoles/kg, about 20 nmoles kg, about 25nmoles/kg, about 30 nmoles/kg, about 40 nmoles/kg, about 50 nmoles/kg,about 60 nmoles/kg, about 70 nmoles/kg, about 80 nmoles/kg, about 90nmoles/kg, about 100 nmoles/kg, about 150 nmoles/kg, about 200nmoles/kg, about 250 nmoles/kg, about 300 nmoles/kg, about 350nmoles/kg, about 400 nmoles/kg, about 450 nmoles/kg, about 500nmoles/kg, about 600 nmoles/kg, about 700 nmoles/kg, about 800nmoles/kg, about 900 nmoles/kg, about 1000 nmoles/kg, about 2000nmoles/kg, about 2500 nmoles/kg or about 3000 nmoles/kg of body weightof the patient. In yet other embodiments, the dose may be about 0.1nmoles/kg, about 0.2 nmoles/kg, about 0.3 nmoles/kg, about 0.4 nmoleskg, or about 0.5 nmoles/kg, about 0.1 nmoles/kg to about 1000 nmoles/kg,about 0.1 nmoles/kg to about 900 nmoles/kg, about 0.1 nmoles/kg to about850 nmoles/kg, about 0.1 nmoles/kg to about 800 nmoles/kg, about 0.1nmoles/kg to about 700 nmoles/kg, about 0.1 nmoles/kg to about 600nmoles/kg, about 0.1 nmoles/kg to about 500 nmoles/kg, about 0.1nmoles/kg to about 400 nmoles/kg, about 0.1 nmoles/kg to about 300nmoles/kg, about 0.1 nmoles/kg to about 200 nmoles/kg, about 0.1nmoles/kg to about 100 nmoles/kg, about 0.1 nmoles/kg to about 50nmoles/kg, about 0.1 nmoles/kg to about 10 nmoles/kg, or about 0.1nmoles/kg to about 1 nmoles/kg of body weight of the patient. In otherembodiments, the dose may be about 0.3 nmoles/kg to about 1000nmoles/kg, about 0.3 nmoles/kg to about 900 nmoles/kg, about 0.3nmoles/kg to about 850 nmoles/kg, about 0.3 nmoles/kg to about 800nmoles/kg, about 0.3 nmoles/kg to about 700 nmoles/kg, about 0.3nmoles/kg to about 600 nmoles/kg, about 0.3 nmoles/kg to about 500nmoles/kg, about 0.3 nmoles/kg to about 400 nmoles/kg, about 0.3nmoles/kg to about 300 nmoles/kg, about 0.3 nmoles/kg to about 200nmoles/kg, about 0.3 nmoles/kg to about 100 nmoles/kg, about 0.3nmoles/kg to about 50 nmoles/kg, about 0.3 nmoles/kg to about 10nmoles/kg, or about 0.3 nmoles/kg to about 1 nmoles/kg of body weight ofthe patient. In these embodiments, “kg” is kilograms of body weight ofthe patient. In one aspect, a single dose or multiple doses of thecompound, or pharmaceutically acceptable salt thereof, may beadministered to the patient.

In various other embodiments, the dose of the compound, or thepharmaceutically acceptable salt thereof, may range from, for example,about 10 nmoles/kg to about 10000 nmoles/kg, from about 10 nmoles/kg toabout 5000 nmoles/kg, from about 10 nmoles/kg to about 3000 nmoles/kg,about 10 nmoles/kg to about 2500 nmoles/kg, about 10 nmoles/kg to about2000 nmoles/kg, about 10 nmoles/kg to about 1000 nmoles/kg, about 10nmoles/kg to about 900 nmoles/kg, about 10 nmoles/kg to about 800nmoles/kg, about 10 nmoles/kg to about 700 nmoles/kg, about 10 nmoles/kgto about 600 nmoles/kg, about 10 nmoles/kg to about 500 nmoles/kg, about10 nmoles/kg to about 400 nmoles/kg, about 10 nmoles/kg to about 300nmoles/kg, about 10 nmoles/kg to about 200 nmoles/kg, about 10 nmoles/kgto about 150 nmoles/kg, about 10 nmoles/kg to about 100 nmoles/kg, about10 nmoles/kg to about 90 nmoles/kg, about 10 nmoles/kg to about 80nmoles/kg, about 10 nmoles/kg to about 70 nmoles/kg, about 10 nmoles/kgto about 60 nmoles/kg, about 10 nmoles/kg to about 50 nmoles/kg, about10 nmoles/kg to about 40 nmoles/kg, about 10 nmoles/kg to about 30nmoles/kg, about 10 nmoles/kg to about 20 nmoles/kg, about 200 nmoles/kgto about 900 nmoles/kg, about 200 nmoles/kg to about 800 nmoles/kg,about 200 nmoles/kg to about 700 nmoles/kg, about 200 nmoles/kg to about600 nmoles/kg, about 200 nmoles/kg to about 500 nmoles/kg, about 250nmoles/kg to about 600 nmoles/kg, about 300 nmoles/kg to about 600nmoles/kg, about 300 nmoles/kg to about 500 nmoles/kg, or about 400nmoles/kg to about 600 nmoles/kg, of body weight of the patient. Invarious other embodiments, the dose of the compound, or thepharmaceutically acceptable salt thereof, may range from, for example,about 1 nmoles/kg to about 10000 nmoles/kg, from about 1 nmoles/kg toabout 5000 nmoles/kg, from about 1 nmoles/kg to about 3000 nmoles/kg,about 1 nmoles/kg to about 2500 nmoles/kg, about 1 nmoles/kg to about2000 nmoles/kg, about 1 nmoles/kg to about 1000 nmoles/kg, about 1nmoles/kg to about 900 nmoles/kg, about 1 nmoles/kg to about 800nmoles/kg, about 1 nmoles/kg to about 700 nmoles/kg, about 1 nmoles/kgto about 600 nmoles/kg, about 1 nmoles/kg to about 500 nmoles/kg, about1 nmoles/kg to about 400 nmoles/kg, about 1 nmoles/kg to about 300nmoles/kg, about 1 nmoles/kg to about 200 nmoles/kg, about 1 nmoles/kgto about 150 nmoles/kg, about 1 nmoles/kg to about 100 nmoles/kg, about1 nmoles/kg to about 90 nmoles/kg, about 1 nmoles/kg to about 80nmoles/kg, about 1 nmoles/kg to about 70 nmoles/kg, about 1 nmoles/kg toabout 60 nmoles/kg, about 1 nmoles/kg to about 50 nmoles/kg, about 1nmoles/kg to about 40 nmoles/kg, about 1 nmoles/kg to about 30nmoles/kg, or about 1 nmoles/kg to about 20 nmoles/kg, In theseembodiments, “kg” is kilograms of body weight of the patient. In oneaspect, a single dose or multiple doses of the compound, orpharmaceutically acceptable salt thereof, may be administered to thepatient.

In another embodiment, from about 20 ug/kg of body weight of the patientto about 3 mg/kg of body weight of the patient of the compound, or thepharmaceutically acceptable salt thereof, can be administered to thepatient. In another aspect, amounts can be from about 0.2 mg/kg of bodyweight of the patient to about 0.4 mg/kg of body weight of the patient,or can be about 50 ug/kg of body weight of the patient. In one aspect, asingle dose or multiple doses of the compound, or the pharmaceuticallyacceptable salt thereof, may be administered to the patient.

In one embodiment, the small molecule ligand linked to the targetingmoiety can be administered to the patient before the CAR T cellcomposition. In another embodiment, the small molecule ligand linked tothe targeting moiety can be administered to the patient at the same timeas the CAR T cell composition, but in different formulations, or in thesame formulation. In yet another embodiment, the small molecule ligandlinked to the targeting moiety can be administered to the patient afterthe CAR T cell composition.

In one illustrative aspect, the timing between the administration of CART cells and the small molecule linked to the targeting moiety may varywidely depending on factors that include the type of CART cells beingused, the binding specificity of the CAR, the identity of the targetingmoiety and the small molecule ligand, the identity of the cancer, thelocation in the patient of the cancer, the means used to administer tothe patient the CAR T cells and the small molecule ligand linked to thetargeting moiety, and the health, age, and weight of the patient. In oneaspect, the small molecule ligand linked to the targeting moiety can beadministered before or after the CAR T cells, such as within about 3, 6,9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, 48, or 51 hours, orwithin about 0.5, 1, 1.5, 2, 2.5, 3, 4 5, 6, 7, 8, 9, 10 or more days.

334. In one embodiment, any applicable dosing schedule known in the artcan be used for administration of the compound, or the pharmaceuticallyacceptable salt thereof, or for the CAR T cell composition. For example,once per day dosing (a.k.a qd), twice per day dosing (a.k.a. bid), threetimes per day dosing (a.k.a. tid), twice per week dosing (a.k.a. BIW),three times per week dosing (a.k.a. TIW), once weekly dosing, and thelike, can be used. In one aspect, the dosing schedule selected for thecompound, or the pharmaceutically acceptable salt thereof, and the CAR Tcell composition can take into consideration the concentration of thecompound, or the pharmaceutically acceptable salt thereof, and thenumber of CAR T cells administered, to regulate the cytotoxicity of theCAR T cell composition and to control CRS.

In one embodiment, to prevent or inhibit cytokine release syndrome (CRS)in the patient, a method of treatment of a cancer is provided, and themethod comprises i) administering to a patient a compound, or apharmaceutically acceptable salt thereof, wherein the compound comprisesa small molecule ligand linked to a targeting moiety by a linker, ii)administering to the patient a CAR T cell composition wherein the CAR Tcell composition comprises CAR T cells and wherein the CAR T cellscomprise a CAR directed to the targeting moiety, and iii) administeringto the patient a folate, a conjugate comprising a folate wherein theconjugate comprising a folate does not comprise a targeting moiety, or adrug that inhibits activation of the CAR T cells.

In this method embodiment, the step of administering to the patient afolate, a conjugate comprising a folate wherein the conjugate comprisinga folate does not comprise a targeting moiety, or a drug that inhibitsactivation of the CAR T cells can be used to prevent or inhibit CRS inthe patient. In this embodiment, any of a folate, a conjugate comprisinga folate wherein the conjugate comprising a folate does not comprise atargeting moiety, or a drug that inhibits activation of the CAR T cellscan be referred to herein as “a rescue agent”. In one embodiment, afolate, such as folic acid, can be administered to prevent or inhibitCRS in the patient. In this embodiment, the folate inhibits interactionof the bridge (i.e., the small molecule ligand linked to the targetingmoiety by a linker) with the receptors for the bridge on the tumorinhibiting tumor lysis and preventing or inhibiting CRS in the patient.

In one embodiment, the folate administered as an inhibitor of binding ofthe bridge to the tumor can be, for example, folic acid, a folic acidanalog, or another folate receptor-binding molecule. In variousembodiments, analogs of folate that can be used include folinic acid,pteropolyglutamic acid, and folate receptor-binding pteridines such astetrahydropterins, dihydrofolates, tetrahydrofolates, and their deazaand dideaza analogs. The terms “deaza” and “dideaza” analogs refers tothe art recognized analogs having a carbon atom substituted for one ortwo nitrogen atoms in the naturally occurring folic acid structure. Forexample, the deaza analogs include the 1-deaza, 3-deaza, 5-deaza,8-deaza, and 10-deaza analogs. The dideaza analogs include, for example,1,5 dideaza, 5,10-dideaza, 8,10-dideaza, and 5,8-dideaza analogs. Theforegoing folic acid analogs are conventionally termed “folates,”reflecting their capacity to bind to folate receptors. Other folatereceptor-binding analogs include aminopterin, amethopterin(methotrexate), N10-methylfolate, 2-deamino-hydroxyfolate, deaza analogssuch as 1-deazamethopterin or 3-deazamethopterin, and 3′,5′-dichloro-4-amino-4-deoxy-N10-methylpteroylglutamic acid(dichloromethotrexate).

In another embodiment, the folate administered as an inhibitor ofbinding of the bridge to the tumor has the formula

wherein X¹ and Y¹ are each-independently selected from the groupconsisting of halo, R², OR², SR³, and NR⁴R⁵;

U, V, and W represent divalent moieties each independently selected fromthe group consisting of —(R^(6a))C═, —N═, —(R^(6a))C(R^(7a))—, and—N(R^(4a))—; Q is selected from the group consisting of C and CH; T isselected from the group consisting of S, O, N, and —C═C—;

X² and X³ are each independently selected from the group consisting ofoxygen, sulfur, —C(Z)—, —C(Z)O—, —OC(Z)—, —N(R^(4b))—, —C(Z)N(R^(4b))—,—N(R^(4b))C(Z)—, —OC(Z)N(R^(4b))—, —N(R^(4b))C(Z)O—,—N(R^(4b))C(Z)N(R^(5b))—, —S(O)—, —S(O)₂—, —N(R^(4a))S(O)₂—, —C(R^(6b))(R^(7b))—, —N(C≡CH)—, —N(CH₂C≡CH)—, C₁-C₁₂ alkylene, and C₁-C₁₂alkyeneoxy, where Z is oxygen or sulfur;

R¹ is selected-from the group consisting of hydrogen, halo, C₁-C₁₂alkyl, and C₁-C₁₂ alkoxy;

R², R³, R⁴, R^(4a), R^(4b), R⁵, R^(5b), R^(6b), and R^(7b) are eachindependently selected from the group consisting of hydrogen, halo,C₁-C₁₂ alkyl, C₁-C₁₂ alkoxy, C₁-C₁₂ alkanoyl, C₁-C₁₂ alkenyl, C₁-C₁₂alkynyl, (C₁-C₁₂ alkoxy)carbonyl, and (C₁-C₁₂ alkylamino)carbonyl;

R⁶ and R⁷ are each independently selected from the group consisting ofhydrogen, halo, C₁-C₁₂ alkyl, and C₁-C₁₂ alkoxy; or, R⁶ and R⁷ are takentogether to form a carbonyl group;

R^(6a) and R^(7a) are each independently selected from the groupconsisting of hydrogen, halo, C₁-C₁₂ alkyl, and C₁-C₁₂ alkoxy; or R^(6a)and R^(7a) are taken together to form a carbonyl group;

p, r, s, and t are each independently either 0 or 1; and

* represents an optional covalent bond to the rest of the conjugate, ifany additional chemical moieties are part of the folate.

335. In yet another embodiment, a conjugate comprising a folate can beadministered to prevent or inhibit cytokine release syndrome (CRS) inthe patient. CRS is a term well-known in the art and this syndrome cancause detrimental effects to the patient, including, but not limited toweight loss, high fever, pulmonary edema, and a dangerous drop in bloodpressure.

In this embodiment, the conjugate comprising a folate does not comprisea targeting moiety, and, thus, the conjugate inhibits interaction of thebridge with the tumor to prevent tumor lysis and reduce CRS in thepatient. In this embodiment, the folate moiety in the conjugatecomprising a folate can comprise any of the folates described in thepreceding paragraphs linked to a chemical moiety that does not comprisea targeting moiety. In one aspect, the conjugate comprising a folate cancomprise a folate linked to one or more amino acids that do not comprisea targeting moiety. Illustratively, the conjugate comprising a folatecan have the formula

This compound can also be referred to as “EC923”. In these embodiments,the folate or the conjugate comprising a folate can be administered tothe patient in molar excess relative to the bridge (i.e., the smallmolecule ligand linked to a targeting moiety by a linker), such as a10-fold excess, a 100-fold excess, a 200-fold excess a 300-fold excess a400-fold excess a 500-fold excess a 600-fold excess a 700-fold excess a800-fold excess a 900-fold excess, a 1000-fold excess, or a 10,000-foldexcess of the folate or the conjugate comprising a folate relative tothe small molecule ligand linked to a targeting moiety by a linker. Theamount of the folate or the conjugate comprising a folate relative tothe amount of the small molecule ligand linked to a targeting moiety bya linker needed to inhibit interaction of the bridge with the tumor canbe determined by the skilled artisan.

In another embodiment, an agent that inhibits activation of the CAR Tcells can be administered to the patient to inhibit CAR T cellactivation and to inhibit or prevent CRS in the patient. In one aspectthe agent can be selected from the group consisting of alymphocyte-specific protein tyrosine kinase inhibitor (e.g., Dasatinib),a PI3 kinase inhibitor (e.g., GDC0980), Tociluzumab, an inhibitor of anIL-2 inducible T cell kinase (e.g., BMS-509744), JAK inhibitors, BTKinhibitors, SIP agonists (e.g. Siponimod and Ozanimod), and an agentthat blocks CAR T cell binding to the bridge, but does not bind to thecancer (e.g., fluoresceinamine, FITC, or sodium fluorescein). It isunderstood by the skilled artisan that FITC (i.e., fluorescein) can bein the form of a salt (e.g., sodium fluorescein), or in its unsaltedform, under physiological conditions or, for example, in a buffer atphysiological pH. Accordingly, in one embodiment, when fluorescein isadministered to a patient it may be in equilibrium between its saltedform (e.g., sodium fluorescein) and its unsalted form. In anotherembodiment, a rescue agent that inhibits activation of CAR T cells canbe a compound of the formula

In various embodiments, the rescue agent can be administered at aconcentration of from about 0.001 nM to about 100 mM, about 0.01 nM toabout 100 mM, about 1 nM to about 100 mM, about 10 nM to about 100 mM,about 50 nM to about 100 mM, or from about 100 nM to about 100 mM in anyappropriate volume, including, for example, 0.1 ml, 0.2 ml, 0.3 ml, 0.4ml, 0.5 ml, 0.6 ml, 0.7 ml, 0.8 ml, 0.9 ml, 1 ml, 2 ml, 3 ml, 4 ml, 5ml, 10 ml, 100 ml, or 1000 ml. In other embodiments, the rescue agentcan be administered at a dose of about 0.01 to about 300 umoles/kg ofbody weight of the patient, about 0.06 to about 100 umoles/kg of bodyweight of the patient, about 0.06 to about 90 umoles/kg of body weightof the patient, about 0.06 to about 80 umoles/kg of body weight of thepatient, about 0.06 to about 70 umoles/kg of body weight of the patient,about 0.06 to about 60 umoles/kg of body weight of the patient, about0.06 to about 50 umoles/kg of body weight of the patient, about 0.06 toabout 40 umoles/kg of body weight of the patient, about 0.06 to about 30umoles/kg of body weight of the patient, about 0.06 to about 20umoles/kg of body weight of the patient, about 0.06 to about 10umoles/kg of body weight of the patient, about 0.06 to about 8 umoles/kgof body weight of the patient, or about 0.06 to about 6 umoles/kg ofbody weight of the patient.

In these embodiments, the rescue agent can be administered to thepatient in molar excess relative to the compound, or itspharmaceutically acceptable salt (i.e., the small molecule ligand linkedto a targeting moiety by a linker), such as about a 10-fold excess,about a 20-fold excess, about a 30-fold excess, about a 40-fold excess,about a 50-fold excess, about a 60-fold excess, about a 70-fold excess,about a 80-fold excess, about a 90-fold excess, about a 100-fold excess,about a 200-fold excess, about a 300-fold excess, about a 400-foldexcess, about a 500-fold excess, about a 600-fold excess, about a700-fold excess, about a 800-fold excess, about a 900-fold excess, abouta 1000-fold excess, or about a 10,000-fold excess of the rescue agentrelative to the small molecule ligand linked to a targeting moiety by alinker. The amount of the rescue agent relative to the amount of thesmall molecule ligand linked to a targeting moiety by a linker needed toinhibit interaction of the compound, or its pharmaceutically acceptablesalt, with the tumor and/or the CAR T cells can be determined by theskilled artisan.

In another embodiment, more than one dose can be administered to thepatient of the folate, the conjugate comprising a folate wherein theconjugate comprising a folate does not comprise a targeting moiety, orthe agent that inhibits activation of the CAR T cells.

In the ‘rescue agent’ embodiments described herein, the folate, theconjugate comprising a folate wherein the conjugate comprising a folatedoes not comprise a targeting moiety, or the agent that inhibitsactivation of the CAR T cells can be administered to the patient beforeand/or after the compound, or the pharmaceutically acceptable saltthereof. In another aspect, the compound, or the pharmaceuticallyacceptable salt thereof, can be administered before and subsequent toadministration of the folate, the conjugate comprising a folate whereinthe conjugate comprising a folate does not comprise a targeting moiety,or the agent that inhibits activation of the CAR T cells. In thisembodiment, the subsequent administration of the compound, or thepharmaceutically acceptable salt thereof, can cause CAR T cellactivation and an increase in cytokine levels in the patient.

In another embodiment, administration of the folate, the conjugatecomprising a folate wherein the conjugate comprising a folate does notcomprise a targeting moiety, or the agent that inhibits activation ofthe CAR T cells can cause reduction in cytokine levels in the patient.In yet another embodiment, the reduction in cytokine levels can occur byabout 1 hour, by about 2 hours, by about 3 hours, by about 4 hours, byabout 5 hours, by about 6 hours, by about 7 hours, or by about 8 hoursafter administration to the patient of the folate, the conjugatecomprising a folate wherein the conjugate comprising a folate does notcomprise a targeting moiety, or the agent that inhibits activation ofthe CAR T cells. In another embodiment, the reduction in cytokine levelsis a reduction to about the cytokine levels in an untreated patient. Inanother illustrative embodiment, CAR T cell number can increase in theblood of the patient after administration of the folate, the conjugatecomprising a folate wherein the conjugate comprising a folate does notcomprise a targeting moiety, or the agent that inhibits activation ofthe CAR T cells, even though cytokine levels in the patient are reduced.In another illustrative aspect, CAR T cell activation can be enhanced ormaintained, relative to a patient not treated with a rescue agent, afteradministration of the folate, the conjugate comprising a folate whereinthe conjugate comprising a folate does not comprise a targeting moiety,or the agent that inhibits activation of the CAR T cells, even thoughcytokine levels in the treated patient are reduced. In still anotherembodiment, the cancer comprises a tumor and tumor size in the patientis not increased when the folate, the conjugate comprising a folatewherein the conjugate comprising a folate does not comprise a targetingmoiety, or the agent that inhibits activation of the CAR T cells isadministered to the patient. In this embodiment, a complete response forthe tumor can be obtained.

In other embodiments, the agent that inhibits activation of the CAR Tcells is administered to the patient when the CRS grade reaches 1, 2, 3,or 4 or when the CRS grade reaches 3 or 4. In another aspect, lung edemais reduced in the patient when the rescue agent is administered.

In one embodiment described herein a method of treatment of a cancer isprovided, and the method comprises i) administering continuously to apatient a compound, or a pharmaceutically acceptable salt thereof,wherein the compound comprises a small molecule ligand linked to atargeting moiety by a linker, ii) administering to the patient a CAR Tcell composition comprising CAR T cells wherein the CAR T cells comprisea CAR directed to the targeting moiety, and iii) ending the continuousadministration of the compound, or the pharmaceutically acceptable saltthereof, to inhibit or prevent cytokine release syndrome in the patient.

In accordance with this embodiment, the term “continuously” can meanadministering the compound, or the pharmaceutically acceptable saltthereof, to the patient, for example, at least one hour, at least fourhours, at least six hours, at least eight hours, at least ten hours, atleast twelve hours, or at least twenty-four hours, or can mean a regimenof daily or weekly administration, such as once a day, two times a day,three times a day, every day, every other day, one time weekly, twotimes weekly, three times weekly, or any other suitable regimen thatwould be considered continuous administration by a person skilled in theart. In another aspect, the term “continuously” can mean any combinationof the embodiments described in this paragraph.

In this method embodiment, the step of “ending the continuousadministration” of the compound, or the pharmaceutically acceptable saltthereof, to inhibit or prevent cytokine release syndrome in the patient,can mean, for example, discontinuing administration after administrationfor a continuous period of time, such as hours or days, or discontinuinga treatment regimen, such as the daily or weekly regimens describedabove. In another embodiment, the step of “ending the continuousadministration” can mean, for example, administration until anunacceptable loss of body weight for the patient occurs, or until anyother unacceptable side effect occurs such as a high fever, a drop inblood pressure, or pulmonary edema. In this embodiment, the step of“ending the continuous administration” of the compound, or thepharmaceutically acceptable salt thereof, does not mean a singletreatment with the compound, or the pharmaceutically acceptable saltthereof, with no subsequent treatment with the compound, or thepharmaceutically acceptable salt thereof. In this method embodiment “toinhibit or prevent” cytokine release syndrome (CRS) means eliminatingCRS or reducing or ameliorating the symptoms of CRS.

In one embodiment of the embodiment involving ending the continuousadministration” of the compound, or the pharmaceutically acceptable saltthereof, the method can further comprise step iv) of re-administeringthe compound, or the pharmaceutically acceptable salt thereof, to thepatient. In one embodiment, the compound, or the pharmaceuticallyacceptable salt thereof, can be administered, for example, once weeklyand one dose can be omitted. In another embodiment, the compound, or thepharmaceutically acceptable salt thereof, can be administered onalternate days (i.e., every other day) and one or more (e.g., two,three, four, etc.) doses can be omitted. In another embodiment, thecompound, or the pharmaceutically acceptable salt thereof, can beadministered twice weekly and one or more (e.g., two, three, four, etc.)doses can be omitted. In another embodiment, the compound, or thepharmaceutically acceptable salt thereof, can be administered Monday,Tuesday, and the following Monday, and then dosing can be stopped fortwo weeks and the cycle repeated. In another embodiment, any of theregimen embodiments described above can be used and one or more (e.g.,two, three, four, etc.) doses can be omitted. In another embodiment,combinations of these embodiments can be used. In these embodiments, theomitted doses can prevent or reduce CRS in the patient.

In yet another illustrative aspect, a method of treatment of a cancer isprovided. The method comprises i) administering to a patient a compound,or a pharmaceutically acceptable salt thereof, wherein the compoundcomprises a small molecule ligand linked to a targeting moiety by alinker, wherein at least a first dose and a second dose of the compound,or the pharmaceutically acceptable salt thereof, are administered to thepatient, wherein the first dose and the second dose are different,wherein the second dose of the compound, or the pharmaceuticallyacceptable salt thereof, is about 2-fold to about 15000-fold greater inamount than the first dose of the compound, or the pharmaceuticallyacceptable salt thereof, and ii) administering to the patient a CAR Tcell composition comprising CAR T cells wherein the CAR T cells comprisea CAR directed to the targeting moiety.

336. In this embodiment, the dose of the compound, or thepharmaceutically acceptable salt thereof, can be escalated gradually toinhibit or prevent cytokine release syndrome in the patient. Forexample, at least a first dose and a second dose of the compound, or thepharmaceutically acceptable salt thereof, can be administered to thepatient, wherein the first dose and the second dose are different,wherein the second dose of the compound, or the pharmaceuticallyacceptable salt thereof, is about 20-fold to about 15000-fold greater,about 2-fold to about 15000-fold greater in amount than the first doseof the compound, or the pharmaceutically acceptable salt thereof. Inother embodiments, the second dose, or a subsequent dose, can be about2-fold to about 5-fold, about 2-fold to about 10-fold, about 2-fold toabout 20-fold, about 2-fold to about 30-fold, about 2-fold to about40-fold, about 2-fold to about 50-fold, about 2-fold to about 60-fold,about 2-fold to about 70-fold, about 2-fold to about 80-fold, about2-fold to about 90-fold, about 2-fold to about 100-fold, about 2-fold toabout 15000-fold, about 2-fold to about 10000-fold, about 5-fold toabout 9000-fold, about 5-fold to about 8000-fold, about 5-fold to about7000-fold, about 5-fold to about 6000-fold, about 5-fold to about5000-fold, about 5-fold to about 4000-fold, about 5-fold to about3000-fold, about 5-fold to about 4000-fold, about 5-fold to about3000-fold, about 5-fold to about 2000-fold, about 5-fold to about1000-fold, about 5-fold to about 750-fold, about 2-fold to about750-fold, about 5-fold to about 500-fold, about 5-fold to about100-fold, about 800-fold to about 15000-fold, about 800-fold to about10000-fold, about 800-fold to about 9000-fold, about 800-fold to about8000-fold, about 800-fold to about 7000-fold, about 800-fold to about6000-fold, about 800-fold to about 5000-fold, about 800-fold to about4000-fold, about 800-fold to about 3000-fold, about 800-fold to about2000-fold, about 800-fold to about 1000-fold, about 8000-fold to about15000-fold, about 8000-fold to about 10000-fold, about 8000-fold toabout 9000-fold, about 15000-fold, about 10000-fold, about 9000-fold,about 8000-fold, about 7000-fold, about 6000-fold, about 5000-fold,about 4000-fold, about 3000-fold, about 2000-fold, about 1000-fold,about 500-fold, about 400-fold, about 300-fold, about 200-fold, about100-fold, about 90-fold, about 80-fold, about 70-fold, about 60-fold,about 50-fold, about 40-fold, about 30-fold, about 20-fold, about10-fold, about 5-fold, or about 2-fold greater in amount than the firstdose of the compound, or the pharmaceutically acceptable salt thereof.

In another illustrative embodiment of the dose escalation method, atleast a first dose, a second dose, and a third dose of the compound, orthe pharmaceutically acceptable salt thereof, can be administered to thepatient, wherein the first dose, the second dose, and the third dose aredifferent, wherein the second dose of the compound, or thepharmaceutically acceptable salt thereof, is about 2-fold to about750-fold greater in amount than the first dose of the compound, or thepharmaceutically acceptable salt thereof, and wherein the third dose ofthe compound, or the pharmaceutically acceptable salt thereof, is about800-fold to about 10000-fold greater in amount than the first dose ofthe compound, or the pharmaceutically acceptable salt thereof.

In another aspect of the dose escalation method, at least a first dose,a second dose, a third dose, and a fourth dose of the compound, or thepharmaceutically acceptable salt thereof, can be administered to thepatient, wherein the first dose, the second dose, the third dose, andthe fourth dose are different, wherein the second dose of the compound,or the pharmaceutically acceptable salt thereof, is about 2-fold toabout 750-fold greater in amount than the first dose of the compound, orthe pharmaceutically acceptable salt thereof, wherein the third dose ofthe compound, or the pharmaceutically acceptable salt thereof, is about800-fold to about 7500-fold greater in amount than the first dose of thecompound, or the pharmaceutically acceptable salt thereof, and whereinthe fourth dose of the compound, or the pharmaceutically acceptable saltthereof, is about 8000 to about 15000-fold greater in amount than thefirst dose of the compound, or the pharmaceutically acceptable saltthereof.

In still another embodiment, the second dose of the compound, or thepharmaceutically acceptable salt thereof, can be about 100-fold greaterin amount than the first dose of the compound, or the pharmaceuticallyacceptable salt thereof, the third dose of the compound, or thepharmaceutically acceptable salt thereof, can be about 1000-fold greaterin amount than the first dose of the compound, or the pharmaceuticallyacceptable salt thereof, and the fourth dose of the compound, or thepharmaceutically acceptable salt thereof, can be about 10000-foldgreater in amount than the first dose of the compound, or thepharmaceutically acceptable salt thereof. In an exemplary embodiment,the first dose of the compound, or the pharmaceutically acceptable saltthereof, is 0.05 nmoles/kg, the second dose is 5 nmoles/kg, the thirddose is 50 nmoles/kg, and the fourth dose is 500 nmoles/kg. In the doseescalation embodiments described herein, the first, second, third,fourth, and any subsequent doses of the compound, or thepharmaceutically acceptable salt thereof, can be administered multipletimes (e.g., the first dose at 0.05 nmoles/kg can be administeredseveral times before the subsequent escalated doses are administered).

In another embodiment described herein, a method of treatment of acancer is provided. The method comprises i) administering to a patient afirst dose of a compound, or a pharmaceutically acceptable salt thereof,wherein the compound comprises a small molecule ligand linked to atargeting moiety by a linker, ii) administering to the patient at leasta second dose of the compound, or a pharmaceutically acceptable saltthereof, wherein the second dose of the compound, or thepharmaceutically acceptable salt thereof, is at least about 50 percentlower in amount than the first dose of the compound, or thepharmaceutically acceptable salt thereof, and iii) administering to thepatient a dose of a CAR T cell composition comprising CAR T cellswherein the CAR T cells comprise a CAR directed to the targeting moiety.

In various embodiments of this dose de-escalation embodiment, the seconddose of the compound, or the pharmaceutically acceptable salt thereof,can be at least about 60 percent lower in amount than the first dose ofthe compound, or the pharmaceutically acceptable salt thereof, at leastabout 70 percent lower in amount than the first dose of the compound, orthe pharmaceutically acceptable salt thereof. at least about 80 percentlower in amount than the first dose of the compound, or thepharmaceutically acceptable salt thereof, at least about 90 percentlower in amount than the first dose of the compound, or thepharmaceutically acceptable salt thereof, at least about 95 percentlower in amount than the first dose of the compound, or thepharmaceutically acceptable salt thereof, at least about 96 percentlower in amount than the first dose of the compound, or thepharmaceutically acceptable salt thereof, at least about 97 percentlower in amount than the first dose of the compound, or thepharmaceutically acceptable salt thereof, at least about 98 percentlower in amount than the first dose of the compound, or thepharmaceutically acceptable salt thereof, at least about 99 percentlower in amount than the first dose of the compound, or thepharmaceutically acceptable salt thereof, or at least about 99.5 percentlower in amount than the first dose of the compound, or thepharmaceutically acceptable salt thereof.

In various embodiments of the dose de-escalation embodiment describedherein, the first dose of the compound, or the pharmaceuticallyacceptable salt thereof, can be about 100 nmoles/kg to about 1000nmoles/kg of body weight of the patient, about 100 nmoles/kg to about900 nmoles/kg of body weight of the patient, about 100 nmoles/kg toabout 800 nmoles/kg of body weight of the patient, about 100 nmoles/kgto about 700 nmoles/kg of body weight of the patient, about 100nmoles/kg to about 600 nmoles/kg of body weight of the patient, about200 nmoles/kg to about 600 nmoles/kg of body weight of the patient,about 400 nmoles/kg to about 600 nmoles/kg of body weight of thepatient, or about 500 nmoles/kg of body weight of the patient.

In various embodiments of the dose de-escalation embodiment describedherein, the second dose of the compound, or the pharmaceuticallyacceptable salt thereof, can be about 0.5 nmoles/kg to about 500nmoles/kg of body weight of the patient, about 0.5 nmoles/kg to about450 nmoles/kg of body weight of the patient, about 0.5 nmoles/kg toabout 400 nmoles/kg of body weight of the patient, about 0.5 nmoles/kgto about 350 nmoles/kg of body weight of the patient, about 0.5nmoles/kg to about 300 nmoles/kg of body weight of the patient, about 1nmole/kg to about 300 nmoles/kg of body weight of the patient, about 2nmoles/kg to about 300 nmoles/kg of body weight of the patient, about 2nmoles/kg to about 250 nmoles/kg of body weight of the patient, about 5nmoles/kg to about 40 nmoles/kg of body weight of the patient, or about40 nmoles/kg to about 150 nmoles/kg of body weight of the patient.

In additional embodiments of the dose de-escalation embodiment describedherein, the method can further comprise administering a third dose ofthe compound, or the pharmaceutically acceptable salt thereof, whereinthe third dose of the compound, or the pharmaceutically acceptable saltthereof, is the same as the second dose of the compound, or thepharmaceutically acceptable salt thereof. In another embodiment, themethod can further comprise administering a fourth dose of the compound,or the pharmaceutically acceptable salt thereof, wherein the fourth doseof the compound, or the pharmaceutically acceptable salt thereof, is thesame as the second dose, or the pharmaceutically acceptable saltthereof, and the third dose of the compound, or the pharmaceuticallyacceptable salt thereof. In yet another embodiment, the dose(s) of thecompound, or the pharmaceutically acceptable salt thereof, administeredafter the first dose of the compound, or the pharmaceutically acceptablesalt thereof, can maintain inhibition of growth of the cancer relativeto the first dose of the compound, or the pharmaceutically acceptablesalt thereof.

In other embodiments of the dose de-escalation embodiment describedherein, the CAR T cells can be administered at a dose of about 1 millionof the CAR T cells to about 40 million of the CAR T cells. In stillother embodiments, the dose(s) of the compound or the pharmaceuticallyacceptable salt thereof, administered after the first dose of thecompound, or the pharmaceutically acceptable salt thereof, can beadministered once or twice weekly.

In still other embodiments of the dose de-escalation embodimentdescribed herein, the method can further comprise the step ofadministering to the patient a folate, a conjugate comprising a folatewherein the conjugate comprising a folate does not comprise a targetingmoiety, or an agent that inhibits activation of the CAR T cells. Inanother embodiment, the agent that inhibits activation of the CAR Tcells is administered to the patient and the agent is an agent thatblocks CAR T cell binding to the compound, or the pharmaceuticallyacceptable salt thereof, but does not bind to the cancer, and the agentis fluoresceinamine, sodium fluorescein, or fluorescein. In yet anotherembodiment, the agent is sodium fluorescein.

In another embodiment, a method of treatment of a cancer is provided.The method comprises i) administering to a patient a first dose of acompound, or a pharmaceutically acceptable salt thereof, wherein thecompound comprises a small molecule ligand linked to a targeting moietyby a linker and wherein the compound, or the pharmaceutically acceptablesalt thereof, is administered to the patient at least about one hourprior to the administration of a CAR T cell composition comprising CAR Tcells wherein the CAR T cells comprise a CAR directed to the targetingmoiety, ii) then administering to the patient a dose of the CAR T cellcomposition, and iii) then administering to the patient a second dose ofthe compound, or the pharmaceutically acceptable salt thereof. Invarious embodiments of this pre-treatment embodiment, the first dose ofthe compound, or the pharmaceutically acceptable salt thereof, can beadministered to the patient at least about two hours prior to theadministration of the CAR T cell composition, at least about four hoursprior to the administration of the CAR T cell composition, at leastabout eight hours prior to the administration of the CAR T cellcomposition, at least about twelve hours prior to the administration ofthe CAR T cell composition, at least about sixteen hours prior to theadministration of the CAR T cell composition, at least about twentyhours prior to the administration of the CAR T cell composition, or atleast about twenty-four hours prior to the administration of the CAR Tcell composition.

In various embodiments of this pre-treatment embodiment, the second doseof the compound, or the pharmaceutically acceptable salt thereof, can beadministered to the patient by at least about twenty-four hours afterthe administration of the CAR T cell composition, by at least abouttwenty hours after the administration of the CAR T cell composition, byat least about eighteen hours after the administration of the CAR T cellcomposition, by at least about sixteen hours after the administration ofthe CAR T cell composition, by at least about fourteen hours after theadministration of the CAR T cell composition, by at least about twelvehours after the administration of the CAR T cell composition, by atleast about ten hours after the administration of the CAR T cellcomposition, by at least about eight hours after the administration ofthe CAR T cell composition, by at least about six hours after theadministration of the CAR T cell composition, by at least about fourhours after the administration of the CAR T cell composition, or by atleast about two hours after the administration of the CAR T cellcomposition.

In various additional embodiments of this pre-treatment embodiment,cytokine release resulting in off-target toxicity in the patient doesnot occur, but CAR T cell toxicity to the cancer occurs or off-targettissue toxicity does not occur in the patient, but CAR T cell toxicityto the cancer occurs, or the cancer comprises a tumor, and tumor size isreduced in the patient, but off-target toxicity does not occur, orreduction in tumor size in the patient is greater than in a patient notpre-treated with the compound, or the pharmaceutically acceptable saltthereof, prior to administration of the CAR T cell composition. As wouldbe understood by a skilled artisan, the “target” can be the cancer (forexample a tumor).

In another embodiment, a method of treatment of a cancer is provided.The method comprises i) administering to a patient a compound, or apharmaceutically acceptable salt thereof, wherein the compound comprisesa small molecule ligand linked to a targeting moiety by a linker, andii) administering to the patient a CAR T cell composition wherein theCAR T cell composition comprises CAR T cells and wherein the CAR T cellscomprise a CAR directed to the targeting moiety, and wherein the smallmolecule ligand is a PSMA ligand and the targeting moiety is FITC. Inthis embodiment, the small molecule ligand linked to a targeting moietyby a linker can have the formula

In yet another embodiment, a method of treatment of a cancer isprovided. The method comprises i) administering to a patient a compound,or a pharmaceutically acceptable salt thereof, wherein the compoundcomprises a small molecule ligand linked to a targeting moiety by alinker, and ii) administering to the patient a CAR T cell compositionwherein the CAR T cell composition comprises CAR T cells and wherein theCAR T cells comprise a CAR directed to the targeting moiety, and whereinthe small molecule ligand is a CAIX ligand and the targeting moiety isFITC. In this embodiment, the small molecule ligand linked to atargeting moiety by a linker can have the formula

In still another embodiment, a method of treatment of a cancer isprovided. The method comprises i) administering to a patient a firstcompound, or a pharmaceutically acceptable salt thereof, wherein thefirst compound, or the pharmaceutically acceptable salt thereof,comprises a PSMA ligand linked to FITC by a linker, ii) administering tothe patient a second compound, or a pharmaceutically acceptable saltthereof, wherein the second compound, or the pharmaceutically acceptablesalt thereof, comprises a CAIX ligand linked to FITC by a linker, andiii) administering to the patient a CAR T cell composition wherein theCAR T cell composition comprises CAR T cells and wherein the CAR T cellscomprise a CAR directed to the targeting moiety. In this embodiment, thefirst compound can have the formula

and the second compound can have the formula

337. In one embodiment of the methods described herein, the cancer isimaged prior to administration to the patient of the compound, or thepharmaceutically acceptable salt thereof, or prior to administration ofthe CAR T cell composition to the patient. In one illustrativeembodiment, imaging occurs by PET imaging. In other illustrativeembodiments imaging occurs by Mill imaging or SPECT/CT imaging. Theimaging method can be any suitable imaging method known in the art. Inone embodiment, the imaging method can involve the use of the smallmolecule ligand described herein, but linked to an imaging agentsuitable for the types of imaging described herein.

In any of the embodiments described herein, cytokine release resultingin off-target toxicity in the patient may not occur even though CAR Tcell toxicity to the cancer occurs. In any embodiment described herein,off-target tissue toxicity may not occur in the patient even though CART cell toxicity to the cancer occurs. In any embodiment describedherein, the cancer may comprise a tumor, and tumor size may be reducedin the patient, even though off-target toxicity does not occur. In anyof the embodiments described herein, CRS can be reduced or prevented andthe method can result in a decrease in tumor volume in the patient. Inany embodiment described herein, body weight loss due to CRS can bereduced or prevented. In any embodiment described herein, the cancer cancomprise a tumor and a complete response for the tumor can be obtained.

338. In another embodiment of the methods described herein, any of themethods described herein can be used alone, or any of the methodsdescribed herein can be used in combination with any other method ormethods described herein.

EXAMPLES Example 1 Synthesis of FITC-Folate

Folate-γ-ethylenediamine was coupled to fluorescein isothiocyanate(FITC) isomer I (Sigma-Aldrich) in anhydrous dimethylsulfoxide (DMF) inthe presence of tetramethylguanidine and diisopropylamine. The crudeproduct was loaded onto an Xterra RP18 preparative HPLC column (Waters)and eluted with gradient conditions starting with 99% 5 mM sodiumphosphate (mobile phase A, pH 7.4) and 1% acetonitrile (mobile phase B)and reaching 90% A and 10% B in 10 min at a flow rate of 20 mL/min.Under these conditions, the FITC-folate main peak typically eluted at27-50 min. The quality of the FITC-folate fraction was monitored byanalytical reverse-phase HPLC with a UV detector. Fractions with greaterthan 98.0% purity (LCMS) were lyophilized to obtain the finalFITC-folate product. As known in the art, the compound with thisstructure is also referred to as EC17.

Example 2 Synthesis of FITC-PEG12-Folate

Universal polyethylene glycol (PEG) Nova Tag™ resin (0.2 g) was loadedinto a peptide synthesis vessel and washed with isopropyl alcohol(i-PrOH) (3×10 mL) and dimethylformamide (DMF, 3×10 mL).9-fluorenylmethoxycarbonyl (Fmoc) deprotection was carried out using 20%piperidine in DMF (3×10 mL). Kaiser tests were performed to assessreaction progress. To the vessel was then introduced a solution ofFmoc-L-glutamic acid 5-tert-butyl ester (Fmoc-Glu-(O-t-Bu)-OH) (23.5 mg)in DMF, N,N-diisopropylethylamine (i-Pr₂NEt) (4 equiv), andbenzotriazol-1-yl-oxytripyrrolidinophosphonium hexafluorophosphate(PyBOP) (2 equiv). Fmoc deprotection was carried out using 20%piperidine in DMF (3×10 mL). To the vessel was then introduced asolution of N¹⁰-TFA-Pte-OH (22.5 mg), DMF, i-Pr₂NEt (4 equiv), and PyBOP(2 equiv). Argon was bubbled for 2 h, and the resin was washed with DMF(3×3 mL) and i-PrOH (3×3 mL). After swelling the resin indichloromethane (DCM), a solution of 1M hydroxybenzotriazole (HOBT) inDCM/trifluoroethane (TFE) (1:1) (2×3 mL) was added. Argon was bubbledfor 1 h, the solvent was removed, and the resin was washed with DMF (3×3mL) and i-PrOH (3×3 mL). After swelling the resin in DMF, a solution ofFmoc-NH-(PEG)₁₂—COOH (46.3 mg) in DMF, i-Pr₂NEt (4 equiv), and PyBOP (2equiv) was added. Argon was bubbled for 2 h, and the resin was washedwith DMF (3×3 mL) and i-PrOH (3×3 mL). Fmoc deprotection was carried outusing 20% piperidine in DMF (3×10 mL). Kaiser tests were performed toassess reaction progress. To the vessel was then introduced a solutionof FITC (Life Technologies 21.4 mg) in DMF and i-Pr₂NEt (4 equiv), thenArgon was bubbled for 2 h, and the resin was washed with DMF (3×3 mL)and i-PrOH (3×3 mL). Then to the vessel was added 2% NH₂NH₂ in DMF (2×2mL). The final compound was cleaved from the resin using a TFA:H₂O:triisopropylsilane (TIS) (95:2.5:2.5) (Cleavage Solution) andconcentrated under vacuum. The concentrated product was precipitated inEt₂O and dried under vacuum. The crude product was purified usingpreparative RP-HPLC (mobile phase: A=10 mM ammonium acetate pH=7, B=ACN;method: 0% B to 30% B in 30 min at 13 mL/min). The pure fractions werepooled and freeze-dried, providing the FITC-PEG12-Folate.

Example 3 Synthesis of FITC-PEG20-Folate

Ethylenediamine, polymer-bound (200-400 mesh)-resin (50 mg) was loadedinto a peptide synthesis vessel and swollen with DCM (3 mL) followed byDMF (3 mL). To the vessel was then introduced the Fmoc-PEG20-COOHsolution (131 mg, 1.0 equiv) in DMF, i-Pr₂NEt (6.0 equiv), and PyBOP(4.0 equiv). Argon was bubbled for 6 h, the coupling solution wasdrained, and the resin was washed with DMF (3×10 mL) and i-PrOH (3×10mL). Kaiser tests were performed to assess reaction progress. Fmocdeprotection was carried out using 20% piperidine in DMF (3×10 mL),before each amino acid coupling. The above sequence was repeated tocomplete the reaction with Fmoc-Glu-OtBu (72 mg, 2.0 equiv) andTfa.Pteroic-acid (41 mg, 1.2 equiv) coupling steps. The resin was washedwith 2% hydrazine in DMF 3×10 mL (5 min) to cleave the trifluoro-acetylprotecting group on pteroic acid and washed with i-PrOH (3×10 mL)followed by DMF (3×10 mL). The resin was dried under argon for 30 min.The folate-peptide was cleaved from the resin using the CleavageSolution. 10 mL of the cleavage mixture was introduced and argon wasbubbled for 1.5 h. The cleavage mixture was drained into a clean flask.The resin was washed 3 times with more cleavage mixture. The combinedmixture was concentrated under reduced pressure to a smaller volume (˜5mL) and precipitated in ethyl ether.

The precipitate was collected by centrifugation, washed with ethyl ether(3 times) and dried under high vacuum. The dried Folate-PEG₂₀-EDA (1.0equiv) was treated with FITC (50 mg, 1.5 equiv) in DMSO and DIPEA atroom temperature. Progress of the reaction monitored by LCMS. After 8 hthe starting material was consumed to give the product. The crudereaction mixture was purified by preparative HPLC, (mobile phase A=10 mMAmmonium Acetate, pH=7; Organic phase B=Acetonitrile; Method: 0% B to30% B in 35 minutes at 13 mL/min) and provided FITC-PEG20-Folate in 60%yield.

Example 4 Synthesis of FITC-PEG108-Folate

Ethylenediamine, polymer-bound (200-400 mesh)-resin (50 mg) was loadedin a peptide synthesis vessel and swollen with DCM (3 mL) followed byDMF (3 mL). To the vessel was then introduced the Fmoc-PEG36-COOHsolution (161 mg, 1.0 equiv) in DMF, I-Pr₂NEt (6.0 equiv), and PyBOP(4.0 equiv). Argon was bubbled for 6 h, the coupling solution wasdrained, and the resin was washed with DMF (3×10 mL) and i-PrOH (3×10mL). Kaiser tests were performed to assess reaction progress. Fmocdeprotection was carried out using 20% piperidine in DMF (3×10 mL),before each amino acid coupling. The above sequence was repeated tocomplete reaction with 2×Fmoc-PEG36-COOH (161 mg, 1.0 equiv),Fmoc-Glu-OtBu (72 mg, 2.0 equiv) and Tfa.Pteroic-acid (41.0 mg, 1.2equiv) coupling steps. At the end the resin was washed with 2% hydrazinein DMF 3×10 mL (5 min) to cleave the trifluoro-acetyl protecting groupon pteroic acid and washed with i-PrOH (3×10 mL) followed by DMF (3×10mL). The resin was dried under argon for 30 min. Folate-peptide wascleaved from the resin using the Cleavage Solution. 10 mL of thecleavage mixture was introduced and argon was bubbled for 1.5 h. Thecleavage mixture was drained into a clean flask. The resin was washed 3×with more Cleavage Solution. The combined mixture was concentrated underreduced pressure to a smaller volume (˜5 mL) and precipitated in ethylether.

The precipitate was collected by centrifugation, washed with ethyl ether(3×) and dried under high vacuum. The dried Folate-PEG108-EDA (1.0equiv) was treated with FITC (50 mg, 1.5 equiv) in DMSO and DIPEA atroom temperature. Reaction progress was monitored by LCMS. After 10 hstarting material was consumed to give the product. The crude reactionmixture was purified by preparative HPLC, (mobile phase A=10 mM AmmoniumAcetate, pH=7; Organic phase B=Acetonitrile; Method: 0% B to 30% B in 35minutes at 13 mL/min) and provided FITC-PEG108-Folate in 64% yield.

Example 5 Synthesis of FITC-DUPA

DUPA-FITC was synthesized by solid phase methodology as follows.Universal Nova Tag™ resin (50 mg, 0.53 mM) was swollen with DCM (3 mL)followed by DMF 3 mL). A solution of 20% piperidine in DMF (3×3 mL) wasadded to the resin, and argon was bubbled for 5 min. The resin waswashed with DMF (3×3 mL) and isopropyl alcohol (i-PrOH, 3×3 mL). Afterswelling the resin in DMF, a solution of DUPA-(OtBu)-OH (1.5 equiv),HATU (2.5 equiv), and i-Pr₂NEt (4.0 equiv) in DMF was added. Argon wasbubbled for 2 h, and resin was washed with DMF (3×3 mL) and i-PrOH (3×3mL). After swelling the resin in DCM, a solution of 1 M HOBt in DCM/TFE(1:1) (2×3 mL) was added. Argon was bubbled for 1 h, the solvent wasremoved and resin was washed with DMF (3×3 mL) and i-PrOH (3×3 mL).After swelling the resin in DMF, a solution of Fmoc-Phe-OH (2.5 equiv),HATU (2.5 equiv) and DIPEA (4.0 equiv) in DMF was added. Argon wasbubbled for 2 h, and the resin was washed with DMF (3×3 mL) and i-PrOH(3×3 mL). The above sequence was repeated for 2 more coupling steps foraddition of 8-aminooctanoic acid and fluorescein isothiocyanate orrhodamine B isothiocyanate. The final compound was cleaved from theresin using the Cleavage Solution and concentrated under vacuum. Theconcentrated product was precipitated in diethyl ether and dried undervacuum. The crude product was purified using preparative RP-HPLC [λ=488nm; solvent gradient: 1% B to 80% B in 25 min, 80% B wash 30 min run;A=10 mM NH₄OAc, pH=7; B=acetonitrile (ACN)]. ACN was removed undervacuum, and purified fractions were freeze-dried to yield FITC-DUPA as abrownish-orange solid. RP-HPLC: tR=8.0 min (A=10 mM NH₄OAc, pH=7.0;B=ACN, solvent gradient: 1% B to 50% B in 10 min, 80% B wash 15 minrun). ¹H NMR (DMSO-d6/D₂O): δ 0.98-1.27 (ms, 9H); 1.45 (b, 3H);1.68-1.85 (ms, 11H); 2.03 (m, 8H); 2.6-3.44 (ms, 12H); 3.82 (b, 2H);4.35 (m, 1H); 6.53 (d, J=8.1 Hz, 2H), 6.61 (dd, J=5.3, 3.5 Hz, 2H); 6.64(s, 2H); 7.05 (d, J=8.2 Hz, 2H), 7.19 (m, 5H); 7.76 (d, J=8.0 Hz, 1H);8.38 (s, 1H). HRMS (ESI) (m/z): (M+H)⁺ calcd for C₅₁H₅₉N₇O₁₅S,1040.3712, found, 1040.3702. UV/vis: λ max=491 nm.

Example 6 Synthesis of FITC-PEG12-DUPA

1,2-Diaminoethane trityl-resin (0.025 g) was loaded into a peptidesynthesis vessel and washed with i-PrOH (3×10 mL), followed by DMF (3×10mL). To the vessel was then introduced a solution ofFmoc-NH-(PEG)₁₂—COOH (42.8 mg) in DMF, i-Pr₂NEt (2.5 equiv), and PyBOP(2.5 equiv). The resulting solution was bubbled with Ar for 1 h, thecoupling solution was drained, and the resin washed with DMF (3×10 mL)and i-PrOH (3×10 mL). Kaiser tests were performed to assess reactionprogress. Fmoc deprotection was carried out using 20% piperidine in DMF(3×10 mL). This procedure was repeated to complete the all couplingsteps (2×1.5 equiv of Fmoc-Phe-OH and 1.5 equiv of 8-aminooctanoic acidand 1.2 equiv of DUPA were used on each of their respective couplingsteps). After the DUPA coupling, the resin was washed with DMF (3×10 mL)and i-PrOH (3×10 mL) and dried under reduced pressure. The peptide wascleaved from the resin in the peptide synthesis vessel using theCleavage Solution. 15 mL of the Cleavage Solution was added to thepeptide synthesis vessel, and the reaction was bubbled under Ar for 15min. The resin was treated with two additional 10 mL quantities of theCleavage Solution for 5 min each. The cleavage mixture was concentratedto about 5 mL and precipitated with ethyl ether. The precipitate wascollected by centrifugation, washed with ethyl ether (3×), and driedunder high vacuum, resulting in the recovery of crude material. To astirred solution of the crude DUPA-(PEG)₁₂-EDA (10 mg) and FITC (5.6 mg)in dimethylsulfoxide (DMSO, 1 mL) was added i-Pr₂NEt (5 equiv) at roomtemperature and stirred for 6 h under argon. The reaction was monitoredby LCMS and purified by preparative HPLC (mobile phase: A=10 mM ammoniumacetate pH=7, B=ACN; method: 0% B to 50% B in 30 min at 13 mL/min). Thepurified fractions were pooled and freeze-dried, providing theFITC-PEG12-DUPA.

Example 7 Synthesis of FITC-PEG11-NK1

To a stirred solution of NK-1 (0.02 g, 0.0433 mmol, 1.0 eq.),O-(2-Aminoethyl)-O′-[2-(Boc-amino)ethyl]decaethylene glycol(BocNH-PEG₁₁-NH₂) (Sigma, 0.0336 g, 0.0521 mmol, 1.2 eq.),Benzotriazol-1-yl-oxytripyrrolidinophosphonium hexafluorophosphate(PyBOP) (0.027 g, 0.0521 mmol, 1.2 eq.) in dry CH₂Cl₂ was addedN,N-Diisopropylethylamine (DIPEA) (0.076 mL, 0.4338 mmol, 10 eq.) underargon at room temperature. The reaction progress was monitored by LCMSand purified by preparative RP-HPLC (Waters, XBridge™ Prep C18, 5 μm;19×100 mm column, mobile phase A=20 mM ammonium acetate buffer, pH 7,B=acetonitrile, gradient 10-100% B in 30 min, 13 mL/min, λ=220 nm, 254nm). The pure fractions were collected, all organic solvents wereevaporated and the sample was lyophilized for 48 h to provide theNK1-PEG₁₁-NHBoc. Yield: 40.13 mg (97%). To the NK1-PEG₁₁-NHBoc (0.0165g, 0.015 mmol) in dry DCM was added trifluoroacetic acid (TFA, 20 eq.)and the reaction mixture was stirred for 4 h at r.t. The excess TFA wasremoved, and the remaining solution was diluted with water and extractedusing CH₂Cl₂ (3×5 mL). The combined organic layers were washed withbrine, dried (Na₂SO₄) and concentrated. The residue obtained was driedunder vacuum and used for the next-step without further purification. Astirred solution of NK1-PEG₁₁-NH₂ (0.008 g, 0.0081 mmol, 1.0 eq.),Fluorescein isothiocyanate (FITC) (Sigma, 0.0037 g, 0.0097 mmol, 1.2eq.) in dry dimethylsulfoxide (DMSO, 0.3 mL) was added todiisopropylethyl amine (0.0028 mL, 0.0162 mmol, 2.0 eq.) at roomtemperature under argon. The reaction progress was monitored by LCMS andthe product was purified by preparative RP-HPLC (Waters, XBridge™ PrepC18, 5 μm; 19×100 mm column, mobile phase A=20 mM ammonium acetatebuffer, pH 7, B=acetonitrile, gradient 10-100% B in 30 min, 13 mL/min,λ=280 nm). The pure fractions were collected, all organic solvents wereevaporated and the sample was lyophilized for 48 h to provide theFITC-PEG11-NK1 in a yield of 8.54 mg (77%).

*Note: The NK-1 compound was synthesized by a two-step procedurestarting from the base ligand, which was prepared by using a procedurein the literature. (Ref: DESIGN AND DEVELOPMENT OF NEUROKININ-1RECEPTOR-BINDING AGENT DELIVERY CONJUGATES, Application Number:PCT/US2015/44229; incorporated herein by reference.

Example 8 Synthesis of FITC-PEG2-CA9

CA9 ligand (53.6 mg) was dissolved in DMF (2-3 mL) in a 50 mL roundbottom flask using a Teflon magnetic stir bar. Ambient air was removedusing a vacuum and replaced with nitrogen gas, this was done in threecycles. The round bottom flask was kept under constant nitrogen gas. Tothe flask, 28.9 mg of N-(3-Dimethylaminopropyl)-N′-ethylcarbodiimidehydrochloride (EDC) was added followed by 21.6 mg 1-Hydroxybenzotriazolehydrate (HOBt) and 18.9 μL of Boc-PEG2-NH₂ (Sigma Aldrich). 5.4 μL oftriethylamine (TEA) was added and the reaction was stirred overnight.The reaction mixture was purified using HPLC and confirmed with UHPLC-MS(target m/z of 831). Acetonitrile was removed using high vacuum rotaryevaporation and the product lyopholized. The compound was mixed with 1:1TFA:DCM for 30 minutes. The TFA/DCM was removed using high vacuum rotaryevaporation followed by 30 minutes on high vacuum. The compound was thendissolved in DMF and combined with 5 molar equivalents of i-Pr₂NEt, 16mg of fluorescein isothiocyanate (Life Technologies) and stirred for 1h. The reaction mixture was purified by HPLC and the target compound wasconfirmed with UHPLC-MS (target m/z of 1120). The samples werelyophilized and stored at −20° C.

Example 9 Anti-FITC CAR T Cell Activation can be Controlled by EitherDiscontinuation of FITC-Ligands Administration or Introduction of ExcessAmount of Competitor Small Molecule

MDA-MB-231 cells were subcutaneously injected into the shoulders of NSGmice (Jackson Laboratory) to establish solid tumor xenografts. Whentumor volume reached around 50-100 mm³, anti-FITC CAR T cells (15×10⁶cells) were intravenously introduced into tumor-bearing mice. Twenty NSGmice were divided into four study groups (5 animals in each group). Thefirst group was treated with anti-FITC CAR T cells withphosphate-buffered saline (PBS) as a negative control. The second,third, and fourth groups were treated with anti-FITC CAR T cells withFITC-Folate (500 nmole/kg) every other day. Once a significant toxicity(e.g. serious loss of body weight) was detected, these groups weretreated with either: continued FITC-Folate administration (secondgroup); discontinuation of FITC-Folate administration until the micerecovered (third group); or a mixture of 100-fold excess of EC0923 (i.e.free folate) and FITC-Folate until the mice recovered (fourth group).The body weight was measured regularly to monitor toxicity. In addition,the blood concentration of interferon (IFN)-gamma for each treatmentgroup was measured to monitor the degree of anti-FITC CAR T activation.Finally, tumor volume was measured to identify anti-tumor efficacy ineach treatment group.

FIG. 1A shows body weight changes in each treatment group. Eachtreatment group, except the PBS-treated group, showed a decrease in bodyweight due to anti-FITC CAR T cell mediated toxicity after the seconddose of FITC-Folate (Day 1 and Day 2). Since toxicity was detected ineach group of mice, treatments to each group were separated as describedabove into: (1) continued dose of FITC-Folate (continued group); (2)discontinue FITC-Folate injection (break group) at day 4 and day 6; and(3) a mixture of 100-fold excess of free folate and FITC-Folate(competitor group) at day 4 and day 6. As shown in FIG. 1A, groupstreated with either discontinued FITC-Folate injection or administrationof a mixture of a competitor molecule and FITC-Folate recovered fromserious anti-FITC CAR T cell mediated toxicity (i.e. gain of bodyweight). However, the group that was continuously treated withFITC-Folate at day 4 and day 6, kept losing body weight to reach alethargic condition (i.e. loss of body weight >20% of original). Asshown in FIG. 1B, a significant amount IFN-gamma was detected in thecontinued dose group. Unlike the continued dose group, the IFN-gammaconcentration decreased in both the break and competitor groups. Theseresults indicate that anti-FITC CAR T cell activation can be controlledby methods resulting in alleviation of CAR T cell mediated toxicity.FIG. 1C summarizes the survival of mice in each treatment group at thefirst week of treatment (%). As toxicity caused by anti-FITC CAR T cellwas detected in the continued dose group, only 40% of mice in thecontinued dose group (i.e. 2 of 5 mice) were able to survive thetreatment. However, as shown in FIG. 1C, all of the mice in both thebreak and competitor groups survived the CAR T cell mediated toxicitydue to the reduction of CAR T cell activation.

Although anti-FITC CAR T cell mediated toxicity can be managed bycontrolling anti-FITC CAR T cell activation, it was determined whetherthe regulation of anti-FITC CAR T cell activation causes any reductionin tumor response. Therefore, tumor volume was measured every other day.As shown in FIGS. 2A and 2B, the control group treated with anti-FITCCAR T cells with PBS showed no tumor response, as expected.Interestingly, the break (100% complete response) and competitor groups(75% complete response) showed more potent tumor response compared tothe continued dose group (delay of tumor growth). The lack of completeresponse in the continued dose group may be due to: (1) too frequentdosing with FITC-Folate causing a saturation of both target receptors(i.e. CAR T cells and folate receptors in the cancer cells) resulting ina reduction of anti-FITC CAR T cell activation; (2) anti-FITC CAR Tcells may have become hyper-activated due to repeatable engagement ofthe cancer cells via continuously injected FITC-Folate. Thishyper-activation may have caused a significant induction of an inhibitormechanism as a feedback response preventing activation. In summary,monitoring the toxicity (Example 9) and the tumor response demonstratethat control of anti-FITC CAR T cell activation can be achieved bymanaging CART cell mediated toxicity (e.g. cytokine storm) without aloss of CART cell's anti-tumor efficacy.

Example 10 The Effect of Anti-FITC CAR T Cell Regulation on TumorResponse

Five experimental groups: (1) anti-FITC CAR T cell with PBS; (2)anti-FITC CAR T cell with FITC-Folate (5 nmoles/kg); (3) anti-FITC CAR Tcell with FITC-Folate (50 nmoles/kg); (4) anti-FITC CAR T cell withFITC-Folate (500 nmoles/kg); (5) anti-FITC CAR T cell with FITC-Folate(2500 nmoles/kg) were designed to identify the relationship betweenanti-FITC CAR T cell response and the dose of FITC-ligands. MDA-MB-231cells were subcutaneously injected into the shoulders of NSG mice(Jackson Laboratory) to establish solid tumor xenografts. When tumorvolume reached around 50-100 mm³, anti-FITC CAR T cells (15×10⁶ cells)and different doses of FITC-Folate were intravenously introduced intothe mice.

To monitor anti-FITC CAR T cell activation with the different doses ofFITC-Folate, IFN-gamma concentration was measured in mouse blood by abead-based immunoassay (Legendplex kit from Biolegend). Tumor volume wasalso measured. General toxicity for each treatment group was monitoredby measuring weight loss.

FIGS. 3A-D show that anti-FITC CAR T cell activation is dependent on theconcentration of FITC-Folate. The concentrations of INF-gamma in eachtreatment group showed a bell-shaped dose-response curve (FIG. 3A).Anti-FITC CAR T cell activation was positively correlated with anincrease in FITC-Folate dose. However, if the dose of FITC-Folate (2500nmole/kg) was over 500 nmole/kg, the CAR T cell activation started todecrease. This may be due to the fact that target receptors in both theCAR T cell (e.g. anti-FITC) and the cancer cell (e.g. folate receptor)may be separately saturated at the higher doses of the FITC-ligands.This may decrease the functionality of the FITC-ligands as a bridgebetween CAR T cells and cancer cells. As shown in FIG. 3B, thebell-shaped dose-response was also confirmed with tumor response. TheCAR T cell's anti-tumor efficacy was induced by increasingconcentrations of FITC-Folate (from 5 nmoles/kg to 500 nmoles/kg).Similar to the levels of the pro-inflammatory cytokine, anti-tumorefficacy of CAR T cells also started to decrease at higher concentrationof FITC-Folate (2500 nmole/kg). As shown in FIG. 3C, the maximumtoxicity (i.e. lowest survival rate of mice) was observed in the grouptreated with 500 nmoles/kg, which also showed the highest anti-tumorefficacy. Moreover, via either a decrease or an increase of theFITC-Folate dose, CAR T cell mediated toxicity was gradually alleviated.Therefore, since anti-FITC CAR T cell activation is dependent on theFITC-ligand dose, management of CAR T cell mediated toxicity can beachieved through altering the FITC-ligand dose.

Example 11 Administration of Drug that can Turn Off Anti-FITC CAR T CellActivation Signal

To test whether anti-FITC CAR T cell activation can be suppressed byagents that inhibit a mediator of the T cell activation signal, thefollowing agents were selected: (1) dasatinib, which is FDA approved foruse in the treatment of adult CML (Dasatinib is known to suppressnatural T cell activation through inhibiting LCK activation), (2) PI3Kinhibitor (GDC0980), which is under a phase 2 clinical trial (PI3K isknown to play a critical role in activation of T cells), (3) Inducible Tcell kinase (ITK, BMS-509744), which is also involved in the T cellactivation signal and is in a preclinical stage. To study the efficacyof each agent in suppressing CAR T cell activation, an in vitro CAR Tcell functional study (e.g. pro-inflammatory cytokine production assayand evaluation of the degree of CAR T cell activation via surfaceactivation markers) was done in the presence several concentrations ofeach agent.

CAR T Cell Functional Study 1: Pro-Inflammatory Cytokine (e.g.IFN-Gamma) Production Assay

An ELISA assay was performed to quantify the level of IFN-gammaproduction by anti-FITC CAR T cells in the presence of each agent usinga Human IFN-gamma detection ELISA kit from Biolegend. To perform theELISA assay, each sample was obtained from the co-incubation ofanti-FITC CAR T cells, MDA-MB-231 cells, FITC-ligands, and each agent.MDA-MB-231 cells were pre-seeded at a density of 10⁴ cells/100 μl ofmedia in each well of a 96-well plate and grown overnight. The followingday, CAR T cells were introduced into each well where the MDA-MB-231cells were seeded. 100 nM FITC-Folate was introduced to activate theanti-FITC CAR T cell. 0.01 nM to 100 μM of each agent was added to eachwell and the cells were cultured 24 hours. After co-incubation, thesupernatants were harvested and centrifuged to remove cell debris at1000 g and 4° C. for 10 min. The cleared supernatants from each samplewere either used to detect IFN-gamma by ELISA directly or stored at −80°C. The ELISA assay was performed according to manufacturer'sinstructions.

CART Cell Functional Study 2: Evaluation of Degree of CAR T CellActivation

To identify the degree of CAR T cell activation in the presence of eachagent, the surface of the CAR T cells was stained with an anti-CD69antibody (CD69 is a T cell activation surface marker). Specifically, CART cells were co-incubated with pre-seeded MDA-MB-231 cells in thepresence FITC-Folate (100 nM) and each agent (0.01 nM to 100 μM) for 24hours. After co-incubation, CAR T cells were harvested and stained withan anti-CD69 antibody for 15 min on ice. The CAR T cells were washed 2times with staining buffer (2% FBS in PBS). After washing, the CAR Tcells were analyzed by flow cytometry.

FIGS. 4A-B show that the activation of anti-FITC CART cells can beregulated by targeting a key mediator of T cell activation signal. Asshown in FIGS. 4A and 4B, dasatinib and GDC0980 showed efficacy insuppressing anti-FITC CAR T cell activation. In the presence of eachagent (>10 nM), IFN-gamma production was significantly inhibited andanti-FITC CAR T cells still targeted cancer cells via FITC-Folate (FIG.4A). Inhibiting CAR T cell activation using each agent was alsoconfirmed by checking a standard T cell activation marker, CD69. Asshown in FIG. 4B, activated CAR T cells (CD69 positive cell) weredecreased in the presence of each agent at a concentration >10 nM.Although PI3K inhibitor and dasatinib showed similar efficacy insuppressing CAR T cell activation in vitro, dasatinib may be preferred.

Example 12 T Cell Preparation

Human peripheral blood mononuclear cells (PBMCs) were isolated fromwhole blood of healthy donors by using Ficoll density gradientcentrifugation (GE Healthcare Lifesciences). T cells were then isolatedfrom PBMCs by using an EasySep™ Human T Cell Isolation Kit (STEM CELLtechnologies). T cells were cultured in TexMACS medium (Miltenyi BiotechInc) with 40-100 IU/mL human IL-2 (Miltenyi Biotech), 2% human AB typeserum, and 1% penicillin/streptomycin sulfate. Dynabeads HumanT-Activator CD3/CD28 (ThermoFisher Scientific) were added to T cells at1:1 ratio to activate T cells. 12-24 hours after activation, T cellswere transduced with FITC-CAR lentiviral particles in the presence of 8μg/mL polybrine (Santa Cruiz Biotech) by spinfection at 1,200 g for 90minutes at 22-32° C. T cell mixture containing those with CARmodification (CAR-Ts) and those without CAR modification(non-transformed Ts) was cultured in the presence of activation beadsfor 6 days before the removal of activation beads.Fluorescence-Activated Cell Sorting was used to sort out CAR-T cells(GFP positive) and non-transformed T cells (GFP negative) based on theirGFP expression. The sorted T cells were cultured for 7-15 days beforeinjection into mice. When a T cell mixture was used, CAR-T cells andnon-transformed T cells were mixed at the desired ratio before mouseinjection. The data shown in FIGS. 6-11 was obtained with T cellsprepared with these procedures.

Example 13 Generation of Lentiviral Vector Encoding CAR Gene

An overlap PCR method was used to generate CAR constructs comprisingscFv against fluorescein. scFV against fluorescein, 4M5.3 (Kd=270 fM,762 bp) derived from anti-fluorescein (4-4-20) antibody was synthesized.Sequence encoding the human CD8α signal peptide (SP, 63 bp), the hinge,and transmembrane region (249 bp), the cytoplasmic domain of 4-1BB(CD137, 141 bp) and the CD3ζ chain (336 bp), as shown in FIG. 5, werefused with the anti-fluorescein scFV by overlapping PCR. The resultingCAR construct (1551 bp) was inserted into EcoRI/NotI cleaved lentiviralexpression vector pCDH-EF1-MCS-(PGK-GFP) (FIG. 5, System Biosciences).The sequence of the CAR construct in lentiviral vector was confirmed byDNA sequencing. Unless otherwise specified herein, the CAR constructused to generate the data for the Examples, has the nucleic acidsequence of SEQ ID NO:1 and the amino acid sequence of SEQ ID NO:2.

An exemplary CAR nucleic acid coding sequence may comprise:

(SEQ ID NO: 1) ATGGCCTTACCAGTGACCGCCTTGCTCCTGCCGCTGGCCTTGCTGCTCCACGCCGCCAGGCCGGATGTCGTGATGACCCAGACCCCCCTCAGCCTCCCAGTGTCCCTCGGTGACCAGGCTTCTATTAGTTGCAGATCCAGCCAGTCCCTCGTGCACTCTAACGGTAATACCTACCTGAGATGGTATCTCCAGAAGCCCGGACAGAGCCCTAAGGTGCTGATCTACAAAGTCTCCAACCGGGTGTCTGGAGTCCCTGACCGCTTCTCAGGGAGCGGTTCCGGCACCGACTTCACCCTGAAGATCAACCGGGTGGAGGCCGAAGACCTCGGCGTCTATTTCTGCTCTCAGAGTACACATGTGCCCTGGACCTTCGGCGGAGGGACCAAGCTGGAGATCAAAAGCTCCGCAGACGATGCCAAGAAAGATGCCGCTAAGAAAGACGATGCTAAGAAAGACGATGCAAAGAAAGACGGTGGCGTGAAGCTGGATGAAACCGGAGGAGGTCTCGTCCAGCCAGGAGGAGCCATGAAGCTGAGTTGCGTGACCAGCGGATTCACCTTTGGGCACTACTGGATGAACTGGGTGCGACAGTCCCCAGAGAAGGGGCTCGAATGGGTCGCTCAGTTCAGGAACAAACCCTACAATTATGAGACATACTATTCAGACAGCGTGAAGGGCAGGTTTACTATCAGTAGAGACGATTCCAAATCTAGCGTGTACCTGCAGATGAACAATCTCAGGGTCGAAGATACAGGCATCTACTATTGCACAGGGGCATCCTATGGTATGGAGTATCTCGGTCAGGGGACAAGCGTCACAGTCAGTTTCGTGCCGGTCTTCCTGCCAGCGAAGCCCACCACGACGCCAGCGCCGCGACCACCAACACCGGCGCCCACCATCGCGTCGCAGCCCCTGTCCCTGCGCCCAGAGGCGTGCCGGCCAGCGGCGGGGGGCGCAGTGCACACGAGGGGGCTGGACTTCGCCTGTGATATCTACATCTGGGCGCCCTTGGCCGGGACTTGTGGGGTCCTTCTCCTGTCACTGGTTATCACCCTTTACTGCAACCACAGGAACCGTTTCTCTGTTGTTAAACGGGGCAGAAAGAAACTCCTGTATATATTCAAACAACCATTTATGAGACCAGTACAAACTACTCAAGAGGAAGATGGCTGTAGCTGCCGATTTCCAGAAGAAGAAGAAGGAGGATGTGAACTGAGAGTGAAGTTCAGCAGGAGCGCAGACGCCCCCGCGTACCAGCAGGGCCAGAACCAGCTCTATAACGAGCTCAATCTAGGACGAAGAGAGGAGTACGATGTTTTGGACAAGAGACGTGGCCGGGACCCTGAGATGGGGGGAAAGCCGAGAAGGAAGAACCCTCAGGAAGGCCTGTACAATGAACTGCAGAAAGATAAGATGGCGGAGGCCTACAGTGAGATTGGGATGAAAGGCGAGCGCCGGAGGGGCAAGGGGCACGATGGCCTTTACCAGGGTCTCAGTACAGCCACCAAGGACACCTACGACGCCCTTCACATGCAGGCCCTGCCCCCTCGCTAA.In the exemplary nucleic acid sequence shown above (SEQ ID NO:1) thefirst ATG is the start codon. An exemplary CAR amino acid sequence maycomprise:

(SEQ ID NO: 2) MALPVTALLLPLALLLHAARPDVVMTQTPLSLPVSLGDQASISCRSSQSLVHSNGNTYLRWYLQKPGQSPKVLIYKVSNRVSGVPDRFSGSGSGTDFTLKINRVEAEDLGVYFCSQSTHVPWTFGGGTKLEIKSSADDAKKDAAKKDDAKKDDAKKDGGVKLDETGGGLVQPGGAMKLSCVTSGFTFGHYWMNWVRQSPEKGLEWVAQFRNKPYNYETYYSDSVKGRFTISRDDSKSSVYLQMNNLRVEDTGIYYCTGASYGMEYLGQGTSVTVSFVPVFLPAKPTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAPLAGTCGVLLLSLVITLYCNHRNRFSVVKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCELRVKFSRSADAPAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKD TYDALHMQALPPR An exemplary insert may comprise:

(SEQ ID NO: 3) GCCACCATGGCCTTACCAGTGACCGCCTTGCTCCTGCCGCTGGCCTTGCTGCTCCACGCCGCCAGGCCGGATGTCGTGATGACCCAGACCCCCCTCAGCCTCCCAGTGTCCCTCGGTGACCAGGCTTCTATTAGTTGCAGATCCAGCCAGTCCCTCGTGCACTCTAACGGTAATACCTACCTGAGATGGTATCTCCAGAAGCCCGGACAGAGCCCTAAGGTGCTGATCTACAAAGTCTCCAACCGGGTGTCTGGAGTCCCTGACCGCTTCTCAGGGAGCGGTTCCGGCACCGACTTCACCCTGAAGATCAACCGGGTGGAGGCCGAAGACCTCGGCGTCTATTTCTGCTCTCAGAGTACACATGTGCCCTGGACCTTCGGCGGAGGGACCAAGCTGGAGATCAAAAGCTCCGCAGACGATGCCAAGAAAGATGCCGCTAAGAAAGACGATGCTAAGAAAGACGATGCAAAGAAAGACGGTGGCGTGAAGCTGGATGAAACCGGAGGAGGTCTCGTCCAGCCAGGAGGAGCCATGAAGCTGAGTTGCGTGACCAGCGGATTCACCTTTGGGCACTACTGGATGAACTGGGTGCGACAGTCCCCAGAGAAGGGGCTCGAATGGGTCGCTCAGTTCAGGAACAAACCCTACAATTATGAGACATACTATTCAGACAGCGTGAAGGGCAGGTTTACTATCAGTAGAGACGATTCCAAATCTAGCGTGTACCTGCAGATGAACAATCTCAGGGTCGAAGATACAGGCATCTACTATTGCACAGGGGCATCCTATGGTATGGAGTATCTCGGTCAGGGGACAAGCGTCACAGTCAGTTTCGTGCCGGTCTTCCTGCCAGCGAAGCCCACCACGACGCCAGCGCCGCGACCACCAACACCGGCGCCCACCATCGCGTCGCAGCCCCTGTCCCTGCGCCCAGAGGCGTGCCGGCCAGCGGCGGGGGGCGCAGTGCACACGAGGGGGCTGGACTTCGCCTGTGATATCTACATCTGGGCGCCCTTGGCCGGGACTTGTGGGGTCCTTCTCCTGTCACTGGTTATCACCCTTTACTGCAACCACAGGAACCGTTTCTCTGTTGTTAAACGGGGCAGAAAGAAACTCCTGTATATATTCAAACAACCATTTATGAGACCAGTACAAACTACTCAAGAGGAAGATGGCTGTAGCTGCCGATTTCCAGAAGAAGAAGAAGGAGGATGTGAACTGAGAGTGAAGTTCAGCAGGAGCGCAGACGCCCCCGCGTACCAGCAGGGCCAGAACCAGCTCTATAACGAGCTCAATCTAGGACGAAGAGAGGAGTACGATGTTTTGGACAAGAGACGTGGCCGGGACCCTGAGATGGGGGGAAAGCCGAGAAGGAAGAACCCTCAGGAAGGCCTGTACAATGAACTGCAGAAAGATAAGATGGCGGAGGCCTACAGTGAGATTGGGATGAAAGGCGAGCGCCGGAGGGGCAAGGGGCACGATGGCCTTTACCAGGGTCTCAGTACAGCCACCAAGGACACCTACGACGCCCTTCACATGCAGGCCCTGCCCCCT CGCTAAIn the exemplary insert described above (SEQ ID NO:3), the first GCCACCsequence may comprise a restriction enzyme cleavage site, followed bythe ATG start codon. The encoded amino acid sequence may comprise:

(SEQ ID NO: 2) MALPVTALLLPLALLLHAARPDVVMTQTPLSLPVSLGDQASISCRSSQSLVHSNGNTYLRWYLQKPGQSPKVLIYKVSNRVSGVPDRFSGSGSGTDFTLKINRVEAEDLGVYFCSQSTHVPWTFGGGTKLEIKSSADDAKKDAAKKDDAKKDDAKKDGGVKLDETGGGLVQPGGAMKLSCVTSGFTFGHYWMNWVRQSPEKGLEWVAQFRNKPYNYETYYSDSVKGRFTISRDDSKSSVYLQMNNLRVEDTGIYYCTGASYGMEYLGQGTSVTVSFVPVFLPAKPTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAPLAGTCGVLLLSLVITLYCNHRNRFSVVKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCELRVKFSRSADAPAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKD TYDALHMQALPPR

Example 14 Production of Lentivirus Containing CAR Gene for Human T CellTransduction

To prepare lentiviral virus containing an anti-fluorescein (i.e.,anti-FITC) single chain fragment variable (scFv) CAR, a HEK-293TNpackaging cell line was co-transfected with the lentiviral vectorencoding anti-fluorescein scFv CAR and a 2nd generation of a lentiviralpackaging plasmid mix (Cellecta) or ViraPower Lentivrial Packaging Mix(ThermoFisher). After 24 and 48 hours of transfection, supernatantscontaining the lentivirus with the CAR gene were harvested and virusparticles were concentrated by the standard polyethylene glycol virusconcentration method (Clontech) for future transduction with human Tcells.

Example 15 Isolation of Human T Cells from Human PBMC

T cells were isolated from human peripheral blood mononuclear cells(PBMC) by Ficoll density gradient centrifugation (GE HealthcareLifesciences). After washing away remaining Ficoll solution, T cellswere isolated by using an EasySep™ Human T Cell Isolation Kit (STEM CELLtechnologies). Purified T cells were cultured in TexMACS™ medium(Miltenyi Biotech Inc) with 1% penicillin and streptomycin sulfate inthe presence of human IL-2 (100 IU/mL, Miltenyi Biotech Inc). T cellswere cultured at density of 1×10⁶ cells/mL in multi-well plates. T cellswere split and re-feed every 2-3 days.

Example 16 Transduction of Human T Cells

Isolated T cells were activated with Dynabeads coupled withanti-CD3/CD28 antibodies (Life Technologies) for 12-24 hours in thepresence of human IL-2 (100 IU/mL), then transduced with lentivirusencoding an anti-fluorescein CAR gene. Cells were harvested after 72hours and the expression of CAR on transduced T cells was identified bymeasuring GFP fluorescent cells using flow cytometry.

Example 17 Test Anti-Tumor Efficacy of CAR T Cells In Vivo

Immunodeficient NSG mice (Jackson Laboratory) were used to identify theefficacy of CAR T cell anti-tumor activity in vivo. A folate receptorexpressing MDA-MB-231 cancer cell line was subcutaneously injected intothe back of NSG mice to establish solid tumor xenografts. When tumorvolume of around 100-300 mm³ was reached, a desired concentration ofEC17 (as shown in the figure legends) was introduced 4 hours before theadministration of a desired number of CAR T cell (as shown in the figurelegends) into the mice bearing tumors. After initial administration ofEC17 and CAR T cells, desired concentrations of EC17 (as shown in thefigure legends) were also introduced (i.v.) three times per week.Control mice were administered T cells without CAR modification. Othercontrol mice were administrated CAR-Ts, but PBS was dosed instead ofEC17. Anti-tumor efficacy was monitored by tumor volume. Generaltoxicity of the therapy was monitored by weight loss, gross animalmorphology and behavior.

Adjusting the bridge dose can reduce cytokine release and toxicity whilemaintaining the anti-tumor effect. As shown in the legends of FIGS.6A-D, either T cells or CAR T cells were administered to mice along with0, 20 nmoles/kg, 100 nmoles/kg, 500 nmoles/kg, 1500 nmoles/kg, or 10000nmoles/kg of EC17. Tumor volume (FIG. 6A) and body weight changes (FIG.6B) were measured over 74 days. The maximal percentage body weight lossfor each EC17 dose is shown in FIG. 6C. The number of mice exhibitingsevere cytokine release syndrome and the number of total mice in eachgroup are shown in parentheses. The percentage of mice showing sCRS foreach EC17 dose is shown in FIG. 6D. Compared to mice in a cohort with ahigher EC17 dose (500 nmoles/kg), mice in a cohort with 20 and 100nmoles/kg EC17 doses had a lower percentage of sCRS and less body weightloss, while they all reached complete cures. With over-saturated bridgeEC17 doses (1500 and 10000 nmoles/kg), less mice showed sCRS but lessmice reached cures.

Reducing the CAR-T dose or dividing the CAR-T dose into 2 doses canavoid severe cytokine release syndrome while maintaining anti-tumorefficacy. The EC17 dose was fixed at 500 nmoles/kg. As shown in thelegends of FIGS. 8A-D different CAR T doses were introduced into themice. Tumor volume (FIG. 8A) and body weight (FIG. 8B) were measuredover 56 days. The number of mice exhibiting severe cytokine releasesyndrome and the number of total mice in each group are shown inparentheses. The maximal percentage body weight loss for each CAR T doseis shown in FIG. 8C. The percentage of mice showing sCRS for each CAR Tdose is shown in FIG. 8D.

Adjusting the CAR T cell dose and the EC17 dose can affect tumor size.Either T cells or CAR T cells were administered to mice along with 100nmoles/kg or 500 nmoles/kg of EC17. As shown in the legends of FIGS.9A-B, control or CAR T cells were administered with differentconcentrations of EC17. Tumor volume (FIG. 9A) and body weight (FIG. 9B)were measured for 75 days. The number of mice exhibiting severe cytokinerelease syndrome and the number of total mice in each group are shown inparentheses. With optimized EC17 amount and CAR T numbers, mice only had2% body weight loss while reaching complete cures.

The presence of CAR T cells in a second dose of T cells can affect tumorsize. As shown in the legends of FIGS. 10A-C, no second dose of T cells,a second dose with 20 million non-transformed T cells, or a second dosewith a mixture of non-transformed T cells and CAR T cells wasadministered to the mice. Tumor volume (FIG. 10A) and body weight (FIG.10B) were measured over time. The measured amounts of CAR T cells/normalT cells in 50 μl of the patient's blood 2 weeks after injection of theCAR T cell mixture are shown in FIG. 10C for one mouse for the treatmentwith no second dose of T cells, and for two mice each for the treatmentgroups of a second dose with 20 million non-transformed T cells, or asecond dose with a mixture of non-transformed T cells and CAR T cells.FIG. 10C also shows corresponding flow cytometry plots of the measuredamounts of normal T cells and CAR T cells, and corresponding tumorvolumes 4 weeks after injection of the CAR T cell mixture.

Adjusting the EC17 dose schedule can lower toxicity and can affect tumorsize. As shown in the legends of FIGS. 11A-B, CAR T cells and EC17 wereadministered to mice using different dosing schedules. Tumor volume(FIG. 11A) and body weight (FIG. 11B) were measured over time. Thenumber of mice exhibiting severe cytokine release syndrome and thenumber of total mice in each group are shown in parentheses. Adjustingbridge dosing frequency (from three times per week (TIW) to once perweek (SIW)) can reduce the toxicity and achieve better anti-tumorpotency.

Example 18 Test Rescue Ability of EC0923 During CAR T Cell Treatment InVivo

CAR T cells were introduced into mice bearing tumors and EC17 was alsointroduced (i.v.) three times per week. When severe cytokine releasesyndrome was observed, one dose of EC0923 at 10 μmoles/kg was introducedto rescue mice. Mice were monitored for 4 more days, and some wereeuthanized to evaluate organs. Organs from mice treated with or withoutEC0923 6 hours, 1 day, and 4 days after treatment are shown in FIG. 7.Mice with one dose of EC0923 started to move and look for food after 4hours, and their spleens and livers were red. Control mice withoutEC0923 didn't move after 6 hours, and their spleens and livers werepale. Mice with EC0923 treatment were active again in 24 hours andexpected to survive, and were put back to a normal EC17 dosing schedule.Control mice without EC0923 started to move a little in 24 hours, buthad to be euthanized to prevent animal suffering. Mice with EC0923looked normal in 4 days. One of the mice was euthanized and found tohave normal colored spleen and liver. The spleen of the rescued mousewas enlarged, which indicates that CAR-Ts were still proliferatingdespite the single dose of EC0923 for rescue. Other remaining mice withEC0923 were given routine EC17 dosing three times per week, and theirtumors disappeared in 4 weeks.

Example 19 Control of CART Cell Activation In Vivo

Anti-FITC CAR T cell activation can be controlled by discontinuation ofFITC-ligands administration, introduction of excess amounts ofcompetitor small molecules (e.g. folic acid (FA)), or a combination ofthese two approaches.

In order to show control of CART T cell activation, a human breastcancer cell line (e.g. MDA-MB-231) was subcutaneously injected into theshoulder of NSG mice (Jackson Laboratory) to establish solid tumorxenografts. When tumor volume reached around 50-100 mm³, about 15×10⁶anti-FITC CAR T cells were introduced into mice with tumorsintravenously. Five study groups were designed to test whether anti-FITCCAR T cell activation can be controlled via temporal termination ofFITC-ligands, by administering a competitor small molecule, or acombination approach of both discontinuing of FITC-ligands and/oradministering an FA competitor. The first group was treated byadministering anti-FITC CAR T cell with phosphate-buffered saline (PBS)as a negative control. Every other day over the course of the study, thesecond, third, fourth and fifth groups were treated with anti-FITC CAR Tcell mixed with FITC-Folate (500 nmole/kg). Once a significant toxicityevent was detected (e.g. serious loss of body weight), the treatmentregimen was altered for the four groups as follows: (1) group 2continued with FITC-Folate injections (Continued); (2) group 3 receivedcombination treatment including termination of FITC-Folate and receivingan excess amount of free folate (Break+FA Competitor); (3) group 4received a discontinuation of FITC-Folate until mice recovered (Break);and (4) group 5 received a mixture containing a 100-fold excess of freefolic acid (i.e. EC0923) relative to FITC-Folate until mice recovered(FITC-Folate+FA Competitor). Mouse bodyweight was measured regularly totest for toxicity.

Results. FIG. 12 (bars about the 0 line=PBS control; first bar in eachgroup below the 0 line=continuous; second bar in each group below the 0line=break+FA competitor; third bar in each group below the 0line=break; fourth bar in each group below the 0 line=FA competitor)shows that anti-FITC CAR T cell mediated toxicity can be managed bycontrolling anti-FITC CAR T cell activation via discontinuation ofFITC-Folate injection, administration of an excess amount of acompetitor molecule, or a combination of both. The FIG. 12 graph andtable show that CAR T cell mediated toxicity (e.g. cytokine storm) canbe managed by controlling CAR T cell activation either bydiscontinuation of FITC-ligands (Break); administration of an excessamount of free folic acid as a competitor with FITC-Folate (500nmole/kg) (FITC-Folate+FA Competitor); or a combination of these twoapproaches (Break+FA Competitor). FIG. 12 further shows groups treatedwith CAR T cells+FITC-Folate demonstrated body weight loss due tohyper-activation of CAR T cells. When serious CAR T cell mediatedtoxicity was detected (i.e. >10% weight loss), three different methodswere tested (mentioned above) to find out whether the degree of CAR Tcell activation can be decreased and CAR T cell mediated toxicity can bemanaged. Based on the data, the three methods are able to control thedegree of CAR T cell activation to alleviate CAR T cell mediatedtoxicity. Furthermore, the combination of discontinuing FITC-Folate andadministering an excess amount of free folic acid showed better efficacyin decreasing CAR T cell mediated toxicity compared to each approachalone. As expected, the degree of CAR T cell activation was decreasedwhen the FITC-Folate amount is limited. Simultaneously, administrationof an excess amount of free folic acid may compete with FITC-Folate byinterfering with the interaction between FITC-Folate and the folatereceptor. Therefore, a combination treatment including termination ofFITC-Folate and administering a folate competitor may promote the rapiddecrease of CAR T cell mediated toxicity.

Example 20 FITC-Folate Dose Escalation Study In Vivo

To test whether gradual escalation of FITC-Folate dose can minimize CARTcell mediated toxicity without compromising anti-tumor efficacy of CAR Tcells, an experiment was designed. A dose of FITC-Folate (0.05 nmole/kg)was introduced first into NSG mice bearing MDA-MB-231 (tumor volumeabout 50-100 mm³) along with anti-FITC CAR T cell injections (usingabout 15×10⁶ cells). An additional two doses of about 0.05 nmole/kgFITC-Folate was administered to the mice. Then doses of FITC-Folate weregradually increased from 5 nmole/kg (single dose) to 50 nmole/kg (twodoses). After a gradual increase of FITC-Folate dose, mice were treatedwith a 500 nmole/kg dose of FITC-Folate. This concentration showed goodtumor efficacy, but also caused toxicity if mice were initially treatedwith the 500 nmole/kg dose. General toxicity of each treatment group wasmonitored by measuring body weight loss. Tumor volume was measured tomonitor anti-FITC CAR T cells' anti-tumor efficacy.

FIG. 13 shows that a gradual dose increase of FITC-Folate can minimizeanti-FITC CAR T cell mediated toxicity without compromising anti-tumorefficacy of CAR T cells. Specifically, FIGS. 13A and 13C demonstrate noserious toxicity (i.e. >10% weight loss) was detected using the gradualtreatment protocols compared to the group that was continuously treatedwith 500 nmole/kg of FITC-Folate. FIG. 13B shows that gradual activationof CAR T cells by a gradual increase in FITC-Folate dose, did notnegatively affect the CAR T cells' anti-tumor efficacy. Therefore, agradual dose increase of FITC-Folate could be used to treat tumors usinga FITC-Folate bridge while avoiding substantial serious toxicity sideeffects.

Example 21 Effect of Folate-FITC on CAR-T Cell Number and on SerumCytokines

The triple negative human breast cancer cell line (i.e. MDA-MB-231) wassubcutaneously implanted into the shoulders of immunodeficient (e.g.NSG) mice. When tumor volume reached around 50-100 mm³, anti-FITC CAR Tcells (10⁷ cells) were intravenously introduced with either FITC-folate(500 nmole/kg) or PBS. To monitor CAR T cell proliferation andpro-inflammatory cytokine production, mice blood was collected at Day 6.CAR T cell proliferation was evaluated by staining a whole blood samplewith anti-human CD3 antibody (Biolegned) and detecting GFP expression onthe CD3 positive T cell population. Pro-inflammatory cytokine productionwas measured by a bead-based immunoassay (Legendplex kit frombiolegend).

FIG. 14A shows that anti-FITC CAR T cells only proliferatedsignificantly when the bridge molecule was introduced into tumor bearingmice. However, in the absence of the antigen matched bridge molecule,anti-FITC CAR T cells did not proliferate significantly. Furthermore,pro-inflammatory cytokines (e.g. IL-2, TNF-α and IFN-γ) weresignificantly produced when tumor-bearing mice were treated with bothanti-FITC CAR T cells and the antigen matched bridge molecule. Takentogether FIGS. 14A and 14B, show that anti-FITC CAR T cells can bespecifically proliferated and activated to produce pro-inflammatorycytokines by targeting cancer cells via the antigen matched bridgemolecule Folate-FITC.

Example 22 In Vitro Interferon-γ Assay

In order to study the relationship between bridge dose and anti-FITC CART cell activation, a folate receptor positive cancer cell line(MDA-MB-231) was seeded at a density of 10⁴ cells/100 ul of media ineach well of a 96-well plate and the cells were grown overnight.Anti-FITC CAR T cells (5×10⁴ cells) were then added into each wellcontaining cancer cells with various concentrations of Folate-FITC (from0.001 nM to 100 μM) for 6-24 hours. After co-incubation, the platescontaining anti-FITC CAR T cells and cancer cells were centrifuged for10 min at 350×g to remove cells and cellular debris, and 50 ul ofsupernatant was assayed by ELISA (Human IFN-γ ELISA kit from Biolegend)to detect IFN-γ production by anti-FITC CAR T cells.

To evaluate the relationship between bridge dose and anti-FITC CAR Tcell activation, the level of IFN-γ produced by anti-FITC CAR T cellswas measured after CAR T cells were co-incubated with cancer cells atvarious concentrations of FITC-folate in vitro as described above. Asshown in FIG. 15, the level of IFN-γ production was increased as bridgedose was increased. However, if the dose of the bridge was higher thanthe optimal dose (i.e. highest IFN-γ level [10 nM]), IFN-γ productiondecreased and eventually was not detected when very high doses (e.g. 10μM and 100 μM) of the bridge were introduced (i.e. bell-shaped bridgedose-response). This result in vitro may be because the high dose of thebridge can saturate all of target receptors on both cancer cells and CART cells in vitro. These results show that CAR T cell mediated toxicitycan be controlled by manipulating the dose of the bridge. In FIG. 15,“Adaptor Dose” on the X-axis is the Folate-FITC dose.

Example 23 Rescue Ability of Competitors During CAR T Cell Treatment InVivo

Excess CAR T cells (8 to 10 million in each study) were introduced intomice bearing MDA-MB-231 tumors, and 500 nmol/kg of EC17 was alsointroduced (i.v.) three times per week. When severe cytokine releasesyndrome was observed, one dose of EC0923 (folate) or untetheredfluorescein (both at 10 μmoles/kg) was introduced intravenously torescue mice (FIG. 16). Mice with one dose of EC0923 or fluoresceinstarted to move and look for food after 4 hours, were active again in 24hours, and looked normal in 4 days. EC17 administration was thencontinued. Control mice without EC0923 or fluorescein didn't move after4 hours, and had to be euthanized because of the sickness. Blood sampleswere collected 6 hours after the administration of competitors, andcytokine levels were measured (see FIG. 16). Four weeks later, tumorswere eliminated from the mice with rescue treatment. All mice tested forcytokine production were injected with 8 million CAR-T cells.

Example 24 CAR-T Activity is Dependent on Both the Bridge Dose Level andthe Presence of the Tumor

CAR-T cells were injected into naïve mice (8 million per mouse) and micebearing MDA-MB-231 tumors (5 million per mouse). Various levels of EC17were administrated three times per week. IFN-γ in blood was measured 10days after CAR-T cell injection. As shown in FIG. 17, cytokineproduction (CAR-T activity) is dependent on both the bridge (EC17) doselevel and the presence of the tumor.

Example 25 CAR-T Cells do not Proliferate in Naïve Mice without Tumors

Five million CAR-T cells were injected (i.v.) into naïve mice withouttumors. 500 nmoles/kg EC17 was administrated three times per week. Micewere monitored for 5 weeks, and some were euthanized every week toevaluate organs. No apparent body weight loss (toxicity) was observedfor any mice, whether EC17 was administrated or not (FIG. 18A). CAR-Tcells did not proliferate in naïve mice with or without EC17administration, as indicated by CAR-T cell number in blood (FIG. 18B)and spleen size (FIG. 18C).

Example 26 EC17 Dependent Anti-tumor Activity of FITC-CAR-T in DifferentFolate Receptor-Positive Tumor Xenograft Models

Immunodeficient NSG mice (Jackson Laboratory) were used to show theefficacy of CAR T cell anti-tumor activity with a single dose of EC17per week. Two folate receptor expressing cancer cell lines were used toestablish subcutaneous solid tumor xenografts: MDA-MB-231 has highfolate receptor expression, while OV90 has low folate receptorexpression. When tumor volume of around 100-250 mm³ was reached, micewere divided into two groups. Mice in the “EC17 500 nmol/kg” group(nmol/kg is equivalent to nmoles/kg as used in this patent applicationfor the bridge) were injected with 500 nmoles/kg of body weight of EC17,while mice in the “no EC17” group were not injected with EC17. Fourhours later, mice in both groups were administered 5 million anti-FITCCAR-T cells. After initial administration of EC17 and CAR-T cells, onlymice in the “EC17 500 nmol/kg” group were injected (i.v.) with 500nmoles/kg of EC17 once per week. Anti-tumor efficacy was monitored bytumor volume.

FIG. 19A shows that anti-FITC CAR-T cells by themselves don't haveanti-tumor activity in MDA-MB-231 tumor models with high folate receptorexpression. Only with the administration of EC17 (single dose per week),do the anti-FITC CAR-T cells eliminate MDA-MB-231 tumors. Therefore, asingle dose per week of EC17 is sufficient in activating and bridginganti-FITC CAR-T cells to tumor cells to eliminate the tumors. FIG. 19Bshows that anti-FITC CAR-T cells also show EC17 dependent anti-tumoractivity in an OV90 xenograft model which has a low expression level offolate receptors on tumor cells.

Example 27 Maintenance of CAR-T Anti-Tumor Activity by Adjusting BridgeDose Level

Immunodeficient NSG mice (Jackson Laboratory) were used to study CAR Tcell anti-tumor activity and its toxicity in the presence of differentEC17 dose levels. MDA-MB-231 tumor cells were used to establishsubcutaneous solid tumor xenografts. When tumor volume of around 100-150mm³ was reached, various concentrations of EC17 were pre-injected 4hours before i.v. injection of 10 million CAR-T cells. Variousconcentrations of EC17 were then administrated three times per weekafter the initial EC17 and CAR-T cell injections. The negative controlgroup was injected with 500 nmol/kg EC17 (4 hour in advance) and 50million unmodified T cells. 500 nmol/kg EC17 was then administratedthree times per week after initial injection. Tumor size and body weightwere measured to monitor the anti-tumor activity and the toxicity. Asshown in FIG. 20A, tumors in mice treated with 10 million CAR-T cellsand EC17 500 nmol/kg, 100 nmol/kg or 20 nmol/kg were all eliminated, buttumors in the negative control group were not eliminated. When comparingthe body weight loss due to treatment in mice administrated 10 millionCAR-T cells but different EC17 dose levels, the group administrated 500nmol/kg EC17 TIW was found to show the strongest toxicity (body weightloss (FIG. 20B)). 20 nmol/kg EC17 TIW showed the least toxicity(indicated by body weight loss) among three EC17 dose groups, but stillmaintained sufficient anti-tumor activity. By adjusting the EC17 doselevel, CAR-T anti-tumor activity can be maintained while the resultingbody weight loss (toxicity) can be reduced. In FIGS. 20A and 20B, EC17is also referred to as “adaptor” or “bi-specific adaptor”.

Example 28 FITC-Car-T/EC17 Therapy Shows Anti-Tumor Activity in VariousFR+ Tumor Models

To test whether FITC-CAR-T/EC17 therapy has anti-tumor activity invarious FR+ tumor models, NSG mice were subcutaneously implanted withMDA-MB-231 (triple negative breast cancer cell line), OV90 (humanovarian cancer cell line), KB (human cervical adenocarcinoma cell line),SKOV-3 (human ovarian carcinoma cell line), or HEK293-FRa (HEK293stably-transfected with human FRa). When tumor size reached 100-300 nm3,one dose of EC17 at 500 nmol/kg of body weight was injected by tail veinfollowed with administering of 5 million FITC-CAR-T cells 4 hours later.500 nmol/kg EC17 was dosed once every week after the initial EC17/CAR-Tadministration (about day 7), tumor size and body weights of mice weremonitored three times per week. The EC17 dosing days were labeled asgreen dashed vertical lines in the graph. As shown in FIGS. 21 to 25,FITC-CAR-T treatment did not show any anti-tumor activity in the absenceof EC17, whereas the FITC-CAR-T/EC17 therapy showed EC17 dependentanti-tumor activity in various FR+ tumor xenograft models. The therapyachieved 100% cures in MDA-MB-231 xenograft mice, 50% cures and 50%stable disease in OV90 mice, stable disease in all KB xenograft mice andSKOV3 xenograft mice, and progressive disease in the HEK293-FRa model.EC17 dose-dependent temporary body weight loss was also observed in alltumor bearing mice, indicating the activation of CAR-Ts isEC17-dependent in these mice.

FITC-CAR-T anti-tumor activity in a MDA-MB-231 model is shown in FIGS.21A and 21B. FITC-CAR-T anti-tumor activity in an OV-90 model is shownin FIGS. 22A and 22B. FITC-CAR-T anti-tumor activity in a KB model isshown in FIGS. 23A and 23B. FITC-CAR-T anti-tumor activity in a HEK-FRamodel is shown in FIGS. 24A and 24B. FITC-CAR-T anti-tumor activity in aSKOV-3 model is shown in FIGS. 25A and 25B.

Example 29 FITC-Car-T Related Toxicity (e.g. SCRS) can be Reduced byPre-Painting Tumors with EC17

To evaluate whether pre-painting tumors with EC17 can reduce thetherapy-related toxicity (e.g. sCRS), NSG mice were implanted withMDA-MB-231. Since larger tumor burden is correlated with more severeCRS, the treatment was started when tumor size reached 400-500 nm3. Micewere divided into two groups and predosed with 500 nmol/kg EC17 atdifferent time points before CAR-T administration (FIGS. 26A and 26B).Group #1 was pre-dosed 4 hours before the administration of 8 millionCAR-T cells, while group #2 was pre-dosed 24 hours before theadministration of 8 million CAR-T cells. 500 nmol/kg EC17 was then i.v.dosed once per week (at days 1, 8, 15 etc.) post CAR-T administration(FIGS. 26D and 26E). Although mice in two groups showed similarEC17-dependent body weight loss, mice in the group with 4 hourpre-painting of EC17 showed worse sCRS than mice in the group paintedwith EC17 24 hours before CAR-T administration. As shown in FIG. 26C, inthe 4-hour pre-painting group, 33% of mice died (or were euthanized dueto sCRS) in Week 2, 33% died in Week 3, 17% died in week 4, and only 17%survived over 5 weeks; in the 24-hour pre-painting group, only 17% micedied (or were euthanized due to sCRS) in Week 2, and 83% survived over 5weeks. No difference in anti-tumor activity was found in these twogroups, and all surviving mice became tumor free eventually. Thus,toxicity was less in mice with 24 hour pre-painting than in mice with 4hour pre-painting with EC17.

Example 30 Pre-Painting Tumors with EC17 Reduces Toxicity (SCRS)

FITC-CAR-T related toxicity (e.g. sCRS) can be reduced by thecombination of EC17 pre-painting and the delay of EC17 dosing post CAR-Tadministration. To explore strategies to control therapy-relatedtoxicity, the combination of the EC17 pre-painting and EC17 dosingschedule optimization was evaluated. Mice bearing MDA-MB-231 tumors(100-200 mm3) were divided into three groups. Mice in group #1 (no EC17pre-painting) were administered with 8 million FITC-CAR-T cells throughthe tail vein, and 500 nmol/kg EC17 was then dosed as a single dose perweek (at days 2, 9, 16, etc.) post CAR-T administration. Mice in group#2 (EC17 4 hour pre-painting) were pre-painted with 500 nmol/kg EC17 4hours before the administration of 8 million CAR-T cells, and 500nmol/kg EC17 was then dosed as a single dose per week post CAR-Tadministration. Mice in group #3 (EC17 4 hour pre-painting+delayedsecond EC17 dose) were also pre-painted with 500 nmol/kg EC17 4 hoursbefore the administration of 8 million CAR-T cells, but the second doseof 500 nmol/kg EC17 was postponed until 7 days after CAR-Tadministration, and the single dose per week schedule of EC17 dosing wasthen followed. Three days after CAR-T administration, mice in the threegroups were evaluated by visual observation. As shown in FIG. 27A, micein group #1 (no pre-painting) showed the worst sCRS, mice in group #2((EC17 4 hour pre-painting) showed sCRS but less severe than those ingroup #1. More importantly, mice in group #3 (EC17 4 hourpre-painting+delayed second EC17 dose) didn't show sCRS. As shown inFIG. 27B, mice in group #3 with the combined treatment with EC17 4-hourpre-painting and the delayed second EC17 dose showed the least bodyweight loss. The variations of the EC17 dosing schedule did not affectCAR-T anti-tumor activity, and mice in all three groups reached completeresponses (FIG. 27C).

Example 31 Car-T Number in Blood is Increased after Rescue

EC17/CAR-T therapy strategy is controllable through bridge displacementby either free folate or free fluorescein. To evaluate whetherFITC-CAR-T therapy strategy is controllable through bridge (e.g. EC17)dose/displacement, NSG mice bearing MDA-MB-231 tumors (100-250 mm3) wereadministered with excess FITC-CAR-T cells (8 million) and dosed with 500nmol/kg EC17 three times per week (at days 1, 3, 5, etc. post CAR-Tadministration). Those mice showed sCRS after one week, and were dividedinto three groups. One group of mice was i.v. injected with 10 umol/kgof unconjugated folate (EC0923), the second group was i.v. injected with10 umol/kg of fluoresceinamine for “rescue”, whereas the third group wasnot treated as a control group. Mice from three groups were theneuthanized at 8, 12, 24 and 48 hours post injection of EC0923 orfluoresceinamine, and their blood samples were analyzed for CAR-T cellnumber and cytokine levels. CAR-T cells in blood were stained withanti-human CD45 antibody labeled with APCeF780 (Biolegend) and countedby FACS. CountBright™ Absolute Counting Beads (ThermoFisher Scientific)were mixed into the samples and used as a reference for cell counting.As shown in FIG. 28A-D, treatments with both 10 umol/kg EC0923(unconjugated folate) and 10 umol/kg fluoresceinamine (unconjugatedfluorescein) caused an increase of CAR-T number in blood circulation,indicating that some CAR-T cells were dissociated from their targettumor cells and returned back to the blood circulation when the bridge(EC17) was displaced by excess unconjugated folate or fluorescein. Theincrease of CAR-T cell count in blood circulation of rescued mice wasfound as early as 6 hours post EC0923/fluorescein injection, indicatingthat the mice responded to the displacement “rescue” quickly.Furthermore, fluorescein seemed to cause more CAR-T displacement thanfolate (EC0923), which is correlated with previously described findingsthat rescue with fluoresceinamine reduced cytokine production in bloodmore strongly than folate did.

Example 32 Comparison of Three Rescue Reagents (Folic Acid, SodiumFluorescein (NAFL) and Leucovorin)

One dose of folate, sodium fluorescein, or leucovorin can “rescue” miceunder sCRS by displacing the bridge EC17 between CART and tumor cells.To evaluate whether mice with FITC-CAR-T therapy related sCRS can berescued by using competitors which may displace EC17 from eitherFITC-CAR-T or FR+ tumor cells, 49 NSG mice bearing MDA-MB-231 tumors(150-250 mm3) were administered with excess FITC-CAR-T cells (8million), 36 of them were then dosed with 500 nmol/kg EC17 48 hours postCAR-T administration, 6 of them were not dosed with EC17 and were usedas “No EC17” control, and 7 of them were dosed with 260 umol/kg sodiumfluorescein (no EC17 but Fluorescein) to test its toxicity. One daylater, while the mice in the “No EC17” control group and “no EC17 butFluorescein” were healthy, mice dosed with EC17 started to show sCRS andwere divided into four groups. Each group was i.v. injected with 10umol/kg of Leucovorin, or 10 umol/kg folic acid, or 260 umol/kg sodiumfluorescein, or nothing as an un-rescued control. Those mice wereevaluated 10 hours after the rescue injection, and were found to havedifferent levels of severity of sCRS. Although all three rescued groupsshowed better recovery from sCRS compared to the un-rescued controlgroup, the levels of recovery in these rescue groups were different. Theorders of sCRS severity were (from worst to least): no rescuegroup>leucovorin rescue group>folic acid rescue group>sodium fluoresceinrescue group>no EC17 group. Mouse body weight changes were alsomonitored as the indication of toxicity. As shown in FIG. 29A-E, micerescued with fluorescein had the least body weight loss comparing to theother two rescue groups. To evaluate whether the rescue injectionsaffect the anti-tumor activity of FITC-CAR-T cells, these mice weredosed with 500 nmol/kg EC17 twice per week (days 9, 11, 15, 18, 22, 25,etc.) and the tumor size was monitored. As shown in FIG. 30A and FIG.30B, almost all mice were cured except 2 out of 9 mice in thefluorescein rescue group still had a tiny tumor left at day 36 post CARTinjection, indicating that a single dose of rescue reagents had littleeffect on the anti-tumor activity of FITC-CAR-Ts.

Example 33 Sodium Fluorescein Rescue

Sodium fluorescein as a rescue agent for mitigation of cytokine releasesyndrome in EC17/CAR-T antitumor therapy is shown.

Materials:

EC17 (folate-FITC, m.w. 873) was synthesized in house. Sodiumfluorescein (AK-FLUOR®, fluorescein injection, USP) was purchased fromPurdue Pharmacy.

In-Vivo Methods: Cell Line

MDA-MB-231 is a human triple-negative breast cancer (TNBC) cell linethat expresses a high level of the human FRa. THP1-FRβ is a CD33+CD123+human acute myeloid leukemia cell line stably expressing human FRβ. Thecells were grown respectively in a folate-free RPMI1640 medium (GibcoBRL) (FFRPMI) containing 5-10% heat-inactivated fetal calf serum (HIFCS)and maintained under a 5% CO₂ atmosphere using standard cell culturetechniques.

Mice

Female NSG™ (NOD.Cg-Prkdc^(scid) Il2rg^(tm1wjl)/SzJ, stock #005557) micewere purchased from The Jackson Laboratory (Bar Harbor, Me.) and usedwhen they reached ˜4 weeks of age. The mice were fed a folate-deficientdiet (TestDiet, St. Louis, Mo.) on the day of arrival.

Tumor Implantation

MDA-MB-231 tumors were generated by subcutaneous implantation ofcultured cells at 2×10⁶ in NSG mice.

CAR-T Cell Preparation

FITC-CAR-T cells were prepared as described previously. After culturingin-vitro for 12-20 days, they were frozen and stored at −80° C. in afreezing reagent containing 50% heat-inactivated AB+ human serum, 40% Tcell culture media, and 10% DMSO. Frozen CAR-T cells were quickly thawedat 37° C., washed twice with PBS, and used for animal injection.

EC17/CAR-T Therapy of Tumor-Bearing Mice

In general, EC17/CAR-T therapy initiated when mouse tumors reached˜200-250 mm³ and weekly EC17 doses at 500 nmol/kg started 2 days afterthe CAR-T administration. All EC17 doses were given towards the end ofday (˜3-4 PM) to allow cytokine release syndrome (CRS) to developovernight. Sodium fluorescein rescue at various doses (0.06-60 μmol/kg)was administrated after the first dose of EC17, when the animalsexperienced a severe CRS of grade 3-4 on a 0-5 grading scale (FIG. 31).Plasma samples at various time points (3-27 hours) post sodiumfluorescein rescue were collected for multiplex cytokine analysis.

Whole Blood Cell Analysis by Flow Cytometry

Plasma was removed from predetermined volumes of whole EDTA treatedblood with a 10-minute 4° C. spin at 3000 g and the resulting cellpellets were incubated with a 10-fold volume of room temperature 1×RBClysis solution [prepared from 10× stock; Biolegend, catalog #420301] for5 minutes, centrifuged at 400 g for 5 min, and the cell pellet waswashed in a 10-fold volume of ice cold phosphate buffered saline pH=7.4and filtered with a 40 μm nylon filter and then pelleted again. Theleukocyte pellets were then resuspended in flow cytometry stainingsolution [1% bovine serum albumin, 50 mg/mL human IgG (Equitech Bio, cat#SLH56-0001), 0.9% sodium azide in a phosphate buffered saline, pH=7.4]supplemented with both anti-mouse FcγIII/II receptor (CD16/CD32) block[clone 2.4G2; BD Bioscience, catalog #553142 at 1:100 (v/v) dilution]and anti-human Fc Block [BD Biosciences, catalog #564220 at 1:50 (v/v)dilution]. Leukocyte surface marker staining was performed with theaddition of the following fluorochrome conjugated monoclonal antibodiesadded to each sample for 20 minutes on ice in the dark: anti-humanCD45-APCeF780 [clone HI30, eBioscience #47-0459-42 at 1:20 (v/v)dilution], anti-human CD137-BV650 [clone 4B4-1, BD Bioscience #564092 at1:20 (v/v) dilution], anti-human CD8α-PECy7 [clone RPA-T8, BDBioscience, catalog #557746 at 1:20 (v/v) dilution], anti-humanCD4-Percpe710 [clone SK3, eBioscience catalog #46-0047-42 at 1:20 (v/v)dilution]. After leukocyte staining, cells were washed with PBS andresuspended in cold PBS containing 53,000 CountBright™ beads [Invitrogencatalog #C36950] and transferred to flow cytometry collection tubes.Flow cytometry data was collected on the Gallios flow cytometer (BeckmanCoulter, Brea, Calif.), where a minimum of 15,000 CountBright™ beadevents were collected in an attempt to collect enough leukocyte eventsfor an accurate count of infused CART cells in each mouse blood sample.Determination of the concentration of CAR T cells in each blood samplewas calculated according to Invitrogen's instructions. Briefly, CAR Tcells were identified as human CD45+ GFP+ events and were easilydistinguished and counted using the Kaluza™ flow cytometry software.CountBright™ beads were uniformly labeled with a fluorochrome notutilized in the antibody panel used to identify the CAR T cells and wereeasily distinguished from the leukocytes and bead events were counted.Because 53,000 CountBright™ beads were added to each sample tube, wecalculated the ratio of 53,000 total beads to bead events collected persample and set the bead ratio equivalent to the unknown number of CAR Tcells in each sample divided by the known number of CAR T cell eventscollected. Solving for the unknown gave us the number of CAR T cellsisolated from each blood sample of known volumes. The number of CAR Tcells in the circulation of each infused mouse was then represented onthe graphs as the total number of CART cells per 50 μL of whole bloodanalyzed. Statistical significance was determined by utilizing anunpaired, two-tailed, students t-test with significance set at p<0.05for comparisons between each of the three groups of mice.

Preparation of Single Cell Suspension of Tumor and Normal Tissues

Solid tumors (100-1000 mm³) were harvested, weighed, and minced intosmall pieces and then transferred into 50 mL tubes containing 20 mL of atumor digestion cocktail. The enzymatic tumor digestion cocktailconsisted of 0.5 mg/mL Collagenase IV (Sigma-Aldrich, Catalog #C5138),0.5 mg/mL Hyaluronidase (Sigma-Aldrich, Catalog #H3506) and 0.1 mg/mLDNase I (Sigma-Aldrich, Catalog #DN25) in serum-free andfolate-deficient RPMI1640 medium supplemented with antibiotics. Thetumor fragments were digested for one hour at 37° C. at 300 rpm on ahorizontal shaker. Afterwards, the tumor digest was centrifuged at 400×gfor 5 minutes and tumor cell pellet underwent a red blood cell lysisstep, was then washed with cold phosphate-buffered saline (PBS, pH 7.4)and finally filtered through a 40 μm nylon cell strainer.

Data and Results:

As shown in FIG. 31, effects of one-time sodium fluorescein rescue at 60μmol/kg on both cytokine production and CAR-T anti-tumor activityin-vivo were evaluated. On day 0, ˜10.4 million FITC-CAR-T cells wereadministered intravenously into MDA-MB-231 tumor bearing NSG mice.Approximately 48 hours after CAR-T cell infusion, mice were separatedinto 3 groups. The first group (#1) was not dosed with EC17 and servedas the CAR-T cell control, the second (#2) and the third (#3) groupswere intravenously injected with a single dose of EC17 (500 nmol/kg). At17 hours post the EC17 dose, mice in groups #2 and #3 that received EC17(500 nmol/kg) showed sCRS while mice in the CAR-T cell control group #1did not show any related toxicity. Group #2 then received a singleintravenous sodium fluorescein (60 μmol/kg) while group #3 was leftun-rescued. Seven hours after sodium fluorescein rescue, mice in group#2 rescued with 60 μmol/kg sodium fluorescein were recovering and scoredat a low grade 3 sCRS while mice without rescue in group #3 still had agrade 3 sCRS. Three satellite animals from each group were euthanized tocollect blood and organs for cytokine analysis and organ toxicityevaluation. Whole blood was obtained via cardiac puncture and collectedinto EDTA containing tubes. Twenty-seven hours after sodium fluoresceinrescue, mice rescued with 60 μmol/kg sodium fluorescein in group #2 wererecovering and sCRS scale decreased to grade 2, while mice withoutrescue in group #3 had worse sCRS (grade 3-4). At this time, 6 satellitemice from each group were euthanized for blood collection and organevaluation. The remaining mice were dosed with a single dose of 500nmol/kg EC17 every week if desired, and the EC17 dosing dates werelabeled in FIG. 36 as dashed vertical lines occurring after the notation“EC17”. Tumor volume and body weight changes were monitored 2-3 timesper week.

As shown in FIG. 36, although tumors in the CAR-T only group grewrapidly, tumors in mice dosed with 500 nmol/kg EC17 SIW kept growingslowly for about one week, and then started to shrink and disappearedeventually. Although it took a few more days for tumors in the rescuedgroups to start to shrink, no significant difference in tumor growthbetween the rescued group and non-rescued group was found. This findingsuggested that one dose of 60 μmol/kg sodium fluorescein did notinterfere with CAR-T anti-tumor activity in vivo. As shown in FIG. 36B,mice in the rescued group seemed to have less body weight loss comparedto those in the un-rescued group, indicating that 60 μmol/kg sodiumfluorescein rescue can reduce the CAR-T therapy related toxicity (shownas less body weight loss).

Organs from all three groups were also evaluated at 7 hours and 27 hourspost sodium fluorescein rescue and their weights were compared as shownin FIG. 32. As shown in FIG. 32A, 7 hours after rescue, lungs from micetreated with CAR-T and EC17 were swollen and heavier than lungscollected from mice in the CAR-T cell only group. As shown in FIG. 32B,27 hours after rescue, lung weights from the rescued group decreasedmore than that of the un-rescued group. Although no obvious weightdifferences in liver or kidneys were found between the rescued group andun-rescued group, organs in the rescued group looked healthier by visualexamination (less discoloring of liver and kidney, and less lung edema).For FIG. 32, lung edema was improved 27 hours after NaFL rescue.

CRS-associated cytokine levels were also measured to determine whetherrescue inactivates CAR-T cells and reduces cytokine production. Humancytokine levels in mouse plasma samples were measured using FACS-basedMulti-Analyte Flow Assay Kits (BioLegend) and ELISA-based cytokinedetection kits (ThermoFisher Scientific) by following the manufacturer'sinstructions. FIG. 33A-G showed cytokine levels 7 hours post rescue. ForFIG. 33, cytokine production in mouse blood was reduced in <7 hoursafter NaFL rescue. FIG. 34A-G show cytokine levels 27 hours post rescue.For FIG. 34, cytokine production in mouse blood was reduced in <7 hoursafter NaFL rescue. FIG. 35A-E show time dependent changes in cytokinelevels. For FIG. 35, there was a delay between cytokine levels in bloodand mouse overall condition (CRS scores). In summary, mice administeredwith CAR-T cells but without EC17 had a very low level of cytokines intheir blood, while mice dosed with EC17 had increased cytokine levels intheir blood, including IL-2, IFN-γ, TNF-α, IL-6, IL-10, GM-CSF, andIL-3. More importantly, cytokine levels in the mice rescued with 60μmol/kg sodium fluorescein were much lower than those in un-rescued mice(both 7 hours and 27 hours post rescue). The levels of some cytokines(e.g. IL-2, TNF-α, IL-3, GM-CSF, and IL-6) were decreased to normalrange 7 hours post rescue, while other cytokines (e.g. IFN-γ) decreasedto near normal range at 27 hours post rescue.

To evaluate whether a lower level of sodium fluorescein can also rescuemice under sCRS, the same rescue study was performed except that sodiumfluorescein was dosed at 0.06, 0.6, and 6 μmol/kg. As shown in FIG. 50,˜8.3 million frozen CAR-T cells were administered and sCRS was inducedwith a 500 nmol/kg EC17 dose. While mice without rescue showed increasedseverity of sCRS, mice rescued with sodium fluorescein showed adose-dependent reduction of sCRS severity (FIG. 50). In summary, micerescued with 6 μmol/kg sodium fluorescein recovered the fastest, whilemice rescued with 0.06 μmol/kg sodium fluorescein showed the slowestrecovery.

As shown in FIG. 51, rescue with one dose of 6 μmol/kg sodiumfluorescein didn't affect the anti-tumor activity of the EC17/CAR-T celltherapy (FIG. 51A, tumor growth curve), but the rescue reduced theEC17-dependent CAR-T toxicity (less initial body weight loss) (FIG.51B). As shown in FIG. 52, cytokine levels in mouse blood were alsodependent on the concentrations of sodium fluorescein used for rescue,and the median effective dose is about 0.6 μmol/kg with key cytokines(e.g. IL-2, TNF-α, IFN-γ, etc.) starting to respond as early as 3 hourspost rescue.

Enumeration of FITC CAR T Cells in the Blood

The experimental timeline is represented in FIG. 53A. On day 0,GFP+FITC-CAR T cells [clone 4M5.3] were removed from cryopreservation,thawed and then infused intravenously into MDA-MB-231 tumor bearing NSGmice at 10 million per mouse [tumors ˜250 mm³]. Approximately 48 hoursafter infusion, mice were separated into three groups to test theeffects of sodium fluorescein on the behavior of CAR T cells, in vivo,specifically in the circulation. The first group served as a no EC17/nofluorescein control (FIG. 53B-C). The second group was intravenouslyinjected with a single dose of EC17 [500 nmol/kg] to generate severecytokine release syndrome (sCRS) (FIG. 53B-C, red). The third group(FIG. 53B-C) received EC17 [500 nmol/kg] to generate sCRS but alsoreceived a single intravenous sodium fluorescein [60 μmol/kg]approximately 18 hours later to inhibit CAR T cell interaction withfolate receptor positive tumor cells. Twenty-seven hours after sodiumfluorescein rescue, mice were euthanized and whole blood was obtainedvia cardiac puncture and collected into EDTA containing tubes and thenblood leukocytes were prepared for analysis, according to the protocoldetailed in the methods section. Monoclonal antibodies specific forhuman surface markers, which do not cross react with mouse markers, wereutilized for flow cytometry analysis. Staining for anti-human CD45allows clear identification of human T cells circulating in the blood ofCART cell infused mice (FIG. 53B, y-axis, dot plots). Additionally,infused human T cells which were successfully transduced with the CARlentivirus construct were visualized by green fluorescence enabled bythe co-expression of cDNA also present in the CAR lentiviral constructthat codes for green fluorescent protein (FIG. 53B, x-axis, dot plot).Thus, by gating on human CD45+ GFP+ double positive events, we are ableto reliably distinguish and count the number of FITC-CAR expressinghuman T cells from either un-transduced human T cells or mouseleukocytes (FIG. 53B).

Human CAR T cells are present at high levels in the mouse circulationfour days after infusion into the control group of mice which have notreceived the CAR bridge molecule, EC17 (FIG. 53B, left dot plot).Interestingly in the group of mice which received one dose of EC17, veryfew CAR T cells are detected in the circulation, presumably because EC17has directed the CAR T cells to localize to the sites of antigen on thesurface of the tumor cells (FIG. 53B, middle dot plot). The shrinkage oftumors by CAR T cells that we routinely observe under this treatmentcondition, results in the production of elevated levels of the humaninflammatory cytokines, including TNFα and IFNγ, causing severe CRS inthese animals. Importantly when we dose these sick animals with 60μmol/kg sodium fluorescein, we not only reduce symptoms of sCRS, we alsoobserve that the CAR T cells reappear in the circulation (FIG. 53B,right dot plot). Thus, excess fluorescein may mediate release of the CART cells from the EC17 CAR bridge molecule that labels folate receptorpositive tumor cells. Upon release of CART cells from tumor cells,production of inflammatory cytokines which drive sCRS will cease, thusleading to rescue of the tumor bearing mice from death.

Activation of T cells through either a T cell receptor or chimericantigen receptor, is visualized by increased expression ofco-stimulatory surface receptors, including 4-1BB (CD137). Thisincreased expression of 4-1BB will last for several days after initialantigen activation of the T cell receptor or chimeric antigen receptor.Not surprisingly, upon characterization of circulating CAR T cells fromthe blood of mice infused with CAR T cells only, we observed very littleexpression of the surface activation marker, 4-1BB, on the surface ofless than 2% of the infused CAR T cells isolated from animals which didnot receive EC17 (FIG. 54). Interestingly, when we measured theactivation state of the circulating CAR T cells from animals whichreceived the CAR T cell infusion plus both EC17 and sodium fluoresceintreatments, the circulating CAR T cells express significant amounts of4-1BB consistent with their recent activation by EC17 within the tumor,two days prior to harvest (FIG. 54). Circulating CAR T cells from thesecond group of tumor-bearing mice which received the CAR T infusionplus EC17 treatment could not be reliably analyzed for 4-1BB expressiondue to their very low numbers in circulation (FIG. 53A-C).

Although sodium fluorescein at 60 μmol/kg is well below the establishedtolerated dose in human patients, knowledge of the minimum effectivedose of sodium fluorescein that rescues patients from sCRS infused withFITC CAR T cells and EC17, would be useful. As shown in FIG. 50 and FIG.55A, CAR-T infused animals were dosed with EC17 to induce sCRS and thenseparated into four different groups one day later. Three groupsreceived low doses of sodium fluorescein rescue at 0.06, 0.6 and 6μmol/kg. Notably, the highest sodium fluorescein dose used in this studywas 10-fold less than the dose given to the mice in FIG. 31. Animalsfrom the above dose groups were euthanized at 3 and 24 hours post sodiumfluorescein rescue so that circulating CAR-T cells in the blood could beenumerated (FIG. 55B-C). Interestingly, the number of circulating CARTcells in animals that received 0.06-6 μmol/kg sodium fluoresceintreatment increased as early as 3 hours post rescue (FIG. 55B). Thissuggests that injection of sodium fluorescein likely displaced CAR Tcells from their targets on FR+ tumor cells. Importantly, at 24 hourspost rescue, CAR T cell extravasation into the blood was increased in asodium fluorescein dose-dependent manner (FIG. 55C). These observationsshown in FIGS. 53-55 suggest that the behavior and localization of theFITC CAR-T cells can be modified to different degrees in animalsexperiencing severe CRS by giving low doses of sodium fluorescein.

Example 34 Previous Rescue Did not Affect EC17-Induced FITC-Car-TRe-Activation

To evaluate whether the rescue affects FITC-CAR-T function, 12 NSG micebearing MDA-MB-231 tumors (150-250 mm3) were administered with excessFITC-CAR-T cells (8 million). Nine mice were then dosed with 500 nmol/kgEC17 48 hours post CAR-T administration, and 3 mice were not dosed withEC17 and used as “CAR-T only” controls. While the mice in the “CAR-Tonly” control group were healthy, mice dosed with EC17 showed sCRS oneday later and were divided into three groups. One group of mice(CAR-T+EC17+FA) was i.v. injected with 10 umol/kg of folic acid, thesecond group of mice (CAR-T+EC17+NaFL) was i.v. injected with 260umol/kg of sodium fluorescein, while the third group (CAR-T+EC17) wasnot rescued. All mice were re-boosted with 500 nmol/kg EC17 six dayslater for FITC-CAR-T re-activation, and their blood samples werecollected 18 hours after EC17 re-boost for blood cytokine analysis.Human cytokine production is an indication of CAR-T activation. As shownin FIG. 37A-B the levels of human cytokines (e.g. IFN gamma, IL-2) inrescued mice (“CAR-T+EC17+FA” group and “CAR-T+EC17+NaFL” group) aresimilar to those in mice without rescue (“CAR-T+EC17” group). The dataindicate that the rescues did not affect EC17-induced CAR-Tre-activation.

Example 35 Cytokine Production in Blood and Body Weight Loss are Car-TDose Dependent

To evaluate whether the cytokine production in mouse blood is correlatedwith CAR-T number in mice, 15 NSG mice bearing MDA-MB-231 tumors(250-500 mm3) were dosed with 500 nmol/kg of body weight of EC17 andthen divided into three groups. Four hours later, each group wasadministered with 2, 5 or 12.5 million FITC-CAR-T cells respectively.Mice in the three groups were then dosed with a second dose of 500nmol/kg EC17 24 hours post CAR-T administration, and their blood sampleswere collected 48 hours later (administration schedule is shown in FIG.38A). As shown in FIG. 38B, mice administered with 12.5 million CAR-Tcells showed the most body weight loss while the mice with 2.5 millionCAR-T administration showed the least body weight loss. The productionof cytokines (e.g. human IL-2, human IFN gamma, human TNF alpha andhuman IL-10) is correlated with the number of CAR-T cells administered(FIG. 39A-D). With the increase of CAR-T cells in mice, the productionof cytokines increases and the body weight loss also increases.

Example 36 FITC-Car-T Cell Proliferation In Vivo is EC17 Dose Dependent

To evaluate whether the bridge dose can control CAR-T proliferation invivo, NSG mice bearing MDA-MB-231 tumors (250-500 mm3) were divided into4 groups and dosed with 0, 5, 50, or 500 nmol/kg of body weight of EC17respectively (as shown in FIG. 40A). Four hours later, the four groupswere administered with 5 million FITC-CAR-T cells which were cultured invitro for 11 days, while one group of mice pre-dosed with 500 nmol/kgEC17 was not dosed with CAR-T cells and was used as a “No CAR-Tcontrol”. Two days later, mice in all five groups were dosed withvarious levels of EC17 as indicated in FIG. 40B. While mice in the “NoCAR-T dose” group showed little CRS related syndrome, mice dosed with 5million CAR-T cells showed EC17 dose-dependent CRS 3 days post CAR-Tadministration. Blood samples were then collected 16 hours post thesecond EC17 dose and analyzed for CAR-T numbers in blood circulation(FIG. 40B). As shown in FIG. 40B, in comparison to mice dosed with 0nmol/kg EC17, mice dosed with 5 nmol/kg EC17 had less CAR-T cells intheir blood circulation, probably due to the EC17-dependent CAR-T celltrafficking to tumor tissues which removed CAR-T cells from the bloodcirculation. Importantly, mice administered with the same amount ofCAR-T cells but dosed with 50 or 500 nmol/kg EC17 had more CAR-T cellsin their blood circulation. The interpretation of this finding is thatCAR-T cells proliferated more in mice dosed with 50 or 500 nmol/kg EC17than in mice dosed with 5 nmol/kg EC17, so that the CAR-T counts inblood circulation were higher.

To further confirm that FITC-CAR-T proliferation is EC17 dose-dependent,we also evaluated CAR-T proliferation in vivo when CAR-Ts were givenmore time to settle down and proliferate. For this purpose, we examinedCAR-T cell number in mice which were administered with CAR-T cells sixdays earlier and four doses of EC17 had been given to boost CAR-Tproliferation in vivo. NSG mice bearing MDA-MB-231 tumors (250-500 mm3)were divided into 4 groups and dosed with 0, 5, 50, or 500 nmol/kg ofbody weight of EC17 respectively (as shown in FIG. 41A). Four hourslater, all mice were administered with 5 million FITC-CAR-T cells whichwere cultured in vitro for 18 days. Various levels of EC17 were thendosed at days 1, 3, 5 post CAR-T administering to boost CAR-Tproliferation. Mouse blood samples were collected 24 hours post the lastEC17 dose, CAR-T cells in blood were stained with anti-human CD45antibody and counted by FACS. As shown in FIG. 41B, CAR-T count was thelowest in mice without EC17 dose, increased in mice with the 5 nmol/kgEC17 dose, reached the highest in mice dosed with 50 nmol/kg EC17, andstarted to decrease when the EC17 dose was 500 nmol/kg probably due tothe oversaturation of EC17 and consequent dissociation of CAR-T cellsfrom tumor cell. In summary, EC17 dose-dependent FITC-CAR-Tproliferation in mice bearing MDA-MB-231 tumors has been observed at twodifferent time points, indicating that control of EC17 dose level cancontrol FITC-CAR-T proliferation in vivo.

Example 37 FITC-Car-T does not Proliferate and Cause Toxicity in NaïveMice

The evaluation of FITC-CAR-T proliferation and related toxicity in bothnaïve mice and mice bearing FR+ tumor xenografts was tested. To evaluatewhether FITC-CAR-T proliferation in vivo is dependent on theco-existence of the bridge (e.g. EC17) and the tumor antigen (e.g.folate receptor), FITC-CAR-T proliferation in vivo was compared in naïvemice and mice bearing FR+ tumor xenografts, either with or without EC17.5-8 million CAR-T cells (as indicated in FIGS. 42 and 43) wereadministered (i.v.) into naïve mice without tumors and mice bearing FR+tumor xenografts (80-200 mm3). 500 nmol/kg EC17 was dosed 4 hours beforeand three times per week post CAR-T administration, if desired. Micewere monitored for body weight changes and CAR-T cell count in bloodcirculation; some mice were also euthanized weekly to evaluate organs.As shown in FIG. 42, naïve mice without tumor burden did not show anyapparent body weight loss (toxicity), no matter whether EC17 was dosedor not. On the other hand, mice bearing FR+ MDA-MB-231 tumors showedEC17-dependent body weight loss: the mice dosed with EC17 three timesper week had body weight loss in the first 10 days, whereas mice withoutEC17 dose did not have body weight loss (FIG. 42). CAR-T cell count inblood samples was also compared to evaluate CAR-T proliferation. Asshown in FIG. 43A, FITC-CAR-T did not proliferate in naïve mice dosedwith either 5 or 8 million FITC-CAR-T cells, no matter whether EC17 wasdosed or not. On the contrary, FITC-CAR-T cells in the mice implantedwith FR+ HEK-FRa xenografts had rapid proliferation when 500 nmol/kgEC17 was given three times per week. Since the enlargement of spleensize is another indicator for CAR-T proliferation in vivo, spleen sizewas also measured as shown in FIG. 43B. Naïve mice without tumor burdendid not show much spleen enlargement (indication of no CAR-Tproliferation), no matter whether EC17 was dosed or not. On the otherhand, mice bearing FR+ MDA-MB-231 tumors had enlarged spleens when theywere dosed with 500 nmol/kg EC17 three times per week. In conclusion,FITC-CAR-T cells do not proliferate or cause toxicity in naïve mice evenin the presence of EC17, but proliferate quickly in FR+ tumor bearingmice when EC17 is also administered.

For FIG. 42, the MDA-MB-231 s.c. model was used. For FIG. 43A, theHEK-FRa s.c. xenograft model was used. For FIG. 43B, the MDA-MB-231 s.c.model was used.

Results show that FITC-CAR-T is not active in naïve mice without a tumorburden. CAR-T cells were i.v. injected into naïve mice (8 million permouse) and mice bearing MDA-MB-231 tumors (5 million per mouse). 500nmol/kg EC17 was administered three times per week when desired (shownin figure label). After one week, mouse blood samples were collected inEDTA coated tubes and centrifugated at 3000 g for 15 min at 4° C., andthe plasma was isolated and stored at −20° C. until analysis.

Cytokine levels including IFN were measured using LEGENDplex humancytokine panel kits (BioLegend, San Diego, Calif.) according to themanufacturer's instructions. Plasma samples were diluted with AssayBuffer, and then mixed with Capture beads immobilized with the antibodydirected to the analyzed cytokine. After 2 hours incubation at roomtemperature with shaking, biotinylated Detection antibody to theanalyzed cytokine was added and incubated for one more hour at roomtemperature with shaking. Phycoerythrin (PE) labeled streptavidin wasthen added to bind with biotin on the Detection antibody, and FACS wasused to read the signal of PE on the binding complex (captureantibody-cytokine-detection antibody). The intensity of PE isproportional to the level of analyzed cytokine. A series of cytokinesolutions with known concentrations were measured at the same time andused as standards to quantitate the cytokine levels in the analyzedsamples.

As shown in FIG. 44, cytokine production (CAR-T activity) is dependenton the presence of the tumor. CAR-T cells are not active in naïve miceeven when mice were dosed with 500 nmol/kg EC17 three times per week.

Example 38 Characterization of Bridge Molecules

To examine the ability of bridge molecules to bind anti-fluorescein scFvon CAR T cells, a competitive binding assay was developed. Measurementof the fluorescein signal from CAR T cell bound bridges could not beused due to the overlap of its fluorescence with that of the GFPexpressing CAR T cells. For this purpose, FITC-Alexa647 (10 nM) wasallowed to bind anti-fluorescein CAR T cells in the absence or presenceof excess (1 μM) competing ligand (i.e. FITC-folate, FITC-DUPA,FITC-CA9) for 1 h at room temperature. After incubation,anti-fluorescein CAR T cells were washed 3× with PBS to remove unboundedFITC-Alexa647, and the washed cells were analyzed for Alexa647fluorescence by flow cytometry.

All of the bridge molecules tested (i.e. FITC-folate, FITC-DUPA,FITC-CA9) were able to bind to the CAR-expressing T cells as establishedby the ability of the bridges to competitively block FITC-Alexa 647binding to the engineered T cells (FIG. 45).

Example 39 The Universal Car T Cell can Eliminate Various Cancer CellsExpressing Orthogonal Antigens Upon Addition of Antigen Matched BridgesIn Vitro

Each human cancer cell line was seeded at a density of 10⁴ cells/100 μlmedia into 96 well plates and grown overnight. Anti-fluorescein CAR Tcells were added to each well in the absence or presence of bridgemolecules. After co-incubation for 6-24 hours, plates were centrifugedat 350×g for 10 min to remove debris and supernatants were analyzed forlactate dehydrogenase release (cell death analysis) using Pierce™ LDHcytotoxicity assay kit (Thermo Fisher Scientific, MA) and interferon γ(IFNγ) levels using a human IFNγ ELISA kit (Biolegend, CA).

In order to evaluate specificity and universality of anti-fluoresceinCAR T cells, anti-fluorescein CAR T cells were co-incubated with HEKcells expressing either FR, PSMA, CA9 or NK1R in the presence or absenceof bridge molecules respectively. As shown in FIG. 46, panel A,anti-fluorescein CAR T cells can eliminate target HEK cells when antigenmatched bridge molecules are present. Universality of anti-fluoresceinCART cells with multiple bridge molecules was further evaluated withvarious human cancer cell lines that express either the folate receptor(KB, MDA-MB-231 and OVCAR3), PSMA (LNCaP and 22RV1), or CA9 (HT29,SK-RC-52, A549 and SKOV3) (FIG. 46B). Lysis was specific for the bridgetested and the corresponding tumor expressing the receptor for thebridge tumor ligand.

Example 40 Relationship Between Concentration of Bridge Molecules andthe Universal Car T Cell's Anti-Tumor Activity

Each human cancer cell line was seeded at a density of 10⁴ cells/100 μlmedia into 96 well plates and grown overnight. Anti-fluorescein CAR Tcells were added to each well in the absence or presence of bridgemolecules. After co-incubation for 6-24 hours, plates were centrifugedat 350×g for 10 min to remove debris and supernatants were analyzed forlactate dehydrogenase release (cell death analysis) using Pierce™ LDHcytotoxicity assay kit (Thermo Fisher Scientific, MA) and interferon γ(IFNγ) levels using human IFNγ ELISA kit (Biolegend, CA).

As shown in FIG. 47, all of the bridge molecules behave similarly. Asconcentration of bridges was increased, CAR T cell anti-tumor activitywas also increased. However, if higher concentrations of bridgemolecules were added, CAR T cell anti-tumor activity was then reduced(i.e. a bell-shaped dose response). This result is due to the fact thatbridge molecules cannot form a bridge between CAR T cells and cancercells when higher concentrations of bridge molecules are added sincehigher concentrations of bridge molecules can saturate both receptors onCAR T cells and cancer cells, respectively.

Example 41 The Universal Car T Cell can Eliminate Various Cancer CellsExpressing Orthogonal Antigens Upon Addition of Antigen Matched BridgeMolecules In Vivo

Multiple clones of MDA-MB-231 expressing orthogonal antigens weregenerated by using a lentiviral gene delivery system. ImmunodeficientNSG mice (Jackson Laboratory, ME) were implanted subcutaneously witheach of MDA-MB-231 cells expressing either the folate receptor, PSMA, orCA9 and were injected intravenously with CAR T cells and then bridgemolecules (i.e. either FITC-folate, FITC-DUPA or FITC-CA9) when tumorsreached ˜100 mm3 in size. Tumors were measured every other day withcalipers, and tumor volume was calculated according to the equation:Tumor volume=½(L×W2) where L is the longest axis of the tumor and W isthe axis perpendicular to L.

In order to evaluate whether each bridge can induce anti-tumor activityof the anti-fluorescein CAR T cells, multiple clones of MDA-MB-231expressing either the folate receptor, PSMA or CA9 were generated. Asshown in FIG. 48, anti-fluorescein CAR T cells could eliminate tumorcells expressing orthogonal antigens when antigen matched bridges wereinjected. Taken together, these data demonstrated that a singleanti-fluorescein CAR T cell could eliminate multiple tumors by injectingantigen-matched bridges to target antigens.

Example 42 The Universal Car T Cell can Eliminate Two Tumors Via aCocktail of Bridge Molecules In Vivo (Two Separated Tumor Model)

In order to evaluate whether a cocktail of bridge molecules caneliminate two tumors expressing orthogonal antigens, we established twodifferent tumor models. As a first tumor model, each of PSMA+ MDA-MB-231and CA9+ MDA-MB-231 were implanted into NSG mice at two differentlocations (i.e. right flank: CA9+ MDA-MB-231, left flank: PSMA+MDA-MB-231). For the second tumor model, PSMA+ MDA-MB-231 and CA9+MDA-MB-231 were pre-mixed at a 1:1 ratio and implanted at one location.As shown in panels A and B of FIG. 49, complete elimination of bothtumor cells expressing either PSMA or CA9 can be achieved when bothbridges (i.e. cocktail of FITC-PSMA and FITC-CA9) were injected.However, a tumor expressing unmatched antigen (i.e either PSMA or CA9)continuously grew if only one of the bridges (i.e. either FITC-DUPAalone or FITC-CA9 alone) was infused. Taken together, these datademonstrate that anti-fluorescein CAR T cells can overcome tumorheterogeneity by utilizing a cocktail of bridge molecules.

PSMA+ MDA-MB-231 and CA9+ MDA-MB-231 were implanted into NSG mice(Jackson Laboratory, ME) either at two different locations (i.e. rightflank: PSMA+ MDA-MB-231, left flank: CA9+ MDA-MB-231) or one locationafter two tumor cells were pre-mixed (i.e. 50% of PSMA+ MDA-MB-231 and50% of CA9+ MDA-MB-231). When tumors reached ˜100 mm3 in size,anti-fluorescein CAR T cells (8×10⁶) were injected plus FITC-DUPA,FITC-CA9 or both. Tumors were measured every other day with calipers,and tumor volume was calculated according to the equation: Tumorvolume=½(L×W2) where L is the longest axis of the tumor and W is theaxis perpendicular to L. Results are shown in FIGS. 49A and 49B.

Synthesis of Bridge Molecules FITC-Folate

Folate-γ-ethylenediamine was coupled to fluorescein isothiocyanate(FITC) isomer I (Sigma-Aldrich) in anhydrous dimethylsulfoxide (DMF) inthe presence of tetramethylguanidine and diisopropylamine. The crudeproduct was loaded onto an Xterra RP18 preparative HPLC column (Waters)and eluted with gradient conditions starting with 99% 5 mM sodiumphosphate (mobile phase A, pH7.4) and 1% acetonitrile (mobile phase B)and reaching 90% A and 10% B in 10 min at a flow rate of 20 mL/min.Under these conditions, the FITC-folate main peak typically eluted at27-50 min. The quality of the FITC-folate fraction was monitored byanalytical reverse-phase HPLC with a UV detector. Fractions with greaterthan 98.0% purity (LCMS) were lyophilized to obtain the finalFITC-folate product.

FITC-DUPA

DUPA-FITC was synthesized by solid phase methodology as follows.Universal NovaTag resin (50 mg, 0.53 mM) was swollen withdichloromethane (DCM) (3 mL) followed by dimethylformamide (DMF, 3 mL).A solution of 20% piperidine in DMF (3×3 mL) was added to the resin, andargon was bubbled for 5 min. The resin was washed with DMF (3×3 mL) andisopropyl alcohol (i-PrOH, 3×3 mL). After swelling the resin in DMF, asolution of DUPA-(OtBu)-OH (1.5 equiv), HATU (2.5 equiv) and DIPEA (4.0equiv) in DMF was added. Argon was bubbled for 2 h, and resin was washedwith DMF (3×3 mL) and i-PrOH (3×3 mL). After swelling the resin in DCM,a solution of 1 M HOBt in DCM/trifluoroethane (TFE) (1:1) (2×3 mL) wasadded. Argon was bubbled for 1 h, the solvent was removed and resin waswashed with DMF (3×3 mL) and i-PrOH (3×3 mL). After swelling the resinin DMF, a solution of Fmoc-Phe-OH (2.5 equiv), HATU (2.5 equiv) andDIPEA (4.0 equiv) in DMF was added. Argon was bubbled for 2 h, and resinwas washed with DMF (3×3 mL) and i-PrOH (3×3 mL). The above sequence wasrepeated for 2 more coupling steps for addition of 8-aminooctanoic acidand fluorescein isothiocyanate or rhodamine B isothiocyanate. Finalcompound was cleaved from the resin using a trifluoroacetic acid(TFA):H₂O:triisopropylsilane:cocktail (95:2.5:2.5) and concentratedunder vacuum. The concentrated product was precipitated in diethyl etherand dried under vacuum. The crude product was purified using preparativeRP-HPLC [λ=488 nm; solvent gradient: 1% B to 80% B in 25 min, 80% B wash30 min run; A=10 mM NH4OAc, pH=7; B=acetonitrile (ACN)]. ACN was removedunder vacuum, and pure fractions were freeze-dried to yield DUPA-FITC asa brownish-orange solid. RP-HPLC: tR=8.0 min (A=10 mM NH4OAc, pH=7.0;B=ACN, solvent gradient: 1% B to 50% B in 10 min, 80% B wash 15 minrun). 1H NMR (DMSO-d6/D2O): δ 0.98-1.27 (ms, 9H); 1.45 (b, 3H);1.68-1.85 (ms, 11H); 2.03 (m, 8H); 2.6-3.44 (ms, 12H); 3.82 (b, 2H);4.35 (m, 1H); 6.53 (d, J=8.1 Hz, 2H), 6.61 (dd, J=5.3, 3.5 Hz, 2H); 6.64(s, 2H); 7.05 (d, J=8.2 Hz, 2H), 7.19 (m, 5H); 7.76 (d, J=8.0 Hz, 1H);8.38 (s, 1H). FIRMS (ESI) (m/z): (M+H)+ calcd for C51H59N7O15S,1040.3712, found, 1040.3702. UV/vis: λ max=491 nm.

FITC-CA9

In a 50 mL round bottom flask CA9 ligand (53.6 mg, synthesized in lab)was dissolved in a desired amount of N,N-Dimethylformamide (DMF) (2-3mL) using a Teflon magnetic stir bar. Ambient air was removed usingvacuum and replaced with nitrogen gas, this was done in three cycles.Then the round bottom was kept under constant nitrogen gas. To theflask, 28.9 mg of N-(3-Dimethylaminopropyl)-N′-ethylcarbodiimidehydrochloride (EDC) was added followed by 21.6 mg 1-Hydroxybenzotriazolehydrate (HOBt) and 18.9 μL of Boc-PEG2-NH2 (purchased from SigmaAldrich). 5.4 μL of triethylamine (TEA) was added last and the reactionwas allowed to stir overnight. The reaction mixture was purified usingHPLC and confirm with UHPLC-MS (target m/z of 831). Acetonitrile wasremoved using high vacuum rotary evaporation and place on lyophilizerfor 48 hours. Deprotection of Boc was done with 1:1 TFA:DCM for 30minutes. TFA/DCM was removed using high vacuum rotary evaporationfollowed by 30 minutes on high vacuum. The compound was then dissolvedin DMF and combined with 5 molar equivalents ofN,N-Diisopropylethylamine (DIPEA). 16 mg of fluorescein isothiocyanate(purchased from Life Technologies) was added to the solution and stirredfor 1 hour. Reaction mixture was purified by HPLC and target compoundwas confirmed with UHPLC-MS (target m/z of 1120). The samples was placedon lyophilizer for 48 hours and store compound at −20° C.

FITC-NK1R

To a stirred solution of NK-1 (0.02 g, 0.0433 mmol, 1.0 eq.),O-(2-Aminoethyl)-O′[2-(Boc-amino)ethyl]decaethylene glycol(BocNH-PEG11-NH2) (Sigma, 0.0336 g, 0.0521 mmol, 1.2 eq.),Benzotriazol-1-yl-oxytripyrrolidinophosphonium hexafluorophosphate(PYBOP) (0.027 g, 0.0521 mmol, 1.2 eq.) in dry CH2Cl2 was addedN,N-Diisopropylethylamine (DIPEA) (0.076 mL, 0.4338 mmol, 10 eq.) underargon at room temperature. The reaction progress was monitored by LCMSand purified by preparative RP-HPLC (Waters, XBridge™ Prep C18, 5 μm;19×100 mm column, mobile phase A=20 mM ammonium acetate buffer, pH 7,B=acetonitrile, gradient 10-100% B in 30 min, 13 mL/min, λ=220 nm, 254nm). The pure fractions were collected, evaporated all organic solventsand lyophilized the sample for 48 h to furnish the NK1-PEG11-NHBoc.Yield: 40.13 mg (97%). To the NK1-PEG11-NHBoc (0.0165 g, 0.015 mmol) indry CH2Cl2 was added trifluoroacetic acid (TFA, 20 eq.) and reactionmixture was stirred for 4 h at r.t. The excess of TFA was removed,diluted with water and extracted using CH2Cl2 (3×5 mL). The combinedorganic layers were washed with brine, dried (Na2SO4) and concentrated.The residue obtained was dried under vacuum and used for next-stepwithout further purification. A stirred solution of NK1-PEG11-NH2 (0.008g, 0.0081 mmol, 1.0 eq.), Fluorescein isothiocyanate (FITC) (Sigma,0.0037 g, 0.0097 mmol, 1.2 eq.) in dry dimethylsulfoxide (DMSO, 0.3 mL)was added diisopropylethyl amine (0.0028 mL, 0.0162 mmol, 2.0 eq.) atroom temperature under argon. The reaction progress was monitored byLCMS and purified by preparative RP-HPLC (Waters, XBridge™ Prep C18, 5μm; 19×100 mm column, mobile phase A=20 mM ammonium acetate buffer, pH7, B=acetonitrile, gradient 10-100% B in 30 min, 13 mL/min, λ=280 nm).The pure fractions were collected, evaporated all organic solvents andlyophilized the sample for 48 h to furnish the NK1-PEG11-FITC (5).Yield: 8.54 mg (77%).

The NK-1 compound was synthesized by a two-step procedure starting frombase ligand, which was prepared by using a literature procedure. (Ref:DESIGN AND DEVELOPMENT OF NEUROKININ-1 RECEPTOR-BINDING AGENT DELIVERYCONJUGATES, Application Number: PCT/US2015/44229, incorporated herein byreference in its entirety).

Example 43 Control of Cytokine Storm with Bridge Molecules

Regulation of the intensity of a CAR T cell-mediated cytokine releasesyndrome with the use of low molecular weight bridge molecules is shown.Four novel strategies for eliminating a toxic and sometimes lethalcytokine release syndrome while simultaneously improving CAR T celltherapeutic efficacy are described.

Cell Lines and T Cells

Folate receptor positive cell lines (e.g. KB and MDA-MB-231) weremaintained in folic acid free RPMI 1640 (Gibco, Ireland) containing 10%heat-inactivated fetal calf serum and 1% penicillin-streptomycin in 5%CO₂ at 37° C. Peripheral blood mononuclear cells (PBMC) were isolated byFicoll density gradient centrifugation (GE Healthcare Lifesciences, USA)of fresh human blood from healthy volunteers (IRB #: 1702018875). PureCD3⁺ T cells were isolated from PBMCs using EasySep™ Human T CellIsolation Kit (STEM CELL technologies, Canada) and then cultured inTexMACS™ medium (Miltenyi Biotech Inc, CA) containing 1% penicillin andstreptomycin sulfate in the presence of human IL-2 (100 IU/ml, MiltenyiBiotech Inc, CA). T cells were divided and the above media was changedevery 2-3 days.

Generation of Lentiviral Vector Encoding Anti-Fluorescein CAR Gene

An overlapping PCR method was used to generate the CAR constructcontaining a single chain fragment variable (scFv) against fluorescein.The coding sequence for the scFv was synthesized (GeneScript, NJ) froman affinity optimized sequence of a human anti-fluorescein antibody,4M5.3 (Kd=270 fM, 762 bp) [21]. Sequences encoding the human CD8α signalpeptide (SP, 63 bp), the hinge and transmembrane regions of CD8α (249bp), the cytoplasmic domain of 4-1BB (CD137, 141 bp) and the cytoplasmicdomain of CD3ζ chain (336 bp) (purchased from GeneScript) were fusedwith the anti-fluorescein scFv by overlapping PCR. The resulting CARconstruct (1551 bp) was inserted into EcoRI/NotI cleaved lentiviralexpression vector pCDH-EF1-MCS-(PGK-GFP) (System Biosciences, CA) andexpanded/purified using PureLink Hipure plasmid midiprep kit(Invitrogen, CA). The sequence of the CAR construct in lentiviral vectorwas confirmed by DNA sequencing (Purdue Genomic Core Facility, IN).

Production of Lentivirus and Human T Cell Transduction

To prepare lentivirus containing the anti-fluorescein (scFv) CAR, 293TNpackaging cell line was co-transfected with lentiviral vector encodinganti-fluorescein scFv CAR and a 2^(nd) generation mixture of packagingplasmids (Cellecta, CA). After 24 and 48 hours transfection,supernatants containing lentivirus encoding the CAR gene were harvestedand virus particles were concentrated using a standard polyethyleneglycol virus concentration method (Clontech, CA).

Transduction of Human T Cells with CAR-Expressing Lentivirus

Isolated T cells (see above) were activated using Dynabeads coupled toanti-CD3/CD28 antibodies (Life Technologies, CA) for 12-24 hours in thepresence of human IL-2 (100 IU/ml) and then transduced with theaforementioned lentivirus encoding both GFP and the anti-fluorescein CAR[50]. After 72 hours transduction, T cells were analyzed for GFPfluorescence by flow cytometry to determine transduction efficiency.

Binding of Bridge to CAR T and Cancer Cell Receptors

Fluorescein-folate (FITC-folate) and fluorescein-PSMA (FITC-DUPA) weresynthesized as previously described. To examine the ability of thesebridge molecules to bind anti-fluorescein scFv on CAR T cells, acompetitive binding assay had to be developed, because measurement ofthe fluorescein signal from CAR T cell bound bridge could not be useddue to the overlap of its fluorescence with that of the GFP expressingCAR T cells. For this purpose, FITC-Alexa647 (10 nM) was allowed to bindanti-fluorescein CAR T cells in the absence or presence of excess (1 μM)competing ligand (i.e. FITC-folate) for 1 h at room temperature. Afterincubation, anti-fluorescein CAR T cells were washed 3× with PBS toremove unbounded FITC-Alexa647, and the washed cells were analyzed forAlexa647 fluorescence by flow cytometry. For analysis of FITC-folate tobinding to folate receptor, FR positive KB cells were incubated withFITC-folate (100 nM) in the absence or presence of excess (10 μM) freefolate (i.e. as a competitive ligand). After washing samples with PBS (3times), samples were analyzed by flow cytometry for fluorescein-folatebinding.

Analysis of Anti-Tumor Activity of Anti-Fluorescein CAR T Cells In Vitro

FR positive cancer cell lines (e.g. KB or MDA-MB-231 cells) were seededat density of 10⁴ cells/100 μl media into 96 well plates and grownovernight. Anti-fluorescein CAR T cells were added to each well in theabsence or presence of bridge molecules. After co-incubation for 6-24hours, plates were centrifuged at 350×g for 10 min to remove debris andsupernatants were analyzed for lactate dehydrogenase release (cell deathanalysis) using Pierce™ LDH cytotoxicity assay kit (Thermo FisherScientific, MA) and interferon γ (IFNγ) levels using human IFNγ ELISAkit (Biolegend, CA), while pellets were either evaluated for CAR T cellactivation by staining with anti-human CD69 APC (Clone: FN50, Biolegend,CA) or examined for CAR T cell proliferation by culturing for 5 days inTexMACS™ medium (Miltenyi Biotech Inc, CA) containing 1% penicillin andstreptomycin sulfate and quantitating by flow cytometry using theintrinsic GFP fluorescence and staining with anti-human CD3 APC antibody(Clone:HIT3a, Biolegend, CA).

Analysis of Anti-Tumor Activity of Anti-Fluorescein CAR T Cells In Vivo

Immunodeficient NSG mice (Jackson Laboratory) were implantedsubcutaneously with MDA-MB-231 cells and injected intravenously with CART cells and then fluorescein-folate (as indicated) when tumors reached˜100 mm³ in size. Mice were maintained on folic acid-deficient diet(TD.95247, Envigo) in order to reduce the level of folic acid in mice toa physiological levels found in humans. Tumors were measured every otherday with calipers, and tumor volume was calculated according toequation: Tumor volume=½(L×W²) where L is the longest axis of the tumorand W is the axis perpendicular to L. Mouse blood was also collected tomeasure cytokine levels (e.g. IL-2, IL-6, IFNγ, and TNFα) usingLEGENDplex bead-based immunoassay (Biolegend, CA) and systemic toxicitywas monitored by measuring body weight loss. All animal care and usefollowed by National Institutes of Health (NIH) guidelines and allexperimental protocols were approved by the Purdue Animal Care and UseCommittee.

Statistical Analyses

The GraphPad Prism version 7 software (Graphpad, CA) was used forgeneration of all graphs and statistical analyses. All figures reportedmean±s.e.m values unless otherwise noted. ANOVA was used for multiplecomparisons.

Construction and Characterization of an Anti-Fluorescein CAR and itInteraction with a Fluorescein-Folate Bridge Molecules

FIG. 63A shows the structure of a fluorescein-folate bridge(FITC-folate). On the structure's left side resides the vitamin, folicacid, which was selected as a representative tumor targeting ligandbecause its receptor (folate receptor alpha, FRa) is over-expressed on˜40% of human epithelial tumors, but largely absent or inaccessible innormal tissues. On the right side lies fluorescein, which was chosen asa ligand for CAR engagement because a human anti-fluorescein antibodywith femtomolar affinity for fluorescein had already been described inthe literature. FIG. 63B outlines construction of the CAR (SEQ ID NOS: 1and 2) that was used to direct the cytotoxic CAR T cell to kill cancercells. The anti-fluorescein scFv from the aforementioned antibody wasfused to the CD3 zeta chain of a T cell receptor that had previouslybeen engineered to contain the intracellular domain of CD137 (4-1BB).Insertion of this CAR construct into a lentiviral vector[pCDH-EF1-MCS-(PGK-GFP)] allowed transduction of pre-activated human Tcells with 50-60% efficiency, as shown by the fraction of T cellsstaining positive for GFP (a fluorescent marker co-transduced with theCAR) (FIG. 63C). FIG. 63D further demonstrates that the CAR-expressing Tcells bind fluorescein-folate, as established by the ability offluorescein-folate to competitively block FITC-Alexa 647 binding to theengineered T cells.

With the ability to generate anti-fluorescein CAR T cells established,the killing potency of the engineered T cells was examined by evaluatingthe ability of the fluorescein-folate bridge molecule to mediate CAR Tcell elimination of tumor cells in culture. As shown in FIG. 64A,fluorescein-folate was found to bind to FR positive KB cells (a cervicalcancer cell line) as demonstrated by i) the shift in KB cellfluorescence upon addition of fluorescein-folate, and ii) the blockadeof this shift upon competition with excess free folic acid. CAR Tcell-mediated KB cell killing was then shown by demonstrating lysis ofKB cells in the presence but not in the absence of the bridge. Thus, asshown in FIG. 64B, lysis of the cancer cells was observed when both CART cells and fluorescein-folate were present, but not whenfluorescein-folate was absent (PBS) or when fluorescein-DUPA (a bridgemolecule that bridges to prostate cancer cells but not to KB cells) waspresent. Moreover, anti-fluorescein CAR T cells were capable oferadicating KB cells at multiple effector to target cell ratios, butagain only when fluorescein-folate was present (FIG. 64C). Analysis ofconcurrent production of IFNγ provided further evidence that theanti-fluorescein CAR T cell's tumoricidal activity was only triggered byaddition of the correct fluorescein-folate bridge (FIG. 64D), andrelated experiments established that both anti-fluorescein CAR T cellproliferation and CAR T cell activation were also dependent on additionof the correct bridge (FIG. 64, panels E and F). Taken together, thesedata demonstrate that anti-fluorescein CAR T cell functionality isinextricably dependent on the availability of the correct tumor-specificbridge to mediate engagement of the CAR T cell with the desired cancercell.

Identification of Conditions that Promote a Cytokine Release Syndrome(CRS)

To explore whether manipulation of the duration, concentration orfrequency of bridge dosing might be exploited to control a CRS, it wasfirst necessary to identify conditions where an easily measurable CRSwould reproducibly occur. After exploration of a number of human tumorxenograft models, it was found that NSG mice implanted with FR positiveMDA-MB-231 cells (a human triple negative breast cancer cell line)reliably displayed a potent CRS upon administration of anti-fluoresceinCAR T cells plus fluorescein-folate. Thus, as shown in FIG. 65A, bodyweight loss of −8% was observed in tumor-bearing mice within 4 days ofinjection of 5×10⁶ CART cells plus 500 nmoles/kg fluorescein-folate;i.e. indicating occurrence of a CRS. In contrast, no weight loss wasobserved in similar tumor-bearing mice upon injection of CART cells inthe absence of fluorescein-folate; i.e. consistent with theaforementioned data demonstrating the bridge is required for CAR T cellactivation. Significantly, no weight loss was detected in tumor-freemice treated with the same anti-fluorescein CAR T cells, regardless ofwhether the bridge was present or absent. These latter data confirm thateven in the presence of CAR T cells and fluorescein-folate bridge, CAR Tcell activation and the consequent body weight loss cannot occur unlessa cell with exposed fluorescein (i.e. a fluorescein-decorated MDA-MB-231cell) can be engaged by the CAR T cell. Because FR expression in healthytissues is primarily restricted to the apical surface of proximal tubulecells in the kidneys (where FR are inaccessible to immune cells), littleor no CAR T cell activation would be expected in tumor-free mice.

To further establish that the intensity of a CRS depends on the numberof CAR T cells that successfully form a cytotoxic synapse with a cancercell, the dependence of body weight loss and IFNγ release was determinedas a function of CAR T cell number. As shown in FIG. 65B, administrationof the bridger alone promoted no bodyweight loss. Similarly, injectionof 10×10⁶ CAR T cells in the absence of the bridge stimulated nodecrease in body weight; i.e. confirming that engagement of a cancercell is required for systemic cytotoxicity. While injection of 2×10⁶ CART cells plus 500 nmole/kg bridge also induced no apparent weight loss,infusion of 5×10⁶ or 10×10⁶ CAR T cells plus the same bridge dosepromoted increasingly greater losses in body weight. That thesedecrements in body mass likely arose from CRS is suggested by concurrentanalyses of IFNγ release, which also display a sensitive dependence onCAR T cell numbers and the presence of the bridge. Taken together, thesedata suggest that both CAR T cells and a bridge must be present forinduction of CAR T cell activation and the associated CRS.

Strategies to Rapidly Terminate a Pre-Existing Cytokine Release Syndrome

With 92% of all CAR T cell treated ALL patients experiencing a CRS, thequestion arose whether the ability to control engagement of a CAR T cellwith its cancer cell target might be exploited to terminate a CRS afterits full activation. To explore this possibility, we first examinedwhether interruption of fluorescein-folate administration mightfacilitate cessation of a CRS. As shown in FIG. 66A, a single treatmentof MDA-MB-231 tumor-bearing mice with 15×10⁶ anti-fluorescein CAR Tcells followed by alternate day administration of 500 nmole/kg offluorescein-folate promoted a rapid and continuous weight loss, leadingto the required euthanasia of three of the mice by day 8 of therapy. Incontrast, identically treated mice in which dosing of fluorescein-folateon days 4 and 6 was omitted (but which received continuous alternate daydosing thereafter) showed only a moderate weight loss from which theyrapidly recovered. That this weight loss was likely related to the levelof cytokine production in the same mice is demonstrated by the relatedchanges in IFNγ levels measured in each mouse's plasma (FIG. 66B). Moreimportantly, the temporary interruption of alternate day dosing not onlyfailed to compromise anti-tumor activity, but instead actually enhancedCAR T cell potency. Thus, as shown in FIG. 66C, whereas untreated orcontinuously treated mice displayed a rapid increase in tumor growth,mice exposed to interrupted bridge dosing exhibited complete remissionof their tumors. These data suggest that a pre-established CRS can becontrolled by temporary discontinuation of bridge dosing withoutsubverting CAR T cell cytotoxicity.

Realizing that transient interruption of bridge dosing can lead to adecrease in CRS, we next wondered whether a more potent decrement in CRSmight be promoted by addition of ligands that would compete withfluorescein-folate for bridging CAR T cells to cancer cells. For thispurpose, we initiated a CRS as described above, and while continuing theusual alternate day dosing of the bridge we simply administered 100-foldexcess of free folate on days 4 and 6 to try to terminate the CRS. Asshown in FIG. 67A, injection of excess folic acid rapidly prevented thecontinuous weight loss observed with the uninterrupted bridge dosing.Moreover, as seen in FIG. 66, this competition with adaptor dosing notonly reduced the level of IFNγ in the treated mice (FIG. 67B), but alsoenhanced the therapeutic potency of the CAR T cell therapy (FIG. 67C).These data suggest that transient administration of a benign competingligand (i.e. the vitamin folic acid) can terminate a CRS withoutsignificantly compromising the tumor therapy.

While folic acid can be used to control CRS whenever CAR T celltherapies exploit fluorescein-folate to mediate bridging between the CART and cancer cell, it seemed prudent to also examine the ability offluorescein to block a CRS, since it should prove useful in controllingCRS associated with any fluorescein-linked tumor-specific bridge.Therefore, as described above, a CRS was induced in MDA-MB-231 tumorbearing mice, and its discontinuation was attempted by administration offree fluorescein on day 3 of the CRS. While injection of competingfluorescein induced a decrease in CRS with an increase in therapeuticefficacy, it did so more rapidly than seen with free folate. Thus, asshown in FIG. 67D, all CRS-relevant cytokines declined within 3 hours offluorescein administration, with IL-2, TNF-α, and IL-6 decreasing >50%over this short timespan. Although IFNγ did not display a decline inplasma concentration at 3 hours, it did demonstrate a decrement by 6hours post fluorescein injection, suggesting its production is alsosuppressed by fluorescein addition. Importantly, plasma concentrationsof IL-2, TNF-α, and IL-6 had all diminished to nearly background levelsby the 6 hour time point.

Strategies to Prevent Emergence of CRS without Compromising Anti-TumorActivity

Although a highly elevated and prolonged CRS can often lead to patientdeath, some level of CRS has been viewed as desirable, since patientsdisplaying no evidence of CRS are not commonly observed to respond toCAR T cell therapies. The question therefore arises whether optimizationof either bridge or CAR T cell dosing conditions can result inminimization of a CRS without loss of antitumor activity. To explorethis possibility, we first examined the effect of bridge dose on tumorcell lysis and IFNγ release in vitro. For this purpose, anti-fluoresceinCAR T cells were added to MDA-MB-231 cell cultures followed by treatmentwith fluorescein-folate concentrations ranging from 0.001 to 100,000 nM.As shown in FIGS. 68A and B, bridge doses below 0.01 nM exerted littleeffect on tumor cell lysis and only minimal effect on IFNγ production.In contrast, somewhat higher concentrations of fluorescein-folatewielded a potent impact on both parameters, whereas still higher dosesof bridge promoted a reduction in both cytokine release and MDA-MB-231cell killing. Based on the mechanism of the bridge, it could bepredicted that excessive bridge concentrations should saturate all siteson both CAR T cells and cancer cells monovalently, and thereby blockbivalent the intercellular bridging function of the bridge.

To evaluate the same bridge concentration dependence in vivo, MDA-MB-231cells were implanted subcutaneously in NSG mice and the effect offluorescein-folate dose was again examined by monitoring tumor growthand cytokine release. Unfortunately, as seen previously in FIG. 66,continuous alternate day dosing resulted in the anticipated toxic CRS,regardless of bridge dose, forcing us to omit bridge administration ondays 4 and 6. However, even with this modification, analysis of theeffect of bridge concentration was possible, revealing a bell-shapeddependence similar to that observed in vitro; i.e. an initial increasein plasma IFNγ was followed by a decrease in its plasma concentration asbridge dose was elevated (FIG. 66C). Importantly, tumor cell shrinkagealso displayed a similar bell-shaped dose response, with 500 nmole/kgexhibiting complete tumor eradication and both lower and higherconcentrations displaying lower potencies (FIG. 66D). These observationsconfirm that maximal bridging between CAR T cells and cancer cells willonly occur at intermediate bridge concentrations, where sufficientbridge is present to maximize bridge formation, but excess bridge hasnot been administered to promote autologous competition for the bridgingfunction.

With the ability to exploit bridge dose to control CAR T cell activationnow established, we decided to investigate whether a therapeuticallyactive bridge dosing regimen might be identified that could preventemergence of a toxic CRS without compromising anti-tumor potency. Basedon a hypothesis that CRS becomes most severe when CAR T cells areactivated too precipitously, we elected to test two less aggressivebridge dosing regimens that might more gradually induce CAR T cellactivation. For the first regimen, fluorescein-folate concentration wasincreased steadily from 0.5 to 500 nmole/kg during each successiveadministration of the adaptor. As shown in FIG. 69A, this slowescalation of bridge concentration caused only a transient weight lossthat resolved within 4 days without any intervention. In contrast,continuous dosing of 500 nmole/kg in the same mice pretreated with15×10⁶ CAR T cells caused a dramatic and continuous weight loss thatforced eventual euthanasia of the mice. More importantly, the gradualdose escalation regimen resulted in complete cures of the tumor-bearingmice, whereas the continuous toxic dosing schedule provided littletherapeutic benefit (FIG. 69B). These data argue strongly thatanti-tumor activity can be uncoupled from CRS and that slower CAR T cellactivation may in fact enhance tumoricidal activity while reducing CRS.

The impact of reducing the frequency of bridge dosing was examined inthe hope that introduction of longer intervals between CAR T cellactivation might permit some CAR T cell relaxation and thereby reduceany exhaustion that would have normally arisen from chronic antigenexposure. As shown in FIG. 69C, three doses of bridge per week causedsignificant animal weight loss, while two doses of bridge per weekcaused less toxicity and a single fluorescein-folate injection per weekcaused no weight loss. As seen in many of the previous studies,anti-tumor activity increased as CRS decreased; i.e. yielding completecures when only one dose of bridge was administered per week.

Example 44 Study Using AML Model

EC17/CAR-T therapy in a folate receptor-0 positive acute myeloidleukemia model is shown.

Materials:

EC17 (folate-FITC, m.w. 873) was synthesized in house. Sodiumfluorescein (AK-FLUOR®, fluorescein injection, USP) was purchased fromPurdue Pharmacy.

In-Vivo Methods: Cell Line

THP-1 is a human monocytic cell line derived from a patient with acutemonocytic leukemia, a type of acute myeloid leukemia (AML). THP-1-FRβ isa GFP-positive subclone of THP-1 stably transfected with a human FRβ.The cells were grown in a folate-free RPMI1640 medium (Gibco BRL)(FFRPMI) containing 10% heat-inactivated fetal calf serum (HIFCS) andantibiotics, and maintained under a 5% CO₂ atmosphere using standardcell culture techniques.

Mice

Female NSG′ (NOD.Cg-Prkdc^(scid) Il2rg^(tm1wjl)/SzJ, stock #005557) micewere purchased from The Jackson Laboratory (Bar Harbor, Me.) and usedwhen they reached ˜4 weeks of age. The mice were fed a folate-deficientdiet (TestDiet, St. Louis, Mo.) on the day of arrival.

Tumor Implantation

THP-1-FRβ tumors were generated by intravenous implantation of culturedcells at 5×10⁶ per animal in 9 NSG mice.

EC17/CAR-T Therapy of Tumor-Bearing Mice

Starting 11 days post tumor implantation, ˜8.3 million of GFP+4M5.3CAR-T cells were intravenously infused into each mouse. Mice weredivided into 3 groups (n=3): (1) CAR-T cell alone, (2) CAR-T cells withweekly EC17 doses at 500 nmol/kg, and (3) CAR-T cells with weekly EC17doses at 500 nmol/kg plus sodium fluorescein rescue when needed. Thefirst EC17 dose was given two days after CAR-T cell administration. AllEC17 doses were given towards the end of day (˜3-4 PM) to allow cytokinerelease syndrome (CRS) to develop overnight. In the following morningafter the first EC17 dose, all 6 mice in Groups 2 and 3 showed an onsetof CRS with a CRS grade of ˜3, sodium fluorescein was then administeredat 6 μmol/kg for Group 3 only. All EC17-dosed mice with and withoutsodium fluorescein rescue completely recovered in the next few days. Noadditional sodium fluorescein rescue was given for additional EC17dosing in Group 3. Mice were weighed and monitored for sign of healthand disease development. Animals were euthanized when they displayedsevere distress/moribund behavior or for comparison purposes. Uponeuthanasia, all mice were subject to gross examination for the presenceof tumor masses. All visible tumor masses were excised, counted andweighed. Blood, tumor metastases (mets) and normal adjacent tissues werecollected for same-day flow cytometry analysis.

Whole Blood Cell Analysis by Flow Cytometry

Plasma was removed from predetermined volumes of whole EDTA treatedblood with a 10-minute 4° C. spin at 3000×g and the resulting cellpellets were incubated with a 10-fold volume of room temperature 1×RBClysis solution (prepared from 10× stock; Biolegend, catalog #420301) for5 minutes, centrifuged at 400×g for 5 min. The cell pellets were washedin a 10-fold volume of ice-cold phosphate-buffered saline (PBS, pH=7.4and filtered with a 40 μm nylon filter then pelleted again. Theleukocyte cell pellets were then resuspended in a flow cytometrystaining solution (1% bovine serum albumin, 50 mg/mL human IgG (EquitechBio, cat #SLH56-0001), 0.9% sodium azide in PBS, pH=7.4) supplementedwith both anti-mouse FcγIII/II receptor (CD16/CD32) block (clone 2.4G2;BD Bioscience, catalog #553142 at 1:100 (v/v) dilution) and anti-humanFc Block (BD Biosciences, catalog #564220 at 1:50 (v/v) dilution).Surface marker staining was performed with the addition of the followingfluorochrome conjugated monoclonal antibodies added to each sample for20 minutes on ice in the dark: anti-human CD45-APCeF780 (clone HI30,eBioscience #47-0459-42 at 1:20 (v/v) dilution), anti-human CD3-BV650(clone SK7, BD Bioscience, catalog #563999 at 1:20 (v/v) dilution),anti-human CD137-BV650 (clone 4B4-1, BD Bioscience #564092 at 1:20 (v/v)dilution), anti-human CD8α-PECy7 (clone RPA-T8, BD Bioscience, catalog#557746 at 1:20 (v/v) dilution), anti-human CD4-Percpe710 (clone SK3,eBioscience catalog #46-0047-42 at 1:20 (v/v) dilution), anti-humanCD25-PE (clone M-A251, BD Bioscience, catalog #555432 at 1:10 (v/v)dilution), anti-human CD33-PE (clone WM53, BD Bioscience, catalog#555450 at 1:5 (v/v) dilution), anti-human CD123-AF647 (clone 9F5, BDBioscience, catalog #563599 at 1:20 (v/v) dilution). Biotinylatedanti-human folate receptor-β (clone m909) was kindly provided by the Lowlab at Purdue University (Arthritis Res Ther. 2011; 13(2):R59) anddetected using streptavidin-eFluor660 (eBioscience, catalog #50-4317 at1:1000 (v/v) dilution). Folic acid binding was interpreted as a measureof functional folate receptor and was determined by incubation with anAlexa Fluor conjugated folic acid which was synthesized in house. Afterleukocyte staining, cells were washed with PBS and resuspended in coldPBS containing 3 μM propidium idodide. Flow cytometry data was collectedon the Gallios flow cytometer (Beckman Coulter, Brea, Calif.), where aminimum of 15,000 CountBright™ bead events were collected in an attemptto collect enough leukocyte events for an accurate count of infused CART cells in each mouse blood sample. Determination of the concentrationof CAR T cells in each blood sample was calculated according toInvitrogen's instructions. Briefly, CAR T cells were identified as humanCD45+ GFP+ events and easily distinguished and counted using the Kaluza™flow cytometry software version 1.5. CountBright™ beads were uniformlylabeled with a fluorochrome not utilized in the antibody panel used toidentify the CAR T cells and were easily distinguished from theleukocytes and bead events were counted. Because 53,000 CountBright™beads were added to each sample tube, we calculated the ratio of 53,000total beads to bead events collected per sample and set the bead ratioequivalent to the unknown number of CAR T cells in each sample dividedby the known number of CAR T cell events collected. Solving for theunknown gave us the number of CAR T cells isolated from each bloodsample of known volumes. The number of CART cells in the circulation ofeach infused mouse was then represented on the graphs as the totalnumber of CAR T cells per 504, of whole blood analyzed. Human peripheralblood mononuclear cells were purchased and used for staining controlsfor leukocyte surface markers (Human PBMCs, Stem Cell Technologies,catalog #70025.22). Statistical significance was determined by utilizingan unpaired, two-tailed, student's t-test with significance set atp<0.05 for comparisons between each of the three groups of mice.

Preparation of Single Cell Suspension of Tumor and Adjacent HealthyTissue

Solid tumors and tumor free adjacent tissues were harvested, weighed,and minced into small pieces then transferred into 50 mL tubescontaining 20 mL of a tumor digestion cocktail. The enzymatic tumordigestion cocktail consisted of 0.5 mg/mL Collagenase IV (Sigma-Aldrich,Catalog #C5138), 0.5 mg/mL Hyaluronidase (Sigma-Aldrich, Catalog #H3506)and 0.1 mg/mL DNase I (Sigma-Aldrich, Catalog #DN25) in serum-free andfolate-deficient RPMI1640 medium supplemented with antibiotics. Thetumor fragments were digested for one hour at 37° C. at 300 rpm on ahorizontal shaker. Afterwards, the tumor digest was centrifuged at 400×gfor 5 minutes and tumor cell pellets were incubated with a 10-foldvolume of room temperature 1×RBC lysis solution [prepared from 10×stock; Biolegend, catalog #420301] for 5 minutes, centrifuged at 400 gfor 5 min, and the cell pellet was washed in a 10-fold volume of icecold phosphate buffered saline pH=7.4 and filtered with a 40 μm nylonfilter then pelleted again. The tumor cells were analyzed by flowcytometry as previously described above.

Gross Examination of Total Tumor Load

All 3 CAR-T cell control animals in Group 1 (#1, #2, #3) were foundbloated on day 45 post tumor implantation (PTI 45) (i.e. 34 days postCAR-T cell administration). Two control animals were euthanized and thethird one was dead right before euthanasia. One animal in Group 2 (#5)was euthanized and served as a same-day comparator for Group 1. On day58 post tumor implantation (PTI 58) (i.e. 46 days post CAR-Tadministration), the remaining two animals in Group 2 (#4 and #6) wereeuthanized (#4 was pre-dosed with EC17 the day before). All 3 animals inGroup 3 (#7, #9, and #10) were also collected (#7 and #10 were pre-dosedwith EC17 the day before). As shown in FIG. 56, metastatic tumor massesof various sizes (large in the ovaries) and locations (except for thelungs) were found in the CAR-T cell only control group. On the same dayof collection, only tiny tumor nodules were identified in the EC17treated animal from Group 2 (#5). FIG. 57 summarizes the estimatednumbers of tumor masses and total tumor weights in all groups examined.In general, mice in the CAR-T cell control Group 1 had the most visibletumor masses and a higher total tumor load than the animals in bothEC17-treated groups regardless of sodium fluorescein rescue. Other thanone animal in Group 3 (#10), five out of the 6 EC17-treated mice (+/−one-time sodium fluorescein rescue) had minimum tumor load at the timeof collection. These preliminary results showed that EC17-controlledCAR-T therapy was highly effective against this AML tumor model.

Characterization of Circulating Tumor Cells

Circulating AML were analyzed and show characteristic surface markerexpression, CD33 and CD123, in approximately 90-95% of all patients. Totest the anti-leukemia activity of our FITC specific 4M5.3 CART cells inthis aggressive AML model, we utilized THP-1 cells stably transfectedwith FRβ and referred to as THP-1-FRβ. We therefore tested our in-vitroTHP-1-FRβ cell line and demonstrated these cells also expressed CD33 andCD123 surface expression (FIG. 58A, left dot plot) suggesting an AMLphenotype. Unstained THP-1-FRβ cells and fresh human PBMCs served asgating and positive controls, giving us confidence in our assay forthese markers (FIG. 58A, middle and right dot plots). When THP-1-FRβcells were intravenously injected into the NSG mice, the human leukemiccells were easily distinguished from mouse leukocytes in the blood byGFP fluorescence and were observed to retain the surface expression ofAML markers, CD33 and CD123 (FIG. 58B). In addition, we confirmed stableFRβ expression on circulating tumor cells in vivo by positive surfacestaining with Alexa Fluor 647 labeled folic acid (FIG. 59A). TheTHP-1-FRβ tumor cells also continued to express FRβ in solid tumormetastases isolated from the liver and ovary as seen by flow cytometricstaining using an anti-human FRβ antibody (FIG. 59B).

Anti-Leukemia Activity of EC17 Directed CAR T Cells

To determine if CAR T cells can be directed to reduce the leukemic loadof NSG mice bearing THP-1-FRβ cells, on day 34 post CAR-T infusion, wecompared GFP+ tumor cells isolated from the blood of an animal receivingCAR T cells alone in Group 1 that had met euthanasia criteria to that ofan animal receiving CART cells plus EC17 (500 nmol/kg; SIW) for 4 weeksin Group 2 (FIG. 60). Clearly there was a high leukemia load in thecontrol animal without EC17 treatment as approximately 23% of the totalleukocytes are GFP+ leukemia cells (FIG. 60A and FIG. 60B, bar graph).However, in the animal that was infused with CAR T cells and dosed withEC17, significant CAR T cell activity was observed as GFP+ leukemiccells became nearly undetectable in the blood (FIG. 60B). Moreover, theobserved anti-leukemia activity of CART cells persisted in animals aslong as 47 days post CAR T cell infusion as THP1-FRβ cells were stillundetectable in the blood (FIG. 60B).

Persistence of Blood-Borne CAR T Cells Post Infusion

The numbers of FITC-CAR T cells in the circulation were measured by flowcytometric analysis to enumerate the GFP+CD3+ CAR T events in wholeblood samples collected from mice at days 34 and 47 (end of study) postCART cell infusion (FIG. 61A). Our human CAR T cells transduced with the4M5.3 construct persisted as long as 34 days post infusion in a controlmouse that did not receive any EC17, suggesting that the THP-1-FRβ tumorbearing NSG mice were able to sustain the viability of human T cells. InCAR-T cell infused THP1-FRβ bearing mice receiving EC17 on a weeklybasis, CAR T cells were noticeably persistent in the blood for as longas 47 days post infusion with number ranging from 3800 to 300,000 CAR Tcells per 1004, of blood (FIG. 61A), with no apparent difference withthe control animals. Interestingly, the CAR T cell phenotype isolatedfrom the mice receiving weekly injections of EC17 was primarily that ofeither central memory/effector memory phenotype (FIG. 61B), whereas theCAR T cells from the mouse which did not receive EC17, still had theeffector T cell phenotype (FIG. 61B). CAR T cells with a memoryphenotype is a desirable trait for T cell therapy as memory T cells arecapable of further cell division to give rise to future effector T cellsavailable for killing cancer cells.

CAR T Cells Localized in Metastatic Tumor Lesions not Adjacent HealthyTissues

Although AML tumor cells are usually found in the blood and bone marrowof patients, occasionally AML cells can form solid tumors anywhere inthe body. THP-1-FRβ tumor model in NSG mice resembles that of AML withtumor cells in the blood and metastatic solid tumor lesions in normaltissues such as ovaries, liver, small intestine, brain and stomach.Since EC17/CAR-T treatment significantly reduced total tumor burden(FIG. 56 and FIG. 57), we wanted to assess the presence of CAR T cellswithin the residual tumors found in EC17 treated animals and study thepreference of CART cells for the tumors relative to their adjacentnormal tissues in the same animal (FIG. 62). Two animals that receivedCAR-T cell infusion plus 5 weekly doses of EC17 (500 nmol/kg) wereeuthanized on day 47 post T cell infusion. Residual tumors were found ina few normal organs (e.g. stomach lining, heart, liver, and duodenum).Using flow cytometry on digested samples, we analyzed the presence ofCAR T cells in visible solid tumor mets and compared CAR-T cellinfiltration to that of adjacent healthy tissue of the same animalswhere tumors were found. In one animal (mouse #4), CAR T cells werepresent at higher numbers in tumors found with the stomach and heart(FIG. 62A) but not in healthy adjacent tissues (FIG. 62A). Similar datawas also seen in another animal (mouse #10) where tumors were foundwithin the duodenum, however, the difference in CAR T cell numbersbetween the liver tumor met and healthy liver tissue was not large.

In an effort to measure any activity of the CAR T cells within thetumors, we also stained the surface of CAR T cells for the activitymarker, CD25. Interestingly we saw higher levels of CD25 on the CAR Tcells in the tumors but not on the CAR T cells isolated from adjacenthealthy tissues (FIG. 62B). Taken together (FIGS. 62A and 62B) thesedata suggest that CAR T cells can follow leukemic cells into healthytissues and attack them at the metastatic sites of tumor formation andare still active 47 days after infusion. Importantly, mouse #10 was inGroup 3 which received sodium fluorescein rescue of sCRS after the firstdose of EC17. Although sodium fluorescein was given to this animal, CARTcells were still persistent in both the blood and the tumors, suggestingthat CAR T cell functionality was preserved and these CAR-T cells can bereactivated by EC17 against FR-positive tumor target.

Example 45 EC17 Dose De-Escalation Cycles can Reduce the Toxicity

The effect of EC17 dose de-escalation was investigated on the anti-tumoractivity and the toxicity (body weight changes) of CAR-T therapy. 8.5million frozen anti-FITC CAR-T cells were thawed and i.v. injected intomice bearing s.c. MDA-MB-231 tumors (100-200 mm3). 500 nmol/kg EC17 wasadministered 2 days after CAR-T injection and caused sCRS in mice. Thosemice were successfully rescued with 6 umol/kg NaFL, and then dividedinto two groups. The first group was dosed with 500 nmol/kg EC17 weekly(SIW), whereas the second group was dosed with two EC17 escalationcycles. Each cycle lasted for 2 weeks (14 days). The dosing schedule ineach cycle included 5 nmol/kg EC17 at day 1, 50 nmol/kg EC17 at day 3,500 nmol/kg EC17 on day 5. After 9 days break, the second escalationcycle started. The dosing schedules of both escalation group and SIWgroup are shown in FIG. 70A. Tumor sizes and body weights were monitored2-3 times per week. Both groups showed similar response to CAR-T therapy(FIG. 70B), whereas the body weight loss of escalation group was muchless than that of the EC17 SIW group (FIG. 70C). The data suggest thatEC17 dose de-escalation can reduce toxicity while maintaining theanti-tumor activity of CAR-T cell therapy.

Example 46 Car-T and EC17 Therapy-Related Toxicity is Correlated withTumor Size

To explore whether CAR-T therapy related toxicity is dependent on tumorload, NSG mice were s.c. implanted with MDA-MB-231. Ten mice withdifferent tumor sizes ranging between 150-900 mm³ were selected for thisstudy. For the CAR-T cells, 10.5 million GFP+FITC-CAR-T cells were i.v.injected followed by 500 nmol/kg EC17 administration 48 hours later(FIG. 71A). Body weights of mice were compared between before CAR-Tinjection and 18 hours post EC17 administration. As shown in FIG. 71B,body weight changes were shown to be tumor size dependent. With highertumor burden, mice lost more body weight after CAR-T and EC17 treatment.Eighteen hours after EC17 administration, mice showed grade 2 cytokinerelease syndrome and their blood samples were collected bycardio-puncture. Plasma samples were separated immediately and stored at−20° C. until the analysis of cytokine levels using a human cytokinedetection kit (Biolegend). As shown in FIG. 71C, the production of IL-6was shown to be tumor size dependent. With higher tumor burden, moreIL-6 was produced after CAR-T and EC17 treatment. IL-6 has been widelyreported to be the predicting biomarker for severe cytokine releasesyndrome in human patients with liquid tumors when they are treated withconventional CAR-T therapy. These data suggest that in CAR-T and EC17therapy, the severity of CRS in solid tumor-bearing mice is alsocorrelated with the tumor burden.

Example 47 Evaluation of EC17-Controlled Anti-FITC Car T-Cell Therapy inan Aggressive Osteosarcoma Model Materials

EC17 (folate-FITC, m.w. 873) was synthesized in house. Sodiumfluorescein (AK-FLUOR®, fluorescein injection, USP) was purchased fromPurdue Pharmacy.

In-Vivo Methods Cell Line

HOS-143b is a cell line purchased from ATCC (CRL-8303) that wasoriginated from a 13-year-old Caucasian girl with osteosarcoma. HOS-FRαis subclone of HOS-143b stably transfected with a human FRα. The cellswere grown in a folate-free RPMI1640 medium (Gibco BRL) (FFRPMI)containing 5-10% heat-inactivated fetal calf serum (HIFCS) andmaintained under a 5% CO₂ atmosphere using standard cell culturetechniques.

Mice

Female NSG′ (NOD.Cg-Prkdc^(scid) Il2rg^(tm1wjl)/SzJ, stock #005557) micewere purchased from The Jackson Laboratory (Bar Harbor, Me.) and usedwhen they reached ˜4 weeks of age. The mice were fed a folate-deficientdiet (TestDiet, St. Louis, Mo.) on the day of arrival.

Tumor Implantation

HOS-FRα cells were implanted subcutaneously with 5×10⁵ per animal in 6animals.

CAR-T Cell Preparation

GFP+ anti-FITC 4M5.3 scFv-CAR T cells were prepared as describedpreviously. After cultured in-vitro for 12-20 days, they were frozen andstored at −80° C. in a freezing reagent containing 50% heat-inactivatedAB+ human serum, 40% T cell culture media, and 10% DMSO. Frozen CAR-Tcells were quickly thawed at 37° C., washed twice with PBS, and used foranimal injection.

EC17/CAR-T Therapy in Tumor-Bearing Mice

As shown in FIG. 72A, at 6 days after tumor implantation, all animalsreceived 10.5 million CAR T-cells intravenously (Day 0). Two days later,the animals were divided in two groups (n=3 for this study) and receivedno EC17 treatment or EC17 was dosed intravenously at 500 nmol/kg,once-α-week (SIW) for 4-5 doses. One animal in the EC17-treated groupreceived two more doses of EC17 at 50 and 100 nmol/kg on Days 40 and 42.All EC17 doses were given towards the end of the day (˜3-4 PM) to allowcytokine release syndrome (CRS) to develop overnight. Sodium fluoresceinrescue was done as needed at 0.6 μmol/kg. Only the last EC17-dosedanimal received sodium fluorescein on day 47.

Whole Blood Cell Analysis by Flow Cytometry

Plasma was removed from predetermined volumes of whole EDTA treatedblood with a 10-minute 4° C. spin at 3000 g and the resulting cellpellets were incubated with a 10-fold volume of room temperature 1×RBClysis solution [prepared from 10× stock; Biolegend, catalog #420301] for5 minutes, centrifuged at 400 g for 5 min, and the cell pellet waswashed in a 10-fold volume of ice cold phosphate buffered saline pH=7.4and filtered with a 40 μm nylon filter and then pelleted again. Theleukocyte pellets were then resuspended in flow cytometry stainingsolution [1% bovine serum albumin, 50 mg/mL human IgG (Equitech Bio, cat#SLH56-0001), 0.9% sodium azide in a phosphate buffered saline, pH=7.4]supplemented with both anti-mouse FcγIII/II receptor (CD16/CD32) block[clone 2.4G2; BD Bioscience, catalog #553142 at 1:100 (v/v) dilution]and anti-human Fc Block [BD Biosciences, catalog #564220 at 1:50 (v/v)dilution]. Leukocyte surface marker staining was performed with theaddition of the following fluorochrome conjugated monoclonal antibodiesadded to each sample for 20 minutes on ice in the dark: anti-humanCD45-APCeF780 [clone HI30, eBioscience #47-0459-42 at 1:20 (v/v)dilution], anti-human CD137-BV650 [clone 4B4-1, BD Bioscience #564092 at1:20 (v/v) dilution], anti-human CD8α-PECy7 [clone RPA-T8, BDBioscience, catalog #557746 at 1:20 (v/v) dilution], anti-humanCD4-Percpe710 [clone SK3, eBioscience catalog #46-0047-42 at 1:20 (v/v)dilution]. After leukocyte staining, the cells were washed with PBS andresuspended in cold PBS containing 53,000 CountBright™ beads [Invitrogencatalog #C36950] and transferred to flow cytometry collection tubes.Flow cytometry data was collected on the Gallios flow cytometer (BeckmanCoulter, Brea, Calif.), where a minimum of 15,000 CountBright™ beadevents were collected in an attempt to collect enough leukocyte eventsfor an accurate count of infused CAR T cells in each mouse blood sample.Determination of the concentration of CAR T cells in each blood samplewas calculated according to Invitrogen's instructions. Briefly, CAR Tcells were identified as human CD45+ GFP+ events and easilydistinguished and counted using the Kaluza™ flow cytometry software.CountBright™ beads were uniformly labeled with a fluorochrome notutilized in the antibody panel used to identify the CAR T cells and wereeasily distinguished from the leukocytes and bead events were counted.Because 53,000 CountBright™ beads were added to each sample tube, theratio was counted of 53,000 total beads to bead events collected persample and the bead ratio was set equivalent to the unknown number ofCAR T cells in each sample divided by the known number of CAR T cellevents collected. Solving for the unknown provided the number of CAR Tcells isolated from each blood sample of known volumes. The number ofCAR T cells in the circulation of each infused mouse was thenrepresented on the graphs as the total number of CAR T cells per 50 μLof whole blood analyzed.

Preparation of Single Cell Suspension of Tumor and Healthy Tissue

For the animal euthanized on Day 47, blood, normal tissues (liver,spleen, and bone marrow), and a subcutaneous tumor were harvested andminced into small pieces then transferred into 50 mL tubes containing 20mL of a tumor digestion cocktail. The enzymatic tumor digestion cocktailconsisted of 0.5 mg/mL Collagenase IV (Sigma-Aldrich, Catalog #C5138),0.5 mg/mL Hyaluronidase (Sigma-Aldrich, Catalog #H3506) and 0.1 mg/mLDNase I (Sigma-Aldrich, Catalog #DN25) in serum-free andfolate-deficient RPMI1640 medium supplemented with antibiotics. Thetumor fragments were digested for one hour at 37° C. at 300 rpm on ahorizontal shaker. Afterwards, the tumor digest was centrifuged at 400×gfor 5 minutes and tumor cell pellets were incubated with a 10-foldvolume of room temperature 1×RBC lysis solution [prepared from 10×stock; Biolegend, catalog #420301] for 5 minutes, centrifuged at 400 gfor 5 min, the cell pellet was washed in 10-fold volume of ice coldphosphate buffered saline pH=7.4 and filtered with a 40 μm nylon filterand then pelleted again. Expression of FRα by tumor cells was measuredby staining with anti-human FRα [clone LK26, Biolegend catalog #908304at 1:20 (v/v) dilution. The tumor cells were analyzed by flow cytometryas previously described above.

Data and Results

The study schema is shown in FIG. 72A. The first HOS-FRα tumor-bearinganimal in the EC17-treated group received 4 weekly EC17 doses at 500nmol/kg, but was euthanized on Day 28 due to neurological issues. Thesecond animal in the same group received 5 weekly EC17 doses at 500nmol/kg, but was found dead on Day 34. The last animal in the same groupreceived 5 weekly EC17 doses at 500 nmol/kg plus two additional EC17doses at 50 and 100 nmol/kg on Days 40 and 42 respectively. This animalwas given sodium fluorescein on Day 47 and was euthanized on Day 53. Allanimals developed GVHD approximately 5 weeks after CAR-T celladministration.

The tumor volume (FIG. 72B) and body weight changes (FIG. 73) wereplotted for each individual animal. The solid lines represent HOS-FRαtumor-bearing mice receiving only CAR-T cells. The dashed linesrepresent HOS-FRα tumor-bearing mice receiving CAR-T cells and EC17treatment as described above. The EC17 dosing dates were labeled asdotted vertical lines. Tumor volumes and body weight changes weremonitored 2-3 times per week. While one CAR-T only group animal wasfound dead on Day 45 with no apparent reason, all 3 CAR-T-cell controlanimals had their tumors grow rapidly once established (FIG. 72B, solidlines). In contrast, tumors in all 3 mice dosed with EC17 SIW at 500nmol/kg started to shrink on Days 28 and 33 (FIG. 72B, dashed lines).Although 2 animals were lost on Days 28 and 34 in the EC17 treatedgroup, the last animal in the same treated group had longer delayedtumor growth and responded to additional low-dose EC17 treatment. Thebody weight changes in these animals (FIG. 73) suggested that CRS wassevere once the tumors reached >200 mm³ in the EC17-treated animals. TheCRS coupled with severe GVHD were likely the reasons for observedtoxicity and mortality in these animals.

Flow cytometry analysis was conducted in the last animal that washarvested on Day 47. As shown in FIG. 74A-F, HOS cancer cells wereidentified as positive for anti-human FRα [clone LK26] staining. HOS-FRαcancer cells were not detectable in the normal tissues tested and onlydetectable in the subcutaneous solid tumor. In addition, these dataconfirmed the continued surface expression of FRα on HOS-FRα tumor cellsin-vivo post EC17/CAR-T treatment.

Example 48 Sodium Fluorescein (NAFL) Rescue can Reduce the Production ofHost MCP-1, IL-6 and IL-10 which are Related to the Development ofSevere Cytokine Release Syndrome

High levels of MCP-1, IL-6 and IL-10 have been reported to be predictivefor cytokine release syndrome (CRS) after CAR-T cell therapy for variousliquid tumors. Production of these cytokines not only occurs for humanCAR-T cells but also for host immune cells including monocytes,macrophages and dentric cells. These cytokines have also been reportedto participate in abnormal marcrophage activation and to drive thedevelopment of CRS in patients treated with CAR-T cells. Reduction ofthese cytokines (e.g. IL-6 and MCP-1) has proved to be efficient inmanaging CRS in CAR-T therapy. Although NSG mice are immune deficient,mouse dentric cells and macrophages are still partially functional. Toevaluate whether CAR-T/EC17 therapy can induce the production of thesehost cytokines in NSG mice, and also to study whether NaFL rescue canreduce the production of these host mouse cytokines, NSG mice bearingMDA-MB-231 tumors were used.

In the first part of the study (FIG. 75), mice were treated with EC17and FITC-CAR-T cells. When mice started to show sCRS, one dose of 60umol/kg NaFL was injected for rescue. Mouse blood samples were thencollected at both 7 hours and 27 hours post NaFL rescue. Mouse cytokinelevels in blood were analyzed using a mouse inflammation panel kit (Cat.No. 740446) from BioLegend by following the manufacturer's instructions.FIGS. 76 A-E show cytokine levels 7 hours post rescue. FIGS. 77A-C showcytokine levels 27 hours post rescue. In summary, mice administered withCAR-T but without EC17 had very low leveled of mouse cytokines in theirblood, while mice dosed with EC17 had increased mouse cytokine levels intheir blood, including MCP-1, IL-6, IL-10, IFN-β, and TNF-α. Moreimportantly, mouse cytokine levels in the mice rescued with 60 μmol/kgsodium fluorescein were much lower than those in un-rescued mice (bothat 7 hours and 27 hours post rescue).

In the second part of the study, a series of concentrations of NaFL weretested for their rescue efficiency (FIG. 78). As shown in FIGS. 79-81,mice cytokine levels in blood were also dependent on the concentrationsof sodium fluorescein used for rescue, and the median effective dose isabout 0.6 μmol/kg with cytokines tested (e.g. MCP-1, IL-6, and IL-10)and the mice started to respond as early as 3 hours post rescue.

In conclusion, CAR-T/EC17 therapy can induce elevated mouse cytokineproduction, and one dose of NaFL rescue can reduce the production ofthese CRS related mouse cytokines and improve overall condition of themice.

Example 49 Mouse MCP-1 Production in Mice is Correlated with Car-T CellNumber

Monocyte chemoattractant protein 1 (MCP-1) is a chemokine molecule thatis chemotactic for monocytes/marcrophages. A high level of MCP-1 hasbeen reported to be a predictive biomarker for cytokine release syndromeafter CAR-T cell therapy for various liquid tumors including acutelymphoblastic leukemia. Although NSG mice are immune deficient, thefunctions of dentric cells and macrophages are defective but not totallyeliminated. To evaluate whether the CAR-T/EC17 therapy can induce theproduction of mouse MCP-1 in NSG mouse, and to study whether theproduction of mouse MCP-1 is correlated with CAR-T number in mice, NSGmice bearing MDA-MB-231 tumors (250-500 mm³) were divided into threegroups and administered 500 nmol/kg of body weight of EC17 and differentamounts of CAR-T cells (2, 5 or 12.5 million respectively), as shown inFIG. 82A. Two days after the second EC17 dose, mouse blood samples werecollected, and the production of mouse MCP-1 in blood was analyzed usinga mouse inflammation panel kit (Cat. No. 740446) from BioLegend. Asshown in FIG. 82B, mouse MCP-1 is found to correlate with the number ofCAR-T cells administered. In conclusion, with the increase in CAR-Tcells, the production of mouse MCP-1 also increases, mostly due to thehigh level of human cytokines released by active human CAR-T cells.

1-12. (canceled)
 13. A method of treating a patient for cancer, themethod comprising: i) administering to the patient a compound, or apharmaceutically acceptable salt thereof, wherein the compound comprisesa small molecule ligand linked to a targeting moiety by a linker; ii)administering to the patient a chimeric antigen receptor T cell (CAR Tcell) composition comprising CAR T cells comprising a chimeric antigenreceptor (CAR) directed to the targeting moiety; and iii) administeringto the patient (a) a folate, (b) a conjugate, which comprises a folateand which does not comprise a targeting moiety, or (c) an agent thatinhibits activation of the CAR T cells, whereupon the patient is treatedfor cancer.
 14. The method of claim 13, wherein the targeting moiety isselected from the group consisting of 2,4-dinitrophenol (DNP),2,4,6-trinitrophenol (TNP), biotin, digoxigenin, fluorescein,fluorescein isothiocyanate (FITC), NHS-fluorescein, pentafluorophenylester, tetrafluorophenyl ester, a knottin, a centyrin, and a DARPin. 15.The method of claim 14, wherein the targeting moiety is FITC.
 16. Themethod of claim 13, wherein the ligand portion of the small moleculeligand linked to a targeting moiety by a linker is a folate and thecancer is a folate receptor-expressing cancer.
 17. The method of claim13, wherein the CAR has a recognition region and the recognition regionis a single chain fragment variable (scFv) region of an anti-FITCantibody, wherein the CAR has a co-stimulation domain and theco-stimulation domain is CD137 (4-1BB), and wherein the CAR has anactivation signaling domain and the activation signaling domain is a Tcell CD3ζ chain.
 18. The method of claim 13, wherein the compound, orthe pharmaceutically acceptable salt thereof, is not an antibody, anddoes not comprise a fragment of an antibody.
 19. The method of claim 13,wherein the targeting moiety does not comprise a peptide epitope. 20.The method of claim 13, wherein the agent that inhibits activation ofthe CAR T cells is selected from the group consisting of alymphocyte-specific protein tyrosine kinase inhibitor, a PI3 kinaseinhibitor, an inhibitor of an IL-2 inducible T cell kinase, a JAKinhibitor, a BTK inhibitor, EC2319, and an agent that blocks CAR T cellbinding to the compound, or the pharmaceutically acceptable saltthereof, but does not bind to the cancer.
 21. The method of claim 20,wherein the agent that inhibits activation of the CAR T cells isadministered and is an agent that blocks CAR T cell binding to thecompound, or the pharmaceutically acceptable salt thereof, but does notbind to the cancer and wherein the agent is fluoresceinamine, FITC, orsodium fluorescein.
 22. A method of treating a patient for cancer, themethod comprising: i) administering to the patient a compound, or apharmaceutically acceptable salt thereof, wherein the compound comprisesa small molecule ligand linked to a targeting moiety by a linker,wherein at least a first dose and a second dose of the compound, or thepharmaceutically acceptable salt thereof, are administered to thepatient, wherein the first dose and the second dose are different,wherein the second dose of the compound, or the pharmaceuticallyacceptable salt thereof, is about 2-fold to about 15000-fold greater inamount than the first dose of the compound, or the pharmaceuticallyacceptable salt thereof; and ii) administering to the patient a chimericantigen receptor T cell (CAR T cell) composition comprising CAR T cellscomprising a chimeric antigen receptor (CAR) directed to the targetingmoiety, whereupon the patient is treated for cancer.
 23. The method ofclaim 22, wherein the targeting moiety is selected from the groupconsisting of 2,4-dinitrophenol (DNP), 2,4,6-trinitrophenol (TNP),biotin, digoxigenin, fluorescein, fluorescein isothiocyanate (FITC),NHS-fluorescein, pentafluorophenyl ester, tetrafluorophenyl ester, aknottin, a centyrin, and a DARPin.
 24. The method of claim 23, whereinthe targeting moiety is FITC.
 25. The method of claim 22, wherein theligand portion of the small molecule ligand linked to a targeting moietyby a linker is a folate and the cancer is a folate receptor-expressingcancer.
 26. The method of claim 22, wherein the CAR has a recognitionregion and the recognition region is a single chain fragment variable(scFv) region of an anti-FITC antibody, wherein the CAR has aco-stimulation domain and the co-stimulation domain is CD137 (4-1BB),and wherein the CAR has an activation signaling domain and theactivation signaling domain is a T cell CD3ζ chain.
 27. The method ofclaim 22, wherein the compound, or the pharmaceutically acceptable saltthereof, is not an antibody, and does not comprise a fragment of anantibody.
 28. The method of claim 22, wherein the targeting moiety doesnot comprise a peptide epitope.
 29. A method of treating a patient forcancer, the method comprising: i) administering to the patient a firstdose of a compound, or a pharmaceutically acceptable salt thereof,wherein the compound comprises a small molecule ligand linked to atargeting moiety by a linker; ii) administering to the patient at leasta second dose of the compound, or a pharmaceutically acceptable saltthereof, wherein the second dose of the compound, or thepharmaceutically acceptable salt thereof, is at least about 50 percentlower in amount than the first dose of the compound, or thepharmaceutically acceptable salt thereof; and iii) administering to thepatient a dose of a chimeric antigen receptor T cell (CAR T cell)composition comprising CAR T cells comprising a chimeric antigenreceptor (CAR) directed to the targeting moiety, whereupon the patientis treated for cancer.
 30. The method of claim 29, wherein the targetingmoiety is selected from the group consisting of 2,4-dinitrophenol (DNP),2,4,6-trinitrophenol (TNP), biotin, digoxigenin, fluorescein,fluorescein isothiocyanate (FITC), NHS-fluorescein, pentafluorophenylester, tetrafluorophenyl ester, a knottin, a centyrin, and a DARPin. 31.The method of claim 30, wherein the targeting moiety is FITC.
 32. Themethod of claim 29, wherein the ligand portion of the small moleculeligand linked to a targeting moiety by a linker is a folate and thecancer is a folate receptor-expressing cancer.
 33. The method of claim29, wherein the CAR has a recognition region and the recognition regionis a single chain fragment variable (scFv) region of an anti-FITCantibody, wherein the CAR has a co-stimulation domain and theco-stimulation domain is CD137 (4-1BB), and wherein the CAR has anactivation signaling domain and the activation signaling domain is a Tcell CD3ζ chain.
 34. The method of claim 29, wherein the compound, orthe pharmaceutically acceptable salt thereof, is not an antibody, anddoes not comprise a fragment of an antibody.
 35. The method of claim 29,wherein the targeting moiety does not comprise a peptide epitope.
 36. Amethod of treating a patient for cancer, the method comprising: i)administering continuously to the patient a compound, or apharmaceutically acceptable salt thereof, wherein the compound comprisesa small molecule ligand linked to a targeting moiety by a linker; ii)administering to the patient a chimeric antigen receptor T cell (CAR Tcell) composition comprising CAR T cells comprising a chimeric antigenreceptor (CAR) directed to the targeting moiety; and iii) ending thecontinuous administration of the compound, or the pharmaceuticallyacceptable salt thereof, to inhibit or prevent cytokine release syndromein the patient, whereupon the patient is treated for cancer.
 37. Themethod of claim 36, wherein the targeting moiety is selected from thegroup consisting of 2,4-dinitrophenol (DNP), 2,4,6-trinitrophenol (TNP),biotin, digoxigenin, fluorescein, fluorescein isothiocyanate (FITC),NHS-fluorescein, pentafluorophenyl ester, tetrafluorophenyl ester, aknottin, a centyrin, and a DARPin.
 38. The method of claim 37, whereinthe targeting moiety is FITC.
 39. The method of claim 36, wherein theligand portion of the small molecule ligand linked to a targeting moietyby a linker is a folate and the cancer is a folate receptor-expressingcancer.
 40. The method of claim 36, wherein the CAR has a recognitionregion and the recognition region is a single chain fragment variable(scFv) region of an anti-FITC antibody, wherein the CAR has aco-stimulation domain and the co-stimulation domain is CD137 (4-1BB),and wherein the CAR has an activation signaling domain and theactivation signaling domain is a T cell CD3ζ chain.
 41. The method ofclaim 36, wherein the compound, or the pharmaceutically acceptable saltthereof, is not an antibody, and does not comprise a fragment of anantibody.
 42. The method of claim 36, wherein the targeting moiety doesnot comprise a peptide epitope.